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Introduction: Cancer risk assessment tools are novel tools that combine risk 
factors and symptoms to predict an individual’s risk of developing cancer. Little 
is known about the views of service users and primary care practitioners on 
how cancer risk assessment tools should be used in primary care. Following 
a scoping review of the literature, the qualitative study explored perspectives 
of service users and primary care practitioners about how best cancer risk 
information can be communicated to patients during primary care 
consultations. The study also explored the enablers (facilitators) and barriers 
to the implementation of cancer risk assessment tools from the perspectives 
of both service users and practitioners. 
Methods: The scoping review followed the framework proposed by Arksey 
and O’Malley for conducting scoping reviews. The scoping review resulted in 
the statement of two research questions: (i) How best can cancer risk 
information be communicated to patients? (ii) What do service users and 
practitioners perceive as enablers and barriers to the implementation of cancer 
risk assessment tools in primary care?  
The next phase was the qualitative study, which involved the use of individual 
and focus group interviews with service users recruited from the public and 
primary care practitioners (GPs and nurses) recruited from general practices 
in Lincolnshire, a large rural county in the East of England. The qualitative data 
were transcribed verbatim and analysed using the framework approach.  
Results: Thirty-six participants (19 service users and 17 primary care 
practitioners) were interviewed before practitioners used cancer risk 
assessment tools in patient consultations. Some of the practitioner participants 
were interviewed again after they had used the tools in patient consultations.  
Participants suggested ways to best communicate cancer risk information to 
patients in primary care consultations. Before using the tools with patients, 
participants emphasised the importance of: tailoring visual representation of 
xvi 
 
risk; being open and honest; informing and involving patients in use of cancer 
risk assessment tools; and providing time for listening, explaining and 
reassuring in the context of a professional approach. After using the tools in 
patient consultations, primary care practitioners maintained these perceptions. 
These findings add to our knowledge and understanding of how best to 
communicate cancer risk information to patients when using cancer risk 
assessment tools in general practice consultations. 
Before using the tools with patients, both service users and practitioners 
agreed on the following as potential enablers to the implementation of cancer 
risk assessment tools: aiding decision making; improving speed and 
processes of diagnosis and treatment of cancer; identifying and raising 
awareness for modifying health risk behaviours; and personalising care. After 
using the tools, primary care practitioners mentioned ‘ease of use’ in addition 
to the enablers already cited.  
Barriers to the uptake of cancer risk assessment tools were also identified by 
participants, which included: the additional time required; worry and anxiety 
generated by referral for investigations; the potential for over-referral; 
practitioner scepticism about using the new tools; and the need for evidence 
of effectiveness before introducing cancer risk assessment tools in general 
practice consultations. These barriers were perceived before the use of the 
tools. After using the tools, practitioners identified the following barriers in 
addition to those already mentioned: the need to integrate the tools into 
general practice IT systems; the need to involve secondary care specialists 
(consultants) in the implementation of the tools; and the need for training of 
practitioners on how to use cancer risk assessment tools in patient 
consultations. 
Conclusion: Ways to best communicate cancer risk information during patient 
consultations were identified in this study, adding to existing knowledge. 
Enablers and barriers to the implementation of cancer risk assessment tools 
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GLOSSARY OF TERMS  
Acceptability: The extent to which those for whom the test is designed agree 
to be tested. 
Cancer: A disease caused by an uncontrolled division of abnormal cells in a 
part of the body. 
EMIS Web: Formerly referred to as Egton Medical Information Systems. EMIS 
Web currently supplies electronic patient record systems and software for use 
in many primary care organisations (general practices) in England. 
General practice consultations: A meeting with between a patient and a 
primary care professional working in general practice, such as a licensed 
general practitioner (GP), GP specialist trainee, or nurse practitioner with the 
purpose of seeking advice and treatment. 
General practice: A general practice provides person centred, continuing, 
comprehensive and coordinated whole person health care to individuals and 
families in their communities. 
General practitioner: A medical doctor who treats acute and chronic illnesses 
and provides preventive care and health education to patients. 
Negative predictive value: the extent to which subjects are free of the 
disease in those that give a negative test result. 
Primary care: Health care provided in the community for people making an 
initial approach to a medical practitioner or clinic for advice or treatment. 
Practice Nurses: General practice nurses are registered nurses employed 
by, or whose services are retained by a general practice. 
Positive predictive value: the extent to which subjects have the disease in 
those that give a positive test result. 
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QCancer: QCancer is a cancer risk prediction (or assessment) tool that works 
out the risk of a patient having a current yet undiagnosed cancer, or developing 
a cancer within two years taking account of their risk factors and current 
symptoms. It does not give a diagnosis of cancer, but a risk. 
Risk Assessment Tool (Hamilton risk assessment tool): The Risk 
Assessment Tool (RAT) is based a series of case-control studies which 
identified symptoms of common cancers that are presented to primary care 
and quantified the risk of cancer associated with them. 
Service user: A service user generally refers to anyone who is a patient or 
other user of health and / or social services. 
SystmOne: A pioneering clinical system which fully supports a 'one patient, 
one record' model of healthcare. With SystmOne, clinicians can access a 
single source of information, detailing a patient's contact with the health 
service across a lifetime. 
Sensitivity: The effectiveness of a test in detecting a cancer in those who 
have the disease. 
Specificity: The extent to which a test gives negative results in those that 
are free of the disease. 
Vision+: This is a management and practice protocol tool for the Quality and 
Outcomes Framework (QOF) information. It includes real-time alerts for 
additional QOF points, practice-based protocols and a simple but powerful 






CHAPTER 1 BACKGROUND TO THE RESEARCH 
1.1 Summary of the chapter 
This chapter covers the background information to the research and is 
separated into the following sections: 
• The problem of cancer in a global context (Section 1.2) 
• The problem of cancer in the United Kingdom (UK) (Section 1.3) 
• Developments to tackle late diagnosis of cancer in the UK (Section 1.4) 
• Direction of travel of cancer risk prediction tools (Section 1.5) 
• Outline of the thesis (Section 1.6) 
1.2 The problem of cancer in a global context 
Cancer is one of the leading causes of morbidity worldwide, with approximately 
14 million new cases in 2012 (Ferlay et al., 2013). The number of new cases 
of cancer is expected to rise by about 70% over the next two decades (WHO 
Media centre, 2017). Globally, cancer is the second leading cause of death; it 
was responsible for 8.8 million deaths in 2015, with the most common causes 
of cancer death attributable to cancers of the lung (1.69 million deaths), liver 
(788 000 deaths), colon-rectum (774 000 deaths), stomach (754 000 deaths) 
and breast [571 000 deaths] (WHO Media centre, 2017).  
Around one third of deaths from cancer are due to five leading behavioural 
and dietary risks: high body mass index, low fruit and vegetable intake, lack of 
physical activity, tobacco and alcohol use. Tobacco use is the most important 
risk factor for cancer, and it is responsible for approximately 22% of cancer 
deaths (Global Burden of Disease [GBD] 2015 Risk Factors Collaborators, 
2016). It is estimated that between 30–50% of cancers can be prevented by 
avoiding risk factors and implementing existing evidence-based prevention 
strategies (WHO Media Centre, 2017).  
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The cancer burden can also be reduced through early detection of cancer and 
effective management of patients who develop cancer, since late-stage 
presentation and inaccessible diagnosis and treatment of cancer are common. 
Indeed, many cancers nowadays have a high chance of cure if diagnosed 
early and treated adequately. 
Some of the most common cancer types, such as breast, cervical, oral and 
colorectal cancers have high cure rates when detected early and treated 
appropriately (WHO Media Centre, 2017). Similarly, other cancer types, even 
when cancerous cells have travelled to other areas of the body (i.e 
metastasised), such as testicular seminoma or leukaemia and lymphomas in 
children, can have high cure rates if appropriate treatment is provided (WHO 
Media Centre, 2017). Despite these possibilities to prevent or treat and cure 
cancer, the problem of cancer persists in many countries including the United 
Kingdom. 
1.3 The problem of cancer in the UK  
Cancer is one of the biggest health problems in the UK with one in two people 
potentially developing some form of cancer in their lifetime (Ahmad et al., 
2015). Consequently, cancer is a major cause of premature mortality in the UK 
and accounts for over one in four of all deaths (NICE, 2015). 
However, mortality rates have been falling since the early 1990s. Thus, the 
proportion of people in the UK who get cancer but do not die from the disease 
has increased by about 70% over the past 20 years (Macmillan Cancer 
Support, 2015). People now live nearly ten times longer after their cancer 
diagnosis compared to the past 40 years. There are now an estimated 2.5 
million people living with cancer in the UK, and this is projected to reach 4 
million by the year 2030 (Macmillan Cancer Support, 2015). 
Despite these improvements in mortality and survival rates of cancer, there 
are still concerns that, in the UK, cancer mortality remains high compared to 
other countries in Europe (Ferlay, 2010; Department of Health, 2011; Office 
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for National Statistics, 2012). A recent study involving 29 European countries 
found that survival rates for almost all common cancers were worse in the UK 
than the overall European average (De Angelis et al., 2014). The poor survival 
rates are related to late diagnosis of cancer, as it is estimated that about 7500 
to 10000 lives are lost annually due to late diagnosis in the UK (Department of 
Health, 2011; Office for National Statistics, 2012).  
Late diagnosis of cancer in the UK is due to late presentation by patients 
(Allgar & Neal, 2005) or non-recognition by primary care general practitioners 
(GPs) or a combination of the two (Bowen, 2002; Koyi et al., 2002). This can 
result in delays in primary care processes of investigation and referral, leading 
to late diagnosis of cancer (Neal, 2009; Al-Azri, 2016). Recent developments 
to tackle late diagnosis of cancer in the UK are discussed below. 
1.4 Developments to tackle late diagnosis of cancer in the UK 
As part of measures to tackle late diagnosis of cancer, the National Awareness 
and Early Diagnosis Initiative (NAEDI) policy was introduced by the 
Department of Health (DH, 2007). One aim of this policy relevant to this study 
was to promote awareness among the public and healthcare professionals in 
recognising and detecting early signs and symptoms of cancer. Another was 
to encourage people with symptoms to seek early advice. The NAEDI policy 
also aimed to support primary care professionals to contribute to effective 
referral and diagnosis of cancer. 
A national audit of primary care was developed to identify the support that 
would help GPs to identify potential cancers earlier. These initiatives have 
helped to improve access to diagnostic technologies and urgent referral 
pathways for suspected cancer (DH, 2007). The efforts to improve early 
diagnosis of cancer have also contributed to an increased interest in the use 
of technology-based interventions such as cancer risk assessment tools to aid 
early detection of cancer risk in symptomatic individuals presenting to primary 
care (e.g Hamilton, 2009; Hippisley-Cox & Coupland, 2011; Hippisley-Cox & 
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Coupland, 2012; Hippisley-Cox & Coupland, 2013). The direction of travel of 
these cancer risk assessment tools is considered below. 
1.5 Direction of travel of cancer risk assessment tools 
It is recognised that cancer risk assessment tools could potentially help to 
improve patient outcomes through early detection of cancer risk, diagnosis and 
treatment (National Cancer Institute, 2010). Some of the cancer risk 
assessments tools, especially the recently developed symptom-based tools, 
are in the public domain, and both patients and clinicians can access them 
from the internet. Patients can potentially use these tools to learn about their 
risk of cancer. While this may appear helpful, some people might inaccurately 
understand or interpret their risk information (Zikmund-Fisher et al., 2007; 
Brown et al., 2011). Consequently, primary care practitioners may be best 
suited to use these risk assessment tools, appropriately interpreting the 
resulting risk and then communicating this to the patient (Usher-Smith et al., 
2017). The general practitioner would then conduct a consultation with the 
patient when referring them for further investigation of symptoms suspicious 
of cancer (Banks et al., 2014). 
A fundamental problem is the uncertainty in the evidence about the use of 
cancer risk assessment tools for symptomatic individuals in primary care 
(Usher-Smith et al., 2015; Williams et al., 2016). For example, it is unclear how 
these tools should be used and how risks should be communicated to 
maximise benefits and minimise harms such as anxiety and false reassurance. 
A starting point for this thesis was a scoping review which explored the 
evidence relating to the use of cancer risk assessment tools in primary care 
settings, which is presented in Chapter 2 of this thesis. The outline of the thesis 
is presented in Section 1.6 below. 
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1.6 Outline of the thesis 
This thesis is organised into seven chapters. Chapter One presents the 
background to the research. The problem of cancer globally and the context 
of the UK is highlighted. Efforts to improve early diagnosis of cancer, such as 
the NAEDI policy and the increased interest in the development and use of 
cancer risk assessment tools in symptomatic individuals, are discussed here. 
Finally, the uncertainty in evidence about the use of these cancer risk 
assessment tools in primary care and the need to explore the evidence using 
a scoping literature review approach is stated in this chapter. 
Chapter Two presents a scoping literature review that explores the evidence 
around use of cancer risk assessment tools available for symptomatic 
individuals in primary care. The methodological approach for the scoping 
review is based on the framework recommended by Arksey and O’Malley 
(2005). The analysis of the evidence extracted from included studies is 
presented as the results. These results are discussed in relation to the 
available literature, and research questions for further qualitative exploration 
are established in this chapter. 
Chapter Three deals with the conceptual background literature that explains 
the key concepts relating to this research. The chapter outlines the policy, 
structure and functions of UK primary care, highlighting the ‘gatekeeping’ 
function of general practitioners when referring patients to secondary care 
specialists. The cancer risk assessment tools of interest (those for 
symptomatic individuals in primary care), the effects of risk assessment or 
prediction on communicating risk to individuals and the relevant 
communication and implementation theoretical frameworks are also discussed 
in this chapter. 
The methodology (including the philosophical stance of pragmatism and the 
approach to the qualitative research) is presented in Chapter Four. The 
methods including the use of individual and focus group interviews to collect 
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qualitative data from service users and primary care practitioners, and the use 
of the framework approach for data analysis, are detailed in this chapter.  
The results from individual interviews with service users and focus group 
interviews with practitioners are presented in Chapter Five. In line with the 
research questions, this chapter suggests ways to better communicate the 
cancer risk information to patients as perceived by participants. This adds to 
our knowledge about how best to communicate cancer risk information to a 
patient during a general practice consultation.  
The perceptions of participants about the enablers and barriers to use or 
implementation of cancer risk assessment tools are also reported, supporting 
the existing evidence on enablers (or facilitators) and barriers to their 
implementation in primary care. In this chapter, the perspectives of participants 
are presented in two parts. In the first part, the perspectives of service users 
and primary care practitioners expressed before they have used the tools are 
presented, comparing the views of each. The second part of the results details 
the perspectives of primary care practitioners after they have had an 
opportunity to use the tools in patient consultations.  
In Chapter Six, the key and original findings are highlighted. The overall results 
are then discussed in relation to the existing literature and the relevant 
theoretical frameworks.  
The overall conclusion to the research is presented in Chapter Seven. A recap 
of the key steps or points from each of the chapters is outlined here. Also, 
highlighted in this concluding chapter are: the developments in the area since 
this research was commenced and completed; a personal reflection of the 
researcher; and next steps going forward.  
1.7 Conclusion of the chapter  
This chapter has covered the background information to the research. A 
discussion of key issues such as the problem of late diagnosis and the high 
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mortality from cancer in the UK points to the need for better cancer diagnosis. 
From the evidence discussed in this background chapter, how cancer risk 
assessment tools for early detection of cancer risk in primary care should be 
used and communicated is unclear.  
Hence, there is a need to scope the literature for evidence of the types of 
cancer risk assessment tools available for symptomatic individuals in primary 


















CHAPTER 2 SCOPING LITERATURE REVIEW 
2.1 Summary of the chapter 
The aim of the scoping review was to explore evidence on cancer risk 
assessment tools available in primary care, and the benefits 
(facilitators/enablers) and barriers to implementation of these tools. 
After analysing 43 included studies, this review found that the use of cancer 
risk assessment tools for symptomatic individuals has some benefits such as 
a potential to improve cancer survival through early detection of risk, leading 
to timely investigation, diagnosis and treatment. 
Despite the benefits, the review found concerns about potential barriers to 
implementation of the tools. These barriers include concerns about: how to 
make the tools accessible to clinicians, where to set the threshold for action, 
and how to communicate cancer risk information to patients.  
Based on the findings from this review, it was proposed that the uncertainty 
about how best to communicate cancer risk information to patients would merit 
further exploration. Also, since evidence of the benefits (enablers or 
facilitators) and barriers to implementation are limited to a few studies, it would 
be useful to add to the existing evidence by exploring these further. Therefore, 
the research questions* arising from the scoping review were:  
• What are the perceptions of patients (or service users) and practitioners 
about how best cancer risk information can be communicated to 
patients during general practice consultation? 
• What do service users and practitioners perceive as enablers (or 
facilitators) and barriers to the implementation of cancer risk 
assessment tools? 
*The research questions were initially formulated around QCancer. Following comments and 
recommendations received from my PhD examiners, and after careful consideration, the QCancer 
component was replaced with ‘cancer risk assessment tools for symptomatic individuals’ since the thesis 
refers more widely to cancer risk assessment tools. 
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2.2 Key points 
The key points in the scoping review include: 
• The scoping review sought to explore for evidence of cancer risk 
assessment tools available in primary care, and the benefits 
(enablers/facilitators) and barriers to the use of these tools. 
• The review was informed by Arksey and O’Malley’s 2005 framework 
recommended for scoping reviews. 
• 43 studies were included in the review and analysed for evidence to 
address the review question. 
• The review found evidence of some cancer risk assessment tools 
designed for detecting cancer risk in symptomatic individuals. 
• The benefits of using cancer risk assessment tools were also identified 
from the literature. 
• The review also found barriers to the implementation of cancer risk 
assessment tools. 
• Based on the findings two research questions are stated (as in Section 
2.1 above). 
2.3 Background to the review 
Using the methodological framework outlined by Arksey and O’Malley (2005), 
this chapter presents a systematic scoping review that explores the evidence 
available on the use of cancer risk assessment tools to support early detection 
of cancer risk in primary care settings.  
Scoping reviews are usually conducted to map the key concepts underpinning 
a research area and the main sources and types of evidence available (Mays 
et al., 2001). In the view of Mays and colleagues, scoping reviews can be 
undertaken as stand-alone projects, for example, in complex areas of study or 
areas that have not been comprehensively reviewed. Hence, scoping reviews 
usually involve a comprehensive coverage of the available literature, although 
the depth of information extracted from studies may also depend on the 
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reasons for conducting the scoping review (Arksey & O’Malley, 2005). Arksey 
and O’Malley (2005) outlined four reasons for conducting a scoping literature 
review: 
• To examine the extent, range and nature of evidence without describing 
the research findings in detail 
• To identify whether a full systematic review is feasible or relevant. 
• To summarise and disseminate research findings by describing in more 
detail the findings and range of research areas of study, which could be 
useful to policy makers, practitioners and consumers who might 
otherwise lack time or resources to undertake such work (Antman et 
al., 1992) 
• To identify research gaps in the existing evidence.  
Arksey & O’Malley (2005) suggest that the four reasons stated above can 
further be grouped into two main reasons for conducting scoping reviews. The 
first two reasons suggest that a scoping review might be viewed as one part 
of an ongoing process of review, with the aim of conducting a full systematic 
review. The third and fourth, however, suggest a scoping review can lead to 
the dissemination of research findings including the identification of gaps for 
further research. 
The aim of this scoping review was to explore the evidence on cancer risk 
assessment tools available for symptomatic patients in primary care, the use 
of the tools (including the benefits and barriers to implementation) and to 
identify research gaps for further exploration.  
While pursuing the aim of this review, it was noted that, unlike systematic 
reviews, scoping reviews do not usually involve a quality assessment 
component and they do not usually seek to determine whether the findings of 
studies are robust or generalisable (Arksey & O’Malley, 2005). Therefore, 
while quality assessment of the evidence was not performed in this scoping 
review, it should be noted that the identification of research gaps depends to 
some extent on the quality of the studies identified in the scoping review. 
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Nonetheless, the framework outlined by Arksey & O’Malley (2005), and 
adopted for this scoping review, is in line with the principles of systematic 
reviews. That is, the methods used throughout the different stages of the 
review were rigorous and transparent (Mays et al., 2001). In addition, the 
process of the scoping review was documented in sufficient detail to enable 
the study to be replicated by others who wish to do so. This explicit approach 
increases the reliability of the findings, and seeks to address concerns about 
the methodological rigour of the scoping review (Mays et al., 2001). The 
methodological framework that guided the conduct of this scoping review is 
presented in Section 2.4. 
2.4 Methodological framework  
The methodological framework adopted for this scoping review was developed 
by researchers at the University of York (Arksey & O’Malley, 2005) and has 
been used by other researchers subsequently (Brien et al., 2010; Davis et al., 
2009; Levac et al., 2010; Daudt et al., 2013; Pham et al., 2014). This 
framework suggests five stages including: identification of the research 
question; identification of relevant studies; study selection; charting the data; 
and collating, summarising and reporting results of the review. A sixth stage, 
which is optional, involves consultation with stakeholders to ensure 
comprehensive inclusion of all relevant material (Arksey & O’Malley, 2005). 
Consultation in this case was limited to one of the project academic 
supervisors (a general practitioner in the study area). The following sections 
describe the stages which guided the process of this scoping review. 
2.4.1 Identification of the review question for the scoping review 
In developing the research question, all aspects of the research area were 
considered to generate a breadth of coverage (Arksey & O’Malley, 2005). 
Therefore, in line with the review aim stated above, the question for this 
scoping review was stated broadly as: what is the evidence on: cancer risk 
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assessment tools available for symptomatic individuals in primary care, and 
use of these tools (including the benefits and barriers to implementation)? 
2.4.2 Identification of relevant studies  
A scoping review needs to be as comprehensive as possible to identify all 
relevant literature suitable for answering the research question (Arksey & 
O’Malley, 2005; Brien et al., 2010; Levac et al., 2010). To ensure coverage of 
most current and relevant literature around cancer risk assessment tools for 
symptomatic individuals in primary care, it was decided that it would be 
appropriate to include only studies published from 2005 (prior to development 
of cancer risk assessment tools) to the date of presentation of the thesis 
(2017). Similarly, studies reported in languages other than the English 
language were excluded because of the cost and time involved in translating 
such studies into English. These considerations guided the development of 
the following list of inclusion criteria for the selection of relevant studies. 
2.4.2.1 Inclusion criteria  
To be considered relevant to this scoping review, studies were included if: 
• They were conducted within the period 2005 - 2017  
• They were conducted in primary care settings such as general practices 
• The studies were reported in the English language  
• The study participants were adults 
• Study participants were patients or service users or practitioners or 
clinicians or general practitioners 
• The studies were about cancer risk assessment tools for symptomatic 
people (and not asymptomatic people). 
Studies that did not meet the above inclusion criteria were excluded. While the 
inclusion criteria were adopted for practical reasons, potentially relevant 
studies, such as those published in languages other than the English 
language, might have been excluded.  
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Having specified the inclusion criteria, the next step in this scoping review 
involved searching for available literature through electronic databases, 
reference lists of published papers and personal records of researchers or 
experts for relevant papers not captured by the search, especially records of 
studies that had not yet been published.  
2.4.2.2 Electronic databases 
For the electronic database search, a search strategy was designed which 
involved the development of search terms and search limits. The search terms 
were a combination of free text or phrases of five key search terms (see Table 
1 below). 
Search strategy 
Using the search terms in Table 1 below, electronic databases (Medline, 
Cumulative Index to Nursing & Allied Health Literature (CINAHL), Scopus, 
Cochrane Database of Systematic Reviews (CDSR), Science Direct and 
Psych-INFO) were searched. These search terms also guided a search for 
relevant published or grey literature in the academic websites of researchers 
or experts in the field of early diagnosis or detection of cancer risk. Details of 
the search strategy including the databases, search terms, search limits and 
the results generated from the search are presented in Table 1. 
14 
 
Table 1 Search terms, limits/expanders and number of results for databases searched  
No of 
searches 
Key search terms /queries Results Limiters/ expanders 








Existing cancer risk assess* tools  
(Cancer risk assess* tool* OR 
model*) AND (early diagnosis OR 
early detect* OR symptomatic 
patient*) AND (primary care OR 























-Full Text; Published Date: 
20050101-20171231; English 
Language; Research Article; 
Human; Language: English; Age 
Groups: All Adult  




Cancer risk assess* tool* use  
(Cancer risk assess* tool* OR 
model*) AND 
 (symptomatic patient* OR 
clinician* or general Pract*) AND 
















Full Text; Published Date: 
20050101-20171231; English 
Language; Research Article; 
Human; Language: English; Age 
Groups: All Adult  




Cancer risk assess* tool* use  
(Cancer risk assess* tool* OR 
model*) AND 
 (symptomatic patient* OR service 
user* clinicians OR general Pract*) 




















Full Text; Published Date: 
20050101-20171231; English 
Language; Research Article; 
Human; Language: English; Age 
Groups: All Adult  






Communication of cancer risk 
(Cancer risk assess* tool* OR 
model*) AND (symptomatic 
patient* OR service user* OR 
clinicians or general pract*) AND 


























Full Text; Published Date: 
20050101-20171231; English 
Language; Research Article; 
Human; Language: English; Age 
Groups: All Adult  




Outcome of cancer risk assess* 
tool* use 
(Cancer risk assess* tool* OR 
model*) AND 
(early refer* OR investigat* OR 
diagnosis*) AND (symptomatic 
patient*) AND (primary care OR 
















Full Text; Published Date: 
20050101-20171231; English 
Language; Research Article; 
Human; Language: English; Age 
Groups: All Adult  
Search modes - Boolean/Phrase 
S6 S1 AND S2 AND S3 AND S4 AND 
S5 
302 105 23 10 5 4  
Number of studies considered by database 302 105 23 10 5 4  
Total number of studies considered  449 + 22 (from citations & other sources =471  
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2.4.2.3 Reference lists and citation search 
To ensure all relevant studies were identified, the reference lists of studies 
found through the electronic database searches were checked. This helped to 
identify several relevant studies. A citation search was also done by using 
Google Scholar and the University of Lincoln search engine to track relevant 
references that were cited in the studies identified from the electronic 
databases. 
2.4.2.4 Academic websites of researchers (experts) in the field 
Existing networks and organisations can provide potentially relevant 
information (Arksey & O’Malley, 2005). Hence, the websites of existing 
network of researchers and organisations, which are within the public domain, 
were searched as listed in Table 2.  
These websites were targeted for searches because they had the potential to 
contain relevant studies. Several relevant studies were identified from the 
websites of individual researchers and organisations involved in cancer 
research, but most of these studies were also found through the electronic 










Table 2 Websites of existing network of researchers searched for relevant 
literature 
Organisation Website Researcher of 
interest 
Cancer research UK  
 
http://www.cancerresearchuk.org/  
Macmillan Support, UK  http://www.macmillan.org.uk/ 
 
 
Nuffield Department of 
primary care, University 
of Oxford  
http://www.phc.ox.ac.uk/  
Division of Epidemiology 








Division of primary care, 








Centre for Statistics in 
Medicine, University of 
Oxford  
http://www.csm.ox.ac.uk/about  Prof D. Altman  
 
Prof. G Collins  
 
Department of Public 
Health and Primary care 
http://www.phpc.cam.ac.uk/people/p
cu-group 
Dr F. Walter 
 Research records at 
School of Medicine, 
Pharmacy and Health, 
University of Durham  





















Many studies were generated from the search which needed to be examined 
before being included in the review. The references generated from the search 
in this review were managed with RefWorks, a bibliographic management 
software available to staff and students of the University of Lincoln.  
2.4.3 Study selection  
The search for evidence for this scoping literature review yielded several 
potentially relevant studies. These included studies from electronic databases 
and studies from the relevant websites of existing network of researchers and 
organisations. Applying the inclusion criteria described under identification of 
studies stated above, all the studies were examined by title, abstract and full 
text and studies that met the inclusion criteria were selected. A flow chart of 






Figure 1 Steps in the study selection process  
 
Number of studies is in brackets [()]. *Other sources: Websites of existing networks/cancer 
researchers 
 
Title & abstract sift of 471 
studies  
• Medline-(302)  
• CINAHL-(105)  
• Scopus-(23) 
• Cochrane-(10) 
• Science direct-(5) 
• Psych INFO-(4) 
• *Other sources-(22) 
 
56 studies full text studies 
retrieved and sifted  
• Medline-(17) 
• CINAHL-(2)  
• Scopus-(6)  
• Cochrane-(4)  
• Science direct-(5)  
• Psych INFO-(0)  
• *Other sources-(22)  
 
 
43 studies selected for the 
review 
415 studies filtered out after title 
& abstract sift 
• Medline-(285) 
• CINAHL-(103) 
• Scopus-(17)  
• Cochrane-(6) 
• Science direct-(0) 
• Psych INFO-(4) 
Discarded  
13 studies excluded after 
filtering out duplicates (same 
studies included from different 
databases searched) and 






2.4.4 Charting the data  
In line with the recommended framework (Arksey & O’Malley, 2005) adopted 
for this scoping review, the charting process was multi-staged and involved 
the extraction of information from individual studies. Scoping reviews usually 
include a mixture of general information about the study, such as the study 
population, type of intervention, outcome measures, the study design and the 
results (Arksey & O’Malley, 2005; Brien et al., 2010; Davis et al., 2009; Levac 
et al., 2010). This scoping review included similar information extracted from 
the selected studies: the author(s), year of publication, sample size, study 
setting or location, study design, outcome measures and results. These details 





















Table 3 Details studies (the QCancer series) for cancer risk assessment tools available for symptomatic individuals in 
primary care  







Hippisley-Cox & Coupland (2011) 
Identifying patients with suspected 




-Patients aged 30-84 years 
in 375 practices for 







of lung cancer in 
the next 2 years 
The algorithm has good discrimination & could 
potentially be used to identify those at highest risk of 
lung cancer 
2 Hippisley-Cox & Coupland (2011) 
Identifying patients with suspected 
gastro-oesophageal cancer in PC: 
Derivation & validation  
Cohort 
study 
-Patients aged 30-84 years 
in 375 general practices for 








cancer in the next 
2 years  
The algorithm has good performance and could be 
used to help identify those at highest risk of gastro-
oesophageal cancer 
3 Hippisley-Cox & Coupland (2012) 
Identifying patients with suspected 
renal tract cancer in primary care 
(PC): derivation & validation 
Cohort 
study 
-All patients aged 30-84 
years in 375 general 
practices for development 




database   
Incident diagnosis 
of renal tract 
cancer in the next 
2 years 
The algorithm has good discrimination and 
calibration and could potentially be used to identify 
those at highest risk of renal tract cancer 
4 Hippisley-Cox & Coupland (2012) 
Identifying women with suspected 




-Women aged 30-84 in 375 
general practices for 







of ovarian cancer 
in the next two 
years 
The algorithm explained 57.6% of the variation. The 
10% of women with the highest predicted risks 
contained 63% of all ovarian cancers diagnosed over 
the next two years 
5 Hippisley-Cox & Coupland (2012) 
Identifying patients with suspected 




-All patients aged 30-84 
years in 375 general 
practices for the 








cancer in the next 
2 years 
The algorithm has good discrimination and 
calibration and could potentially be used to help 
identify those at highest risk of current colorectal 
cancer 
6 Hippisley-Cox & Coupland (2012) 
Identifying patients with suspected 




-All patients aged 30-84 
years in 375 general 
practices for development 







cancer in the next 
2 years 
The algorithm has good discrimination and 
calibration and could potentially be used to help 
identify those at highest risk of pancreatic cancer 
7 Hippisley-Cox & Coupland (2013) 
Symptoms and risk factors to 
identify women with suspected 
cancer in PC: derivation and 
validation of an algorithm 
Cohort 
study 
-Women patients aged 25 - 














The receiver operator characteristic (ROC) statistics 
were lung (0.91), colorectal (0.89), gastro-
oesophageal (0.90), pancreas (0.87), ovary (0.84), 
renal (0.90), breast (0.88), blood (0.79), uterus 
(0.91), cervix (0.73), other cancer (0.82). 10% of 
females with highest risks had 54% of all cancers 
diagnosed over 2 years 
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8 Hippisley-Cox & Coupland (2013) 
Symptoms and risk factors to 
identify men with suspected cancer 




-Male patients aged 25 - 89 
















The 10% of males with the highest risks contained 
59% of all cancers diagnosed over 2 years. The 
algorithm has good discrimination and could be used 
to identify those at highest risk of cancer to facilitate 
more timely referral and investigation. 
9 Collins & Altman (2012)  
Identifying patients with undetected 
colorectal cancer: independent 
validation of QCancer 
Cohort 
study 
All patients in general 








cancer during the 
2 years after study 
Very good discrimination with an area under the 
receive operator characteristic (AUROC) curve of 
0.92 (women) and 0.91 (men). Well calibrated across 
all tenths of risk & over all age ranges with predicted 
risks closely matching observed risks 
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Collins & Altman (2013) 
Identifying patients with undetected 
renal tract cancer in PC: 




Patients in general 






of bladder, kidney, 
ureter or urethra 
cancers 
-Had very good discrimination with AUROC curve of 
0.92 and 0.95 for women and men respectively 
-Well calibrated across all tenths of risk and over all 
age ranges with predicted risks closely matching 
observed risks 
11 Collins & Altman (2012) 
Identifying patients with undetected 
gastro-oesophageal cancer in 




Patients in general 









-Demonstrated good performance. Had very good 
discrimination with c-statistics of 0.93 & 0.94 for 
women and men. QCancer - (Gastro-Oesophageal) 
was well calibrated across all tenths of risk & over all 
age ranges with predicted risks closely matching 
observed risks. Explained 74.4% and 75.6% of the 
variation in men and women respectively 
12 Collins & Altman (2013)  
Identifying women with undetected 
ovarian cancer: independent and 
external validation of QCancer® 
(Ovarian) prediction model 
Cohort 
study 
Patients in general 
practices in THIN database  
 




of ovarian cancer 
Had very good discrimination with an AUROC curve 
of 0.86 & explained 59.9% of the variation. 10% of 
women with the highest predicted risks included 64% 
of all ovarian cancer diagnoses over the next 2 years 
13 Collins & Altman (2013)  
Identifying patients with undetected 
pancreatic cancer in primary care: 
an independent & external 






Patients in general 
practices in THIN database 
 






Had very good discrimination, with AUROC curve of 
0.89 and 0.92 for females and males respectively. 
QCancer (Pancreas) explained 60% and 67% of the 
variation in females and males respectively. 
QCancer (Pancreas) over-predicted risk in both 




Table 4 Details studies (the RATs series) for cancer risk assessment tools available for symptomatic individuals in 
primary care  





1 Hamilton (2009)  
The CAPER studies: five 
case-control studies for 
identifying and quantifying 
the risk of cancer in 




Review of 5 studies in  











Symptoms matched previous series from secondary care, 
though the risks of cancer, expressed as positive predictive 
values were lower 
2 Marshall et al. (2011)  
The diagnostic 
performance of scoring 
systems to identify 
symptomatic colorectal 
cancer compared to 
current referral guidance 
Case-control 
study 
Patients with suspected 
colorectal cancer in 












Both multivariable symptom scoring systems performed 
significantly better than NICE referral. Areas under the curve 
were: BB 0.92 (95% CI 0.91 to 0.94); CAPER 0.91 (95% CI 
0.89 to 0.93) 
3 Shephard et al. (2012) 
Clinical features of bladder 
cancer in primary care 
Case-control 
study 
 4915 patients aged ≥40 
years, diagnosed with 
bladder cancer Jan 2000 
to December 2009, and 












Seven features were independently associated with bladder 
cancer, with the most being visible haematuria, odds ratio 
34 (95% confidence interval [CI] = 29 to 41) with a positive 
predictive value for visible haematuria in patients aged ≥60 
years was PPV of 2.6% (95% CI = 2.2 to 3.2) 
4 Stapley et al. (2012)  
The risk of pancreatic 
cancer in symptomatic 
patients in primary care: a 
large case–control study  
Case-control 
study 
3635 cases aged ≥40 













9 features were associated with pancreatic cancer. Positive 
predictive values for patients aged X60 were o1%, apart 
from jaundice at 22% (95% CI 14, 52), though several pairs 
of symptoms had PPVs >1%. 
5 Shephard et al. (2013)  
Clinical features of kidney 
cancer in primary care: a 
case-control study using 
primary care records 
Case control 
study 
3149 patients aged ≥40 
years, with kidney cancer 
between 2000 & 2009, & 














Fifteen features were independently associated with kidney 
cancer: visible haematuria, odds ratio 37 (95% CI = 28 to 
49) being the commonest and most powerful single predictor 
of kidney cancer, with positive predictive value for visible 
haematuria in patients aged ≥60 years was 1.0% (95% CI = 
0.8 to 1.3) 
6 Dommett et al. (2013)  
Risk of childhood cancer 
with symptoms in primary 




1267 children aged 0–14 
years diagnosed with 
childhood cancer was 










12 symptoms were associated with PPVs of ≥0.04%, which 
represents a greater than tenfold increase in prior 
probability. The 6 symptoms with the highest PPVs were 








lymphadenopathy, symptoms/signs of abnormal movement, 
and bruising  
7 Walker & Hamilton (2013)  
Risk of uterine cancer in 
symptomatic women in 
primary care: case–control 




2732 women aged ≥40 
years with uterine cancer 
between 2000 & 2009, & 












9 features were significantly associated with uterine cancer, 
and these features are important for diagnosis of uterine 
cancer, particularly postmenopausal bleeding. The PPV of 
uterine cancer with postmenopausal bleeding was 4%, and 
was higher in women with multiple or repeated symptoms 
8 Stapley et al. (2013) 
The risk of oesophago-
gastric cancer in 
symptomatic patients in 
primary care: a large 




7471 cases and 32 877 













16 features independently associated with 
oesophagogastric cancer (all Po0.001): dysphagia; reflux; 
abdominal pain; epigastric pain; dyspepsia; nausea and/or 
vomiting; constipation; chest pain; weight loss; 
thrombocytosis; low haemoglobin; low MCV; high 
inflammatory markers; raised hepatic enzymes; high white 
cell count; & high cholesterol. The only PPV 45% in patients 
≥55 years was for dysphagia. In patients > 55 years, all 
PPVs were >1%.  
9 Walker et al. (2014)  
Risk of breast cancer in 
symptomatic women in 
primary care: a case–






3994 women aged ≥40 
years with breast cancer 
between 2000 & 2009, & 










Four features were significantly associated with breast 
cancer: breast lump (odds ratio [OR] 110; 95% CI = I88 
to150), breast pain (OR = 4.2; 95% CI = 3.0 to 6.0), nipple 
retraction (OR = 26; 95% CI = 10 to 64), nipple discharge 
(OR = 19; 95% CI = 8.6 to 41): all P-values <0.01. The PPV 
of breast cancer with a breast lump was 4.8% in women 
aged 40–49 years, rising to 48% in women aged >70 years. 
PPVs were lower in women who also reported breast pain 
10 Hamilton et al. (2014)  
The risk of cancer in 
primary care patients with 
hypercalcaemia: a cohort 








Patients aged ≥40 years 
(54 267) had calcium, 
with control participants 











Hypercalcaemia was strongly associated with cancer, 
especially in males: OR 2.92, 95% CI 2.17–3.93, P¼o0.001; 
positive predictive value (PPV) 11.5%; females: OR 1.86, 
95% CI 1.39–2.50, Po0.001: PPV 4.1% 
11 Price, et al. (2014) Non-
visible versus visible 
haematuria and bladder 
cancer risk: a study of 




4915 patients (aged ≥40 
years) diagnosed with 
bladder cancer between 
Jan 2000 and Dec 2009 
matched to 21 718 












Non-visible haematuria was independently associated with 
bladder cancer. The PPV of non-visible haematuria was 
1.6% (95% CI = 1.2 to 2.1) in those aged ≥60 years and 
0.8% (95% CI = 0.1 to 5.6) in 40–59-year-olds. The PPV of 
visible haematuria was 2.8% (95% CI = 2.5 to 3.1) and 1.2% 
(95% CI = 0.6 to 2.3) for the same age groups respectively, 
lower than those calculated using coded data alone. 
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Table 4 Details of studies (the RATs series) for cancer risk assessment tools available for symptomatic individuals in 
primary care  
No Author, date & title Design Sample size & setting Data collection Outcome measure  Results  
12 Hamilton et al. (2015)  
Clinical features of 
metastatic cancer in 
primary care: a case–





162 cases, 152 cancer 




Medical records Association between 
clinical features & 
metastatic cancer 
Groin pain was uncommon, but strongly 
associated with (16 [10%] cases and 1 
[1%] cancer control, as was pleural 
disease (9 [6%] cases & 1 [1%] cancer 
control, but fairly common occurrence of 
non-specific symptoms (vomiting and loss 
of appetite) is important and may explain 
delays in diagnosis of metastases 
13 Shephard et al. (2015) 
Quantifying the risk of non-
Hodgkin lymphoma (NHL) 
in symptomatic primary 




4362 patients aged ≥ 40 
years, with NHL between 
2000 and 2009, & 19 468 







clinical features and 
NHL 
Unexplained lymphadenopathy (OR) 263 
(95% CI = 133 to 519) had a PPV of 13% 
for NHL in patients ≥60 years, and 
produces a very high risk of NHL in primary 
care this group of patients 
14 Grewal & Hamilton (2015) 
Ovarian cancer prediction: 
development of a scoring 
system for primary care 
Case-control 
study 
212 women with ovarian 




data from a case-
control study 
The ROC curve 
value 
-Scoring system could potentially direct 
general practitioners to appropriate 
investigations for ovarian cancer based on 
symptoms. The area under the ROC curve 
was 0.883 (95% CI 0.853-0.912). 
-The chosen cut-off had a sensitivity of 
72.6% & a specificity of 91.3%. 
15 Shephard et al. (2015)  
Quantifying the risk of 
Hodgkin lymphoma in 
symptomatic primary care 




283 patients aged ≥40 
years, diagnosed with HL 
between 2000 & 2009, & 







clinical features & HL 
-Lymphadenopathy (OR 280, 95% CI = 25 
to 3100), has a positive predictive value 
(PPV) of 5.6% for HL in patients aged ≥60 
years 
-i.e lymphadenopathy is the clinical feature 
with the highest risk of HL in primary care 
and warrants urgent investigation 
16 Shephard et al. (2015)  
Quantifying risk of multiple 
myeloma from symptoms 
reported in primary care 
patients: a large case-
control study  
Case-control 
study 
2703 patients aged ≥40 
years, diagnosed with 
myeloma between 2000 
and 2009, & 12 157 age, 
sex, & general practice-
matched controls  
-In UK 
GPRD primary care 
electronic records 
-Association of 
clinical features with 
myeloma 
- Positive predictive 
values (PPVs) 
-Hypercalcaemia and leucopenia are 
particularly important abnormalities, and 
coupled with symptoms, strongly suggest 
myeloma - Sixteen features were 
independently associated with myeloma, 
with hypercalcaemia - odds ratio 11.4 (95% 
CI = 7.1 to 18) 
17 Schmidt-Hansen et al. 
(2015) Symptomatic 
diagnosis of cancer of the 
A systematic 
review 
6 studies with 159 938 





Quantified the risk of 
brain/CNS cancer in 
symptomatic 
All the individual and combined symptoms 
of brain tumours had low PPVs of less than 
0.39%, apart from new-onset epilepsy. 
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brain and central nervous 
system in primary care: a 
systematic review 
-In UK Cochrane Library, 




in primary care 
This gives a diagnostic problem, as brain 
tumours have all the expected features 
seen with cancer diagnostic delay, with 
high proportions presenting as an 
emergency and having had multiple 
primary care consultations before referral 
18 Williams et al. (2016) 
Risk prediction models for 
colorectal cancer in people 





18 papers describing 15 








identify & compare 
the performance of 
models that predict 




9 studies were developed in primary care 
populations and 6 in secondary care. Four 
had good discrimination (AUROC > 0.8) in 
external validation studies, & sensitivity & 
specificity ranged from 0.25 and 0.99 to 




Schmidt-Hansen et al. 
(2016)  
 Symptoms of pancreatic 
















of pancreatic cancer 
-The only high-risk feature of pancreatic 
cancer in primary care was jaundice, and 
this clearly warrants investigation. The 
PPV of jaundice was more than 4.1% in 
patients 40 years or older and increased 
with age, although only 30% of patients 
reported jaundice 
20 Shephard et al. (2016) 
Symptoms of adult chronic 
and acute leukaemia 
before diagnosis: large 
primary care case-control 




- cases diagnosed 
between 2000 and 2009, 
4655 aged ≥40 years 





profiles of chronic 
and 
acute leukaemia in 
adults in primary 
care 
-10 symptoms were independently 
associated with CL, the three strongest 
being: lymphadenopathy; weight loss; and 
bruising. No individual symptom or 
combination of symptoms had a PPV >1% 
21 Walker & Hamilton (2017) 
Risk of cervical cancer in 
symptomatic women aged 
≥40 in primary care: A 




1,006 women aged ≥40 
years diagnosed with 
cervical cancer and 













7 symptoms & 2 abnormal investigations 
were associated with cervical cancer: All p 
< .005. The PPV of cervical cancer in 
women aged ≥55 with post-menopausal 
bleeding was 4.6% (2.5, 8.3) 




new cancer diagnoses in 
UK primary care patients 
A cohort 
study 
100 122 participants who 
had at least one albumin 
test result were followed 
A large a UK 
database of adult 




and a new diagnosis 
of cancer is yet 
unknown. 
Hypoalbuminaemia was associated with 
an increased risk of subsequent cancer 
diagnosis within 12 months (odds ratio 
[OR]: 2.29; 95% confidence interval [CI]: 
2.15-2.43), although this association was 
smaller in magnitude after controlling for 
other conditions known to affect albumin 
levels (OR: 1.29; 95% CI: 1.12-1.49). 
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Table 5 Details of other studies for cancer risk assessment tools available for symptomatic individuals in primary care  







1 Grewal et al. (2013) Ovarian 
cancer prediction: 
development of a scoring 
system for primary care (PC)  
Case-control study 212 women with 
ovarian cancer and 
1060 age, sex and 
practice-matched 
controls in 39 general 










Has a highly acceptable ROC value of 0.883 
(95% CI 0.853–0.912). Using a - 4-point cut-off, 
the scoring system has a specificity of 91.32% 
and sensitivity of 72.64%. The scoring system 
could potentially direct general practitioners to 
appropriate investigations for ovarian cancer on 
the basis of symptoms and save a substantial 
number of unnecessary ultrasound scans 
2 Iyen-Omofoman et al. (2012) 
Using socio-demographic 
and early clinical features 
in general practice to identify 





Case control 12 074 cases of lung 
cancer and 
120 731 controls in a 









-Socio-demographic features (age, sex, S-E 
status) and smoking history were independently 
associated with lung cancer 
-4 to 12 months before diagnosis, symptom 
(cough, haemoptysis, dyspnoea, weight loss, 
lower 
respiratory tract infections, non-specific chest 
infections, chest pain, hoarseness, upper 
respiratory tract infections and chronic 
obstructive pulmonary disease were 
independently predictive of lung cancer 
-On validation, the model performed well with an 
area under the ROC curve of 0.88. 
 
3 Toftegaard et al. (2016) 
Development of an algorithm 
to identify urgent referrals for 
suspected cancer from the 
Danish Primary Care 
Referral Database 
Cohort -417 GP clinics with 
831 GPs and ~8,000 




Analysis of data 







The algorithm had a sensitivity of 0.939 (95% 
[CI]: 0.905–0.963) & a specificity of 0.937 (95% 
CI: 0.925–0.963) compared to the gold standard, 
with positive and negative predictive values of 
69.8% (95% CI: 65.0-74.3) & 99.0% (95% CI: 
98.4-99.4), respectively, which increased to 
83.6% (95% CI: 78.7–87.7) & the specificity to 
97.3% (95% CI: 96.4–98.0) for populations 






Table 6 Details of studies for benefits of using cancer risk assessment tools for symptomatic individuals in primary 
care 
No Author, date & title Design 
  
Sample size & setting Data collection 
method 






Implementation of a 
diagnostic tool for 
symptomatic colorectal 
cancer in primary care: a 
feasibility study 
A feasibility study (trial)  122 patients with bowel 
related symptoms in 25 
general practices in five 
regions 
 




with the assessment 
tool & clinical 
outcomes 
GP compliance with 
completing the 
CAPER score 
-4 patients diagnosed with 
colorectal cancer; all met the 
referral criteria for the CAPER 
score; but only 3 met the NICE 
referral criteria. Assessment 
tool compliance was low 
2 Hamilton et al. (2013) 
Evaluation of risk 
assessment tools for 
suspected cancer in 
general practice: A 
cohort study 
Cohort study with 
nested qualitative 
study 
614 GPs from 165 






were conducted with 
34 individuals (11 
project managers 
and 23 GPs) 





-Compared with preceding 6 
months, there were 292 more 
chest X-rays, 104 extra 2-week 
chest clinic appointments, & 47 
additional diagnoses of lung 
cancer. 
-Colorectal cancer: 304 more 2-
week referrals, 270 more 
colonoscopies& 10 more 
cancers identified 
3 Green et al. (2015) 
Exploring GPs' 
experiences of using 
diagnostic tools for 
cancer: a qualitative 
study in PC 
  
Qualitative study to 
explore GPs' 
experiences of 
incorporating the RATs 
for lung and bowel 
cancers into their 
clinical practice 
11 project managers who 
implemented the study 





interviews over the 
telephone 
GPs' experiences of 
incorporating the 
RATs 
-RAT helped GP’s referral 
decision & lung & colorectal 
cancer symptom recognition. 
-Embedding of clinical decision 
support tools achievable if used 
with clinical judgement 
- GPs’ use of the RATs 
increased diagnostic activity 
and led to additional cancer 
diagnoses 
4 Chiang et al. (2015) 
Implementing a QCancer 






15 General practitioners  
 
 -In Australia 
 
Semi-structured 






implementation of the 
tool 
-Potentially useful for patients 
with complex histories 
- Useful resources that can help 
GPs with early detection of 
cancer 
5 Dikomitis et al. (2015) 
Embedding electronic 
decision-support (eCDS) 
tools for suspected 
cancer in PC 
Qualitative study for 
views of GPs 
(GPs) who piloted 
(Ecds 




Telephone interviews Whether GPs able to 
integrate the eCDS 
(tools) into their 
everyday practice 
-eCDS tools are useful for 
detecting cancer risk.  
-The tools could raise 
awareness about cancer  
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Table 7 Details of studies for barriers/challenges to implementation of cancer risk assessment tools for symptomatic 
individuals in primary care 
No Author, date & title Design 
  
Sample size & 
setting  
Data collection Outcome measure  Results  
1 Chiang et al. (2015) 
Implementing a QCancer 
risk tool into general 





















-Inconsistency in the interpretation 
of symptoms,  
-Difficulty in introducing the tool into 
primary care consultation  
-Uncertainty about where to set the 
threshold  
-Uncertainty about how best to 




Dikomitis et al. (2015)  
Embedding electronic 
decision-support (eCDS) 
tools for suspected cancer 
in primary care 
Qualitative study for 
views of GPs 
(GPs) who piloted 
(eCDS 
 








Whether GPs able to 
integrate the eCDS 
(tools) into their 
everyday practice 
Potential for ‘prompt fatigue 
3 Green et al. (2015) 
Exploring GPs' 
experiences of using 
diagnostic tools for cancer: 
a qualitative study in 
primary care 
Qualitative to explore 
GPs' experiences of 
using the RAT for 
lung & bowel 
cancers in clinical 
practice & to identify 
constraints & 
facilitators to 
disseminate the tool 
 
11 project managers 
who implemented 





interviews over the 
telephone 




-Extra time requirement 
-Potential for alarming patients -
Potential burden especially on 
secondary care resources 
-Challenge of integrating the tools 









2.4.5 Collating, summarising and reporting the results 
In the first stage of summarising and reporting the data, the study type and 
study setting or location of included studies were summarised using tables 
(see Tables 8 and 9 below). Details of the sample sizes of studies were also 
summarised as stated below. 
Table 8 Type of study  
Study type  No 
Mixed (quantitative & qualitative) 2 
Cohort  15 
Case control 20 
Qualitative 2 
Systematic reviews  3 
Others/feasibility study (trial) 1 
Total 43 
 
Table 9 Study setting/location 






2.4.5.1 Study sample size 
The sample sizes for the studies identified and included in the review are 
indicated in Tables 3 – 7. Participants in most of the studies were practitioners 
and/or patients depending on the type of study. Eighteen (18) years was the 
minimum cut off age in line with the inclusion criteria for this scoping review. 
This resulted in the exclusion of studies with participants who were less than 
18 years of age, although one RATs study (Dommett et al., 2013) about the 
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risk of childhood cancer (children aged 0-14 years) was included (just to 
demonstrate awareness of existence of RAT for children) (see Table 4). In the 
second stage of summarising and reporting the evidence, the evidence from 
41 included studies (Tables 3 – 7) was examined, analysed and organised 
thematically as the results. 
2.5 Results 
The results from the 43 included studies were analysed and the evidence 
organised into two main themes. The first theme was about evidence on 
cancer risk assessment tools available for symptomatic patients in primary 
care (38 studies including 13 QCancer series papers, 22 RATs series papers 
and 3 others). The second theme related to evidence on the use of the tools 
(8 studies) including the benefits (5 studies) and barriers (3) to use. These are 
presented in detail below.  
2.5.1 Evidence on cancer risk assessment tools available for 
symptomatic individuals in primary care 
From the evidence gathered in this scoping review, tools that predict the risk 
of cancer in individuals with symptoms are developed for a range of cancers 
in primary care in the United Kingdom. The two popular tools are the Hamilton 
risk assessment tool (RAT) initially developed from case-control studies in 
primary care (Hamilton, 2009) and the QCancer series developed using data 
from QResearch, a primary care electronic research database (e.g Hippisley-
Cox & Coupland, 2013).  
The Risk Assessment Tool (RAT) was initially developed from the Cancer 
Prediction in Exeter (CAPER) studies (five case-control studies) for identifying 
the risk of symptomatic patients having colorectal and lung cancers (Hamilton, 
2009). There are now RATs for a range of cancers including: leukaemia 
(Shephard et al., 2016); oesophago-gastric (Stapley et al., 2013), ovarian 
(Grewal et al., 2013), kidney (Shephard et al., 2013), bladder (Shephard et al., 
2012), pancreas (Stapley et al., 2012), breast (Walker et al., 2014), cervical 
(Walker & Hamilton, 2017), uterine (Walker eta al., 2013), brain (Schmidt-
32 
 
Hansen et al., 2015), childhood (Dommett et al., 2013), metastatic (Hamilton 
et al., 2015a), Hodgkin’s lymphoma (Shephard et al., 2015), non-Hodgkin’s 
lymphoma (Shephard et al., 2015), multiple myeloma (Shephard et al., 2015). 
Other symptom-based RATs include risk of cancer in people with 
hypercalcaemia (Hamilton et al., 2014), low albumin (Merriel et al., 2016) and 
haematuria (Price et al., 2014) have also been published.  
The QCancer series also included a range of cancers: lung (Hippisley-Cox & 
Coupland, 2011), gastro-oesophageal (Hippisley-Cox & Coupland, 2011), 
colorectal (Hippisley-Cox & Coupland, 2012), renal tract (Hippisley-Cox & 
Coupland, 2012; ovarian (Hippisley-Cox & Coupland, 2012), pancreatic 
(Hippisley-Cox & Coupland, 2012), suspected cancer in women (Hippisley-
Cox & Coupland, 2012), and suspected cancer in men (Hippisley-Cox & 
Coupland, 2013).  
The RAT provides risk estimates for patients with single symptoms of possible 
cancer, pairs of symptoms and repeat attendances with the same symptoms 
(e.g. Hamilton, 2009; Shephard et al., 2016; Stapley et al., 2013; Grewal et al., 
2013; Shephard et al., 2013; Shephard et al., 2012; Stapley et al., 2012; 
Walker et al., 2014; Walker & Hamilton, 2017; Walker et al., 2013; Schmidt-
Hansen et al., 2015; Dommett et al., 2013; Shephard et al., 2015a; Shephard 
et al., 2015b; Shephard et al., 2015c; Hamilton et al., 2014).  
In contrast to the RATs, the earlier QCancer series of tools are designed for 
symptomatic patients who might have an existing but undiagnosed cancer by 
estimating an absolute risk of any cancer with a breakdown of type of cancer 
based on both risk factors and symptoms suggestive of cancer already present 
(e.g Hippisley-Cox & Coupland, 2013). A more recent QCancer series (e.g. 
Hippisley-Cox & Coupland, 2015) can be used to estimate a 10-year risk of 
cancer in asymptomatic individuals.  
Three other relevant risk assessment tools for symptomatic patients include: 
a scoring system developed for ovarian cancer prediction in primary care 
(Grewal et al., 2013); a tool that combines sociodemographic and early clinical 
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features to identify people with lung cancer in primary care (Iyen-Omofoman 
et al., 2012) and an algorithm developed from the Danish Primary Care 
Referral Database to identify urgent referrals for suspected cancer in Denmark 
(Toftegaard et al., 2016), but may be useful in other countries.  
An independent validation for many of the risk assessment tools for 
symptomatic individuals using data from separate populations has been done 
- for example, the QCancer risk assessment series of tools (e.g. Collins & 
Altman, 2012; Collins & Altman, 2013) and the RATs (Marshall et al., 2011). 
These studies suggest the tools have good discrimination with Area Under the 
Receiver Operating Characteristic Curves (AUROCs) between 0.79 and 0.95, 
and sensitivities of 46.0 - 61.3 with a specificity of 95% (Collins & Altman, 2012; 
Collins & Altman, 2013; Marshall et al., 2011) as noted by Usher-Smith et al. 
(2015). 
Similarly, a systematic review of risk prediction models for colorectal cancer in 
people with symptoms presenting to both primary and secondary care 
suggests the risk models had good discrimination (AUROC > 0.8) in external 
validation studies, with sensitivity and specificity ranging from 0.25 and 0.99 
to 0.99 and 0.46 (Williams et al., 2016). One exception relates to the RATs for 
brain tumour for which all the individual and combined symptoms of brain 
tumours had low PPVs of less than 0.39%, apart from new-onset epilepsy, 
thus making diagnosis for brain cancer problematic, as brain tumours have all 
the expected features seen with cancer diagnostic delay (Schmidt-Hansen et 
al., 2015).  
To aid understanding, the statistical terms of AUROC, Sensitivity, Specificity 








Box 1 Definition of AUROC, PPV, Sensitivity and Specificity 
• Area Under the Receiver Operating Characteristic (AUROC): The AUROC 
is used to measure the accuracy of a test, that is, how well the test 
separates the group being tested into those with and without the disease of 
interest. Thus, an area of 1 represents a perfect test; an area of 0.5 
represents a worthless test. 
• Sensitivity: Sensitivity refers to the ability of a test to detect an individual 
with disease as positive. A highly sensitive test means that there are few 
false negative results, with fewer cases of disease missed.  
• Specificity: The specificity of a test is its ability to detect an individual who 
does not have a disease as negative.  
• Positive Predictive Value (PPV) and Negative Predictive Value (NPV): The 
PPV and NPV describe the performance of a diagnostic test. That is, PPV 
and NPV are the proportions of positive and negative results in diagnostic 
tests that are true positive and true negative results, respectively.  
 
The evidence on the use of the tools in primary care is presented in Section 
2.5.2 below. 
2.5.2 Evidence on use of cancer risk assessment tools for symptomatic 
individuals in primary care including benefits and barriers to use 
The evidence generated from studies about the implementation of cancer risk 
assessment tools for symptomatic individual in primary care included evidence 
on benefits of use and barriers to implementation.  
2.5.2.1 Benefits of using cancer risk assessment tools  
This review found evidence from an evaluation study which suggests that the 
RATs helped clinicians to confirm a need for investigation (Hamilton et al., 
2013). The tools allowed for reassurance when investigation was not needed 
(Hamilton et al., 2013). Similarly, in an exploration of GPs' experiences of 
using diagnostic tools for cancer, participants perceived the RAT as beneficial 
in helping GPs to recognise symptoms of lung and colorectal cancers, and to 
confirm referral decisions (Green et al., 2015). However, Green and 
colleagues noted that the implementation of clinical decision support tools was 
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more likely to be achieved when the tools were perceived to support rather 
than supersede clinical judgement (Green et al., 2015). 
This review also found evidence that a cancer risk assessment tool like 
QCancer can be useful for patients with complex histories (Chiang et al., 
2015), although GPs were less likely to use a cancer risk assessment tool if 
they did not perceive cancer as a likely diagnosis (Chiang et al., 2015). This 
finding contrasted with the findings of Dikomitis and colleagues in the 
Macmillan eCDS pilot study (Dikomitis et al., 2012). In that qualitative study of 
GPs’ experiences of electronic decision-support tools for suspected cancer in 
primary care, Dikomitis and colleagues found electronic decision-support tools 
were useful resources that could help GPs with early detection of cancer as 
well as raise awareness about cancer, although there was a potential for 
‘prompt fatigue’, where frequent or multiple prompts led to a greater likelihood 
of them being ignored (Dikomitis et al., 2015). As noted by Chiang and 
colleagues, the contrasting evidence between Dikomitis and colleagues and 
Chiang and colleagues may be due to the sustained efforts in the UK to raise 
awareness about early cancer diagnosis (Chiang et al., 2015). 
Further evidence of the benefits of using cancer risk assessment tools relate 
to increased referral and diagnosis. An evaluation of the use of a cancer risk 
assessment tool for suspected cancer in general practice revealed that, 
compared with the preceding 6 months, there were 292 more chest X-rays, 
104 extra 2-week chest clinic appointments, and 47 additional diagnoses of 
lung cancer (Hamilton et al., 2013). For suspected colorectal cancer, there 
were 304 more 2-week referrals, 270 more colonoscopies, and 10 more 
cancers identified (Hamilton et al., 2013). Overall, there was an increase in 
referral and diagnosis of cancer (Khan et al., 2009; Hamilton et al., 2013). 
Similarly, an exploration of GPs’ experiences of using a diagnostic tool for 
cancer detection, revealed that GPs’ use of the RAT increased diagnostic 
activity and led to additional cancer diagnoses (Green et al., 2015). The next 




2.5.2.2 Barriers to implementation of the tools 
While the cancer risk assessment tools designed for symptomatic patients 
have a beneficial potential, this review has found that there can be some 
barriers to the implementation of these tools in primary care.  
One challenge is about making the tools easy to access by primary care 
clinicians. Evidence from the QCancer study in Australia suggests there was 
inconsistency in the interpretation of symptoms, and that practitioners had 
trouble in introducing the tool into the primary care consultation (Chiang et al., 
2015). 
Other barriers include uncertainty about where to set the threshold for action 
(Chiang et al., 2015) and how best to communicate cancer risk to patients 
(Chiang et al., 2015). Other studies have identified further barriers including: 
extra time requirement, potential for alarming patients, potential burden 
especially on secondary care resources, the challenge of integrating the tools 
into general practice IT systems to ease use (Green et al., 2015) and a 
potential for ‘prompt fatigue’ (Dikomitis et al., 2015).  
In summary, this scoping review found no evidence of randomised controlled 
trials (RCTs) relating to the implementation of cancer risk assessment tools 
for symptomatic individuals in primary care. The evidence mentioned here is 
limited to the non- RCT feasibility studies (Hamilton et al., 2003; Green et al., 
2015; Dikomitis et al., 2015; Chiang et al., 2015), as opposed to studies based 
on a widespread implementation of the tools. These findings are discussed 
further in Section 2.6 below.  
2.6 Discussion 
The aim of this scoping review was to explore the literature for evidence 
relating to cancer risk assessment tools available in primary care for 
symptomatic individuals, the use of these tools including the benefits and 
barriers to their implementation. 
37 
 
Using the methodological framework outlined by Arksey & O’Malley (2005), 
this scoping review explored the literature and identified studies relevant to the 
research question. These studies were examined and analysed. The findings 
suggest that most of the literature referred to two cancer risk assessment tools, 
designed for symptomatic individuals in primary care.  
While these tools are currently not widely implemented, they have potential to 
aid earlier diagnosis of cancer through early detection of cancer risk in 
symptomatic individuals when used in primary care patient consultations. In 
particular, findings from feasibility studies involving the use of the RAT (Khan, 
2009; Hamilton et al., 2013; Green et al., 2015), the electronic cancer decision 
support tools (eCDS) in the UK (Dikomitis et al., 2015), and the QCancer tool 
in Australia (Chiang et al., 2015) suggest the tools may have benefits including 
improvement in the number of referrals for cancer investigations and 
diagnoses (Hamilton et al., 2013; Green et al., 2015). To maximise these 
benefits, these tools may need to be used in combination with the clinical 
judgement of practitioners when deciding about a patient’s cancer risk (Chiang 
et al., 2015). This is in line with the new NICE guidelines for cancer which 
support clinicians’ use of their clinical judgement, freeing them from having to 
make patients fit guidelines (Hamilton, 2015b). 
Despite the potential benefits reported by the feasibility studies, there are 
concerns about barriers to the use of the tools. These include how to make the 
tools available to clinicians (Chiang et al., 2015), uncertainty about the 
threshold for action to be taken (Chiang et al., 2015) and how best to 
communicate cancer risk information to patients (Chiang et al., 2015). Other 
barriers relate to extra time requirement, potential for causing alarm to 
patients, potential burden on resources, the challenge of integrating the tools 
into general practice workflow (Green et al., 2015), and a potential for ‘prompt 
fatigue (Dikomitis et al., 2015) when using the tools in primary care 
consultations. These findings are similar to those from previous studies on 
barriers to the use of cardiovascular disease risk predicting tools, which 
include: lack of time, poor knowledge or understanding of the tools and poor 
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computer software (Van Steenkiste et al., 2004; Muller-Riemenschneider et 
al., 2010).  
Regarding making the tools accessible to practitioners, recent developments 
suggest that the tools have been integrated into general practice IT systems 
through a collaboration between Macmillan Cancer Support, Cancer Research 
UK and individual experts in this area (Macmillan Cancer Support, 2015). 
Despite this development, there may still be a need to support practitioners 
further on how to access the integrated tools on their computers. 
The uncertainty about the threshold for referral is an important challenge, but 
current developments suggest that the threshold for referral currently stands 
at 2% (Macmillan Cancer Support, 2015). It is worth noting that, while a 
threshold of 2% or even less may help to identify more patients for 
investigations or referral for diagnosis, this greater sensitivity is balanced by 
reduced specificity, where a lower threshold can lead to over-investigation, 
over-diagnosis and unnecessary harmful treatment (Usher-Smith et al., 2015). 
To complicate matters further, clinicians are expected to use the tools to 
support their clinical judgement in deciding what to do with a patient’s risk, 
rather than relying solely on the threshold for intervention. 
The uncertainty around how best to communicate risk information when using 
the tools with patients is an important challenge to the use of the tools. The 
format in which risk information is presented is important, as this can affect 
both clinicians’ use of the tool and patients’ understanding and perception of 
the risk information (Usher-Smith et al., 2015). For example, findings from the 
QCancer simulated study with GPs suggest a preference for traffic-light colour 
coding of risks (red, amber and green) with secondary access to the numeric 
risks, if needed, rather than absolute numeric risks or being presented with 
diagnostic guidance as the primary output (Chiang et al., 2015).  
Lessons about how best risk information can be presented to patients can be 
learnt from the area of cardiovascular disease. Research in this area suggests 
that numerical presentation of risk as opposed to simple risk categories and 
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time-frames of 10 years lead to more accurate risk perceptions (Waldron et 
al., 2011; Usher-Smith et al., 2015). On the other hand, presenting relative risk 
reductions helps to increase acceptance of treatment and ‘heart age’ may 
increase intention to change behaviour (Waldron et al., 2011). In the absence 
of further research, it remains unclear whether this evidence will apply to the 
communication of cancer risk information to patients, as noted in a recent 
review (Usher-Smith et al., 2015).  
In the face of the barriers identified, there is a need for evidence on facilitators 
or enablers to the implementation of the tools. These will merit further research 
exploration. In the context of policy, the implications of the findings from this 
scoping review are discussed further in Section 2.6.1 below.  
2.6.1 Policy context  
The findings about the benefits of using cancer risk prediction tools for 
symptomatic individuals in primary care support the objectives of the National 
Awareness and Early Diagnosis initiative (NAEDI), particularly in relation to 
early detection of cancer in primary care. The tools have potential to prompt 
investigations, referral for diagnosis, treatment and improvement in quality of 
life. Existing evidence suggests that earlier diagnosis efforts may benefit 
patients by helping to improve earlier staged diagnosis, survival and quality of 
life in different cancers (Neal et al., 2015). 
There have been efforts to integrate the tools into the general practice IT 
systems to facilitate general practice clinicians’ access to the tools (Macmillan 
Cancer Support, 2015), but there may still be a need for training or education 
on how to access the tools from the general practice IT system, as well as how 
to communicate the risk to patients. 
The potential benefit of the tools in helping to alert practitioners to a possible 
cancer risk during a patient consultation suggests a policy need for the 
Department of Health to integrate the tools with the existing NICE guidelines. 
This will enable practitioners to combine clinical judgment with the use of 
cancer risk assessment tools and NICE guidelines. Integrating the tools into 
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general practice consultation may imply the need to review the current 10-
minute patient-practitioner consultation time. The issues presented and 
discussed in this chapter are concluded in Section 2.7 below. 
2.7 Conclusion of the chapter 
This review found that cancer risk assessment tools for symptomatic 
individuals have the potential to improve cancer survival through early 
detection of risk, and timely investigation, diagnosis and treatment. Despite 
the potential benefits of the tools, there are concerns about barriers to the 
implementation of the tools including how to make the tools accessible to 
clinicians, where to set the threshold for action and how to communicate 
cancer risk information to patients. 
The uncertainty about how best to communicate cancer risk information to 
patients requires further research exploration. Given that the evidence on the 
barriers to implementation are limited to a few studies, it will also be useful to 
explore further the barriers to implementing cancer risk assessment tools in 
symptomatic individuals presenting to primary care. In addition, in the face of 
barriers, it will be useful to explore the enablers (facilitators) to implementation 
of the tools. Therefore, there is a need to use appropriate research methods 
to explore the following research questions:  
• What are the perceptions of patients (or service users) and practitioners 
about how best cancer risk information can be communicated to 
patients during general practice consultations? 
• What do service users and practitioners perceive as barriers and 
enablers (facilitators) to the implementation of cancer risk assessment 
tools?  
To appropriately address the above research questions, it is important to 
review the conceptual background literature to understand the relevant 
concepts around risk, risk prediction models or tools, risk communication and 
related risk communication theory. Chapter Three follows next with the 
conceptual background literature. 
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CHAPTER 3 CONCEPTUAL BACKGROUND LITERATURE 
REVIEW 
3.1 Summary of the chapter 
This chapter discusses the key ideas underpinning the research, specifically 
policy and practice relating to primary care and issues concerning early 
detection of risk. It covers risk prediction models, highlighting cancer risk 
assessment tools for symptomatic individuals and their psychological impact 
when communicating risk information with individual service users. There is a 
more general discussion on risk communication. Relevant theories informing 
the research including a risk communication framework and an 
implementation theoretical framework are discussed. 
3.2 Key points 
The key points noted in this chapter include: 
• Primary care policy, structure and function highlighting policies for early 
diagnosis of cancer 
• Risk prediction models 
• Cancer risk assessment tools for symptomatic individuals in primary 
care 
• Effects of cancer risk assessment 
• Communicating cancer risk information 
• Theoretical frameworks informing the research including a risk 
communication framework and an implementation theoretical 
framework. 
3.3 Primary care policy, structure and functions  
Primary care is usually the first point of contact that service users have with a 
health care professional, often a general practitioner (GP), when they have an 
illness, injury or symptoms that are new to them. The National Health Service 
(NHS) provides both primary and specialist health care which is free at the 
point of delivery (Roland, 2012). In primary care, GPs are responsible for 
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registered populations of patients, often working in groups of self-employed 
doctors working as partners in a partnership arrangement. To support their 
work GPs often employ non-partner (salaried) GPs, nurses and ancillary staff 
(Roland, 2012). 
Recent reforms include a wide range of national quality improvement initiatives 
and a pay-for-performance scheme, the Quality and Outcomes Framework, 
that accounts for around 25% of family practitioners' income (Gillam & 
Siriwardena, 2011). The four countries of the UK differ in some important 
aspects of health care organisation, but generally in the United Kingdom 
patients can access primary care services through their local general practice, 
community pharmacy, optometrist or dental surgery.  
Services are usually provided free-of-charge through the NHS, and patients 
do not usually have direct access to specialists or consultants in secondary 
care, as this is controlled by GPs (Royal Commission on the NHS Chapter 7, 
1979), which is referred to as ‘gatekeeping’. Critics have called for this 
‘gatekeeping’ policy to be revisited to accommodate the government’s aim of 
modernising the NHS and giving patients more choice (Greenfield et al., 2016). 
Such calls are yet to materialise, because any relaxation of the gatekeeping 
policy needs to be evaluated to ensure the clinical and non-clinical benefits 
outweigh the costs (Greenfield et al., 2016).  
The functions or activities of GPs, community pharmacists and other primary 
care service providers include primary or secondary prevention. Primary 
prevention entails avoidance of disease through measures including 
immunisation and smoking cessation. Primary care practitioners also provide 
secondary and tertiary prevention, that is, prevention of recurrent disease and 
long-term complications respectively, through providing support for people 
with long term conditions.  
Overall, the evidence suggests important services provided by primary care 
include: comprehensive and accessible first point of contact care for all 
members of a community; continuous person and family focussed care with 
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opportunities for choice; effective and systematic management of chronic or 
long-term diseases; and referral to and coordination of outpatient and inpatient 
specialist care as and when appropriate. 
The primary care function of referral to and coordination of specialist care is 
important for this research, as it relates to early detection of cancer risk and 
referral for investigations and early diagnosis. The policy relating to early 
diagnosis of cancer is discussed below. 
3.3.1 Early diagnosis of cancer policy 
From a broad perspective, the World Health Organisation (WHO) recognises 
that early diagnosis of cancer can increase the chances for successful 
treatment by focusing on detecting symptomatic patients as early as possible 
(WHO, 2017). The WHO also regard early diagnosis as an important public 
health strategy in all settings, as it can help to improve cancer outcomes by 
providing care at the earliest possible stage (WHO, 2017). 
Specifically, in the UK, evidence suggests that cancer patients in England 
have more advanced disease by the time they are diagnosed (Coleman et al., 
2011; De Angelis et al., 2014) compared with patients using other healthcare 
systems in Europe (DH, 2007). To reduce the gap between England and the 
rest of Europe, the Department of Health introduced several policy actions to 
improve early diagnosis, which together is estimated would help save about 
5000 lives a year (DH, 2011). Relevant among these policy actions was the 
introduction of National Awareness and Early Diagnosis Initiative (NAEDI) 
policy which had several aims (DH, 2007): increasing awareness among the 
public and healthcare professionals to recognise and detect early signs and 
symptoms of cancer; encouraging people with symptoms to seek early advice, 
and supporting primary care professionals to contribute to effective referral 
and diagnosis of cancer. 
A national audit of primary care was also developed to identify the support that 
would help GPs to identify potential cancers earlier. These initiatives 
supported primary care services by improving access to diagnostic 
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technologies and urgent referral pathways for suspected cancer (DH, 2007). 
These diagnostic technologies relate most importantly to risk prediction 
models. Relevant risk prediction models that may be used in primary care 
general practice settings to aid early detection of risk are discussed below. 
3.4 Risk prediction models 
Risk has been described as the possibility of losing something of value, such 
as physical and emotional health and well-being (Kungwani, 2014). Risk has 
also been described as an intentional interaction with uncertainty (Cline, 
2005). Uncertainty here refers to a potential, unpredictable, and uncontrollable 
outcome (Cline, 2005).  
A risk prediction model is designed to predict the probability of a condition 
occurring among individuals or groups, using a combination of known factors 
(Usher-Smith et al., 2015). Risk prediction or assessment tools represent how 
risk prediction models are implemented in clinical practice (Usher-Smith et al., 
2015). Examples of risk prediction tools include the: Cardiovascular Disease 
(CVD) risk prediction tools such as the Framingham Equation (Wilson et al., 
1998; D'Agostino et al., 2008) and QRisk (Hippisley-Cox et al., 2008); 
osteoporosis (fracture) risk assessment tools such as the FRAX (Kanis & 
WHO Scientific Group, 2008) and QFracture (Hippisley-Cox & Coupland, 
2009; Hippisley-Cox & Coupland, 2012); diabetes risk assessment tools such 
as the Diabetes UK ‘Know your risk’ tool and QDiabetes (Hippisley-Cox and 
Coupland, 2011); kidney failure risk assessment tool [QKidney] (Hippisley-Cox 
and Coupland, 2010); and cancer risk prediction tools such as the Hamilton 
Risk Assessment Tool [RAT] (Hamilton, 2009), QCancer (Hippisley-Cox & 
Coupland, 2011; Hippisley-Cox & Coupland, 2012; Hippisley-Cox & Coupland, 
2013) and the Electronic Clinical Decision Support (eCDS) tools (Green et al., 
2015; Macmillan Cancer Support, 2015), which are the focus of this research.  
There are also the National Institute for Health and Care Excellence (NICE) 
guidelines, which are not risk assessment (or prediction) tools, but are used to 
support clinical decision-making in primary care consultations. Several NICE 
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guidelines are available to patients and health professionals to support early 
detection of risk and diagnosis of a range of conditions including cancer, 
diabetes and cardiovascular disease. For example, the NICE guidance for the 
early detection and treatment of cancer advises primary care practitioners to 
request specific blood tests for patients with symptoms suggestive of certain 
cancers (DH, 2011).  
Regarding the use of risk assessment tools there are several challenges, 
which are particularly the case with cancer risk assessment tools, in setting 
thresholds for investigation and specialist referral. To improve early diagnosis 
of cancer, and to avoid missing individuals with cancer, a low threshold might 
be set for further assessment of symptomatic patients. Although a low 
threshold risk may increase case selection for screening, preventive measures 
and investigation for suspected cancer, this might also increase the risk of 
over-investigation, over-diagnosis and potentially unnecessary or harmful 
procedures (Usher-Smith et al., 2015).  
There are other common challenges to using these risk assessment tools and 
communicating the risk generated to patients. For example, evidence about 
challenges relating to the use of CVD risk prediction tools include: lack of time, 
poor knowledge or understanding of the tools, the perception that clinical 
judgement is as good as or better than risk tools, uncertainty about how to 
account for risk factors perceived to be important but not included in the tools 
and poor computer software (Van Steenkiste et al., 2004; Müller-
Riemenschneider et al., 2010). Similarly, in the use of cancer risk assessment 
tools particularly for symptomatic individuals, there may be challenges of how 
to make the tools accessible or available to clinicians, while presenting the risk 
information in a format that can easily be understood by practitioners and 
patients (Usher-Smith et al., 2015). For example, one study found that when 
using a risk assessment tool, GPs were inconsistent in their interpretation of 
symptoms, had trouble introducing the tool into the consultation process, or 
were sometimes reluctant to use the tools for fear of alarming or frightening 




Furthermore, in communicating risk, the format in which risk information is 
presented is an important aspect of risk assessment tools. The format affects 
both clinicians' use of the tool and patients' understanding and perception of 
risk. Evidence from the study cited above, which involved GPs and simulated 
consultations using QCancer (a cancer risk assessment tool), suggested that 
GPs may prefer traffic-light colour coding of risks (red, amber and green) with 
secondary access to the numeric risks, rather than being presented with 
absolute numeric risks or diagnostic guidance (Chiang et al., 2015).  
Similarly, in terms of how best to present risk information to patients, evidence 
from CVD risk assessment suggests that numerical presentation of risk rather 
than simple risk categories, and timeframes <10 years lead to more accurate 
risk perceptions (Waldron et al., 2011; Usher-Smith et al., 2015). On the other 
hand, presenting relative risk reductions maximises acceptance of treatment 
and ‘heart age' appears to increase intention to change behaviour (Waldron et 
al., 2011). Since cancer risk assessment tools for symptomatic individuals are 
the focus of this study, a further discussion of these are detailed below. 
3.5 Cancer risk assessment tools for symptomatic individuals in 
primary care 
As mentioned earlier, cancer risk assessment tools are novel tools that have 
been developed to identify and quantify cancer risk in people with initial 
symptoms to aid early detection of cancer in primary care. These include the 
Risk Assessment Tool [RAT] (Hamilton, 2009) and QCancer (Hippisley-Cox & 
Coupland, 2011; Hippisley-Cox & Coupland, 2012; Hippisley-Cox & Coupland, 
2013). The RAT, which was initially developed as a desktop tool, but now 
available in electronic version, was initially used for assessing risk of colorectal 
and lung cancers (Hamilton, 2009), but now covers several cancers. The 
desktop version of the RAT tables is printed on a mouse mat or a desk easel, 
and contains the risk values for each symptom in isolation, and repeat 
attendances at the general practice with the same symptom and in 
combination with one other symptom.  
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The QCancer tool provides specific risks of different cancers according to 
combinations of baseline risk factors: age, body mass index (BMI), smoking, 
family history and alcohol, current symptoms and specific clinical conditions 
(Hippisley-Cox & Coupland, 2012). QCancer predicts the risk for a broad range 
of more than 10 different types of cancer as listed in Box 2. 
Box 2 List of QCancer predicting cancers 
• Colorectal cancer 
• Gastro-oesophageal cancer 
• Pancreatic cancer 
• Blood cancers 
• Lung cancer 
• Renal track cancer 
• Testicular cancer 
• Breast cancer 
• Uterine cancer 
• Ovarian cancer 
• Cervical cancer 
• Other cancers (including some rare cancers) 
 
Many of these cancers such as colorectal, gastro-oesophageal, lung, 
haematological, renal, pancreatic and ovarian cancers, often present with 
vague and overlapping symptoms. The symptoms included in the QCancer 
calculator are those symptoms which the patient has been sufficiently 
concerned about and has decided to consult a GP. Two calculators, one for 
women and another for men, have been developed (Hippisley-Cox & 
Coupland, 2013). The QCancer calculators for men and women may be used 
in two main ways in primary care: within a doctor-patient consultation and in a 
batch processing mode. 
Within a doctor-patient consultation, QCancer can be used to calculate the 
absolute risk of symptomatic patients either having or developing a currently 
undiagnosed cancer within two years. This can be done by entering all the 
data required directly into the QCancer calculator or by using QCancer 
integrated into the clinical computer system. Many of the variables needed for 
48 
 
the calculation are already recorded in the patient’s underlying electronic 
medical record whilst others can be entered during the consultation. The 
results from the calculation can be shared with the patient and further 
investigations or referral can be considered between the patient and 
practitioner. 
When using QCancer in a ‘batch processing’ mode, the calculation is 
performed automatically with data already in the electronic medical record. A 
risk profile for each patient is generated, which can be stored in the medical 
record or an ancillary table and can then be used to sort patients per their 
overall cancer risk or risk of an individual type of cancer. Below is an illustration 
of how QCancer estimates cancer risk based on the risk factors and symptoms 
presented by a patient.  
An illustration of how the QCancer tool estimates cancer risk  
Imagine: 
• A 55-year old woman (height 172 cm, weight 85kg)  
• Living in Lincoln (postcode - LN6 7TS) 
• Moderate smoker 10-19 cigarettes/day 
• Abdominal pain, abdominal swelling, indigestion 
• What is her risk of developing cancer in the next 2 years? 
• How does this compare with a typical person of the same age and sex 
without symptoms? 
By entering the above patient data in the QCancer calculator, the following 










Figure 2 Vignette (example) of QCancer risk scores  
• No cancer 86.83% represented by the yellow smiley faces 
• Any cancer 13.17% represented by the blue sad faces 
  
Estimates for the 
individual cancers  
 
• Ovarian 9.16% 
• Other 1.46% 
• Colorectal 0.58% 
• Pancreatic 0.55% 
• Gastro-oesophageal 
0.43% 
• Lung 0.41% 
• Breast 0.24% 
• Renal tract 0.11% 
• Blood 0.11% 
• Cervical 0.09% 





 score 13.17% 







The QCancer model has been internally validated in terms of finding the 
cancers it was designed to predict. In other words, the developers of QCancer 
(Hippisley-Cox & Coupland, 2011; Hippisley-Cox & Coupland, 2012; 
Hippisley-Cox & Coupland, 2013) tested it using rigorous statistical techniques 
with general practice patient data from QResearch, a large primary care 
database. The QCancer tool has also been independently tested using a 
database different from the database used for the development of the tool, and 
found to accurately predict a range of cancers (Collins & Altman, 2012; Collins 
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& Altman, 2013). Box 3 below presents details of the RAT and QCancer tools 
(Usher-Smith et al., 2015). 







• Designed to be used in symptomatic populations 
presenting to primary care. 
• Developed from case–control studies in primary care. 
• So far, tools for 14 separate cancer sites have been 
published (colorectal, oesophageal, lung, ovarian, kidney, 
bladder, pancreas, breast, uterine, brain, prostate, 
Hodgkin lymphoma, non-Hodgkin lymphoma and multiple 
myeloma). 
• Provide risk estimates for patients with single symptoms 
of possible cancer, pairs of symptoms and repeat 







• Hybrid models that can be used both in symptomatic and 
asymptomatic populations. 
• Developed in the QRESEARCH database, a large 
database comprising over 12 million anonymised health 
records from 602 general practices throughout the United 
Kingdom using the EMIS (Egton Medical Information 
Systems) computer system. 
• Six models have been published for symptomatic 
populations (for colorectal, gastro-oesophageal, lung, 
renal, pancreatic and ovarian cancer), plus models 
predicting risk for multiple cancers for males and females. 
• Provide estimates of absolute risk of any cancer with a 
breakdown of type of cancer based on both risk factors 
such as age, gender and family history, which increase 
the likelihood of cancer, and risk markers such as 
haemoptysis or weight loss, which are features, usually 
symptoms, suggesting that cancer is already present. 
• Available on line at www.qcancer.org. 
Adopted and modified from: Usher-Smith et al., 2015 
In 2012/13, funding was provided by NAEDI for the e-RAT and QCancer to be 
put together as electronic Clinical Decision Support (e-CDS) tools and to be 
made available as widely as possible to GPs (Green et al., 2015). The tools 
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each consist of three components namely: (i) on-screen prompts that display 
calculated cancer risk in percentage format and flash up on the computer 
screen during consultation; (ii) an interactive risk calculator, which is accessed 
from a drop-down menu at the top of the prompts box. GPs can then enter 
new symptoms and re-calculate cancer risk during consultation; and (iii) tables 
of patients with calculated Positive Predictive Values (PPV), which enables 
GPs to review the cancer risk of their practice population. The project was 
managed by Macmillan Cancer Support, while Cancer Research UK (CRUK) 
funded the evaluation of the project (Green et al., 2015; Usher-Smith et al., 
2015). 
In terms of how the tools can be used, it has been suggested that, the relevant 
cancer risk assessment tools (e.g. RAT and QCancer) can be either integrated 
into clinical computer systems or used as standalone/web-based electronic 
tools such as the Disease Risk Index developed by the Harvard School of 
Public Health (Usher-Smith et al., 2015, Macmillan Cancer Support, 2015). 
The output can be presented either as absolute or relative risk, rank or peer 
comparison, with more sophisticated tools presenting risk in a variety of 
formats along with the potential impact of risk-reducing interventions. 
For patients with symptoms, these tools can then be used to guide 
investigation and referral. Consequently, working in collaboration with 
Macmillan Cancer Support, BMJ Informatica developed the e-CDS tools within 
general practice computer systems to provide three functions for GPs (Usher-
Smith et al., 2015, Macmillan Cancer Support, 2015): (a) Prompts during 
consultations if patients have a risk of 2% (adjustable) for the different cancers 
e.g. lung, colorectal, pancreatic, ovarian or oesophago-gastric cancer; (b) A 
series of ‘symptom checkers’ for patients in whom GPs have identified 
symptoms suggestive of cancer, which enable them to enter additional 
symptomatic information and update the cancer risk estimates; and (c) A risk 
stratification tool intended for use separately from consultations. Working as 
an audit tool, it allows practices to generate lists of all registered patients in 
whom a risk score can be calculated and sorts them by cancer type and risk 
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category. To provide more understanding relating to these cancer risk 
assessment tools, several relevant questions are discussed below. 
How do these cancer risk assessment tools differ from other types of risk 
prediction tools, and how do they fit into the framework of predictive/prognostic 
tools? 
I have mentioned (see page 45 above) other types of risk prediction tools such 
as the QRisk (a cardiovascular risk prediction tool), QDiabetes (a diabetes risk 
prediction tool), QFracture (a fracture risk prediction tool) etc., that operate on 
a similar principle as risk prediction tools designed for use in primary care. 
That is, these other risk tools are like the cancer risk assessment tools of 
interest to my research, because they may all be used to predict risk in primary 
care. 
However, some of these tools like the QRisk are usually used for 
asymptomatic individuals who may be administered preventive interventions 
(or treatment) when a risk of disease is detected. In contrast, the cancer risk 
assessment tools of interest to this research are designed for symptomatic 
individuals who should be referred for investigation and diagnosis of cancer 
before appropriate treatment may be prescribed. In addition, tools like QRisk 
are already integrated into the general practice IT systems, while cancer risk 
assessment tools which are relatively newer are not yet widely integrated and 
used in general practice systems and consultations. 
With reference to the Prognosis Research Strategy (PROGRESS) framework 
the cancer risk assessment tools in this study fit into the prognostic model (or 
predictive model) which is a combination of multiple predictors from which risks 
of a specific endpoint can be calculated for individual patients (Steyerberg et 
al., 2013). They also fit into one of the four themes of the Prognosis Research 
Strategy (PROGRESS) framework (Hemingway et al., 2013): the 
development, validation, and impact of statistical models that predict individual 
risk of a future outcome [prognostic model research] (Steyerberg et al., 2013), 
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which includes cancer risk assessment tools like QCancer and RATs that 
predict individuals’ risk of a current or future cancer. 
What is the evidence that these cancer risk assessment tools will be used or 
are used and why they are not used? 
I have discussed and referred to evidence from previous studies (Hamilton et 
al., 2013; Green et al., 2015; Dikomitis et al., 2015; Chiang et al., 2015) in the 
scoping review and discussion chapters. For example, the evidence suggests 
that using the tools in primary care consultations could be beneficial, although 
the tools are currently not widely used. 
It is worth adding that the evidence from the previous feasibility studies on 
cancer risk assessment tools such as the eCancer Decision Support Tools 
(eCDS) points to potential benefits associated with the use of the tools in 
primary care. These potential benefits may encourage a wider implementation 
of the tools across general practices in the UK.  
One question that arises given the evidence about potential benefits, is why 
the cancer risk assessment tools are not currently widely used. As found in the 
scoping review for this research, possible reasons may include barriers to use 
such as lack of integration of the tools into the general practice IT system, 
difficulties in terms of practitioners understanding how to access and use these 
tools in consultations and how best to communicate the risk information to 
patients once a risk is generated through using the tools. 
These barriers to implementation of the tools are outlined in my scoping review 
as reported in previous literature (e.g. Green et al., 2015; Chiang et al., 2015; 
Usher-Smith et al., 2015), and were also found in the current study based on 
the views of service users and practitioners. 
What is the precedent, or lack of it, for practitioners using these types of risk 
tools? 
It is worth considering the precedent for practitioners using cancer risk 
assessment tools in primary care consultations. Similar risk tools like the 
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QRisk, QDiabetes, QFracture etc. are already integrated in general practice 
computer systems and being used in patient consultations. These serve as 
examples or precedent for practitioners to use cancer risk assessment tools in 
primary care consultations.  
It is recognised here that tools like QRisk are used to identify risk in 
asymptomatic individuals leading to preventive interventions, while cancer risk 
assessment tools predict risk in symptomatic patients leading to investigations 
and referral for diagnosis and treatment. Despite this difference, all the tools 
predict a risk of an individual’s disease or health problem and the risk 
information is then communicated to the individual. Hence, the current use of 
QRisk in UK primary care serves as a precedent that cancer risk assessment 
tools can be successfully implemented, if due processes are followed. 
What is the actual place these cancer risk assessment tools could have in 
practice? 
For the actual place of these cancer risk assessment tools in practice, using 
the Macmillan electronic cancer decision support tools (eCDS) tools, Usher-
Smith et al. (2015) outlined potential ways by which the tools could be used 
by practitioners in clinical practice. 
One way is that, the tools could be used as prompts during consultations if 
patients have a risk of ≥2% (or whatever risk is chosen as the threshold) for 
lung, colorectal, pancreatic, ovarian or oesophago-gastric cancers, using 
information added as read-codes in the past. That is, when the tools are 
integrated in the general practice system and activated during a consultation, 
practitioners could be alerted of a potential cancer. Practitioners may then 
apply the NICE guidelines to activate an urgent referral or, if appropriate, make 
a normal referral. Practitioners could use these tools when they are in doubt, 
when the presenting symptoms are not clear, or when they are considering 
cancer as a differential diagnosis. Using these tools practitioners could then 
be alerted to investigate a patient’s symptoms based on their quantified risk 
information even if the patient does not qualify for urgent referral.  
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Another way of using the tools is through a series of ‘symptom checkers’ for 
patients in whom GPs have identified symptoms suggestive of cancer, which 
enable them to enter additional symptomatic information and update the 
cancer risk estimates. 
The tools could also be used to stratify the risk of patients outside a 
consultation. That is, for auditing, the tools could be used by practices to 
generate lists of all registered patients in whom a risk score can be calculated 
and sorted by the likely cancer type and risk category. 
It is also possible for the tools to be used to help monitor the risk level in 
patients who have been referred but turned out (initially) to be false positives 
(i.e. no immediate cancer diagnosis). Such patients can be advised on life style 
and other health risk modifications with the hope of reducing the initial risk to 
a lower (less harmful) level. 
What is the difficulty in how patients and practitioners perceive different levels 
of risk presented by the tools and the consequence of this? 
 
One difficulty in perception of the different levels of risk is that patients could 
be concerned about or even frightened when a low risk of cancer is generated 
using the tools, which practitioners may consider too small to act. This can 
happen if a risk level is not framed well by a practitioner during communication 
with patients who may perceive a relatively low level of risk as high. Therefore, 
the use of the tools can be difficult for both patients and practitioners, 
especially around understanding and communicating a risk generated.  
Another difficulty is the possibility of false positives and negatives which can 
lead to over-referral and under-referral respectively for investigations and 
diagnosis. This can result in unnecessary worry or anxiety on the part of 
patients, and practitioners may also be concerned about the consequences of 
these false positives and negatives and the resulting pressure on limited 




How do other types of risk prediction tools actually work? 
 
Other risk prediction tools like QRisk, a cardiovascular disease (CVD) risk 
prediction tool, estimate a patient's 10-year risk of developing cardiovascular 
disease [CVD] (Hippisley-Cox et al., 2008). This tool is used in the United 
Kingdom to identify high-risk people aged 30-84 years for primary prevention, 
calculating risk compared with the contemporary UK population, adjusted for 
variables such as obesity, social deprivation, ethnicity, rheumatoid arthritis and 
current treatment with anti-hypertensive drugs. It has been validated in the UK 
and is being updated every year to ensure that it takes account of changes in 
the population, improvements in data quality and changes in national 
guidelines and requirements (Tidy, 2016). 
Other CVD risk calculators are based on the Framingham risk equation, but it 
is thought that such tools have a limitation in terms of overestimating risk by 
about 5% for UK populations of men (Collins & Altman, 2012). Although the 
QRisk score is relatively less well established than the Framingham score, the 
wide range of advantages of QRisk (stated above) may explain why it is more 
widely integrated into all major GP computer systems and included in national 
guidelines (Tidy, 2016). This may also explain why it is preferred in the UK 
over the other CVD risk tools such as ETHRISK and other coronary risk 
prediction tools (e.g. ASSIGN, Reynolds risk score and INDANA etc). Other 
risk prediction tools, such as those for frailty; falls; dementia and admission, 
work slightly differently. These are discussed further. 
Frailty risk tools include the QFrailty categories (Hippisley-Cox & Coupland, 
2017), Electronic Frailty Index [eFI] (Clegg et al., 2016) and the LASA-Frailty 
Index [LASA-FI] (Hoogendijk et al., 2016). These tools work by grouping 
individuals into four categories: fit, mild, moderate and severe frailty, for 
example, in the QFrailty score based on an individual’s absolute risks of an 
unplanned hospital admission or death within a year (Hippisley-Cox & 
Coupland, 2017). 
Similar to the QFrailty score, the eFI score is calculated by the presence or 
absence of individual deficits as a proportion of the total possible (Clegg et al., 
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2016). This frailty risk tool aids identification of older people who are fit, and 
those who have mild, moderate and severe frailty. Hence, using the eFI tool, 
increasing severity of frailty suggests an older person is at increased risk of 
future nursing home admission, hospitalisation, longer length of hospital stay, 
and mortality (Clegg et al., 2016). 
The falls risk assessment score is considered better than other falls risk tools 
in primary care because it is able to discriminate between multiple and non-
multiple fallers; it identifies people at increased risk of multiple falls based on 
multiple performance items or risk factors including: low contrast visual acuity, 
tactile sensitivity, sit to stand, alternate step, and near tandem stand ability; 
and measures of previous falls and medications (Tiedemann et al., 2010). The 
ability of this tool to identify multiple falls is important since multiple falls within 
a 1-year period are more predictable and are likely to indicate underlying 
physiological impairments and chronic conditions (Newitt et al., 1989; Lord et 
al., 1994).  
Like the frailty risk tools mentioned above, admission risk tools such as the 
QAdmission tool can be used to assess individuals’ risk for hospital admission. 
However, unlike the frailty risk tools, the QAdmission tool predicts an 
individual's risk of emergency admission to hospital over the next one or two 
years based on a patient’s variables record including age, sex, ethnicity, and 
clinically relevant variables such as diagnoses, medication, prior admissions 
and laboratory measurements (Hippisley-Cox & Coupland, 2013). Hence, the 
QAdmission tool operates by identifying patients at high risk of an emergency 
admission for further assessment and management to reduce their risk of 
hospital admission. 
As for the cancer risk assessment tools, dementia risk scores work by 
predicting an individual’s risk of developing dementia. For example, the 5-year 
dementia risk score derived from primary healthcare data, can be used to 
predict a risk of dementia based on several risk factors: age, sex, social 
deprivation, smoking, BMI, heavy alcohol use, anti-hypertensive drugs, 
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diabetes, stroke/TIA, atrial fibrillation, aspirin, depression (Walters et al., 
2016).  
How are these cancer risk assessment tools based on ‘partial knowledge’? 
In the development of the QCancer algorithms there is a possibility of missing 
data, since not all patients with symptoms will attend their GP, and in those 
who do, not all symptoms will be reported or recorded by practitioners 
(Hippisley-Cox & Coupland, 2012). This could have resulted in an 
overestimate of the hazard ratios if they were derived from more severe 
symptoms, or an underestimate, if symptoms were not recorded (Hippisley-
Cox & Coupland, 2012).  
The cancer risk assessment tools of interest to this research are based on 
specific knowledge of risk factors. There are other risk factors which may not 
be recorded or added to the calculation of a patient’s cancer risk during 
consultation. One factor is genetic, for example the Breast Cancer (BRCA) 
genes. Recent estimates indicate that 55 to 65 percent of women who inherit 
a harmful BRCA1 mutation and around 45 percent of women who inherit a 
harmful BRCA2 mutation will develop breast cancer by the age of 70 years 
(Antoniou et al., 2003; Chen & Parmigiani, 2007). Environmental factors such 
as exposure to carcinogens like asbestos and soot are also important cancer 
risk factors. In fact, individuals who experienced consistent exposure to 
asbestos were found to have increased risk of mesothelioma. Yet, these 
environmental factors have been excluded in the cancer risk prediction 
algorithms, which may therefore underestimate risk of cancer in some 
individuals with histories of asbestos exposure. Another example relates to 
behavioural factors, e.g. exercise and diet, which are known to increase a 
person’s cancer risk (America Cancer Society, 2017). 
The use of these risk assessment tools may have psychological impacts for 
individual service users, patients and their carers or families. Such 
psychological issues related to risk assessment are discussed below. 
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3.6 Effects of cancer risk assessment  
Many individuals may express distress in the form of anxiety or depression 
when told about being at risk of developing a disease. Some level of distress 
may be useful in terms of promoting participation in risk assessments and 
adherence to risk related advice (Shaw et al., 1999). However, excessive 
distress can be harmful in many ways including: reducing individuals' quality 
of life; reducing understanding of information leading to poor informed 
decision-making about treatment options (Lerman & Croyle, 1995); and 
reducing participation in future risk assessment programmes (Kash et al., 
1992; Lerman et al., 1993). Evidence from a systematic review of the 
psychological impact of predicting individuals' risks of illness found several 
effects of positive test results including: increased anxiety; depression; 
psychological distress; intrusive thoughts; poor perception of health and 
absenteeism (Shaw et al., 1999). 
In this systematic review, the receipt of positive test results relates to a short-
term increase in anxiety (Bennett et al., 1990; Ironson et al., 1990; Huggins et 
al., 1991; Wardle et al., 1995; Bennett et al., 1995; LaPerriere et al., 1990; 
Croyle et al., 1997). However, the anxiety disappeared or decreased in the 
long-term (Ambrosio et al., 1984; Rudd et al., 1986; Perry et al., 1993; Jadresic 
et al., 1994; Pugh et al., 1994). This suggests that risk assessment related 
anxiety could be more of a problem in the short-term than in the long-term. 
Similarly, depression can be a problem in the short-term (Wiggins et al., 1992; 
Bloom & Monterossa, 1981; Antoni et al., 1991; Huggins et al., 1991; 
LaPerriere et al., 1990; Lerman et al., 1996; Croyle et al., 1997) following the 
receipt of a positive result for a risk assessment. Psychological distress also 
increased shortly after test results were given (Wiggins et al., 1992; Soghikian 
et al., 1981; Monk, 1981; Kash et al., 1992; Wardle et al., 1995; Reelick et al., 
1984). However, there was mixed evidence of the long-term effect of 
depression with some studies reporting an increase (Brandt et al., 1989; 
Sands et al., 1981; Fischer et al., 1990; Lerman et al., 1991; Codori et al., 
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1997; Quaid & Wesson, 1995;) while others reported a decrease in 
psychological distress (Wiggins et al., 1992; Mann, 1977).  
Another psychological effect of positive test results is intrusive thoughts, which 
evidence suggests can increase in the short term (Ironson et al., 1990) or 
decrease in the longer term (Hornsby et al., 1985). Perception of poor health 
is also a psychological effect which is more likely to occur among recipients of 
positive results (Bloom & Monterossa, 1981; Houts & McDougall, 1988).  
Overall, the evidence suggests that adverse psychological effects are a 
common immediate outcome of positive test results from risk assessment, but 
these disappear after about a month after receipt of test results (Shaw et al., 
1999). Also, explaining the test results to the understanding of patients and 
providing relevant support can be useful for reducing psychological distress 
generated by risk assessments, particularly for positive test results (Shaw et 
al., 1999).  
The above psychological effects of positive test results may also relate to how 
the risk or a test result is communicated to individuals, which is discussed in 
the next section. 
3.7 Communicating cancer risk  
Risk communication has been described as an open two-way exchange of 
information and opinion about risk, leading to better understanding and 
decisions about clinical management (Edwards et al., 2000; Edwards et al., 
2001., Schwart, 1999; Mazur, 2001; Elwyn et al., 2001; O’Connor et al., 2001; 
Wilson et al., 1988). This definition distances itself from the views that 
information is communicated only from clinician to patient and acknowledges 
that acceptability (or not) of the risk is communicated back (Edwards et al., 
2002).  
Similarly, risk communication has been defined as the “process of exchanging 
information among interested parties about the nature, magnitude, 
significance, or control of a risk” (Covello, 1992:359). Other definitions of risk 
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communication emphasise the need for dialogue between communicators and 
stakeholders (Palenchar, 2005), and the need for ongoing risk monitoring 
(Coombs, 2012).  
This dialogue refers, for example, to the discussion between a primary care 
practitioner and a patient about a result indicating a high risk of cancer. This 
may lead to the practitioner having to share some relatively unexpected or 
unpleasant information with a patient, which may be described as ‘breaking 
bad news’.  
Bad news has been described as information that affect an individual’s view 
of his or her future in an adverse way (Buckman, 1992). Breaking bad news to 
cancer patients has been described as “hitting the patient over the head” or 
“dropping a bomb” (Miyaji, 1993). Breaking bad news can be more stressful 
with a less experienced practitioner, when the patient is young, or if the 
treatment options are limited in their prospect of success (Ptacek & Eberhardt, 
1996).  
Despite the unpleasant nature of bad news, patients may still want to hear the 
truth. Since the late 1970s many practitioners have approached cancer 
patients with openness when telling them about their diagnosis (Novack et al., 
1979). However, evidence suggests that patients often desire additional 
information (Edwards et al., 2002). A study involving 1,251 Americans found 
96% desired to know if they had a diagnosis of cancer, while 85% wished to 
be told realistically how long they had to live (Morris & Abram, 1982), and these 
findings are supported by several other studies from the United States 
(Ley,1982; Cassileth et al., 1980; Blanchard et al., 1988; Davison et al., 1995; 
Sutherland et al., 1989; Dunsmore & Quine, 1995; Benbassat et al., 1998). 
Patient expectations for additional information have not always been met 
(Degner et al., 1997; Davidson et al., 1999; Hoffman et al., 1997; Lobb et al., 
1999). The wishes of European patients for further information in addition to 
the diagnosis are like those expressed by American patients: for example, a 
study involving 250 patients recruited from an oncology centre in Scotland 
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revealed 91% and 94% of patients, respectively, desired to know the chances 
of cure for their cancer and the side effects of treatment (Meredith et al., 1996). 
There are also ethical and legal imperatives driving patient – practitioner 
communication which relate directly to the problem of risk communication. The 
principles of informed consent and patient autonomy oblige doctors to provide 
patients with as much information as they desire about their illness and related 
treatment (Goldberg, 1984; Annas, 1994). In other words, GPs are expected 
to share medical information with the patient who requests it even if negative 
effects on the patient are anticipated. However, disclosing the truth needs to 
be done with concern for the sensitivity and the obligation to support the 
patients in their decision-making process; otherwise, the patient can be as 
upset as not being told the truth (Lind et al., 1989).  
Other barriers to communicating risk to patients are due to difficulties of 
breaking bad news on the part of the bearer of bad news. In the view of Tesser 
et al. (1971), the bearer of bad news may experience stress in the form of 
strong anxiety and a burden of responsibility for the news. This can lead to a 
reluctance to deliver bad news - the so-called “MUM” effect (Tesser et al., 
1971), particularly when the recipient of the bad news is already distressed 
(Tesser & Comlee, 1973). These risk communication problems may be more 
apparent when it comes to delivering bad news of possible cancer to patients 
(DelVecchio-Good et al., 1990; Buckman, 1984).  
The format for presenting risk information is crucial, as it affects both clinicians’ 
use of the tool and patients’ perception of risk (Usher-Smith et al., 2015). As 
mentioned earlier, a study with GPs and simulated consultations using the 
QCancer tool found that GPs preferred traffic-light colour coding of risks (red, 
amber and green) with secondary access to numeric risks, rather than initially 
being presented with absolute numeric risks or diagnostic guidance (Chiang 
et al., 2015). Despite this finding, it is possible that GPs may differ in their 
preferences and such preferences may change over time with different 
patients, so it is not entirely clear how best to present risk information to 
patients (Usher-Smith et al., 2015). From the field of cardiovascular disease, 
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it is known that numerical presentation of risk rather than simple risk categories 
together with time-frames of 10 years lead to more accurate risk perceptions 
(Usher-Smith et al., 2015). On the other hand, presenting relative risk 
reductions maximises acceptance of treatment and ‘heart age’ appears to 
increase intention to change behaviour (Waldron et al., 2011). 
Further problems of risk communication relate to the risk language, as terms 
like probably, unlikely and rarely may convey “elastic” concepts (Schydlower 
et al., 1995). That is, one person may interpret “likely” as a chance of 1 in 10, 
while another may understand it as a chance of 1 in 2 (Edwards et al., 2002). 
Also, there could be problems with the interpretation of numerical information. 
For example, Yamagishi found that death rates of 1286 out of 10 000 were 
rated as riskier than rates of 24.14 out of 100 (Yamagishi, 1997). 
In addition, the interpretation of the probabilistic elements of risk cannot be 
divorced from the importance of the harm, which includes the meaning of the 
harm and its implications for lifestyle and health (such as the threat of cancer). 
To standardise the language of risk, a scale with standardised terms for 
specified frequencies (for example, “high” for risks of 1 in 100 or greater and 
“moderate” for between 1 in 100 and 1 in 1000) has been proposed (Calman 
& Royston, 1997; Paling, 1997) to familiarise the public and professionals with 
different risks. This could have many advantages, although language evolves 
and patients may not interpret such standardised terms consistently over time 
(Edwards et al., 2002).  
Another risk communication problem arises from framing effects, due to 
different patient perceptions of prognosis depending on whether survival or 
mortality data are used (Wilson et al., 1988). Framing effects are also used to 
encourage individuals to adopt a course of action, such as pharmaceutical 
companies using persuasive techniques to present effects of their drugs to 
professionals. Similarly, a study on mammography revealed that using only 
information on relative risk was more “effective” in encouraging uptake (Slater, 
1998). While this may seem appropriate in some situations, such as 
maximising public health gain, using framing effects or persuasive approaches 
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may conceal the whole truth, which is inconsistent with genuine informed 
decision making (Elwyn & Edwards, 2001). Although these problems can 
affect the effectiveness of risk communication, adhering to recommended 
principles (outlined below in Box 4 below) can eliminate or minimise the impact 
of risk communication problems. 
Box 4 Principles for effective communication of risk information 
• Relative risk should not be presented in isolation. May use both absolute and relative risk 
formats, and information should be presented clearly. 
• It is advisable to present information as absolute risk such as percentages or integers 
(Skolbekken, 1998). 
• Present as ‘number needed to’, for example: Number needed to treat (NNT) and Number 
Needed to Harm (NNH). Number Needed to Screen, Number Needed to Test, and 
Number (of tablets) Needed to Take (NTNT) to Prevent an adverse outcome 
(Skolbekken, 1998). 
• Visual presentation of risk information. Many patients might prefer simple bar charts to 
other formats such as thermo-meter scales, crowd figures (e.g showing how many of 100 
people are affected), survival curves, or pie charts (Lipkus & Hollands, 1999; Fortin et al., 
2001). 
• Avoid overload of information. Many patients express a strong desire for information 
(Ende et al., 1989), but people's ability to assimilate information varies. Hence, it is useful 
to consider providing and discussing information over several consultations. 
• Risk information relevant to individuals is more valuable than average population data 
(Edwards et al., 2000). 
• Decision aids e.g booklets, tapes, videodiscs, interactive computer programs, or paper-
based charts, may help to present and discuss risk information with patients (O'Conner 
et al., 2001). 
• Paper based graphs can be used to support discussions with patients (Edwards et al., 
2002). 
• Patients could be referred to sources like the Database of Individual Patient Experiences, 
the UK National Electronic Library for Health, and Health Crossroads (Edwards et al., 
2002). 
• Time is a problem in the short term. External sources may enable much of information 
gathering from outside consultations. Discussions will still be required, but an investment 
of time at the decision-making stage may result in more succinct discussions in the future 




In addition to the above principles, the application of relevant risk 
communication theories might contribute to effective risk communication. 
Relevant risk communication theories for this study are presented below. 
3.8 Theoretical models that support effective risk communication 
From the perspective of this research, two theoretical models of risk 
communication are considered: the heuristic-systematic model (Griffin et al., 
2002) and the risk analysis [risk perceptions and communication unplugged: 
20 years of process] framework (Fischhoff, 1995). Although these theoretical 
models are both relevant to the research, more attention will be paid to the risk 
analysis framework (Fischhoff, 1995), because, despite its inherent irony, it 
provides helpful strategies to support how cancer risk information may be best 
communicated to patients in primary care consultations.  
 3.8.1 The heuristic-systematic model 
The heuristic-systematic model helps communicators like primary care 
practitioners to understand the connections between a person’s desire for 
accurate and sufficient information and their drive or ability to process that 
information (Griffin et al., 2002).  
While the heuristic part of the model looks at how individuals use superficial 
cues such as colour, visual information, or identity of the source to process 
information, the systematic part of the model looks at how individuals 
comprehensively analyse information to understand it (Sheppard et al., 2012). 
Hence, the overall model states that individuals will use superficial cues and/or 
comprehensive strategies in accordance with the risk situation. A review of 
three case studies investigating suspected cancer clusters in individuals found 
that superficial cues were associated with a lower evaluation of risk, and that 
individuals who focussed on message credibility instead of message content 
may have perceived the risk presented as being less important (Trumbo, 
2002). Additionally, being confident in one’s intellectual abilities was a good 
predictor of using shortcuts to make risk-based decisions (Trumbo, 2002).  
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Similarly, a study involving over 1,000 telephone interviews of adults living in 
the Midwestern United States found that individuals with previous knowledge 
(or hold strong beliefs) about the information presented were more likely to 
use systematic processing (Griffin et al., 2002). This suggests that, primary 
care practitioners with knowledge of processing abilities and interest in cancer 
risk may be able to adapt messages and determine how to best present 
complicated cancer risk information to patients. 
The heuristic model concentrates on how people use cues to make sense of 
information. This could be useful for patients understanding of risk information, 
but it does not help to understand how practitioners can best communicate risk 
information to patients. The risk analysis framework discussed below clearly 
outlines potential risk communication strategies as stages of risk 
communication, helping to explain how cancer risk information might be 
communicated to patients. 
3.8.2 The risk analysis framework 
The risk analysis framework consists of 8 developmental stages derived from 
a review of the history of risk communication research and practice over 20 
years (Fischhoff, 1995). The 8 stages or strategies are stated, partly ironically, 
with each stage being built on the previous stage as discussed in detail below. 
1. Get the numbers right 
This communication strategy places emphasis on accuracy of the risk, with no 
intention to mention the risk involved in a situation. Primary care practitioners 
may sometimes perceive they are experts who understand risk and may not 
see the need to tell a patient about their specific risk, or may feel that the risk 
is too small to tell a patient (Fischhoff, 1995). However, this approach can be 
problematic if the risk results in a complication and the patient questions why 
the risk was not mentioned in the first place. This ethical principle of autonomy 




2. Tell them the numbers 
This stage is about telling patients what the risk is, especially if this is 
demanded by the patient, but suggests this is done without offering any 
explanation. How well practitioners tell patients about the numerical risk 
numbers will depend on the accuracy of the numbers.  
There can be problems here depending on how the risk number is framed and 
presented, as there can be uncertainty and misinterpretation by patients. The 
uncertainty and misinterpretation can lead to mistrust, worry, anger and refusal 
to cooperate with investigations (Fischhoff, 1995). It is also possible that the 
patient will just follow instructions from the practitioner without questioning, 
which could mean a decision-making process which does not involve the 
patient. Hence, any unwanted consequences (e.g. anxiety or depression) 
experienced by patients following a misinterpretation of the results, in the case 
of a cancer risk assessment in general practice, can be blamed on the lack of 
explanation by practitioners. The next communication strategy that follows 
telling the numbers is about explaining what the numbers mean as discussed 
below.  
3. Explain what we mean by the numbers 
Relating this stage to the previous (second stage above), when the numbers 
told patients are not self-explanatory or understandable to patients, 
practitioners should explain them. Depending on the approach used, the 
explanation could end up confusing patients if technical or professional 
jargons are used, or expressions of uncertainty (Funtowicz & Ravetz, 1990) 
show up in the process of explaining what the risk numbers mean. 
While it is important for practitioners not to hide any information from patients, 
it is possible for patients to remain uncertain and even begin to question the 
risk information presented to them (Fischhoff, 1995). Hence, telling more than 
necessary information to the patient may not be helpful. Practitioners need to 
tell patients only about the risk information they need to know, although that 
will require thinking and knowing more about individual patient circumstances 
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(Fischhoff, 1995). It can be difficult to select the information patients need to 
know. However, practitioners may refer to evidence from researchers (Merz, 
1991; Merz et al., 1993) who selected a decision-relevant information by 
creating explicit models of peoples’ decisions. By applying the models to a 
medical procedure, Merz found that only a few of many side effects made 
practical sense. Hence, while practitioners should not hide any information 
from patients, their main concern should be to ensure the few important facts 
are understood by patients about their risk of a disease condition (Fischhoff, 
1995). 
4. Show them that they've accepted similar risks in the past 
This stage relates to comparing an existing risk with a new and different risk. 
For example, practitioners may ask patients to accept a risk of cancer because 
the patient might have previously accepted a risk for cardiovascular disease. 
However, even when they are created with a good intention, risk comparisons 
can backfire, since the two risk situations may not be the same. 
An example of comparison of risk is when practitioners try to impress upon a 
patient that there is a risk in everything (Freudenberg & Pastor, 1992), but 
there is limited evidence to support this claim (Zentner, 1979). Hence, 
comparison of risk may not be helpful for communicating risk information to 
individuals with different risk situations. 
5. Show them that it's a good deal for them 
This stage is like telling patients about the benefits of using cancer risk 
assessment tools and engaging in a discussion with the practitioner about 
possible referral for investigations. This may involve telling patients that the 
benefits outweigh the risk. However, there may be problems like ‘framing 
effect’ with presenting benefits versus risk. In ‘framing effects’ inconsistent 
evaluations may result from formally equivalent representations of the same 
trade-offs (Fischhoff, 1991; Fischhoff, et al., 1980; Hogarth, 1982; Kahneman 
& Tversky, 1984). For example, a health programme may appear more 
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attractive if described with respect to the lives to be saved as opposed to lives 
that will be lost (Fischhoff, 1995).  
Another example of framing effects is, explicitly showing the cumulative 
benefits of a protective measure, which may increase its attractiveness, 
although that can be inferred directly from its short-term benefits (Fischhoff, 
1995).  
Framing effects can also lead to suspicions of manipulations in the choice of 
frames. However, as with risk comparison in stage 4 above, the choice of 
frames does not necessarily indicate a bad or harmful intention, as 
practitioners may usually just choose to present a risk in the way that makes 
sense to them.  
6. Treat them nicely 
Individual people usually want to be treated with respect as people see 
disrespect as disenfranchising or disempowering. Hence, to communicate 
cancer risk effectively to patients, practitioners need to have a suitable 
demeanour, which is being recognised as a practical necessity (Fischhoff, 
1995). However, treating people with respect may be a challenge in terms of 
knowing the best way to communicate with them, but this challenge can be 
addressed with training in communication skills (Fischhoff, 1995).  
To effectively communicate cancer risk information to patients, in-person 
communication may be helpful, but this presents both pitfalls and 
opportunities. For example, blank looks and hostile expressions can quickly 
expose messages that need refinement, while adlib responses may make 
matters better or worse (Fischhoff, 1995). Also, nonverbal cues can support or 
undermine an open message. For example, nervousness over speaking can 
be misinterpreted as discomfort over what is being said. To help reduce or 
keep nervousness under control, practitioners involved in risk communication 
may benefit from training in presentation skills, and this can help to eliminate 
unnecessary suspicions (Fischhoff, 1995).  
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Another approach to communicating nicely and respectively with individuals 
like primary care patients is the act of a smooth delivery of the risk message. 
However, this approach may bring problems if the content of the message is 
inadequate, resulting in smoothness being misinterpreted as a substitute for 
substance (Fischhoff, 1995).  
7. Make them partners 
Being nice or respectful when communicating risk information is important but 
it is also important to make patients partners. Some people may have 
information to discuss or they may just want a seat at the table, and these are 
elements of partnership in risk communication (Hallman & Wandersman, 
1992). 
To encourage patient involvement when communicating risk information, 
practitioners should do well to ask patients for their views, and indeed, it will 
help to encourage patients to ask about any concerns they may wish to 
consider. Asking helps to redefine a relationship, in ways that recognise the 
public’s reality and competence (Fischhoff, 1995).  
Risk information about cancer, for example, should be presented in ways that 
suit patients’ understanding, and if practitioners perceive things differently, 
then a mutually respectful relationship will provide a forum for making their 
case clear to patients. Additionally, regarding cancer risk information, the more 
people know about a technology like a cancer risk assessment tool, the more 
they will like or dislike it-as its true colours emerge (Maharik & Fischhoff, 1993).  
Overall, it will be helpful for effective risk communication if practitioners 
recognise that patients are humans with emotions, and that a mutual 
partnership with patients is important for creating the human relations needed 
to avoid the social amplification of minor risks-as well as to generate concern 





8: All the above 
Fischhoff concludes that for effective risk communication all the seven stages 
or strategies should be combined, while ensuring that each strategy is used 
as it applies to a risk situation and communication. 
As mentioned above, this risk analysis model is chosen to inform this research 
because it more clearly informs the research question about risk 
communication. While the risk analysis framework presented here is meant to 
inform the question of how best to communicate cancer risk information, it will 
be useful to discuss a relevant implementation theoretical framework for 
informing the secondary research question about barriers and enablers to the 
implementation of cancer risk assessment tools. A relevant implementation 
theoretical framework is discussed below. 
3.9 Implementation theories 
To help inform the secondary research question about barriers and enablers 
to the implementation of cancer risk assessment tools, some relevant 
implementation theories were considered. These included: Normalization 
Process Theory [NPT] (May, 2006), Diffusion of Innovations [DOI] (Roger, 
1995) and the Consolidated Framework for Implementation Research [CFIR] 
(Damschroder et al., 2009). Although these three theories appeared relevant 
and are referenced in the discussion of the results where relevant, more details 
of the CFIR are presented here. This CFIR serves as the main theoretical 
framework for informing the barriers and enablers as reflect in the interview 
guide, the analysis, presentation and discussion of the results. This is because 
the CFIR provides a pragmatic structure which unifies and consolidates the 
overlapping key constructs from other relevant implementation theories 
through its five domains.  
3.9.1 Consolidated Framework for Implementation Research (CFIR) 
The CFIR is derived from 19 theories about dissemination, innovation, 
organisational change, implementation, knowledge translation, and research 
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uptake (Damschroder et al., 2009). Well-suited for implementation research 
on health service delivery, CFIR addresses the need to assess and maximise 
the effectiveness of implementation within a specific context and to promote 
dissemination to other contexts (Damschroder et al., 2009; Kalkan et al., 
2014).  
CFIR can inform the implementation of innovations like cancer risk 
assessment tools through its five domains (Damschroder et al., 2009): 
intervention characteristics, outer setting, inner setting, characteristics of 
individuals, and process of implementation. These five domains are all 
important, but as recommended (Damschroder et al., 2009), the first domain 
of the CFIR (the intervention characteristics), and specific constructs within the 
remaining four domains (the outer setting, inner setting, characteristics of 
individuals involved and the process of implementation) which are more 
applicable to this study were used. The fifth concept (the process of 
implementation) will be more applicable to future research relating to the 
piloting of QCancer in primary care settings. The five domains of CFIR and the 
constructs within them as shown in Figure 3 are described further. 
Figure 3 Main domains of the Consolidated Framework for Implementation 
Research 
 




3.9.1.1 Intervention characteristics 
Within the intervention characteristics, there are eight constructs that can 
influence the implementation of cancer risk assessment tools: intervention 
source, evidence strength and quality, relative advantage, adaptability, 
trialability, complexity, design quality and packaging and cost (Damschroder 
et al., 2009). 
The intervention source relates to the perception of key stakeholders as to 
whether an innovation was developed externally (outside their own setting) or 
internally [within their own setting] (Damschroder et al., 2009). Potential users 
of cancer risk assessment tools may be more willing to implement them in 
primary care consultations if they believe the tools were developed within 
primary care, rather than outside it. 
The strength and quality of evidence refers to the notion that stakeholders 
such as service users and practitioners may be more likely to adopt a new 
technology relating to cancer risk assessment tools, if they believe there is 
valid and accurate evidence in support of the effectiveness of the tools 
compared with current practice (Damschroder et al., 2009). That is, if there is 
evidence to suggest that using cancer risk assessment tools is linked with 
improvement in early diagnosis of cancer. 
From the perspective of CFIR, relative advantage relates to the notion that, 
people may be more willing to implement cancer risk assessment tools if they 
perceive them to be more effective than alternatives such as existing 
guidelines (Damschroder et al., 2009).  
In terms of adaptability, practitioners may be more likely to use the new tools 
if they thought that it was possible to tailor, refine or modify them to meet local 
needs (Damschroder et al., 2009).  
Trialability relates to the possibility of testing cancer risk assessment tools 
even on a small scale in primary care (Greenhalgh et al., 2004), and to be able 
to reverse its implementation if necessary (Damschroder et al., 2009).  
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The complexity of an intervention might discourage people who feel it will be 
difficult to use (Damschroder et al., 2009). This may be due to the duration 
and disruptiveness during patient consultations, and the number of steps 
required to implement the intervention. Integrating cancer risk assessment 
tools in general practice computer systems to facilitate use, and how best to 
communicate cancer risk information to patients, without causing undue 
anxiety, also relate to complexity. 
Design, quality and packaging might also contribute to the uptake of cancer 
risk assessment tools if the way the tools are presented is perceived as 
excellent (Damschroder et al., 2009). The final construct of the intervention 
characteristic is cost (Damschroder et al., 2009). This refers to costs of the 
intervention, implementation and opportunity costs. For example, extra 
consultation time and workload could represent additional costs to users of 
cancer risk assessment tools. 
3.9.1.2 Outer setting  
Outer setting is about the economic, political, and social context of an 
organisation (Pettigrew, 2001). Outer setting relates to the implementation of 
cancer risk assessment tools in terms of four constructs: patient needs and 
resources, cosmopolitanism, peer pressure and external policy and incentives 
(Damschroder et al., 2009). 
Patient needs and resources relate to knowing for example, how patients want 
to be communicated to (Damschroder et al., 2009). This could facilitate the 
use of cancer risk assessment tools, as communicating risk to patients 
currently appears to be problematic. 
Cosmopolitanism refers to the degree to which an organisation is networked 
with other external organisations (Damschroder et al., 2009). In this case, 
general practices within one network (or close networks) may influence each 
other to implement cancer risk assessment tools when they share their 
success stories about the impact or effectiveness of the tools. 
75 
 
Peer pressure may also play a vital role in the adoption of the new tools 
(Damschroder et al., 2009). This could relate to competitive pressure to use 
the tools because peer (e.g federated) general practices might have already 
implemented them or about to do so. In order, not to be left behind users may 
be influenced to implement cancer risk assessment tools as others have done.  
Similarly, the presence of external policy and incentives can encourage the 
implementation of cancer risk assessment tools in the primary care setting 
(Damschroder et al., 2009). For example, a government policy relating to pay-
for-performance or some other funding in support of implementation of the 
tools may encourage or promote their use among practitioners. 
3.9.1.3 Inner setting 
The inner setting is described as the features of structural, political, and 
cultural contexts through which the implementation process will proceed 
(Pettigrew, 2001). There are five constructs in the inner setting domain that 
may influence the implementation of cancer risk assessment tools: structural 
characteristics; networks and communications; culture, implementation 
climate and readiness for implementation (Damschroder et al., 2009).  
Structural characteristics can influence the use of the tools through the 
demographic characteristics of general practices such as a practice size or 
number of patients relative to the number of practitioners (Damschroder et al., 
2009). Practitioners may be reluctant to implement the tools if they feel that 
using them for their patients may give extra workload. This may particularly 
apply if they choose to use the tools for assessing all patients rather than just 
those suspected of cancer symptoms.  
Networks and communications refers to the nature and quality of relationships 
and formal and informal communications within an organisation (Damschroder 
et al., 2009). General practice staff who meet regularly to discuss improvement 
in practice including research findings and new ideas may be more likely to be 
interested in implementing cancer risk assessment tools. This is also linked to 
culture, in terms of norms and values of general practices and their 
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practitioners (Damschroder et al., 2009), which can influence them to value 
improvement in quality of care using innovations like cancer risk assessment 
tools.  
Implementation climate relates to the willingness of individual practitioners 
within an organisation to accept and implement innovations (Damschroder et 
al., 2009). The level of reception by practitioners will depend on the 
expectation or perception of the usefulness of cancer risk assessment tools. 
Implementation climate can influence the uptake of these tools in terms of: 
tension for change or practitioners perceiving the need for change relative to 
cancer risk detection; compatibility, that is, if use of the cancer risk assessment 
tools fits in with current practice and relative priority, or if use of the tools is 
considered most important relative to other innovations (Damschroder et al., 
2009). The presence of organisational incentives and rewards, goals and 
feedback and a learning climate are also implementation climate factors that 
can encourage the uptake of cancer risk assessment tools (Damschroder et 
al., 2009).  
In addition to the other constructs of inner setting, readiness for 
implementation can contribute to the implementation of cancer risk 
assessment tools if there are: favourable leadership engagements such as 
practice managers and leading partners committing to using the tools; and 
available resources such as extended consultation time and sufficient number 
of practitioners to support the use of the tools (Damschroder et al., 2009). 
3.9.1.4 Characteristics of individuals involved 
Potential individual users of cancer risk assessment tools may contribute to 
the implementation of the tools in a range of ways that are largely influenced 
by the individual characteristics (Damschroder et al., 2009). 
The knowledge and beliefs of individuals about the tools is relevant for their 
effective implementation, as individuals who value the tools as useful may be 
interested in using the tools in their practice. Self-efficacy is another 
characteristic of individuals that can contribute to the success of cancer risk 
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assessment tools implementation, in terms of self-efficient people utilising their 
capabilities to achieve the goals of planning and implementing the tools 
(Bandura, 1982; Damschroder et al., 2009). An individual practitioner’s stage 
of change (Damschroder et al., 2009), may also contribute to the 
implementation of the tools in consultation as they progress from the initial 
trialling to become more experienced and interested in sustaining the use of 
the tools in consultation.  
Another attribute relates to a practitioner’s identification with their general 
practice organisation (Damschroder et al., 2009). This could mean that 
practitioners who are committed to their general practices may be ready to use 
the tools if they perceive it as useful for improving consultation or practice. 
Other characteristics of individuals relate to personal traits. For example, 
potential users may support the implementation of the tools to succeed, if they 
are tolerant to ambiguity or uncertainty, less sceptical; or if they are innovators 
or early adopters (Roger, 1995).  
3.9.1.5 Process of implementation 
From the perspective of CFIR, the process of implementing cancer risk 
assessment tools may relate to four constructs: planning, engaging, 
implementation process and reflecting and monitoring (Damschroder et al., 
2009). 
Planning for implementation of the tools relates to a process of identifying 
relevant resources by users. It will also involve identifying how best the tools 
may be rolled out across practices. 
Engaging users of the tools may be achieved by developing a protocol and 
involving or training key practitioners [who may be innovators and early 
adopters (Roger, 1995)] at primary care general practices. Within the construct 
of engaging, the following influencing groups may support an effective 
implementation process: opinion leaders; formally appointed internal 
implementation leaders; champions and external change agents. 
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Executing, which is about carrying out or accomplishing the implementation 
plan relates to implementation of cancer risk assessment tools in terms of the 
rolling out process of the tools across general practices in primary care.  
The process of reflecting and monitoring relates to evaluative and feedback 
processes about the impact on quality of care following the use of the tools in 
patient consultations. In relation to this research, a formal evaluation of the 
impact of implementing cancer risk assessment tools may be one way of 
reflecting and monitoring the process of implementation. Another example 
relates to informal evaluations such as individual or group of practitioners 
discussing and self-questioning about the effectiveness of the tools on patient 
consultations and detection of cancer risk and diagnosis.  
Like other theoretical frameworks, CFIR has weaknesses but it also has 
strengths. One weakness is that the long list of constructs can be a source of 
confusion when all the domains and constructs are used in one study 
(Damschroder et al., 2009). Secondly, the broad and comprehensive nature 
of CFIR (which is also its strength) does not discriminate between the relative 
importance of its many constructs (Varsi et al., 2015). In this study, the 
weakness of CFIR were managed by being selective and giving more weight 
to some domains and the constructs within them than others. 
The CFIR is a useful implementation framework because of its strength of 
providing a broad and comprehensive list of clearly defined constructs for 
which data can be collected, and the possibility that CFIR can be used for 
outcome and impact evaluations. This is not only relevant for this study but will 
be relevant for the future research plans arising from the findings of this study. 
Several implementation studies have used CFIR. Some studies have used it 
as an evaluation framework (Alexander & Hearld, 2011; Kalkan et al., 2014; 
Williams et al., 2011), while others have used it for detecting factors influencing 
implementation (Kalkan et al., 2014; Sanchez et al., 2014; Ramsey et al., 
2014). Other studies have also used it for classifying influencing factors as 
facilitators or barriers (Lash et al., 2011; Robins et al., 2013; Balas et al., 2013). 
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More recently, CFIR has been used to inform a qualitative study to identify 
barriers and facilitators for the implementation of an internet-based patient-
provider communication service in five settings (Varsi et al., 2015). 
For this study, CFIR was used to inform the qualitative research design 
(including the methods [for example the interview guide] for data collection, 
the approach to the data analysis as well as the presentation and discussion 
of the results) to explore perceptions of service users and practitioners about 
the barriers and enablers to the implementation of cancer risk assessment 
tools use in primary care consultations.  
3.10 Conclusion of the chapter 
This conceptual background chapter has covered the key ideas underpinning 
the research. The policy structure and functions of primary care in the UK are 
discussed, and the referral or gatekeeping function of primary care is related 
to risk assessment for early detection using risk assessment tools.  
Issues relating to the effects of risk assessment and the communication of risk 
information are also discussed. Finally, theoretical frameworks that inform the 
research are discussed. These include a risk communication framework to 
inform how risk information may be best communicated to patients, and an 
implementation theoretical framework informing the implementation of cancer 
risk assessment tools in primary care consultations. Chapter Four follows this 









CHAPTER 4 METHODOLOGY 
4.1 Summary of the chapter 
The scoping literature review in Chapter Two identified two research 
questions: (i) What are the perceptions of service users and practitioners about 
how best cancer risk information can be communicated to patients during 
general practice consultations? (ii) What do service users and practitioners 
perceive as barriers and enablers (facilitators) to the implementation of cancer 
risk assessment tools?  
This chapter discusses the methodology in the context of these research 
questions aligned to the aims and objectives, the philosophical stance that 
informs the research design and methods. The chapter is therefore organised 
into the following four main sections: the aim and objectives, philosophical 
stance, qualitative research design and methods. The key points from these 
main parts of the chapter are stated in Section 4.2 below 
4.2 Key points  
 The key points in this chapter include a discussion of:  
• The aim and objectives which restated are to explore (i) the views of 
participants about how best to communicate cancer risk to patients, and 
(ii) the enablers and barriers to implementation of cancer risk 
assessment tools in primary care consultations 
• The philosophical stance, which highlights pragmatism as the position 
adopted for this research to enable the use of the methods which best 
address the research question, for example, the use of individual and 
focus group interviews and framework analysis to this study 
• The qualitative research design which led to an in-depth exploration of 
views of participants using individual and focus group interviews  
• Ethics and governance approval from the relevant bodies obtained 




4.3. Aim and objectives of this study 
The aim of this study was to explore the perceptions of service users and 
practitioners about the use (implementation) of cancer risk assessment tools 
in primary care consultations. The specific objectives were set: 
• To explore the perceptions of service users on how best cancer risk 
information can be communicated to patients during a consultation 
• To explore what service users and practitioners perceive as barriers 
and enablers to the implementation of cancer risk assessment tools in 
primary care 
• To compare the service user and practitioner perceptions 
• To make recommendations for practice and further research. 
The next section discusses the philosophical stance for this research. 
4.4 Philosophical stance 
This research was grounded in a philosophical position for the following 
reasons. Firstly, it enabled understanding of the different methods which might 
be employed. Next, it helped refine and clarify the research methods used to 
gather the relevant evidence to appropriately address the research questions 
and aim of this thesis. The relevant philosophical lens that informs the 
research is discussed below. 
4.4.1 Relevant philosophical lenses considered 
Research philosophy includes ontology, axiology and epistemology, each of 
which influence consideration of the research process. Ontology refers to the 
nature of reality and assumptions about the way the world operates, whereas 
axiology concerns judgments about value, and epistemology the theory of 
knowledge in a field of study (Blaikie, 2009).  
Ontology is often considered in two polar forms: objectivism and subjectivism. 
Objectivism relates to the position that social entities exist externally to social 
actors concerned with their existence (Saunders et al., 2012; Bryman, 2012). 
Subjectivism (sometimes called constructionism or interpretivism) relates to 
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the position that social phenomena are created from the perceptions and 
consequent actions of those social actors concerned with their existence 
(Bryman, 2012).  
Epistemology is sometimes considered in terms of a continuum between 
positivism and interpretivism: both are considered in relation to the current 
study. Positivism usually relates very specifically to a set of beliefs about 
objective reality which can be verified scientifically (Saunders et al., 2009) 
whereas interpretivism is about understanding social phenomena in the social 
contexts in which they are constructed and reproduced through their activities 
(Ormston et al., 2013 in Ritchie et al., 2013:19).  
There are several interpretivist approaches in research that were considered 
for this study: symbolic interactionism, phenomenology, realism, hermeneutics 
and naturalistic inquiry (Gray, 2004). Symbolic interactionism relates to the 
symbolic meaning people develop and use in social interactions (Blumer, 
1969). Phenomenology relates to the experiences of people about an event 
and how those experiences are interpreted (Willis, 2007). Realism relates to the 
idea of independence of the reality from the human mind, and this is classified 
into two types: direct and critical realism (Saunders et al., 2012; Novikov & 
Novikov, 2013). Hermeneutics places emphasis on subjective interpretations 
in the research of meanings of texts, art, culture, social phenomena and 
thinking, while naturalistic enquiry relates to how people behave when they 
are in genuine natural settings (Frey et al., 1999). 
Research approaches are usually seen somewhere on a positivist or 
interpretivist scale, with a deductive reasoning often used by positivist 
researchers while an inductive reasoning is usually used by interpretivist 
researchers. While a deductive approach to research relates to the 
development and testing of a conceptual or theoretical framework using 
empirical observations, an inductive research relates to the development of 
theory from observing a phenomenon (Hussey & Hussey, 1997; Goddard & 
Melville, 2004; Bradford, 2015).  
83 
 
While inductive approaches are usually associated with qualitative research, 
deductive approaches usually relate to quantitative research (Gabriel, 2013). 
This gives the impression that the deductive and inductive approaches are 
opposites. However, there are no fixed rules as some qualitative studies may 
have deductive elements (Gabriel, 2013). In fact, individual researchers 
usually fall somewhere along the continuum between the inductive and 
deductive approaches (Deshpande, 1983; Bryman, 1988). This might relate to 
the view that the research question should determine the approach to be used 
(Mays & Pope, 1995; Silverman, 2005; Creswell, 2007).  
This study has both deductive and inductive elements because it involved 
using data to explore existing theory as well as generating new theory from 
the research question, so a pragmatic position was adopted which enabled a 
framework approach to be used (Richie & Spencer, 1994). Framework is a 
type of thematic data analysis (Boyatzis, 1998; Braun & Clarke, 2006) which 
is appropriate for analysing both deductive (‘a priori’) and inductive (‘de novo’) 
themes. A pure interpretivist inductive approach such as grounded theory 
(Glaser & Straus, 1967) would have only addressed the inductive element 
while the framework approach was useful in supporting a mixed inductive and 
deductive approach to coding and analysing the qualitative data (Boyatzis, 
1998; Fereday & Muir-Cochrane, 2006; McQueen et al., 2009). Pragmatism 
as adopted for this study is discussed in Section 4.4.2 below. 
4.4.2 Pragmatism  
The philosophical assumptions underlying this research are based on a 
pragmatic stance, which it is argued, is appropriate for answering the research 
question. Pragmatism is a philosophical view that the research question 
should determine the methods used (Saunders et al., 2009). Thus, a pragmatic 
researcher may adopt a middle or dual position between positivist and 
interpretivist positions to appropriately address a particular research question 
(Goles & Hirschheim, 2000). The pragmatic position is often adopted in mixed 
method research which uses multiple methodological approaches, such as 
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combining the quantitative and qualitative research designs to address a 
research question.  
However, since pragmatism supports the research approach that best 
addresses the research question, it can also inform the use of qualitative 
designs, particularly where these employ a dual interpretivist-positivist 
(inductive-deductive) approach to the collection and analysis of qualitative 
data to appropriately address a specific research question. This pragmatist 
position guided the selection of the qualitative research approach (Section 4.5 
below) and the specific methods used for the data collection and analysis, 
which are presented in Section 4.6 below. To inform and provide a background 
understanding to the specific methods selected for this study, the qualitative 
research approach is discussed in Section 4.5 below. 
4.5 Qualitative research design 
This study aimed to explore the perspectives of service users and practitioners 
on how cancer risk information could be communicated to patients. The study 
also aimed to explore what participants perceived as barriers and enablers to 
implementation of cancer risk assessment tools. Hence, a qualitative research 
design was considered most appropriate. The qualitative research design as 
the approach of choice for this study is discussed here in comparison with the 
quantitative research design which is one of the main research designs 
commonly used by researchers in the study area. In doing so, I provided 
reasons in support of the choice of the qualitative research approach for this 
study. 
Both the qualitative and quantitative research methodologies have been 
referred to as processes used to collect data for any research (Clark, 1999; 
Lincoln & Guba, 2000), but there have also been arguments for and against 
qualitative and quantitative research methodologies (Clark, 1999; Lincoln & 




Qualitative research methodology implies a process where researchers realise 
that all knowledge-production is related to the perceptions that researchers 
take with them to their study (Clark, 1999). Here, reality is argued to be 
'knowable' except that it may be imperfect. Hence, qualitative researchers 
seek to get as close as possible to the meanings attributed to different words 
and actions by the research participants they want to study. Mostly, using the 
constructivist paradigm, researchers in the qualitative divide have much 
interest in the co-construction of knowledge between the researcher and the 
research participants. Through this, any bias with the situation is discussed 
between the researcher and the participant (Clark, 1999). 
Qualitative research has also been described as a universal term of 
interpretive techniques that can be used to describe, decode, translate and 
understand the meaning of some naturally occurring phenomena in the social 
world (Van Manen, 1990; Al-Busaidi, 2008). Hence, researchers regard 
qualitative research as the approach of choice when the main goal is a search 
for meaning, understanding and to generate ideas (Rotchford et al., 2002). To 
generate ideas qualitative studies usually address clearly defined questions 
that begin with words like: ‘how’, ‘why or ‘what’ (Greenhalgh, 2007).  
Qualitative research designs are useful for a range of reasons (Snape & 
Spencer, 2003). Firstly, qualitative research allows research participants to 
express their views about a phenomenon or subject of study. Secondly, 
qualitative research is open ended, in the sense that respondents’ own 
priorities can lead the data collection. In addition, small samples which are 
common in qualitative studies allow rich or detailed data to be collected and 
such data may also be context-rich. 
However, qualitative interpretive approaches have been criticised in several 
ways. These include criticisms relating to the issues of bias, issues in 
replicating a study, lack of precision, and issues relating to trustworthiness and 
validity. From the view of some critics, qualitative approaches may not be 
independent of the unmethodical observations of the researcher, in addition to 
establishing close ties with the individuals studied (Bryman, 1994; Bryman, 
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2001). Qualitative strategies may be difficult to reproduce, in the view of its 
critics. This may be so because of the individuality of the study participants, 
the fact that the interview questions during interviews may be unstructured, 
and the direct involvement of the researcher in data collection process. I have 
reflected on some of these issues in this study, and I have highlighted the 
relevant limitations in the discussion of the results in Chapter Six.  
In contrast to qualitative research, quantitative research often places 
emphasis on generalisability, which ensures that, the knowledge arising from 
the research is representative of the population a study sample represents 
(Palinkas et al., 2015). The empirical data is then regarded as a reflection of 
the real world, thereby constituting what is considered as adequate knowledge 
(Bryman, 2001). This position suggests that research is devoid of personal 
values, meanings, and moral judgments. Hence, quantitative approaches 
which are usually based on methods such as surveys could be used to 
generate quantitative data to measure the outcomes of implementing cancer 
risk assessment tools such as rates of investigations, referrals and diagnoses. 
However, this approach cannot adequately explore in-depth views or 
perspectives of service users and practitioners as this study seeks to achieve. 
Consequently, the qualitative research approach and related methods are 
considered most suitable for exploring the research questions in this study. 
Depending on the subject of investigation, qualitative researchers usually 
employ a wide range of data collection methods which include individual 
interviews, focus groups, participant and non-participant observations and 
documentary analysis (Denzin & Lincoln, 2005; Greenhalgh, 2007). When 
qualitative research designs involve the use of interviews, these could be 
unstructured or semi-structured and may include a list of open-ended 
questions that allow for the participant to respond and express what is 
important to them.  
The decision to use the qualitative research design for this study was guided 
by a pragmatist position, using both deductive and inductive approaches as 
highlighted in Sections 4.4.1 and 4.4.2 above. In line with this position, 
87 
 
individual and focus group interviews based on semi-structured questions 
were used to collect data, and framework method was used for analysis. 
These are discussed further within the methods used for this study in Section 
4.6 below. 
4.6 The methods used for this study 
The previous sections in this chapter have explained the philosophical lens 
(pragmatism) and methodological (qualitative) approach taken by the 
researcher in the conduct of this study. These positions informed the selection 
of the methods for the data collection and analysis for this research. This 
section now describes recruitment of participants, collection and analysis of 
data.  
The qualitative study took place in three phases to address the research 
questions stated in Section 4.1 above. Before describing these phases, the 
study setting is described. 
4.6.1 Setting 
The study was set in Lincolnshire, a large rural county in England. Cancer 
statistics from Lincolnshire show that more than 4,500 people are diagnosed 
with cancer each year and over 2,100 ultimately die of the disease, accounting 
for 29% of all deaths in the area annually (Lincolnshire Public Health 
Observatory, 2012).  
Cancer prevalence rates within Lincolnshire are significantly higher than the 
national average. Someone is diagnosed with cancer every two minutes in the 
UK (Cancer Research UK). Cancer in England is on the rise, with the number 
of cancer diagnoses expected to reach over 300,000 a year by 2020 (Cancer 
Research UK). This increase is reflected in Lincolnshire with a rising diagnosis 
of all cancers.  
The most common cancers in the UK are breast, lung, colorectal and prostate 
cancers (ONS, 2017; Lincolnshire Research Observatory, 2017). Of these, 
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colorectal cancer is the most common in Lincolnshire (Lincolnshire Research 
Observatory, 2017).  
Early diagnosis of cancer across Lincolnshire is poor in comparison to national 
averages (Lincolnshire Research Observatory, 2017). This may be due to 
patients in Lincolnshire presenting their symptoms at a late stage in primary 
care (Lincolnshire Research Observatory, 2017), or it may be due to late 
detection by practitioners.  
4.6.1.1 Cancer survival in Lincolnshire 
Reports from the Lincolnshire Research Observatory show the picture of 
cancer survival in Lincolnshire (The Lincolnshire Research Observatory, 
2017), as follows. One-year survival rates for all cancers across Lincolnshire 
are comparable to the national average (70.2%), South Lincolnshire (72.3%) 
is the only Clinical Commissioning Group (CCG) area where survival rates 
exceed the national equivalent. Of the defined types of cancer, survival rates 
are highest for breast cancer (all Lincolnshire CCGs have over 95.8% survival 
rate), with rates comparable to England (96.7%). Around three quarters of 
adults across Lincolnshire initially diagnosed with colorectal cancer survive at 
one year (all Lincolnshire CCGs have over 73.9% survival rate) compared to 
the national average of 77.7%. One-year survival rates for lung cancer at 
between 30.5% and 39.4% are much lower across Lincolnshire but are like the 
national average of 35.4%. Any measures to improve early diagnosis in 
Lincolnshire could potentially improve the cancer survival further. 
4.6.1.2 Cancer mortality in Lincolnshire 
Mortality information from the Lincolnshire Research Observatory shows the 
picture of cancer mortality in Lincolnshire (The Lincolnshire Research 
Observatory, 2017), as follows below. 
Premature cancer mortality rates in Lincolnshire are lower than the national 
equivalent for all persons (both male and female). Deaths from all cancers 
were lowest across South and South West Lincolnshire and highest in 
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Lincolnshire East. Between 2012 and 2014, there were 2,896 cancer deaths 
of people aged under-75 in Lincolnshire. Lung cancer deaths made up the 
largest proportion of cancer deaths. In the same period, Lincolnshire West had 
672.8 Potential Years of Life Lost (PYLL) per 10,000 due to cancers, while 
South West Lincolnshire had 627.8 PYLL per 10,000. In comparison, the 
national equivalent rate was 620.5 PYLL per 10,000. Hence, all areas of 
Lincolnshire present higher rates of PYLL. 
The overall cancer mortality rate in Lincolnshire was 274.3 per 100,000 
population in 2012-14, closed to the national rate of 276.8 per 100,000. 
Lincolnshire East had the highest mortality rate of 283.6 per 100,000, and 
South Lincolnshire had the lowest mortality rate of 258.4 per 100,000 
(Lincolnshire Research Observatory, 2017). 
The three phases of the study, the perspectives of service users (Phase 1), 
the perspectives of practitioners prior to using the tools in general practice 
consultations (Phase 2) and the perspectives of practitioners after they have 
used the tools in general practice consultations (Phase 3), are presented in 
the following sections. 
4.6.2 Phase 1: Service user perspectives 
Phase 1 was aimed at exploring views of service users on using cancer risk 
assessment tools in primary care consultations. Service users were recruited 
from public places which included the: The University of Lincoln; the central 
library located in Lincoln city centre; community centres; and voluntary groups.  
4.6.2.1 Sampling 
A purposive sample of service users (aged 18 years and above) was recruited 
from the public. In deciding on the sample size of participants for this 
qualitative study, the aim of the research, the resources available including 





While there may be other factors that affect sample size in qualitative studies, 
researchers generally use saturation as a guiding principle during their data 
collection and analysis (Mason, 2010). Glaser & Strauss (1967) argue that, if 
the principles of qualitative research are complied with, sample size in most 
qualitative studies should generally follow the concept of data saturation. In 
fact, in a recent study, the concept of data saturation has been described as 
important in guiding sample sizes in qualitative studies (Hennink et al., 2016). 
Hennink and colleagues believe that, data saturation relates to code saturation 
(researchers have heard it all) with about 9 interviews and meaning saturation 
(researchers have understood it all) with 16 to 24 interviews (Hennink et al., 
2016). This phase of the study clearly achieved both code and meaning data 
saturation with the 19 service users. Thus, the achievement of both code and 
meaning data saturation were the main reasons why it was decided not to 
recruit more service users. 
4.6.2.2 Recruitment of service users for individual interviews 
As mentioned above a purposive sample of individual service users (n=19), 
with an interest in the delivery of cancer services who might have survived 
cancer or had a relative or friend who might have survived cancer, or who 
might have an interest in cancer for other reasons and who were 18 years or 
older) was recruited from the public through three different approaches.  
Service users who might have survived cancer or had a relative or friend who 
has survived cancer were recruited instead of people with cancer, mainly 
because cancer risk assessment tools are used in people who are yet to be 
diagnosed with cancer and are less relevant to people already diagnosed with 
the condition. Moreover, cancer risk assessment tools are meant for use with 
people presenting with initial symptoms (which may be those of cancer to aid 
earlier diagnosis), rather than those already diagnosed with cancer. Service 
users who had survived a previous cancer, were included in the study because 
in was considered that they would also be interested in early diagnosis of a 
(subsequent) cancer. In addition, although some cancer patients might have 
important views to contribute, it was important to balance this with the need to 
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avoid causing potential distress to patients with active or recent cancer during 
the interviews. The three approaches are described below.  
Recruitment plan 1 (through voluntary groups) 
A consultation about the research was carried out with the Healthier Ageing 
Patient and Public Involvement (HaPPI) group. This consultation included the 
development of the participant information sheet containing information about 
the study, informed consent and topic guide materials.  
The HaPPI group, which was established by the Community and Health 
Research Unit (CaHRU) at the University of Lincoln in 2014, works with 
CaHRU researchers to: inform bids for funding, give a patient and public 
perspective on current research projects, review documents to help make 
them more accessible to the public and actively help with the recruitment of 
participants for studies. For this study, the HaPPI group members assisted 
with the identification of individuals from voluntary groups that were willing to 
participate in the research, as HaPPI group were also involved in several other 
voluntary groups. These voluntary groups are concerned with supporting 
those individuals with cancer or their relatives, or those who might have 
survived cancer or having a relative or friend who has survived cancer. 
A flyer (see Appendix 2.4) was provided to these representatives, who raised 
this information with their group members. For groups that agreed, the flyer 
about the research was placed on their notice boards or websites with details 
to contact the researcher. Interested individuals then contacted the researcher 
and they were given information about the research by post or by email as 
preferred by participants (see Appendices 2.1 and 2.2 for copies of participant 
invitation letters and participant information sheets respectively). Participants 
then confirmed their willingness to participate in the research after reading the 
information about the research. This recruitment plan helped to recruit a total 
of 8 participants, which was considered successful relative to the total number 




The only challenge of this plan was that some participants preferred to be 
interviewed at their own homes, and there was a potential risk of external noise 
and interruptions when the interviews were conducted at participants’ homes. 
However, this was managed with the help of participants, by having the 
interviews in a quiet location in a participant’s home, and participants advised 
their family members not to interrupt once the interviews were in progress.  
Recruitment plan 2 (through the University of Lincoln community) 
The second approach was to recruit participants from the University of Lincoln 
community. Information about the research was sent out using a flyer (see 
Appendix 2.4 for copy of flyer) to students and staff through the University 
Daily Alerts System. As in Plan 1 above, a flyer was sent out to potential 
participants aged 18 years and above (who might have survived cancer or 
having a relative or friend who has survived cancer or having an interest in 
cancer for another reason) inviting them to participate in face-to-face individual 
interviews. The information on the flyer indicated clearly that, individuals 
interested in participating in the research should contact the researcher for 
further details about the research. The contact details for the researcher (email 
address and telephone number) were stated on the flyer, which was sent out 
to students and staff through the University Daily Alerts System. Participants 
who expressed interest through email or telephone to the researcher, were 
contacted by the researcher with information (see Appendices 2.1 and 2.2 for 
copies of service user invitation letters and participant information sheets 
respectively) about the research. Participants then contacted the researcher 
again to confirm their willingness to participate after reading the information 
sent to them by email as preferred. Following this, an appointment for a face-
to-face individual interview was arranged with participants. 
This recruitment plan yielded 9 participants (consisting of students and 
University staff). This plan appeared to be the most successful, relative to the 
total number of 19 participants, in terms of the promptness in contacting the 
researcher after hearing about the research through the University Daily Alert 
System, and in terms of the number of participants that responded and agreed 
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to participate. It is possible that the willingness of students and staff to 
participate in the research was influenced by their membership of the 
University community, which is a research or academic setting. However, my 
perception after interviewing and interacting with participants was that, the 
University students and staff were willing to participate in the study because 
of their interest in cancer services. There were no real challenges as all 
interviews were conducted in University interview rooms, which were pre-
booked for the interviews. 
Recruitment plan 3 (through the central library and community halls in Lincoln)  
Flyers (see copy in Appendix 2.4) were put up at the central library and 
community halls in Lincoln with permission from the respective authorities. The 
information on the flyer was clear that, individuals interested in participating in 
the research should contact the researcher for further details about the 
research. The contact details for the researcher (email address and telephone 
number) were stated on the flyer. Participants who expressed interest by 
emailing or telephoning the researcher, were contacted by the researcher with 
information about the research (see Appendices 2.1 and 2.2 for copies of 
service user invitation letters and participant information sheets respectively). 
After reading the information sent to them, participants then contacted the 
researcher again to confirm their willingness to participate, and an 
appointment for a face-to-face individual interview was arranged. This plan 
yielded only two participants and may be considered the least successful 
relative to the total number of 19 service user participants. It could be that 
people saw the flyers at the central library and community halls, but they were 
either not interested in cancer research or they could not find time to 
participate in the research. 
Summary of the recruitment procedure for service users 
Once interested participants were identified the researcher contacted them 
with a research pack consisting of invitation letters and participant information 
sheets with the contact details of the researcher using their preferred method 
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of contact. Participants were asked to contact the researcher to confirm their 
willingness to participate and to arrange a date for a face-to-face individual 
interview or for more information if they wished to know more about the 
research. The information sheet was clear that participation was entirely 
voluntary, and participants were free to withdraw from the study at any stage 
without giving reasons for their withdrawal. Any information already collected 
was not used if participants so wished. It was made clear to participants that 
all the data collected would be treated as confidential and only key members 
of the research team would have access to the data. Twenty-four hours prior 
to the interview, the participant was contacted again, to discuss any concerns 
and to reiterate that they were free to withdraw at any time or stage of the 
research. 
4.6.2.3 Data collection using individual face-to-face interviews with 
service users 
To capture relevant and detailed views of service users about the use of 
cancer risk assessment tools, semi-structured questions were used to conduct 
face-to-face interviews with individual service users. The interview guide for 
the individual interviews was piloted with two members of the HaPPI group 
who participated as service users. The semi-structured questions were then 
refined following comments from the pilot interviews. 
Face-to-face individual interviews based on semi-structured questions were 
preferred for the data collection because these techniques offered several 
advantages (Gubrium & Holstein, 2002). One advantage was that, these 
techniques offered the researcher the opportunity to obtain detailed and varied 
information from participants. Secondly, these allowed the researcher who 
conducted the interviews to utilise social cues such as voice, intonation and 
body language (Opdenakker, 2006). These social cues gave the interviewer a 
lot of extra information relative to the topic of interest or what the interviewer 




However, face-to-face interviews can lead to interviewer effects, for example 
when the interviewer guides the interviewee in a special direction (Gubrium & 
Holstein, 2002). In study, this disadvantage was minimised by using an 
interview guide (Patton, 2015), and by the awareness of the interviewer of this 
effect. For this purpose, the interview guide (see Appendix 2.5) was designed, 
pilot tested with members of HaPPI group, and then revised for the data 
collection. Furthermore, in conducting the interviews care was taken not to 
misguide the service users towards the researchers own perceptions about 
the topic being discussed. 
A further advantage is that face-to-face interviews can be recorded with the 
permission of the interviewee. Using a recorder can be useful in enhancing the 
accuracy of the interview report than writing out notes. However, recording 
also brings with it the danger of not taking any notes during the interview. 
Taking notes during the interview is important for the interviewer, even if the 
interview is audio recorded for the following reasons: to check if all the 
questions have been answered and in case the recorder fails to function. In 
addition, transcribing recorded interviews can be time consuming. In the view 
of Bryman (2001), one hour of a recorded interview can take up to six hours 
to transcribe. In this research, the data were recorded using a digital voice 
recorder, and some notes were taken which proved useful when part of the 
recording for one service user was not clear and the service user was not 
available to be interviewed the second time. Thus, my analysis for 
approximately 10 minutes of a 50-minute interview with one service user was 
based on partial written notes, rather than a verbatim transcript. 
Another advantage of the face-to-face interview method is that it is apparent 
when the interview is finished as compared to other methods (Wengraf, 2001). 
At the end of the interviews service users were thanked for their cooperation 
and asked if they had further remarks. This sometimes led to emergence of 
new information from some participants (Wengraf, 2001).  
It is worth noting that some individuals preferred to be interviewed at their own 
homes where they felt comfortable, while others preferred to be interviewed at 
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an interview room in the University. The choices of participants were 
respected. For those who preferred to be interviewed at the University, a quiet 
and comfortable interview room was booked, and participants were given 
directions to the room. Participants who were interviewed at their own homes 
ensured there was a quiet and comfortable home environment conducive for 
a face-to-face individual interview. 
During the individual face-to-face interviews with service users 
At the interviews, I introduced myself as the researcher. I then explained and 
clarified concerns about the research and the consent forms (see Appendix 
2.3 for copy of service user consent form) were signed by the participant 
before the commencement of the interview. Introductory questions were 
asked, and then three vignettes of how cancer risk assessment tools (using 
the QCancer tool as an example) work were shown to service users. Each 
vignette showed how some risk factors and symptoms presented by a person 
could be entered in the QCancer tool to calculate a cancer risk represented by 
blue sad faces (those at risk of having cancer within two years) and yellow 
smiley faces (those not at risk of cancer).  
After showing the vignettes to interviewees and using the interview guide 
(which was informed by the theoretical frameworks discussed in Chapter 3, 
Sections 3.8 and 3.9), questions were asked to explore the views of 
participants about cancer risk assessment tools relative to the research 
questions in mentioned earlier. During the interview, care was taken to support 
the individual being interviewed. For example, it was planned that if an 
individual became distressed, the interview was to be stopped, the recorder to 
be switched off and support to be provided. The interview was only to be 
continued if the individual felt ready and happy to continue. If the individual 
wished to continue but preferred to do so on another day, this was to be 
respected and a further interview was to be arranged. Where individuals 
became distressed in the interview and wished to withdraw this was to be 




Prior to leaving, I asked the individual interviewee if they wished for me to 
contact their GP, their friends or family. Interviewees were encouraged to 
contact their GP if they became distressed later after the interviews. In 
addition, it was planned that additional support such as counselling was to be 
arranged in consultation with the individual’s GP, if they required it. However, 
throughout the interviews no participant experienced distress and no one 
required referral to their GP or a counselling service. When all the semi-
structured questions were asked, each interview was terminated by thanking 
participants, reassuring them of maintaining confidentiality of the data, and 
then asking them if they had any more information to add. 
Period of data collection from service users 
Overall, the process of recruitment and interviewing the 19 service users 
lasted a total of 12 months (from March 2014 to February 2015). About half of 
this period was used for the interviewing of service users (from September 
2014 to February 2015). 
4.6.3 Phase 2: Practitioner perspectives before using the tools 
The aim of this phase of the study was to explore the views of primary care 
practitioners about using cancer risk assessment tools in patient consultations. 
The setting for this phase of the study was primary care general practices in 
Lincolnshire. General practice settings were selected because these were 
considered the first point of access for service users with health problems or 
concerns. Hence, general practice settings are likely places where a person’s 
risk of developing cancer based on their presenting symptoms can first be 
detected. Additionally, practitioners whose views are required before the 
cancer risk assessment tools may be implemented are usually located in 
general practice settings. 
The sampling and sample size of practitioners, recruitment of practitioners and 
data collection using individual and focus group interviews with practitioners 




4.6.3.1 Sampling and sample size of practitioners  
The target population was all practitioners in general practice settings in 
Lincolnshire, but a purposive sample of 17 practitioners (Practice Nurses and 
GPs who were interested and willing to participate in the research) were 
interviewed. Although the resources available were considered important in 
determining the sample size for the research, the researcher was prepared to 
interview more participants. However, only the 17 practitioners responded to 
the invitation and expressed interest to participate in the research. The 
researcher could have sent more invitation letters and reminders to 
practitioners who had not responded. However, after analysing the data 
collected from 17 practitioners, no new themes or ideas were generated, and 
so this was considered a data saturation point. Therefore, the 17 practitioners 
were recruited based on the principle of data saturation as discussed above 
under sample size for service users (see Section 4.6.2.1 above). 
4.6.3.2 Recruitment of practitioners for individual and focus group 
interviews 
There were two approaches to the recruitment of practitioners. Practitioners 
with an interest in the delivery of cancer services were identified through the 
Lincolnshire Community Health Service (LCHS) NHS Trust.  
The research pack consisting of invitation letters and participant information 
sheets with the contact details of the researcher (see Appendices 2.1 and 2.2 
for copies of practitioner invitation letters and participant information sheets) 
was given to interested practitioners by the LCHS. After reading the research 
pack, practitioners then contacted the researcher to confirm their willingness 
to participate and to arrange a date for either individual interviews or focus 
groups and/or more information about the research. 
The information sheet was clear that participation was entirely voluntary and 
that participants were free to withdraw from the study at any stage of the 
research without having to explain their reasons for withdrawal. Any 
information already collected was not used if participants so wished. It was 
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also made clear to participants that all the data collected would be treated as 
confidential and only key members of the research team would have access 
to the data. Twenty-four hours prior to the interview, the individual practitioner 
was contacted again to discuss any concerns and to reiterate that they were 
free to withdraw at any time.  
The practitioners who participated in focus groups made it easy for me to meet 
them by inviting me to one of their monthly meetings. Interested practitioners 
then stayed after their meeting to attend a focus group discussion with me. In 
total, there were 17 practitioners, 12 of whom participated in focus groups, and 
5 in individual face-to-face interviews, as described below in the data collection 
with practitioners using individual and focus group interviews. 
4.6.3.3 Data collection with practitioners using individual interviews and 
focus groups 
To capture relevant and detailed views of practitioners to address the research 
questions, individual interviews and focus groups were used as preferred by 
practitioners. This approach has been used in previous studies for exploring 
research questions around improving the quality of clinical care (Lambert & 
Loiselle, 2008; Togher et al., 2013; Davy et al., 2015). 
As for the service users in Phase 1, the practitioner interview guides 1 and 2 
(see Appendix 2.5) for the individual interviews and focus groups with 
practitioners were piloted. My supervisor who is a practising General 
Practitioner also reviewed the interview guide and offered useful suggestions. 
The semi-structured questions were then refined making use of the comments 
and suggestions offered.  
The individual interviews with practitioners 
In order, not to miss the valuable contributions of practitioners who were 
unable to join focus groups, they were interviewed as individuals. A total of five 
practitioners from five different practices were recruited for individual 
interviews. The advantages of using individual interviews with service users 
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noted above (see Section 4.6.2.3) also apply to the use of individual interviews 
with practitioners. For example, the face-to-face individual interviews with 
practitioners were useful in terms of making it easier to explore issues in depth. 
Other practitioners were willing to be interviewed in focus groups as discussed 
below. 
Focus groups interviews with practitioners 
As mentioned above, practitioners from 2 general practices were willing to 
meet up for group discussions. Hence, two focus groups (1 in each of the two 
practices) were conducted. There were 6 participants (2 practice nurses and 
4 GPs) in each focus group making a total of 12 participants for the focus 
groups. 
One important feature of the focus groups in this study was the opportunity for 
the research participants (practitioners in general practice) to be involved in 
discussing the possibility of using cancer risk assessment tools in primary care 
consultation, which can potentially inform a policy decision (Race et al., 1994), 
about the implementation of the tools. Rather than relying on the views of 
individual practitioners, it was useful to have practitioners who usually work as 
a team, to meet up in a group to discuss and share their views about using the 
tools. 
The focus group discussions also had the advantage of empowering the 
participants as this was an opportunity for practitioners to be valued as 
experts, with the opportunity to express their views through working with 
researchers (Goss & Leinbach, 1996), and contributing to the validation of 
cancer risk assessment tools that could be useful in primary care 
consultations. Although, focus groups can be intimidating especially for 
inarticulate or shy participants (Gibbs, 1997), this was not the case in this study 
as all the practitioners in the focus groups actively participated in the 
discussion. Also, primary care practitioners have very busy schedules and it 
is usually difficult to get them to meet in groups for research data collection. 
Fortunately, for this research, more practitioners were willing to meet up for 
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focus group interviews or discussions. The details of what happened during 
the individual and focus group interviews are described below. 
During the individual and focus group interviews with practitioners 
During the individual interviews and focus groups, practitioners were asked 
introductory questions and then shown an actual working cancer risk 
assessment tool (using the QCancer tool as an example) whenever it was 
possible to do so. Whenever it was not possible due to lack of internet 
connection, the three vignettes of the QCancer tool were shown to them. 
Questions were then asked to explore the views of practitioners in respect of 
the research questions. With permission from participants, the interviews were 
recorded and later transcribed verbatim for analysis. 
At the individual interviews and focus groups, I explained or clarified any 
concerns about the research and the consent forms (see Appendix 2.3 for 
copy of practitioner consent form) were signed by the participant before the 
commencement of the interviews. During the interviews, care was taken to 
accommodate the practitioner’s work schedules. For example, it was planned 
that if the practitioner was unable to continue with the interview for some 
reason such as work pressure, the interview would be stopped, and another 
appointment arranged to complete the interview.  
However, there were no problems during the interviews. The individual 
interviews and focus groups commenced and finished as scheduled with no 
interruptions. As in the individual service user interviews described above, the 
individual interviews and focus groups with practitioners were terminated by 
thanking participants, reassuring them of maintaining confidentiality of the 
data, and then asking them if they had any more information to add. 
Period of data collection from practitioners 
I anticipated challenges such as practitioners being too busy and not having 
enough time to participate in the interviews. However, this was not the case, 
as interested practitioners arranged to meet and be interviewed within 
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reasonable time of receiving the invitation to participate in the study. Overall, 
the process of recruitment and interviewing of the 17 practitioners lasted a total 
of 6 months (from April 2015 to September 2015).  
4.6.4 Phase 3: Practitioner perspectives after using the tools 
The aim of this phase of the research was to explore the perspectives of 
practitioners after they had used the cancer risk assessment tools, and to 
compare these perspectives with those expressed before the use of the tools. 
Any other perceptions expressed by practitioners after using the tools were 
also considered. 
The practitioners that had already participated in the earlier individual 
interviews and focus groups were contacted, and practitioners from only one 
general practice agreed to meet up to discuss their perceptions after using the 
cancer risk assessment tools. An initial meeting with practitioners in this 
practice revealed that they had not used the tools in patient consultations since 
hearing about the tools during the initial data collection for this research. The 
practitioners however, agreed to use the tools with patients for a minimum of 
one month before sharing their views and experiences. A focus group 
discussion which consisted of 4 practitioners (all GPs) was subsequently 
arranged and conducted as agreed.  
These 4 practitioners also participated in one of the earlier focus groups. As 
these practitioners were already part of the study, the sample size of 17 
practitioners remained the same. Also, the conduct of this third focus group 
with practitioners was as discussed for the first and second focus groups with 
practitioners in Section 4.6.3.3 above. 
4.6.5 Data analysis  
I considered several qualitative data analysis methods including grounded 
theory and interpretive phenomenological analysis (IPA) approaches before 
choosing the framework approach (Richie & Spencer, 1994) for this study.  
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Grounded theory is an approach for developing theory that is grounded in data 
systematically gathered and analysed (Glaser & Strauss, 1967; Strauss & 
Corbin, 1994). In grounded theory, the data analysis is mainly inductive and 
arising from the data collected, which usually leads to the development of a 
theory.  
However, this study has some elements of both inductive (arising from the 
data collected) and deductive (a priori) themes. The deductive themes were 
derived from the interview guide which related to the cancer risk assessment 
tools and the relevant constructs within the risk communication framework 
(Fischhoff, 1995) and implementation theoretical framework (Damschroder et 
al., 2009) chosen for this research. Hence, while grounded theory was a 
possible approach, it was considered less suitable for this study. Similarly, IPA 
was considered unsuitable at this stage of the research because, the 
phenomena (cancer risk assessment tools) had not yet been experienced by 
majority of the participants so their experiences could not be analysed. Indeed, 
all the service user participants and most of the practitioners expressed their 
views and beliefs before the tools were used in patient consultations.  
The framework approach was developed by social policy researchers in the 
UK (Ritchie & Spencer, 1994), as a pragmatic approach to different types of 
research, and is increasingly used in healthcare studies (Furber, 2010; 
Swallow et al., 2011; Tierney et al., 2011). Framework approach was 
developed for addressing specific questions. In that sense, it is an applied 
research approach that is useful for informing both policy and practice (Ward 
et al., 2013). The framework approach (Ritchie & Spencer, 1994), was used 
for the data analysis in this study, because this approach is appropriate for 
analysing both inductive and deductive data. It was useful for analysing the 
data in this study as it allowed for different aspects of the phenomenon under 
investigation to be covered (Ritchie & Lewis, 2003). The process of data 





4.6.5.1 The process of framework analysis in this study 
The analysis of the data in this study was conducted using the five stages of 
the Framework approach: familiarization; identifying recurrent and important 
themes; indexing and charting; summarising the data and mapping and 
interpreting. 
Stage 1: Familiarisation – through immersion in the data 
This stage usually involves immersing in the details of each transcript, to gain 
a sense of the whole interviews prior to dividing them into sections and 
identifying recurring themes (Rabiee, 2004).  
In this study, I familiarised myself with all the transcripts. I undertook all the 
interviews and transcription which enhanced my effort to fully familiarise 
myself with the data (Ritchie & Lewis, 2003). In addition, I read the field notes 
(that I made immediately following each interview) alongside the transcripts to 
ensure that the context was taken into consideration. I also found the field 
notes useful when it came to the development of the codes or themes and 
indexing later in the analysis process (in stages 2 and 3 below). It is known 
that field notes enable the researcher to record what is seen and heard during 
interviews, what thoughts and feelings occur and issues that may be relevant 
during analysis (Arthur & Nazroo, 2003).  
Due to a large volume of data in some qualitative studies, not every piece of 
material may be reviewed at this stage (Srivastava & Thomson, 2009). 
However, in this study, I felt that the sample size was small enough for all 
transcripts to be studied. This ensured that all data from all participants were 
considered and that no data were overlooked. Although a considerable 
amount of time was spent reviewing all the transcripts, it was worth the time 
commitment for a full inclusion and understanding of data. 
Stage 2: Identifying recurrent and important themes 
At this stage, the recurring codes identified in stage 1 above can be added to 
a chart either on paper or using a computer software such as NVIVO, Microsoft 
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excel (Swallow et al., 2003) and Microsoft Word (Furber, 2010). In this study, 
the recurrent codes were added to an NVIVO version 10 software to facilitate 
the analysis process. Referring and comparing with the framework of 
deductive themes (see Tables 11-13 and Tables 14-16 in Chapter Five) which 
was derived from the interview guide which related to the relevant constructs 
within the theoretical frameworks for this research), a framework of inductive 
themes (see Tables 11-13 and Tables 14-16) were derived from immersing in 
the data and in consultation with my supervisory team. This stage took several 
weeks to complete because it was as time consuming as the first stage above. 
Stage 3: Indexing and charting 
At this stage I applied the framework of themes developed in stage 2 above 
back to the transcripts. This allowed me to become further immersed in the 
data, and the themes were refined (Ritchie & Lewis, 2003). The decisions I 
took at this stage were based on similarities and differences between initial 
themes and themes becoming clearer through further data immersion. It was 
identified that some themes in the initial framework could belong in either of 
the initial themes. This formed the basis for the adjustment of themes to more 
accurately reflect the data. At this point a refined framework resulted to ensure 
that the themes were grouped into key themes. 
Stage 4 Summarising data  
This stage allowed me to reduce the material into understandable but brief 
summaries of what was said by participants (Ritchie & Lewis, 2003), to support 
the themes identified. Again, I used a computer package (NVIVO) to manage 
the data, making it easy for me to link summaries back to full text in the 
transcripts (Swallow et al., 2003). 
Stage 5 Mapping and interpreting 
This stage demonstrates the transparency of framework analysis, because at 
each stage, the analysis process can be compared back to the original data, 
which enhances rigour as well as facilitating the inductive and iterative 
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approach in qualitative research (Ezzy, 2002). At this stage of the data 
analysis, I reviewed the charts to see the whole data set. This included 
checking the summaries on the charts against the original data and comparing 
the themes with each other to see if any further merging of themes was 
required. However, no changes were required to be made to the themes, and 
the final framework of themes was agreed. These final themes were then 
described, interpreted and presented as the results.  
4.7 Ethics and governance 
In the UK, all research on National Health Service (NHS) patients must be 
approved by a Local or Multicentre Research Ethics Committee (LREC or 
MREC) (Central Office for Research Ethics Committee, 2006), and non-NHS 
research may require approval from one or more other bodies such as a 
university ethics committee or a school governing body. Ethical approval from 
a formal body does not necessarily make a research study ethical, nor does 
the refusal of an ethics committee to grant approval necessarily make it 
unethical, though it may make it illegal to continue with the project (Rotchford 
et al., 2002; Rocha, 2004; Central Office for Research Ethics Committee, 
2006). However, active involvement of participants such as service users and 
practitioners in the management and governance of the research projects may 
reduce the chance of unethical practices (Central Office for Research Ethics 
Committee, 2006).  
The data collection for this study did not involve NHS patients. Therefore, an 
NHS Ethics approval was not required. The protocol for the research was 
reviewed and approved by the College of Social Science Ethics Committee of 
the University of Lincoln (see Appendix 3.1). The issues that were potentially 
of ethical concerns in relation to the recruitment and data collection procedures 
with service users and practitioners included: informed consent, anonymity, 
confidentiality and data storage. 
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4.7.1 Informed consent  
Informed consent, usually in the form of a document signed by the research 
participant, relays all relevant research information, such as risks and benefits, 
to the potential participants (Rotchford et al., 2002; Rocha, 2004; Central 
Office for Research Ethics Committee, 2006). This allows the participants to 
make an informed decision about participating in the research, and it also 
allows for the confirmation of anonymity among all research participants. 
However, informed consent is not merely a legal requirement or a document 
to be signed; it is a communication process between the researcher and the 
participant that starts before the research is initiated and continues throughout 
the study (Rotchford et al., 2002; Rocha, 2004; Central Office for Research 
Ethics Committee, 2006). Therefore, it is important that the information 
provided is understood by the potential participant and empowers that person 
to make a voluntary decision about whether to participate in the study. 
Subsequently, the participant is given the opportunity to withdraw from the 
research at any time before the end of the study without giving any reasons.  
To ensure informed consent for the recruitment and collection of data from 
service users and practitioners in this research, in accordance with the 
National Patient Safety Agency (NPSA) and National Research Ethics Service 
(NRES) guidance, the research procedures described below for recruitment of 
participants, collection and analysis were followed in relation to the anonymity 
and confidentiality of the data (NPSA & NRES, 2010).  
4.7.2 Anonymity of the data 
Safeguarding the research data especially personal identifying information is 
a key part of the relationship of trust and respect that exists between the 
researcher and the participant. Depending on the type of study, researchers 
are expected to take steps to ensure privacy and confidentiality by 
anonymising personal identifiable information such as names, birthdates and 
places of residence (Department of Health, 2005; Department of Health, 
2008). This may be done by: 
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• Using participant codes to label data instead of using names, and 
keeping a separate list of code-to-name match-ups 
• In interview studies, using the participant’s first name only (or even 
using an alias) when recording or publishing data to help protect the 
participant 
• Being careful not to publish enough information that the participant can 
be identified. 
To ensure anonymity of the data collected from service users and 
practitioners, several measures were observed. Firstly, all interviews were 
transcribed anonymously, removing names and identifiable locations of all 
participants. The data were transcribed by the researcher who holds a current 
Disclosure and Barring Service (DBS) document as an NHS employee. 
Secondly, once the interviews were transcribed, the software version of the 
anonymous transcriptions were stored in a University of Lincoln password 
protected computer and hard copies of data were stored in a locked file cabinet 
stored in a locked office at the Community and Health Research Unit 
(CaHRU), University of Lincoln. Only the researcher and his supervisor had 
direct access to the soft and hard copies of the data. 
4.7.3 Data confidentiality 
One of the conditions on which informed consent depends is respect for the 
privacy of participants. Hence, a participant should not be forced to reveal 
information to the researcher that the participant does not wish to reveal. 
Confidentiality of the information is important (Rotchford et al., 2002; Rocha, 
2004; Central Office for Research Ethics Committee, 2006), and researchers, 
particularly those involved in medical research, are responsible for 
safeguarding personal information that participants have agreed to disclose.  
To ensure confidentiality of the data collected from participants in this 
research, the data were stored in a confidential manner per the requirements 
of the research governance framework for health and social care (Department 
of Health, 2008). In line with this, it was planned that all relevant data would 
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be archived confidentially for seven years after the study. It was made clear to 
participants that all the data collected would be treated as highly confidential. 
4.7.4 Governance and access  
Research governance is the system of administration and supervision through 
which research is managed, participants are protected, and accountability is 
assured. In the UK, the main reference point is the Research Governance 
Framework for Health and Social Care (Department of Health, 2002) whose 
stated purpose is to enhance ethical and scientific quality, promote good 
practice, reduce adverse incidents and ensure lessons are learned.  
The protocol for the study was reviewed and the governance and access to 
NHS premises and staff were granted by the Lincolnshire Community Health 
Services (LCHS) NHS Trust (see Appendix 3.2). The University ethics and 
NHS governance approvals were received before the commencement of data 
collection. As an NHS employee, the researcher did not require a research 
passport. Instead, the researcher was granted access to NHS premises and 
staff (Practitioners).  
4.8 Insurance and indemnity for the research 
Insurance and indemnity for the participants (practitioners) was covered within 
the NHS Indemnity Arrangements for clinical negligence claims in the NHS, 
issued under cover of Health and Safety Guidance (HSG) (96) 48. There were 
no special compensation arrangements, but study participants had recourse 
through the NHS complaints procedures. Service user participants recruited 
from the public (Non-NHS participants) were covered by the University of 
Lincoln Insurance and Indemnity Arrangement for researchers and research 
participants. 
4.9 Trustworthiness 
Various approaches have been published for assessing trustworthiness or 
quality of qualitative studies (Mays & Pope, 1995; Mays & Pope, 2000; 
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Barbour, 2007). For this study, several measures were carried out, contributing 
to the trustworthiness of the results from this research.  
Firstly, the interview guide was piloted with two volunteers who were members 
of the HaPPI group and acted as service users. The project supervisor who is 
a GP, also reviewed the semi-structured questions within the interview guide. 
This helped to refine the interview guide.  
The audio recorded interviews and transcripts were shared with my supervisor 
who confirmed the quality of the recorded data and the detailed transcripts. 
The analysis process base on the Framework technique, was overseen by my 
supervisor. The codes or themes and subthemes generated from the analysis 
were shared with all members of my supervisory team who then met with me 
and discussed, and we agreed on the final themes and subthemes. 
Applying the Framework technique to the data gathered 
In Section 4.6.5.1 above, I have described the process of data analysis in line 
with the five key stages of the framework data analysis. The Framework 
approach to qualitative data analysis is suitable for analysing data with both 
deductive (a priori) and inductive themes (Richie & Spencer, 1993). Using the 
framework approach in my analysis meant a framework of several deductive 
or a priori themes were predetermined based on key concepts or themes from 
the theoretical frameworks selected for the study. In fact, these theoretical 
concepts formed the basis for the interview questions stated in the interview 
guides. Using each of these deductive themes, data or statements from each 
interviewee that matched or fitted the deductive themes were noted down as 
codes.  
The codes were then examined, and similar codes were grouped into one 
overarching theme. This was repeated for all the transcripts of individual 
interviews and focus groups. While looking out for codes that agreed with the 
deductive themes, some unexpected but relevant codes emerged from the 
data and these were also noted down as inductive themes until a point of data 
111 
 
saturation was reached - no new codes emerging from additional transcripts 
of data. 
The relationship of the use of Framework analysis to the theoretical 
frameworks 
The relationship of this framework analysis to the theoretical frameworks, lies 
in the fact that, the framework of deductive themes used to guide the search 
for appropriate codes from the data, were derived from the relevant key 
concepts or themes of the theoretical frameworks that informed the study. 
These concepts also helped in the design or formulation of the interview guide 
and questions for the data collections.  
Presentation of the results at a GP Educator 
In addition to the above measures of trustworthiness for this study, the results 
were presented in the form of a workshop which was attended by 15 GP 
Educators at a conference organised by the GP Educators in Lincolnshire. The 
GP educators were also practitioners in their respective general practices and 
some of them had already participated in the individual and focus group 
interviews conducted for this study. I was invited by the organisers of the GP 
Educators conference to coordinate the workshop relating to the research 
findings from this study. To begin the workshop, I asked the GPs to discuss in 
groups the following questions which related to the findings from the research:  
• Group 1: What are the implications for you as a GP using cancer risk 
assessment tools to quantify cancer risk? 
• Group 2: What are the potential benefits of cancer risk prediction tools 
in general practice consultations? 
• Group 3: In what ways, can cancer risk information be discussed with 
patients? 
• Group 4: What do you perceive as barriers to the use of cancer risk 
assessment tools in general practice consultations? 
Each group then shared their reflections on the above questions to the rest of 
the groups. After the discussions, I presented the actual results from the study 
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to the workshop participants. It was clear that the results were in line with the 
reflections of the workshop participants in relation to the questions they had 
discussed. This was confirmed by participants when they were asked for their 
reflections at the end of the presentation of the results. The workshop was an 
opportunity for me to listen to the views of GP Educators. It was also an 
opportunity for me to share the findings from my study with them, a group who 
were likely to use cancer risk assessment tools in patient consultations as well 
as share the information about the tools with other practitioners under their 
mentorship. 
4.10 Conclusion of the chapter 
The aim of the study was to explore the perspectives of service users and 
primary care practitioners about how best cancer risk information can be 
communicated to patients; and the enablers and barriers to the 
implementation of cancer risk prediction tools. This Methodology chapter has 
presented the pragmatic philosophical stance which informed the use of 
individual interviews and focus group techniques, and the analysis of the data 
using the framework analysis method. The pragmatic stance of this study was 
to allow for a combination of the inductive and deductive (that is to combine 
the interpretivist and positivist) elements in this research with respect to the 
data analysis. 
The ethics approval for the study was granted by the College of Social Science 
Ethics Committee, University of Lincoln. The research governance and access 
to primary care practitioners were granted by the Lincolnshire Community 
Health Services NHS Trust. These ethics and governance documents were 
received before the commencement of recruitment of participants, data 
collection and analysis of the data. 
There was a purposive sample of 19 service users recruited from the public 
and 17 primary care practitioners recruited from general practices in 
Lincolnshire. This resulted in a total sample of 36 participants from whom data 
were collected and analysed.  
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The data collection was done using face-to-face individual interviews with 
service users. Face-to-face individual interviews and focus groups were also 
used to collect data from primary care practitioners. The interview guide was 
developed in line with the relevant constructs within two theoretical 
frameworks [a risk communication framework (Fischhoff, 1995) and 
Consolidated Framework for Implementation Research (Damschroder et al., 
2009)] which were chosen for this research. The interview guide was piloted 
with two members of the Healthier Ageing Patient and Public Involvement 
group (HaPPI). Comments from the pilot interviews and the project supervisors 
were used to refine the semi-structured questions within the interview guide. 
In addition to piloting the interview guide, the trustworthiness of the results of 
the study was established through several measures in the research process. 
These measures included presentation of the results at a GP Educators 
conference in Lincoln. The workshop was attended by several practitioners 
some of whom had participated in the interviews. The process of data 
collection, transcription and analysis was shared, discussed and agreed with 
the project supervisory team, adding to the trustworthiness of the results. The 
results of the qualitative data analysis are presented in Chapter Five, which 
















CHAPTER 5 RESULTS 
5.1 Summary of the chapter 
The aim of this chapter is to present the results of the qualitative study 
addressing the two research questions: 
i. What are the perceptions of service users and practitioners about how 
best cancer risk information can be communicated to patients during 
general practice consultation? 
ii. What do service users and practitioners perceive as enablers and 
barriers to the implementation of cancer risk assessment tools?  
The results are organised into: the characteristics of the participants (Table 
10); summary of the codes and themes from the analysis of the qualitative 
data (Tables 11-13 and Tables 14-16 below); perceptions about how best to 
communicate cancer risk; and perceptions about the enablers and barriers to 
implementation of cancer risk assessment tools. These are presented in terms 
of the perceptions of participants before and after using cancer risk 
assessment tools. Participants (service users and practitioners) were 
interviewed before and only practitioners were interviewed after they had used 
cancer risk assessment tools in patient consultations. 
For Phase 3, the interview guide was redesigned to accommodate 
practitioners who had used any of the cancer risk assessment tools of interest 
(either RAT or QCancer). During the data collection, practitioners discussed 
their perceptions after using the tools but indicated that they preferred 
QCancer to the RAT because QCancer was easier to understand and use, 








5.2 Key points 
The findings presented in this chapter include: 
• Suggested ways to best communicate cancer risk information to 
patients during a general practice consultation. These include tailoring 
a visual representation of risk; being open and honest; involving 
patients in the use of cancer risk assessment tools and providing time 
for listening 
• Perceived enablers to the implementation of cancer risk assessment 
tools including supporting clinical decision-making; identifying and 
modifying health risk behaviours; improving process and speed of 
assessment and treatment; personalising care and ease of use 
• Perceived barriers to implementation of cancer risk assessment tools 
including: additional time requirement; worry or anxiety related to 
referral for investigations; potential over-referral; conflict with existing 
guidelines; symptoms suggestive of cancer will need referral whatever 
the quantified risk; need for integration of the tools into all general 
practice IT systems; need to involve secondary care or hospital 
consultants and other specialists in the use of the tools; and the need 











5.3 Characteristics of participants  
The characteristics of participants are presented in Table 10 and described 
further below. 
Table 10 Participant characteristics 
Thirty-six participants, 19 service users (aged between 21 and 71 years) and 
17 practitioners (aged between 33 and 55 years) were interviewed. Out of the 
19 service users, there were two who had survived cancer, and the rest either 
had relatives or family members and friends who had survived cancer, which 
motivated them to participate in the study. The summary of codes and themes 
following the data analysis are presented in the next section. 
5.4 Summary of the codes, themes and quotes 
The themes and quotes following a framework analysis informed by the 
relevant theoretical frameworks are presented in Tables 11-13. 
  Service users Practitioners 
Gender    
 Male  7 13 
 Female 12 4 
Age group    
 20-29 3 - 
 30-39 4 3 
 40-49 1 10 
 50-59 3 4 
 60-69 5 - 
 70-79 3 - 
Ethnicity    
 White British 19 6 
 Indian - 6 
 Pakistani - 3 
 Asian British - 1 
 Bangladeshi - 1 
Practice 
patient list size 
   
 200-2900 - 1 
 3000-3900 - - 
 4000-4900 - - 
 5000-5900 - - 
 6000-6900 - 8 
 7000-7900 - - 
 8000-8900 - - 
 9000-9900 - 8 
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Table 11 How best to communicate cancer risk information – themes, codes and quotes  
Stages of risk 
communication 
framework 
 Key words/phrases/codes Key themes Meaning of 
themes 
 Quotes 
 Service users (SU) Practitioners (P) 
Services users Practitioners  
-Tell them the 
numbers 















of risk e.g. 





n of risk 
 
 
Seeing the risk 
presented in a 
visual way will 
enhance 
understanding  
“I really like this. I like the pictorial 
representation; I like the fact that it is 
simple but it's effective because it 
draws you really right to the point. You 
know the happy faces and a mixed of 
smiley and sad faces can get you an 
idea. I think it is simple and clear so 
most people will be able to understand 
this and take that information on board 
as opposed to if the doctor just 
mentions cancer risk it will put you off. 
But if you look at this and they talk you 
through this I think that will be really 
useful” (SU12: individual interview) 
“I like the smiley faces as well, it's a good 
way of showing things. But I think it should 
be lined not random. I will like the blue sad 
faces to be in line, in a row, otherwise if 
they are scattered it gives the impression 
that they are many when they are not. 
And it's easier to read when they are lined 
in rows” (P 6 [GP]: Focus Group1) 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-Listen to patients 
during consultation 
-Explain to patient’s 
understanding 
-Both oral and 
written information 
(to take away) 
-General 
information patients 





















how to explain a 
person’s risk (to 
both patient and 
practitioners) 
















Enough time for 
informing and 
explaining will 




- “You wouldn't want to feel that you've 
been rushed, you would want them to 
take time to talk with you, and if they try 
to cut this conversation short you 
would think that they didn't care, and 
again that could reduce your 
confidence” (SU12: individual 
interview). 
 
- “I think with that, if you're looking 
more likely that you're going to have 
something then I suppose you would 
probably want some reassurance, 
more also about treatment. But 
whereas before it's coming up which 
you were worried, I think it's probably 
now that you need reassurance that is 
finding it early and treatment, if it can 
be treated and if they know the risk of 
having it there's also the possibility of 
surviving it” (SU5: individual interview). 
 
- “What I feel is, I would try and give as 
much time as possible and be as accurate 
as possible” (P1 [GP]: individual 
interview). 
 
- “I normally give them a chance to ask 
questions, what they think, what they 
know about cancer and the kind of 
support they will need” (P3 [GP]: 
individual interview). 
 
-In contrast: “It’s more a question of more 
time really, because at the moment we're 
in crisis, GPs are in crisis, and the future 
is very bleak for GPs. Because you come 
in at 5 in the morning and you get back 
home in the night and it’s a nightmare 
really. So, we don't want more work” (P6 
[GP]: Focus Group1) 
 
- “talking about risk is quite difficult” (P3 




- “In my opinion clinicians should 
discuss the patients' risks with them, 
but they should take time to do so in a 
professional and responsible manner 
in order to help the patient understand 
and feel less worried about their 
situation” (SU15: individual interview). 
 
- “Yes, you wouldn't want them to 
speak in difficult medical terms; you 
would want them to bring it down to the 
level of the person you're speaking to” 
(SU14: individual interview) 
- “do the patients actually understand me, 
what I am trying to tell them?” (P3 [GP]: 






-Being open  
-Being honest  
-Manners and 
attitude of clinicians 
 















the truth about 
their risk of 
cancer will 
make them feel 
respected and 
able to make 
informed 
decisions 
- “I would like to be told the truth about 
what this 10% means and whether I've 
got a chance” (SU3: individual 
interview). 
 
- “When I go to the doctor I expect to 
be honest with him and be clear as best 
as I can and you would expect the 
same from the practitioner, open 
conversation, open details from both 
sides to avoid misunderstanding” 
(SU19: individual interview) 
 
 
- “I will be quite open and honest with 
them that, you've come with these 
symptoms, some of them are already in, 
and we can use the tool to work out what 
it is. If you bear with me, I will check your 
risk and I could put those figures and what 
is coming out is your risk, and we can try 
that” (P6 [GP]: Focus Group1). 
 
-“I think the only time you might do it 
without informing the patient is when you 
are uncertain, you might go back and use 
it and then call the patient and inform 
them when you are sure of the risk” (P1 














-patients seeing the 
results on computer 
screen 

































partners in their 
care and will 
promote 
autonomy 
- “Again, I will like to be involved and I 
will like to see them using the tool and 
I like to see the smiley faces on the 
screen, and I will expect them to then 
explain to me what the results mean in 
terms of my risk” (SU15: individual 
interview) 
 
- “I think the word prompt is important 
because a lot of patients might be 
embarrassed to tell you something but 
if they are prompted, they can then tell 
you” (SU4: individual interview). 
 
 
- “If you don't tell them before using the 
tool it means you are not being honest. I 
mean you can't do anything without telling 
the patient, you need their consent” (P4 
[GP]: individual interview). 
 
-“I think the only time you might do it 
without informing the patient is when you 
are uncertain, you might go back and use 
it and then call the patient and inform 
them when you are sure of the risk” (P1 




Table 12 Facilitators/enablers to implementation of cancer risk assessment tools – themes, codes and quotes  
CFIR 
construct 
 Key words/phrases/codes Key themes Meaning of theme Quotes 

































could aid decision 
making 
-Aid at initial 
consultation  
-For a differential 





-Those with suspicion 
of cancer 
-For patients with 
vague or doubtful or 
borderline symptoms 
-Empowering 
patients in decision 
making 
-Breaking bad news 
to patients 
- Will generate data 







perceive the benefit 
of supporting 
decision making as 
a facilitator to the 
implementation of 
CRATs 
 - “a structured way of going through risk” 
(SU7: individual interview) 
 
- “It will help to make decisions appropriately” 
(SU1: individual interview). 
 
- “Yes, it is useful because the tool will help the 
practitioners to ask the right questions, and I 
know you have just 5 or 10 minutes with the 
doctor, and if the use of the risk assessment 
tools helps with the process then I think they 
should be used” (SU18: individual interview) 
- “I think somebody where you 
thought they have a cancer, probably 
you wouldn't go on a QCancer, and 
you would do what you do now. I 
think with people who are at the 
borderline, I think for these people 
you might want to use it” (P4 [GP]: 
Focus Group2) 
 
- “I think one of the ways I can use 
this tool is when you have got a 
differential in your mind, how can you 
put the cancer which may be at the 
lower end of the spectrum to come 
on top?” (P5 [GP]: Focus Group1). 
 
In contrast: 
“GP experience is more important 
than tools and guidelines” (P5 [GP]: 
individual interview), 
 
- “I will recommend that CRATs like 
QCancer be available to patients to 
use before coming to their GP.” (P5 










-Will help to improved 
speed of assessment  






-Capture of cases 








The benefit of 
helping to 
improving process 







- “it will help with early diagnosis through early 
detection of cancer risks” (SU10: individual 
interview) 
 
- “I think my first worry is that I may have 
cancer and most of us would like to know early 
so they can get it sorted. But a lot of things can 
be picked up, can't they, if they spot check risk 
if you like” (SU4: individual interview) 
- “Well as a tool, it's useful, for 
helping practitioners' ability to spot 
cancer or the possibility of cancer at 
an earlier stage than we could do. 
You know all emphasis is on cancer 
care, and GPs are sometimes a bit, a 
bit stuck to know what to pick as 
symptoms of cancer” (P3 [GP]: 
Focus Group1) 
 
- “With everyone on board because 
we need more investigations, we 
120 
 
-Will generate data 
e.g. for research 























about cancer risk 
-Support lifestyle 
advice and patient 
motivation to reduce 
cancer risk 
-Encourage patients 
to check risk and 








benefit of helping to 
identify and advise 
people to modify 
their health risk 
behaviours is 
perceived as a 
facilitator for the 
implementing 
CRATs 
“I think it might be just raising awareness, so 
people realise what's happening, and what can 
go wrong with them and where the risks are 
and may be, they can reinforce them where 
someone else like the young person who has 
given up smoking it might be used to reinforce 
by saying well you've got a very low risk so if 
you've given up smoking carry on with that. 
Rather than saying you've got a very high risk 
later” (SU5: individual interview) 
 
- “to be forewarned is to be forearmed, so they 
change their lifestyles such as stopping 
smoking or drinking alcohol” (SU10: individual 
interview) 
 
- “It can help to identify the individual's risk, 
isn't it? Because the input you've given is about 
your own risk rather than the general 
population, and if it's done over some years 
and your risk is increasing they could turn 
around and say well we need to increase or 
make more changes in your life style. So, if 
they were to do it every 5 years and if they see 
that the risk is increasing then maybe they 
could start giving me some lifestyle advice” 
(SU18: individual interview) 
“They don't understand the risks, you 
know what I mean? I mean like 
someone who is a smoker, he is 
smoking, smoking. You can use this 
tool to help them modify their 
lifestyle. People who are refusing 
referral, you can use the tool to 
estimate their risk to show and 
explain to them” (P2 [GP]: individual 
interview 
 
- “I am saying they could also check 
and then come to us, and they could 
be helping us as well. If what they 
regard as risk, you know almost the 
fact that they've come that might 
suggest they regard whatever 
number they've got as something we 
will be able to discuss with them. We 
go over it and you could recheck. 
You could recheck the cancer risk 
with the patient to see whether you 











-More accurate and 
specific information 
for individual patients 
-Individualised 
assessment and care 
-Reassurance for 
both low and high 
cancer risk 
-Reduced complaints 
from different patients 
 
Personalising 
patient care  
 
The benefit of 
helping to 
personalise patient 
care is perceived a 
facilitator to CRATs 
implementation 
- “I think it will make the care more patient-
centred because you're presenting them with 
their own risk not a general risk, it's personal 
to them and it will just make the consultation 
more patient focused, and I think it will make 
patients feel more involved in the consultation 
and just feel more cared for I think” (SU12: 
individual interview) 
 
- “So, it needs to be about me. I think it’s an 
excellent idea, the tool. I mean it's dealing with 
the individual very specifically and there's an 
opportunity to explain things in more details 
and delay the inevitable anxiety” (SU19: 
individual interview) 
“Patients will go away with a lot more 
targeted information about their 
personalised risk of cancer rather 






Table 13 Barriers to implementation of cancer risk assessment tools – themes, codes, and quotes –before use of the tools  
CFIR 
constructs 
Key words/phrases/codes Key themes Meaning of theme  Quotes 




-More time to 
discuss risk of 
cancer) 
-There may be 







-That will give 








information in, it 











time required for the 





- “more time to use the tool in 




- “the uncertainty and putting all the data 
manually” (P1 (GP): Focus Group2) 
 
- “It should be integrated in our system 
SystmOne, rather than every time we have to go 
on Google to get it. Like you put all that 
information in, it will be difficult, it should be 
completely automatic, and think of the 
investigations, people are more likely to use it” 
(P1 [GP]: Focus Group2) 
 
- “It’s more a question of more time really, 
because at the moment we're in crisis, GPs are 
in crisis, and the future is very bleak for GPs. 
Because you come in at 5 in the morning and 
you get back home in the night and it’s a 
nightmare really. So, we don't want more work. 
But we can target and do what we need, so 
unless we really suspect cancer” (P6 [GP]: 
Focus Group1) 
 
- “Well I believe if, in the ideal world, you may be 
aware of that, if there is a push to implement that; 
I think we should have 15 minutes’ 
appointments. That will give us a little bit extra 
time, which is assuming the patient has only one 
problem, but they have multiple problems in one 
appointment, I think it will be done well if 
something like cancer risk assessment, 
communication, organising of the test that follow, 





-Worry due to 
investigations  














to using CRATs 
could challenge the 
- “Some people may not 
understand and they can be too 
worried especially if they don't 
explain that it is just a risk but it is 
not guaranteed that they will get 
- “You can probably make them more worried” 










cancer, then it is not good enough 
ethically” (SU11: individual 
interview). 
 
- “I think they may be, have to 
assess their patients first to see if 
they were going to promote great 
anxiety on the patients by using 
some of these tools. I think 
emotionally I would be quite 
distraught and worried, and this is 
where having another person in 
there is important, I think. But I 
think until you've got some sort of 
appointment and then further tests 
and so forth, you will be in a state 
of limbo, I think, you know, not 
being able to concentrate properly” 
(SU6: individual interview) 
- “The thing is if you tell the patient they've got 
1% cancer, which is creating unnecessary 














and burden or 




















- “It could be useful if the right 
patients are referred but it could 
also lead to over referral as some 
people may have a certain risk but 
will not have cancer after they have 
been referred and tested” (SU17: 
individual interview) 
- “But on the other side it will put a strain on the 
NHS; you know what I mean, on the services 
there. You know, you don't want to over burden 
the services as well” (P4 [GP]: individual 
interview) 
 
- “I think we should not be worried about 
resources. Now many more people are dying 
from cancer, so they want more referral and 
diagnosis earlier. I am not sure using the tool is 
cheaper but I will say it is good for patient safety 
because people will be diagnosed earlier if 
referred earlier and they will be helped earlier” 








Table 13 Barriers to implementation of cancer risk assessment tools – themes, codes, and quotes –before use of the tools 
CFIR 
constructs 















assessment is based 
on practitioners’ 
knowledge of patients' 
symptoms, cancer risk 
factors and NICE 
guideline 
-Referral also 
depends on important 












the use of 
CRATs 
- “I think it is good 
for everybody to 
have the same sort 




use the same sort 
of guidelines” (SU1: 
individual 
Interview). 
 - “I will be quite confused about using the tool. I mean you know 
with the NICE guidelines; you couldn't focus on another criterion 
for any other risk here” (P6 [GP]: Focus Group1). 
 












whatever the risk 
percentage 
-High risk prompts 
further investigation 
-Some patients may 
wish to be 
investigated at a low 
1% risk 
-Varying perception of 
risk from 1-10%, e.g. 
4%-10% risk of cancer 
is high and needs 
referral with 
investigations for low 










The tools may 





- “It doesn't really 
matter about 
percentages; I 
know 1% is less 
risk. But the fact is 
the symptom is 
there, the coughing 
out of blood, which 




- “to see whether it 




- “as I said, if I suspect cancer and I put in the tool 1%, 2% 
doesn't matter to me” (P5 [GP]: individual interview) 
 
- “Since they've got symptoms, it is urgent x-ray straight away. I 
always send my patients for x-ray and say not to worry about 
the symptom, because I am going to investigate. Because even 
if he came with 1%, that's the thing. Regardless of what 
QCancer said I will refer them for investigation with the 
symptoms. So, it doesn't matter 1% or 0%, I will always do one 
thing, investigation if the symptoms are suggestive of cancer” 











N/A -Some practitioners 








about the new 
tools may be 
unwilling to use 
them  
N/A  - “GP experience is more important than tools and guidelines” 
(P5 [GP]: Focus Group1) 
 
- “Until you said this thing, you know initially I was very sceptical 
about this tool” (P3 [GP]: individual interview) 
 
- “I think for it to be useful there needs to be some benchmarks 








I think they need to tell us. So, for cancers, unless we have those 













-Need to compare with 
current practice 









Waiting to pilot 
and evaluate 
the tools before 
rolling them out 
could delay or 
challenge full 
implementation 
- “But I think if you 
are going to roll 
something out 
rather than going to 
everybody I would 
start with the 
doctors, see how 
the doctors do with 
it after evaluation 
and then move on 





- “review, we have to make sure that it is better than what we 
are already doing” (P2 [GP]: Focus Group2) 
 
- “One of the things I think will be really useful is, it's been 
devised but getting it in real life and then reporting back on that, 





The codes (see Tables 11 – 13 above) generated using Framework analysis, 
were examined and similar codes merged. After merging the similar codes, 
several themes from both service users and practitioners emerged in respect 
of the two research questions. These themes included: perceived ways about 
how best to communicate cancer risk information to patients; and the 
perceived enablers and barriers to the implementation of cancer risk 
assessment tools in primary care consultations. These perceptions were 
gathered from service users and practitioners before practitioners used the 
tools with patients. 
5.5 Perceived ways about how best to communicate cancer risk 
information to patients 
To address the research question about how best cancer risk information can 
be communicated during general practice consultation, the analysis of data 
and presentation of the results were informed by the 8-staged risk 
communication framework described in detail above (see 3.8.2 Fischhoff, 
1995): 
1. Get the numbers right  
2. Tell them the numbers 
3. Explain what the numbers mean 
4. Show them they have accepted similar risks in the past  
5. Show them it is a good deal for them 
6. Treat them nicely/with respect 
7. Make them partners 
8. All the above 
The views expressed by service users and practitioners about how best to 
communicate cancer risk to patients included: 
• Tailoring visual representation of risk 
• Providing time for informing, listening, explaining and reassuring in a 
professional manner  
• Being open and honest 
• Involving patients when using cancer risk assessment tools.  
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5.5.1 Tailoring visual representation of risk  
Tailoring a visual representation of risk relates to the risk communication 
framework stage of telling patients and explaining to their level of 
understanding what the cancer risk information means (Fischhoff, 1995). 
Visual representation suggests the use of visual aids such as pictures, 
symbols etc. to enhance understanding of the risk being explained to the 
patient. It relates to the notion that seeing a pictorial illustration of a 
phenomenon like risk, makes the explanation less abstract and enhances 
understanding of the information being presented.  
Referring to the QCancer tool as an example, both service users and 
practitioners discussed the idea of tailoring a visual representation of risk 
reflected in the QCancer risk chart. The QCancer risk chart consists of an icon 
array or Cates plot with a 10 by 10 arrangement of blue sad (each expressing 
1% 2-year cancer risk) and yellow smiling (no risk) faces. Service users 
believed that, using the QCancer graphics would ensure a visual 
representation which is clear and easy to understand by patients. For example, 
one service user said: 
“I really like this. I like the pictorial representation; I like the fact that it is simple 
but it's effective because it draws you right to the point. You know the happy 
faces and a mixed of smiley and sad faces can get you an idea. I think it is 
simple and clear, so most people will be able to understand this and take that 
information on board as opposed to if the doctor just mentions cancer risk it 
will put you off. But if you look at this and they talk you through this I think that 
will be really useful” (Service User 12: individual interview). 
Practitioners liked the idea of pictorial representation expressed by service 
users. In contrast, some practitioners felt that the QCancer icon arrays should 
be presented differently, for example, the icons representing risk could be 
arranged together in rows or lines rather than placed at random. Arranging the 
risk icons together would make them easier to read, count and understand, 
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whereas this was more difficult when they were scattered, which sometimes 
made them appear more numerous. For example, a practitioner explained:  
“I like the smiley faces as well, it's a good way of showing things. But I think it 
should be lined not random. I will like the blue sad faces to be in line, in a row, 
otherwise if they are scattered it gives the impression that they are many when 
they are not. And it's easier to read when they are lined in rows” (Practitioner 
6 [GP]: Focus Group1).  
The next point discussed by participants was about providing time. 
5.5.2 Providing time for listening, explaining and reassuring in the 
context of a professional approach 
The provision of time for listening, explaining and reassuring patients in a 
professional manner was expressed by participants as an important 
communication strategy that needed to be considered when planning for 
implementing cancer risk assessment tools in the primary care consultation. 
This relates to the risk communication framework stage of explaining to 
patients what the cancer risk information means (Fischhoff, 1995). This means 
that if enough time is not provided for explaining risk information and the 
related plan of care to patients, they may feel rushed and may not understand 
important information communicated to them. This could make patients feel 
anxious and less reassured by practitioners, and they may even feel 
disrespected and lose trust or faith in the healthcare delivery system. This was 
reflected in the views expressed by participants in this study. 
Service users preferred a longer consultation time to discuss cancer related 
risks, stating that they would otherwise feel not cared for, which could result in 
loss of their confidence. For example, one service user said the following: 
“You wouldn't want to feel that you've been rushed, you would want them to 
take time to talk with you, and if they try to cut this conversation short you 
would think that they didn't care, and again that could reduce your confidence” 
(Service User 12: individual interview).  
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Many of the practitioners interviewed agreed with the views of service users, 
that more time should be provided in the form of a longer consultation, to have 
clearer communication and an opportunity for service users to ask questions 
or discuss what was being conveyed. Such a discussion would also enable 
service users to express their views about cancer and the support they would 
require. One practitioner said: “What I feel is, I would try and give as much 
time as possible and be as accurate as possible” (Practitioner 1 [GP]: 
individual interview). Another practitioner stated: “I normally give them a 
chance to ask questions, what they think, what they know about cancer and 
the kind of support they will need” (Practitioner 3 [GP]: individual interview). 
Although many practitioners saw the importance of allowing more time for the 
patient to listen and understand what they had been informed about, some 
practitioners expressed concerns about the limited patient consultation time 
currently available. For example, a practitioner said:  
“It’s more a question of more time really, because now we're in crisis, GPs are 
in crisis, and the future is very bleak for GPs. Because you come in at 5 in the 
morning and you get back home in the night and it’s a nightmare really. So, 
we don't want more work” (Practitioner 6 [GP]: Focus Group 1). 
Service users also wanted practitioners to demonstrate professional manners 
and a reassuring attitude towards them especially when it came to using 
cancer risk assessment tools and discussing the risk with patients. Such a 
professional approach would help service users to understand what was being 
communicated but would also help them feel reassured and less worried about 
the situation. Below are examples of these views: 
“I think with that, if you're looking more likely that you're going to have 
something then I suppose you would probably want some reassurance, more 
also about treatment. But whereas before it's coming up which you were 
worried, I think it's probably now that you need reassurance that is finding it 
early and treatment, if it can be treated and if they know the risk of having it 
there's also the possibility of surviving it” (Service User 5: individual interview). 
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“In my opinion clinicians should discuss the patients' risks with them, but they 
should take time to do so in a professional and responsible manner to help the 
patient understand and feel less worried about their situation” (Service User 
15: individual interview). 
In addition to good manners and a reassuring attitude, service users felt that 
practitioners should avoid difficult medical terms and convey information at a 
level appropriate to the service user. For example, a service user stated that:  
 
“Yes, you wouldn't want them to speak in difficult medical terms; you would 
want them to bring it down to the level of the person you're speaking to” 
(Service User 14: individual interview).  
Practitioners admitted that, “talking about risk is quite difficult” (Practitioner 3 
(GP): Focus Group 1), but it would be important to check, “do the patients 
actually understand me, what I am trying to tell them?” (Practitioner 3 [GP]: 
Focus Group1).  
Participants also discussed openness and honesty when communicating 
cancer risk information. 
5.5.3 Being open and honest 
Being open and honest relates to the risk communication framework stage of 
treating patients nicely or with respect (Fischhoff, 1995). This relates to the 
importance of recognising the right of individuals to know the truth about their 
health information as far as possible and in the interests of the individual. 
Patients can feel disrespected, worried or even lose trust in health practitioners 
if they perceive that practitioners are being dishonest or hiding something from 
them. 
Service users and practitioners in this study expressed the view that being 
open and honest would enhance cancer risk communication during the patient 
consultation. From the perspectives of service users, it was important to know 
the implications of a quantified cancer risk including whether they had a 
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chance of not getting cancer or surviving cancer if they were diagnosed with 
the condition. A service user said, “I will like to be told the truth about what this 
10% means and whether I've got a chance” (Service User 3: individual 
interview). Service users expected to be told the truth about their health when 
they consulted a practitioner. In the same vein, service users believed that 
practitioners should be ready to tell them everything about their health. Failure 
to tell the patient the truth or missing key information could mean the 
practitioner was hiding something which could bring about misunderstanding 
or even loss of confidence or trust between the practitioner and the patient 
when the truth was eventually known. Below is an example of what another 
service user said: 
“When I go to the doctor I expect to be honest with him and be clear as best 
as I can, and you would expect the same from the practitioner, open 
conversation, open details from both sides to avoid misunderstanding” 
(Service User 19: individual interview). 
Practitioners supported the views of service users about the importance of 
honesty. They confirmed that being open and honest with patients and about 
the nature of their symptoms, explaining and planning their care with them was 
more helpful. In other words, as perceived by service users, openness and 
honesty cultivated confidence and trust in the patient-practitioner relationship 
and the health care delivery system. Below is an example of views expressed 
by practitioners: 
 “I will be quite open and honest with them that, you've come with these 
symptoms, some of them are already in, and we can use the tool to work out 
what it is. If you bear with me I will check your risk and I could put those figures 
and what is coming out is your risk, and we can try that” (Practitioner 6 [GP]: 
Focus Group1). 
Although many practitioners supported the idea of being open and honest with 
patients, one practitioner did state that they may not be open with a patient if 
they were uncertain of the patient’s risk information. The practitioner said: 
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“I think the only time you might do it without informing the patient is when you 
are uncertain, you might go back and use it and then call the patient and inform 
them when you are sure of the risk” (Practitioner 1 [GP]: Focus Group2). 
Participants also expressed views about informing and involving patient when 
using cancer risk assessment tools as detailed below. 
5.5.4 Informing and involving patients when using cancer risk 
assessment tools 
Informing or involving patients in their risk assessment during a consultation 
is in line with the risk communication framework stage of making patients 
partners in the use of cancer risk assessment tools (Fischhoff, 1995). This 
means that patients could be given the opportunity to see the visual 
representation of their risk on the computer screen which could enhance 
understanding when the practitioner then conveys the risk information to the 
patient. Also, without involving patients before using the tools to assess them 
could mean their ethical right of giving consent to their care is ignored. If 
patients feel ignored, this could negatively impact on healthcare policies 
relating to patient-centred care and making patients partners in their care. This 
reflects in the views of participants in this study. 
Service users and practitioners expressed the need to inform and involve 
patients in the use of cancer risk assessment tools during the consultation. In 
addition to informing them before using the tools, service users felt that it would 
be good practice for practitioners to involve them in the consultation process 
such that they could see and view the risk assessment results on the 
practitioner’s computer. One service user said: 
“Again, I will like to be involved and I will like to see them using the tool and I 
like to see the smiley faces on the screen, and I will expect them to then explain 




Service users also felt that, to encourage patient involvement in a cancer risk 
communication process, there was a need to prompt discussion about relevant 
health issues during the consultation process especially for those who might 
be too embarrassed or unable to talk for one reason or another. For example, 
a service user stated: 
 “I think the word ‘prompt’ is important because a lot of patients might be 
embarrassed to tell you something but if they are prompted, they can then tell 
you” (Service User 4: individual interview). 
Supporting the views of service users, a practitioner suggested that, it would 
be an act of dishonesty to perform a risk assessment on a patient without first 
seeking their consent. Although some patients may not know that a practitioner 
is using a tool to assess their risk of cancer, not informing patients would be 
unethical and could result in loss of trust and confidence if the patients 
eventually get to know later. A practitioner said: 
“If you don't tell them before using the tool it means you are not being honest. 
I mean you can't do anything without telling the patient, you need their consent” 
(Practitioner 4 [GP]: individual interview).  
In contrast, another practitioner thought that there may be times when they 
were uncertain or unsure about risk, and therefore reluctant to inform the 
patient when using the tool: 
“I think the only time you might do it without informing the patient is when you 
are uncertain, you might go back and use it and then call the patient and inform 
them when you are sure of the risk” (Practitioner 1 [GP]: Focus Group2). 
Other practitioners agreed that it can be difficult to inform the patient when 
they were uncertain about the risk information but noted that patients would 
need to be informed once some certainty about use of the tool has been 
established. This is because failure to inform could amount to not involving 
patients in the consultation process. The next section deals with what service 
users and practitioners perceived as enablers and barriers to implementation. 
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5.6 Perceived enablers and barriers to implementation of cancer 
risk assessment tools in primary care 
To address the perceptions of service users and practitioners about enablers 
and barriers to the implementation of cancer risk assessment tools, data 
analysis was informed by relevant constructs within the Consolidated 
Framework for Implementation Research [CFIR] (Damschroder et al., 2009): 
relative advantage (for enablers); patient needs and resources, compatibility, 
knowledge and beliefs of individuals involved, and reflecting and monitoring 
the implementation process (for the barriers to implementation). 
5.6.1 Perceived enablers to implementation of cancer risk assessment 
tools  
In relation to the CFIR construct of relative advantage (Damschroder et al., 
2009), participants expressed four potential benefits of cancer risk 
assessment tools, which they perceived as enablers to the implementation of 
cancer risk assessment tools in primary care: supporting decision making, 
improving processes and speed of assessment and treatment, identifying and 
raising awareness for modifying health risk behaviours, and personalising 
care. That is, practitioners perceived these as enabling their use of the tools if 
they thought the tools were useful or had relative advantage. 
 
5.6.1.1 Supporting decision-making 
The perception of cancer risk assessment tools as having the potential to 
support decision-making means that practitioners could use the tools to detect 
cancer risk sooner than later. This could also lead to earlier investigations, 
diagnosis, treatment and improvement in the rates of survival of people 
diagnosed with cancer. In line with this, service users and practitioners in this 
study expressed views suggesting that cancer risk assessment tools had the 
potential to support decision-making in primary care consultations. Service 
users believed that, using a cancer risk assessment tool like QCancer would 
be “a structured way of going through risk” (Service User 7: individual 
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interview), which could help practitioners “to make decisions appropriately” 
(Service User 1: individual interview). In other words, the tool could enable 
practitioners to ask the right questions within the limited time available for the 
consultation. 
“Yes, it is useful because the tool will help the practitioners to ask the right 
questions, and I know you have just 5 or 10 minutes with the doctor, and if the 
use of the risk assessment tools helps with the process then I think they should 
be used” (Service User 18: individual interview). 
While supporting the views of service users that the tools enabled appropriate 
decision-making, practitioners insisted that they would be more likely to use a 
cancer risk assessment tool for patients with vague, doubtful or borderline 
symptoms than for patients with symptoms suggestive of cancer. A practitioner 
said: 
“I think somebody where you thought they have a cancer, probably you 
wouldn't go on a QCancer, and you would do what you do now. I think with 
people who are at the borderline, I think for these people you might want to 
use it” (Practitioner 4 [GP]: Focus Group2). 
Furthermore, practitioners believed cancer risk assessment tools could help 
with differential diagnosis. In other words, if a patient presented with symptoms 
suggestive of conditions other than cancer, practitioners could rule out or rule 
in cancer by using a cancer risk assessment tool before referring for further 
cancer investigations. According to one practitioner: 
“I think one of the ways I can use this tool is when you have got a differential 
in your mind, how can you put the cancer which may be at the lower end of 
the spectrum to come on top? I think that's something which I find useful” 
(Practitioner 5 [GP]: Focus Group1). 
Although practitioners generally perceived the potential benefit of supporting 
clinical decision-making as an enabler to the implementation of cancer risk 
assessment tools, one practitioner did state that: “GP experience is more 
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important than tools and guidelines” (Practitioner 5 [GP]: individual interview), 
and others felt that cancer risk assessment tools should be made available to 
patients to use at home before consulting their practitioners for further advice. 
A practitioner stated further: “I will recommend that QCancer be available to 
patients to use before coming to their GP” (Practitioner 5 [GP]: individual 
interview). 
The next enabler is about the benefit of improving processes and speed of 
assessment and treatment.  
5.6.1.2 Improving process and speed of assessments and treatment  
Improving the process and speed of cancer risk assessments and treatment 
through early detection was also mentioned by participants as a potential 
benefit which could serve as an enabler to the implementation of cancer risk 
assessment tools. They implied that using the tools could streamline and 
speed up necessary clinical processes such as investigations and referral to 
specialists at secondary care settings. In other words, the use of the tools 
could avoid or reduce the usual delay in the processes of assessment and 
referral, which usually results in late diagnosis and treatment. 
Service users in this study believed that, the tools “will help with early 
diagnosis through early detection of cancer risks” (Service User 10: individual 
interview). In the view of service users, the use of cancer risk assessment tools 
to improve processes and speed of cancer assessments and treatment was 
important because many people worry about cancer; hence, checking and 
detecting cancer risk early and managing cancer risk in time would be helpful 
to them. One service user stated: 
“I think my first worry is that I may have cancer and most of us will like to know 
early so they can get it sorted. But a lot of things can be picked up, can't they, 
if they spot check risk if you like” (Service User 4: individual interview). 
Practitioners expressed similar views. According to practitioners, although 
emphasis is currently on early detection of cancer, practitioners are sometimes 
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unable to detect cancer at an early stage of symptoms. Cancer risk 
assessment tools could bridge that gap by enhancing the ability of a 
practitioner to spot cancer risk earlier. One practitioner stated: 
“Well as a tool, it's useful, for helping practitioners' ability to spot cancer or the 
possibility of cancer at an earlier stage than we could do. You know all 
emphasis is on cancer care, and GPs are sometimes a bit, a bit stuck to know 
what to pick as symptoms of cancer” (Practitioner 3 [GP]: Focus Group1). 
Practitioners also believed that to achieve early detection of cancer there is 
often a need for cancer investigations to be done prior to patients seeing a 
consultant in secondary care. Hence, the use of cancer risk assessment tools 
could prompt earlier investigations and referral. One practitioner stated: 
 “With everyone on board because we need more investigations, we need 
more tests quickly” (Practitioner 6 [GP]: Focus Group1). 
Another perceived enabler to the use of cancer risk assessment tools was in 
helping to identify health risk behaviours and raise awareness for modifying 
these. 
5.6.1.3 Identifying and raising awareness for modifying health risk 
behaviours 
One potential benefit (perceived as an enabler to use) of cancer risk 
assessment tools is that, the tools could be used by practitioners to generate 
a patient’s risk of having or developing cancer. They could then use the 
information to advise the patient on ways to eliminate or reduce their health 
risk behaviours such as smoking and excessive alcohol intake. They may also 
be advised on having regular suitable exercises. Indeed, participants 
expressed the view that the use of cancer risk assessment tools could help to 
identify and raise awareness of cancer risk behaviours, and that this could 
facilitate implementation of the tools.  
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From the perspective of service users, this could also help people to modify 
their risk behaviours, reducing risk and promoting health and wellbeing. One 
service user said: 
“I think it might be just raising awareness, so people realise what's happening, 
and what can go wrong with them and where the risks are and may be, they 
can reinforce them where someone else like the young person who has given 
up smoking, it might be used to reinforce by saying well, you've got a very low 
risk, so if you've given up smoking carry on with that. Rather than saying you've 
got a very high risk later” (Service User 5: individual interview). 
In terms of identifying and modifying cancer risk factors, service users felt that, 
“to be forewarned is to be forearmed, so they change their lifestyles such as 
stopping smoking or drinking alcohol” (Service User 10: individual interview). 
Service users also believed that if an individual’s risk of cancer was identified 
and monitored over a period, the individual might benefit from lifestyle 
modification and risk reduction advice. One service user said:  
“It can help to identify the individual's risk, isn't it? Because the input you've 
given is about your own risk rather than the general population, and if it's done 
over some years and your risk is increasing they could turn around and say 
well we need to increase or make more changes in your life style. So, if they 
were to do it every 5 years and if they see that the risk is increasing then maybe 
they could start giving me some lifestyle advice” (Service User 18: individual 
interview). 
Similarly, practitioners believed that the use of cancer risk assessment tools 
might help people to modify risk factors such as smoking, as well as using the 
estimated risk to encourage people to accept a referral for further 
investigations or to adopt lifestyle changes. This would be important for people 
refusing lifestyle changes or those not willing to be referred for further 
investigations. 
“They don't understand the risks, you know what I mean? I mean like someone 
who is a smoker, he is smoking, smoking. You can use this tool to help them 
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modify their lifestyle. People who are refusing referral, you can use the tool to 
estimate their risk to show and explain to them” (Practitioner 2 [GP]: individual 
interview). 
In addition, practitioners suggested that it would be useful to encourage 
patients to use cancer risk assessment tools to check their risk and then seek 
advice from practitioners if they were concerned about their risk of cancer. In 
the view of practitioners, the fact that a patient had checked their own risk and 
decided to consult a practitioner suggested their level of concern and 
willingness to engage in discussion and possibly referral for further 
investigations. This could be helpful to the practitioner in terms of making a 
patient-informed decision. 
“I am saying they could also check and then come to us, and they could be 
helping us as well. If what they regard as risk, you know almost the fact that 
they've come that might suggest they regard whatever number they've got as 
something we will be able to discuss with them. We go over it and you could 
recheck. You could recheck the cancer risk with the patient to see whether you 
have the same result” (Practitioner 3 [GP]: Focus Group1). 
The next perceived enabler relates to the potential benefit of helping to 
personalise patient care. 
5.6.1.4 Personalising care 
Personalising care was mentioned by service users and practitioners as 
another way that cancer risk assessment tools could be useful, hence an 
enabler to the use of the tools. This means, a cancer risk assessment tool like 
QCancer could help to personalise care and encourage patient-centred care 
by highlighting the patient’s own specific cancer risk and a plan of care rather 
than a more generalised plan of care. Because the risk that would be 
presented to patients would be specific and personal to them, patients would 
feel more involved and reassured of being well cared for in the consultation 
process. This could in turn allay any worries or anxiety relating to being 
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informed about a cancer risk and subsequent referral for further investigations. 
Below are examples of the views expressed by service users: 
“I think it will make the care more patient-centred because you're presenting 
them with their own risk not a general risk, it's personal to them and it will just 
make the consultation more patient focused, and I think it will make patients 
feel more involved in the consultation and just feel more cared for I think” 
(Service User 12: individual interview). 
“So, it needs to be about me. I think it’s an excellent idea, the tool. I mean it's 
dealing with the individual very specifically and there's an opportunity to 
explain things in more details and delay the inevitable anxiety” (Service User 
19: individual interview). 
The views of practitioners supported those of services users. For example, a 
practitioner said, “patients will go away with a lot more targeted information 
about their personalised risk of cancer rather than a vague statement” 
(Practitioner 1 [GP]: individual interview), which they felt would be helpful in 
conveying understanding to the patient and allaying anxiety associated with 
cancer risk assessments and related processes. 
Service users and practitioners also perceived barriers to the use0 of cancer 
risk assessment tools which are discussed below. 
5.6.2 Perceived barriers to the implementation of cancer risk assessment 
tools 
Practitioners perceived issues related to CFIR constructs of: readiness for 
implementation; patient needs and resources; compatibility; knowledge and 
beliefs of individuals involved; and monitoring the implementation process 
(Damschroder et al., 2009), as potential barriers to the implementation of 
cancer risk assessment tools in primary care. The barriers identified were:  
• Additional consultation time required (related to CFIR constructs of 
readiness for implementation and patient needs and resources) 
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• Worry/anxiety related to investigations (relates to CFIR construct of 
patient needs and resources) 
• Over referral and burdening of services (patient needs and resources) 
• Practitioner scepticism (relates to CFIR construct of knowledge and 
beliefs of individuals involved) 
• Conflict with existing guidelines (relates to CFIR construct of 
compatibility) 
• High risk symptoms need referral (i.e. compatibility) 
• Need for piloting and monitoring of CRATs implementation (relates to 
CFIR construct of reflecting and monitoring the implementation 
process). 
5.6.2.1 Additional consultation time required  
In line with the CFIR constructs of readiness for implementation and patient 
needs and resources, service users were concerned that general practices 
were already busy, and that introduction of a new risk assessment tool would 
mean additional work for general practitioners. Hence, practitioners in general 
practice would need “more time to use the tool in consultations” (Service User 
7: individual interview).  
Practitioners also agreed with these views stating that more time would be 
needed for using a cancer risk assessment tool like QCancer during the 
consultation. That is, incorporating additional tasks of using a cancer risk 
assessment tool and spending time to discuss the options with the patient 
(which may include immediate action) will suggest more time should be added 
to current consultation time. 
Indeed, practitioners felt the use of the tools could be time-consuming because 
of, “the uncertainty and putting in all the data manually” (Practitioner 1 [GP]: 
Focus Group2); unless the tool was automated and integrated in the general 
practice information system (for example, SystmOne or EMIS) making it easier 
to use the tool during consultations.  
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“It should be integrated in our system, SystmOne, rather than every time we 
have to go on Google to get it. Like you put all that information in, it will be 
difficult, it should be completely automatic, and think of the investigations, 
people are more likely to use it” (Practitioner 1 [GP]: Focus Group2). 
Furthermore, practitioners were concerned that general practices had become 
very busy making it difficult to introduce cancer risk assessment tools, because 
practitioners would not want more work, unless they targeted patients who 
were likely to benefit from the use of the tool. A practitioner said: 
“It’s more a question of more time really, because now, we're in crisis, GPs are 
in crisis, and the future is very bleak for GPs. Because you come in at 5 in the 
morning and you get back home in the night and it’s a nightmare really. So, 
we don't want more work. But we can target and do what we need, so unless 
we really suspect cancer” (Practitioner 6 [GP]: Focus Group1). 
Practitioners also felt that one way to address the issue of time was to increase 
the time available, from a standard consultation length of 10 minutes to at least 
15 minutes. A longer consultation would make room for the processes of a 
cancer consultation including risk assessment, communicating the risk to the 
patient and referral for further investigations if needed. 
 “Well I believe if, in the ideal world, you may be aware of that, if there is a 
push to implement that; I think we should have 15 minutes’ appointments. That 
will give us a little bit extra time, which is assuming the patient has only one 
problem, but they have multiple problems in one appointment, I think it will be 
done well if something like cancer risk assessment, communication, 
organising of the test that follow, 15 minutes will be ideal” (Practitioner 1 [GP]: 
individual interview). 






5.6.2.2 Worry or anxiety generated by referral for cancer investigation  
Participants identified unnecessary worry generated for patients as a potential 
barrier to the use of cancer risk assessment tools during consultations. This 
related to the concept of ‘patient needs, and resources’ as expressed within 
the CFIR (Damschroder et al., 2009). For example, patients may worry if their 
need for involvement and understanding of the risk information presented to 
them, is not met. 
Indeed, participants felt that people might worry if it was not explained to them 
that the tool provided a risk assessment rather than a cancer diagnosis. In the 
absence of adequate explanation, it was felt that some people might assume 
that a referral for cancer investigations meant a cancer diagnosis, which may 
not have been the case. This indicates the importance of involving patients 
when assessing their risk of cancer while ensuring adequate explanation is 
done to their understanding. Many people consider cancer as bad news and 
they can be frightened and become worried or anxious when they are told that 
they have cancer.  
In view of potential worry or anxiety that could make some patients miss or 
misunderstand important information when being informed about their risk of 
cancer with the practitioner, it was felt that some patients might like someone 
(e.g a family member or friend) to be with them at an appointment to discuss 
their cancer risk. Some of these views expressed by service users are stated 
below: 
“Some people may not understand, and they can be too worried especially if 
they don't explain that it is just a risk, but it is not guaranteed that they will get 
cancer, then it is not good enough ethically” (Service User 11: individual 
interview). 
“I think they may be, have to assess their patients first to see if they were going 
to promote great anxiety on the patients by using some of these tools. I think 
emotionally I would be quite distraught and worried, and this is where having 
another person in there is important, I think. But I think until you've got some 
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sort of appointment and then further tests and so forth, you will be in a state of 
limbo, I think, you know, not being able to concentrate properly” (Service User 
6: individual interview). 
Practitioners were also concerned that, “you can probably make them more 
worried” (Practitioner 5 [Practice Nurse]: Focus Group2), especially if the 
explanation was not tailored properly to the understanding of patients. One 
practitioner observed that care must be taken not to start a patient worrying 
about an apparently low risk of cancer such as 1%: 
“The thing is if you tell the patient they've got 1% cancer, which is creating 
unnecessary anxiety” (Practitioner 2 [GP]: individual interview). 
Participants were also concerned about the potential for over-referral and 
over-burdening of services. 
5.6.2.3 Over-referral and over-burdening of services 
The issue of over-referral was mentioned by several participants as a potential 
challenge to the implementation of cancer risk assessment tools. This was 
linked to the CFIR construct of patient needs and resources. In other words, 
there is a potential for too many patients to be referred for investigations or 
specialist attention and they may not have cancer at the end of the day and 
did not need to be referred in the first place. These unnecessary referrals and 
investigations could cause worry and anxiety to patients and could also 
overburden the limited healthcare resources.  
Indeed, expressing their views, some service users suggested that the use of 
a cancer risk assessment tool like QCancer could result in too many people 
being referred for cancer investigations, and some of those referred may end 
up not having cancer, and this may give the impression that they were referred 
unnecessarily. A service user said: 
 “It could be useful if the right patients are referred but it could also lead to over 
referral as some people may have a certain risk but will not have cancer after 
they have been referred and tested” (Service User 17: individual interview). 
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Some practitioners supported the views of service users about over-referral 
but suggested further that over-referral could put a strain on the NHS 
resources which could have been reserved for patients who genuinely needed 
them. A practitioner said: 
“But on the other side it will put a strain on the NHS; you know what I mean, 
on the services there. You know, you don't want to over burden the services 
as well” (Practitioner 4 [GP]: individual interview). 
In contrast, another practitioner noted that despite the potential strain on 
resources due to over referral, it was important to continue to refer patients for 
further investigations if they met referral criteria because the advantages of 
referral outweighed the disadvantages. In other words, the number of people 
dying from cancer was increasing, and more referrals could lead to earlier 
diagnosis and treatment which could help to save lives. 
“I think we should not be worried about resources. Now many more people are 
dying from cancer, so they want more referral and diagnosis earlier. I am not 
sure using the tool is cheaper, but I will say it is good for patient safety because 
people will be diagnosed earlier if referred earlier and they will be helped 
earlier” (Practitioner 3 [GP]: individual interview). 
The next barrier identified by participants was the potential conflict with 
existing guidelines. 
5.6.2.4 Conflict with existing guidelines (relates to CFIR construct of 
compatibility) 
In line with the CFIR constructs of compatibility and complexity, participants 
identified conflict with existing guidelines as a potential barrier to the 
implementation of cancer risk assessment tools. This implies a potential 
confusion between the use of cancer risk assessment tools and guidelines like 
the NICE guidelines, which are currently used to support cancer risk 




Indeed, service users were of the view that, to avoid confusion, it would be a 
good idea for all practitioners to use the same guidelines or tools in assessing 
patients’ risk of developing cancer, rather than different tools or guidelines. 
There were concerns that a cancer risk assessment tool like QCancer could 
conflict with existing guidelines such as the NICE guidelines for cancer referral. 
For example, a service user stated: 
“I think it is good for everybody to have the same sort of guidelines, so to use 
risk assessment tools everybody should use the same sort of guidelines” 
(Service User 1: individual Interview). 
Similar to the views of service users, practitioners felt that there may be some 
confusion in using the new cancer risk assessment tools alongside existing 
clinical decision tools such as the NICE guidelines, which could confuse 
practitioners about when to refer to secondary care. Practitioners felt that using 
both could result in a repeated cancer assessments and referrals to secondary 
care, unless existing NICE guidelines were modified in such a way as to 
incorporate the cancer risk assessment tools. Below is an example of the 
views expressed by practitioners. 
 “I will be quite confused about using the tool. I mean you know with the NICE 
guidelines; you couldn't focus on another criterion for any other risk here” 
(Practitioner 6 [GP]: FGD1). 
Another barrier identified was high risk symptoms needing referral. 
5.6.2.5 Symptoms suggestive of cancer will need referral whatever the 
quantified risk- compatibility 
In line with the CFIR construct of compatibility and complexity, service users 
and practitioners expressed the view that referral for further investigations 
might be warranted whatever the quantified risk when using a cancer risk 
assessment tool. Service users spoke about their preference for a referral for 
further investigation of possible cancer symptoms irrespective of the 
calculated risk. This suggests that, what mattered to service users was the 
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presence of the symptom which would worry them more than a percentage 
risk. Therefore, if they had high risk symptoms, service users expressed that 
they would prefer to be referred for further investigations, even if the 
percentage risk, for example a 1% risk, was considered low. One service user 
said: 
“It doesn't really matter about percentages; I know 1% is less risk. But the fact 
is the symptom is there, the coughing out of blood, which is quite worrying” 
(Service User 13: individual interview). 
Service users explained that when a symptom such as coughing up blood was 
worrying for them, they would want to be referred for further investigation, “to 
see whether it is cancer or something else” (Service User 9: individual 
interview). 
Similarly, practitioners stressed that if a patient presented with symptoms 
suspicious of cancer, they would refer them for investigation. As one 
practitioner put it, “as I said, if I suspect cancer and I put in the tool 1%, 2% 
doesn't matter to me” (Practitioner 5 [GP]: individual interview). Indeed, 
practitioners made their views clear that it was more important to look at the 
symptoms and refer especially if the symptoms were suggestive of cancer. 
This implied that, for practitioners, symptoms suggestive of cancer could mean 
the presence of cancer irrespective of the risk calculated. Therefore, 
practitioners could tell patients with high risk symptoms that their symptoms 
would be investigated immediately to rule out cancer. Below is an example of 
the views expressed by practitioners. 
“Since they've got symptoms, it is urgent x-ray straight away. I always send 
my patients for x-ray and say not to worry about the symptom, because I am 
going to investigate. Because even if he came with 1%, that's the thing. 
Regardless of what QCancer said I will refer them for investigation with the 
symptoms. So, it doesn't matter 1% or 0%, I will always do one thing, 




The next barrier identified by participants is practitioner scepticism. 
5.6.2.6 Practitioner scepticism 
In line with the CFIR construct of knowledge and beliefs of individuals involved 
in the implementation process, practitioner scepticism was perceived as a 
potential barrier to implementing cancer risk assessment tools in primary care. 
In other words, some practitioners may not like the new tools especially if they 
are not innovators, and they may trust their clinical experience more than 
guidelines or risk assessment tools.  
Indeed, a practitioner remarked that, “GP experience is more important than 
tools and guidelines” (Practitioner 5 [GP]: Focus Group1). This perception 
which was shared by other practitioners could be due to the fact that cancer 
risk assessment tools are currently not widely known or used by practitioners. 
Hence, many practitioners could be uncertain about how the tools work. Being 
uncertain of how the tools work could discourage some practitioners from 
using them, especially at the initial stages when practitioners have not yet fully 
become familiar with the tools. A practitioner said: “Until you said this thing, 
you know initially I was very sceptical about this tool” (Practitioner 3 [GP]: 
individual interview). 
Similarly, participants felt some practitioners might be reluctant to use the tools 
until a recommended risk threshold to prompt investigations or referral was 
established. In other words, it would be difficult to use the tools without 
knowing at what percentage risk a practitioner should investigate or refer: 
“I think for it to be useful there needs to be some benchmarks for us to really 
relate with. If you say 7% or 6%, should I worry? I think they need to tell us. 
So, for cancers, unless we have those things it will probably be difficult to use 
the tool” (Practitioner 1 [GP]: Focus Group2). 
The next barrier identified was about need for piloting and monitoring before 




5.6.2.7 Need for piloting before rolling out cancer risk assessment tools 
In line with the CFIR construct of reflecting and monitoring, participants 
identified the need to establish evidence of effectiveness of the tools by piloting 
and monitoring before rolling out. Service users suggested that it would be 
useful to trial the tools with doctors and evaluate the outcomes of using the 
tools before expanding the use of the tools to all primary care practitioners 
including nurses.  
Due to the busy nature of the general practice system, one service user felt 
that there may be times when experienced practice nurses do the initial 
assessments before referring patients to doctors for key or major decisions 
especially with serious conditions like cancer. Since doctors make the key and 
final decisions in terms of referral for cancer investigations and diagnosis by 
the specialists at secondary care, it makes sense to trial the tool with doctors 
before rolling out to all practitioners at general practice. A service user said: 
“But I think if you are going to roll something out rather than going to everybody 
I would start with the doctors, see how the doctors do with it after evaluation 
and then move on to the practice nurses” (Service User 12: individual 
interview).  
Similarly, practitioners pointed out that, it would be useful to test the impact of 
the tools through trials in a real-life situation, measure the outcomes and then 
review. Indeed, a practitioner noted, “we have to make sure that it is better 
than what we are already doing” (Practitioner 2 [GP]: FGD2). Trialling the tool 
would not only test its effectiveness but could also highlight any challenges 
associated with using the tool. One practitioner said: 
“One of the things I think will be really useful is, it's been devised but getting it 
in real life and then reporting back on that, it will be really useful to know how 
good a tool it is. I don't know whether that makes sense, what I am saying? It's 
almost like an ongoing research where people use the tool and then say well 
actually the 4% risk that we calculated when we are using in finding who is at 
risks, we are sending 500 people and 1% is getting diagnosed. Or it’s an 
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underestimate. So, to get it to start it will be really useful” (Practitioner 1 [GP]: 
individual interview). 
The next section deals with perceptions and experiences of practitioners after 
they had had an opportunity to actively use cancer risk assessment tools 
during patient consultations. These perceptions included ways to best 
communicate cancer risk information to patients and the perceived enablers 
and barriers to the use of cancer risk assessment tools. 
5.7 Perceptions of practitioners after using cancer risk assessment 
tools in patient consultations 
In Section 5.6 above, the views expressed by practitioners before using cancer 
risk assessment tools related to: perceived ways to best communicate cancer 
risk information to patients; perceived enablers and perceived barriers to the 
use (implementation) of the tools. 
The purpose of exploring the views of practitioners after they used the tools 
was to know whether they experienced the earlier perceptions before using 
the tools. Any other perceptions expressed by practitioners after using the 
tools were also considered. 
As mentioned earlier, the general practices that had already participated in the 
earlier individual and focus group interviews were contacted, and one general 
practice agreed to meet to discuss their perceptions after using the tools. A 
meeting with practitioners was held in the practice, and practitioners agreed to 
use the tools for a minimum of one month before meeting for a second focus 
group interview. A focus group with 4 practitioners was subsequently 
conducted. Using the themes from the interviews conducted before the use of 
the tools as a guide, the perceptions gathered from the focus group with 
practitioners after they had used the cancer risk assessment tools with patients 
were analysed using the Framework approach. The resulting codes were 
examined, and similar codes were merged. The emerging codes and themes 
are presented in Tables 14 – 16 below. 
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Table 14 Perceptions of how best to communicate cancer risk information – themes, codes and quotes –after practitioners 








Key themes Meaning of themes  Quotes 
Practitioners 
Practitioners  








convinced patients  
- The yellow smiley 
faces and blue sad 
faces were easy to 
understand 
- The presentation and 
icon arrays were very 
user friendly 
-Showed them the 
QCancer chart, the 
yellow smiley and blue 
sad faces 
Tailoring a visual 
representation of risk 
Before using the cancer risk 
prediction tools, practitioners had 
perceived that tailoring a visual 
representation of risk was one 
way to best communicate cancer 
risk information to patients. That 
is, seeing the risk presented in a 
visual way will enhance 
understanding. After using the 
tools in patient consultations, the 
practitioners interviewed 
expressed similar views about 
tailoring a visual representation 
of risk as stated below. 
“The pictorial representation and 
multi cancer symptom approach is 
useful with QCancer” P1 [GP]: 
Focus Group 3). 
 
“I showed them the QCancer chart, 
the yellow smiley and blue sad 
faces, and it was easy for them to 
understand” P1 [GP]: Focus 
Group3) 
 
“The Pictorial presentation will 
convince the patient about their risk 
as it is yellow smiley faces and blue 
sad faces are easy to understand. 
The presentation and icon arrays 
are also very user friendly” (P2 
[GP]: Focus Group 3). 






-took time in explaining  
-reassured by 
explaining 
- it’s only a risk and not 
a cancer diagnosis 
- They understood and 
were alright with that 
Providing time for informing, 
listening, explaining and 
reassuring in a professional 
away  
After using the cancer risk 
assessment tools, practitioners 
expressed similar views as 
before using the tools in patient 
consultation. In using the tools 
with patients, practitioners took 
time to explain what the risk 
meant and indicated any plans 
e.g. for investigations and 
referral to a specialist. 
“I reassured the patient by 
explaining that the risk is only a risk 
and not a cancer diagnosis. I 
explained what a 2% risk, meant, 
which is not a diagnosis of cancer, 
but a risk. I also explained that, 
early detection of risk will help with 
early investigations, diagnosis and 







I explained that I needed to do 
some investigations and possibly to 
refer them. They understood and 















Like the views expressed by 
practitioners before using the 
tools, practitioners who used the 
tools believe telling the truth will 
make people feel respected and 
able to make informed decisions. 
Hence, practitioners believed 
patients were less worried or 
anxious because they were 
honest with them as they did not 
hide anything from them when 
they used the tools during 
consultation. 
“I didn’t hide anything from the 
patient, I was honest with them 
throughout. I think that help to ease 










-All the above 
-I informed them 
-Asked for their 
consent to use the tool.  
-They agreed  
-I involved them from 
the beginning 
Involving patients when 
using cancer risk 
assessment tools  
Like the views expressed before 
practitioners used the CRATs 
with patients, practitioners who 
used the tools believe that, 
involving patients when using the 
tools will mean recognising them 
as partners in their care and will 
promote autonomy. 
Consequently, practitioners 
involved patients in the use of the 
tools by informing, explaining 
and seeking the consent of 
patients, which patients were 
happy with. 
“As I said, I informed them and 
asked for their consent to use the 
tool. They agreed and I involved 
them in the use of the tool from the 
beginning, when I was about to use 
the tool” (P1 [GP]: Focus Group3) 
 
“Yes, I also involved them from the 
beginning by taking time in 
explaining what I wanted to do to 
assess their risk of cancer and the 
patient I was dealing with was 




Table 15 Perceived facilitators to implementation of cancer risk assessment tools – themes, codes and quotes – after 




er et al., 
2009) 
Key words/phrases Key 
themes 













 -The tools will help to guide the 
clinician to see the broad level of 
differential diagnosis. 
- It also facilitates referral of 
patients  





As perceived before using the 
tools, the practitioners who later 
used the tools confirmed that the 
tools helped them to enabled 
them to make a clinician decision 
like referral of the patient 
“I think the tools will help to guide the 
clinician to see the broad level of differential 
diagnosis. It also facilitates referral of 
patients by presenting quantitative risk 
value to help explain risk and make a 
decision” (P2 [GP]: Focus Group3).  
 
-Time saving 
-Faster consultation, the 











Before using the tools with 
patients, the benefit of helping to 
improving process of and speed 
of assessments and treatment 
was perceived an enabler to the 
implementing CRATs. After 
using the tools in patient 
consultation, practitioners 
confirmed that the tools helped 
with quicker processes of 
assessment and referrals. 
“I think when the tools are fully integrated in 
our IT systems and every practitioner get 
familiar with using them, it will be time 
saving in the long term, as the consultation, 
the assessments, investigations and 
referral processes will be faster” (P1 [GP]: 
Focus Group3). 
 
“It was easy to assess a patient’s risk of 
cancer by entering their symptoms and risk 
factors into the QCancer calculator. It was 
also easy to use the risk generated to 
explain why they I needed to refer them for 
investigations and for a more specialised 
attention in the hospital, where early 
diagnosis and treatment could be done 
sooner than later” (P1 [GP]: Focus Group3). 
-Potential for using the tools for 
screening in other health 







Another perception before using 
tools was a potential benefit of 
helping to identify and advise 
people to modify their health risk 
behaviours is perceived as a 
“I think there is a potential for using the tools 
for screening in other health categories. The 
tools could be modified or redesigned to suit 
other conditions in primary care. They could 
also be modified for asymptomatic patients, 
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-Modify or redesigned the tools to 
suit other conditions in primary 
care 
-They could also be modified for 
asymptomatic patients 
-The tool helped in using the risks 
generated to advise patients who 
need behavioural changes. 
-Told them to maintain healthier 
lifestyles by exercising, eating a 
healthy diet, less alcohol and to 
stop smoking if they were smoking.  
-The tools can help to empower 
patient to take control of their risk 




facilitator for the implementing 
CRATs. This reflected in the 
views of practitioners who used a 
cancer risk prediction tool in 
patient consultation. The views of 
practitioners included a 
suggestion to modify or redesign 
the cancer risk prediction tools 
for other conditions or 
asymptomatic individuals as the 
statements below reflect 
for example the QCancer 10 years’ risk tool, 
I understand can be used to predict of 
cancer in asymptomatic individuals” (P3 
[GP]: Focus Group3). 
 
“I also found that using the tool helped in 
using the risks generated to advise patients 
who need behavioural changes. Their risk 
was small, and I told them to maintain 
healthier lifestyles by exercising, eating a 
healthy diet, less alcohol and to stop 
smoking if they were smoking. Yes, as I 
said, these tools can help to empower 
patient to take control of their risk factors 






-QCancer is based on current 
presentation (Q cancer) and easier 
to understand 
-We don’t quite understand the 
RAT yet  
-The pictorial representation and 
multi cancer symptom approach is 
useful with QCancer 
 
 
Ease of use Practitioners thought ease of 
user was an enabler to the use of 
the tools. Those interviewed 
used the use QCancer tool 
because they found it easier to 
use than the RAT which they 
don’t seem to understand 
“QCancer is based on current presentation 
(Q cancer). But I think, we don’t quite 
understand the RAT yet. The pictorial 
representation and multi cancer symptom 
approach is useful with QCancer” (P1 [GP]: 









Table 16 Perceived barriers to implementation of cancer risk assessment tools – themes, codes, and quotes – after practitioners 
used the tools  
CFIR  
constructs 




Key themes Meaning of theme Quotes 
Practitioners Practitioners 
Patient needs  
& resources 
-Thought it was going to 
be time consuming using 
the tool.  
-But time is only a short-
term issue  
-Only when you must 
google the tools  
-Time saving when fully 
integrated in IT systems 
-Time saving when 
practitioners are familiar 
with using the tools 
-Time saving in the long-
term 




in the short-term 
 
Before using the tools, 
there was perceived 
additional time required for 
the extra task of using 
CRATs the 
implementation of CRATs. 
After using the tools with 
patient, practitioners 
perceived that additional 
consultation time will only 
be need initially, and that 
the using the tool can save 
time in the long term. 
“I thought it was going to be time 
consuming using the tool. But I realised 
that will only be the case in the short term 
when you must google the tools before 
using for every patient. I think when the 
tools are fully integrated in our IT systems 
and every practitioner get familiar with 
using them, it will be time saving in the 
long term, as the consultation, the 
assessments, investigations and referral 
processes will be faster” (P1 [GP]: Focus 
Group3). 
 
Patient needs  
& resources 
-helped to reassure 
patients 
- Knowing that their 
symptoms were not 
cancer related  
-Knowing their 
symptoms would be 
investigated and cancer 
ruled out 
Worry/anxiety 





Before using the tools, 
practitioners thought there 
would be anxiety, but no 
patients were anxious 
when practitioners used 
the tool. It may be too early 
to conclude with a few 
patients in a short time of 
use. But practitioners 
explained that using the 
tools rather helped to 
reassure and calm 
patients once they got to 
“There was no problem. You are probably 
expecting them to be worried, but they 
were not. The patients I dealt with using 
the tool didn’t appear worried at all. I think 
that was partially because they 
understood that it was a small risk and it 
was not that they had cancer but just a 
risk” (P2 [GP]: Focus Group3). 
 
“…and using the tools, I think helped to 
reassure patients who probably were 
anxious about their symptoms before 
coming to see the GP. Knowing that their 
symptoms were not cancer related and 
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know something is being 
done. 
 
Also, the neutral colour of 
the QCancer icon arrays 
help to prevent anxiety or 
worry upon when you 
show it to the patients. 
that their symptoms would be 
investigated, and cancer ruled out, could 
have helped with to reduce anxiety” (P2 
[GP]: Focus Group3). 
 
“Background colours of icons in QCancer 
for the risk levels could have been red 
rather than the blue sad faces which are 
more neutral. But then, I think we may 
have to leave them that way, because the 
neutral colour probably helped patients 
not to be anxious - red could have scared 
them” (P3 [GP]: Focus Group3). 
Patient needs 
 & resources 
-Clinical judgements is 
used as well 
-Referred only those that 
needed referral  
-There will be over 
referral, 
-Haven’t referred many 
in a month 









Before using the tools, it 
was perceived that using 
the tool could cause over-
referrals. But after using 
the tools practitioners felt 
this may not happen as 
they use their judgement 
alongside the tools to 
refer. So far just a few 
patients qualified for 
referral in a month  
“Yes, we were thinking that using the tools 
in consultation could result in unnecessary 
…. over referrals. But as we have said 
before, we are not just referring but we are 
using our clinical judgements as well, so 
we only referred those patients that 
needed to be referred and we haven’t 
seen many in a month – I don’t think there 




-The tools are not known 
to the secondary or 
hospital setup.  
-They may not recognise 
QCancer referrals 
-They are only used to 






Before using the tools, it 
was perceived that there 
will be conflict with existing 
guidelines. After using the 
tools, Practitioners 
maintained that using 
CRATs could conflict with 
NICE referral guidelines 
as the specialists in 
hospitals expect only 
referrals relating to NICE 
2-week or urgent referral 
guidelines 
“My concern is that the tools are not 
known to the secondary or hospital setup. 
So, I referred some patients, and I am 
concerned they may not recognise my 
QCancer referral as they are only used to 
NICE referral guidelines, that is the two-
week waiting or urgent referrals. So, when 
I am thinking, if they see the patients, I 
referred using QCancer, they will ask - 
who is this? Is this a new doctor, a new 
GP?” (P1 [GP]: Focus Group3) 
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the quantified risk 
Before using the tools, it 
was perceived that 
patients with symptoms 
suggestive of cancer 
would need whatever the 
quantified risk. After using 
the tools, practitioners 
suggested that they only 
used the tools when they 
were not clear or wanted 
to differentiate cancer 
symptoms for other 
conditions. 
“You know, I won’t use these tools if the 
symptoms are clear to me that there is a 
















Table 16 Perceived barriers to implementation of cancer risk assessment tools – themes, codes, and quotes – after practitioners 












-The tools are useful  
-For clinical decision 
making  
-Happy to use the tools 
-Will use the QCancer 
which is easier to use. 
-Have no problem using the 
tools 
-believed it will be good to 
use the tools 
Willingness to 




Practitioner before using the 
tools had expressed scepticism 
on using the tools. Although 
only a few practitioners have 
used the tools, they have 
expressed a willingness to roll a 
cancer risk assessment tools 
out with no scepticism. 
"Yes, I will use the tools. I think the tools 
are useful in helping with clinical 
decision making as we already 
discussed” (P1 [GP]: Focus Group3). 
 
“Me too, I am happy to use the tools 
especially the QCancer, which is easier 
to use” (P3 [GP]: Focus Group3). 
 
“I have no problem using the tools, and I 
believe it will be good to use cancer risk 
assessment tools to facilitate early 
diagnosis of cancer, and as you know, 
early diagnosis will help with early 
treatment” (P2 [GP]: Focus Group3). 
Patient/practitioner 
needs & resources 
 
-Problem of accessing the 
tools as they are not 
integrated in our IT system. 
- It was not easy 
downloading or googling 
the tools during patient 
consultation. 
-The tools are not linked 










Practitioners who used the 
tools in patient consultation 
found it difficult because the 
tools are currently not 
integrated into their general 
practice IT system. To use the 
tool, practitioners had to search 
for the QCancer tool from the 
internet for each patient they 
needed to assess for cancer 
risk. Practitioners expressed 
the following views. 
“There was a problem of accessing the 
tools as they are not integrated in our IT 
system. It was not easy downloading or 
googling the tools during patient 
consultation, but that was the only option 
as I wanted to use the QCancer tool to 
check whether the patient was at risk of 
cancer, as the symptoms were a bit 
unclear” (P2 [GP]: Focus Group3). 
 
“The tools are not linked with the current 
NHS system, so you can’t really use 
them in patient consultation, unless you 
google and then use, all that, while the 





needs & resources 
 
 
-Problem is the RAT is not 
clear. 
-The RAT is more 
complicated to use than the 
QCancer.  
-We don’t quite understand 
how to use that tool.  
We need to have proper 
education or training on 
using these tools.  
Need for training 




Another barrier identified by 
practitioners who used the tool 
was that practitioners don’t 
understand clearly how to use 
the tools, and that practitioners 
need to know how to use the 
tools, especially the RAT. 
Training on how to use the tools 
in consultation is needed. 
“One problem is that the RAT is not very 
clear. The RAT is looking more 
complicated to use than the QCancer. 
We don’t quite understand how to use 
that tool. I think we need to have proper 
education or training on using these 
tools. The other day I met a lady from the 
Macmillan Cancer I support, and I asked 
them to see if they could come and give 
us a training session or talk on how to 
use the cancer risk assessment tools in 
patient consultations. I think we need to 
follow that up because the tools look 
good to use” (P2 [GP]: Focus Group3). 
Patient/practitioner 
needs & resources 
 
-The tools are not known to 
the secondary or hospital 
setup.  
- They may not recognise 
my QCancer referral as 
they are only used to NICE 
referral guidelines, that is 
the two-week waiting or 
urgent referrals.  
Need to involve 
in-hospital 
specialists in use 
of the tools  
 
After using the tools 
practitioners also identified that 
Specialist in hospital need to be 
aware and expect referrals 
relating to the tools, otherwise 
the staff at hospitals will not 
recognised cancer risk referrals 
based on the use of cancer risk 
prediction tools. 
“My concern is that the tools are not 
known to the secondary or hospital 
setup. So, I referred some patients, and 
I am concerned they may not recognise 
my QCancer referral as they are only 
used to NICE referral guidelines, that is 
the two-week waiting or urgent referrals. 
So, when I am thinking, if they see the 
patients, I referred using QCancer, they 
will ask - who is this? Is this a new 





-We will use these tools for 
a while and then evaluate. 
-Need to see effectiveness 
of the tools they are against 
existing practice.  
-Need to assess the impact 









As identified before using the 
tools in patient consultation, 
practitioners who used a 
cancer risk assessment tool 
confirmed the need for further 
evaluation of the impact of 
using the tools on outcomes 
such as investigations, referral, 
diagnosis and patient and 
practitioner satisfaction 
“The only thing is, as I have said before, 
we will need to use these tools for a 
while and then evaluate to see how 
effective they are against existing 
practice. I mean we have to assess the 
impact of using these tools on 
investigations, referral, diagnosis etc” 





5.7.1 Perceptions of practitioners after using the tools, about how best 
to communicate cancer risk information to patients  
When practitioners were interviewed before they used cancer risk assessment 
tools in patient consultations, they suggested several strategies that could help 
to best communicate cancer risk information to patients. After using the tools, 
practitioners maintained these suggestions as presented below. As in Section 
5.6 above, these perceptions are informed by Fischhoff’s risk communication 
framework (Fischhoff, 1995).  
5.7.1.1 Tailoring a visual representation of risk 
Before using the cancer risk assessment tools, practitioners perceived that 
tailoring a visual representation of risk was one way to best communicate 
cancer risk information to patients. That is, seeing the risk presented in a visual 
way, such as through pictures or symbols, could enhance understanding of a 
patient’s risk information. After using the tools in patient consultations, 
practitioners maintained these views about tailoring a visual representation of 
risk as the following statements indicate: 
“The pictorial representation and multi cancer symptom approach is useful with 
QCancer” P1 [GP]: Focus Group 3). 
“I showed them the QCancer chart, the yellow smiley and blue sad faces, and 
it was easy for them to understand” P1 [GP]: Focus Group3). 
“The Pictorial presentation will convince the patient about their risk as it is 
yellow smiley faces and blue sad faces are easy to understand. The 








5.7.1.2 Providing time for informing, listening, explaining and 
reassuring in a professional away  
After using the cancer risk assessment tools, practitioners expressed similar 
views as they did before they used the tools in patient consultation. That is, in 
using the tools with patients, practitioners took time to explain what the risk 
meant and indicated to patients that there was a plan to investigate and refer 
for a specialist’s attention in hospital. Explaining and reassuring patients can 
help them to understand the risk information presented to them. 
Understanding of the risk information can also help to reduce unnecessary 
worry or anxiety that may be experienced by patients during a consultation 
with a practitioner. In line with this, some practitioners said: 
“I reassured the patient by explaining that the risk is only a risk and not a 
cancer diagnosis. I explained what a 2% risk, meant, which is not a diagnosis 
of cancer, but a risk. I also explained that, early detection of risk will help with 
early investigations, diagnosis and early treatment” (P3 [GP]: Focus Group 3). 
“I explained that I needed to do some investigations and possibly to refer them. 
They understood and were alright with that” (P1[GP]: Focus Group3). 
5.7.1.3 Being open and honest with patients 
Like the views expressed by practitioners before using the tools, practitioners 
who used the tools with patients believed not telling patients the right 
information about their health could mean practitioners may be ‘hiding 
something’ from the patient. On the other hand, telling patients the truth about 
their risk of cancer could make them feel respected, less worried and able to 
make informed decisions. Hence, practitioners believed patients were less 
worried because they were honest with them as they did not hide anything 
from them when they used the tools during consultation. A practitioner said: 
“I didn’t hide anything from the patient, I was honest with them throughout. I 




5.7.1.4 Involving patients when using cancer risk assessment tools  
Similar to the views expressed before practitioners used the cancer risk 
assessment tools with patients, practitioners who used the tools believed that, 
involving patients when using the tools would mean recognising them as 
partners in their care and will promote autonomy or empowerment. 
Consequently, practitioners involved patients in the use of the tools by 
informing, explaining and seeking the consent of patients, which patients were 
happy with. Practitioners expressed the following views: 
“As I said, I informed them and asked for their consent to use the tool. They 
agreed and I involved them in the use of the tool from the beginning, when I 
was about to use the tool” (P1 [GP]: Focus Group3). 
“Yes, I also involved them from the beginning by taking time in explaining what 
I wanted to do to assess their risk of cancer and the patient I was dealing with 
was happy for me to carry on” (P2 [GP]: Focus Group3). 
The next section deals with the enablers to the implementation of cancer risk 
assessment tools as perceived by practitioners after using the tools. 
5.7.2 Perceived enablers to implementation after practitioners used the 
tools 
After using cancer risk assessment tools in patient consultations, practitioners 
perceived several enablers to the use of the tools which are similar to those 
expressed before the use of the tools in patient consultations: supporting 
decision-making; improving process and speed of assessment and treatment; 
identifying and modifying health risk behaviours; and ease of use. These are 
explained further below and informed by the CFIR construct of relative 
advantage (Damschroder et al., 2009) as stated in Section 5.6 above. That is, 
practitioners perceived these as enabling their use of the tools if they thought 




5.7.2.1 Supporting decision making 
As perceived before using the tools, the practitioners who later used the tools 
confirmed that the tools enabled them to make clinical decisions like referral 
of the patients. This was more likely to be the case when practitioners were 
not sure if a patient’s symptoms related to cancer or another condition. In line 
with this, a practitioner said: 
“I think the tools will help to guide the clinician to see the broad level of 
differential diagnosis. It also facilitates referral of patients by presenting 
quantitative risk value to help explain risk and make a decision” (P2 [GP]: 
Focus Group3). 
5.7.2.2 Improving process and speed of assessments and treatment 
Before using the tools with patients, the benefit of helping to improve process 
and speed of assessments and treatment was perceived as an enabler to the 
implementation of cancer risk assessment tools in primary care. After using 
the tools in patient consultation, practitioners maintained that the tools helped 
with quicker processes of assessment and referrals of patients. This was 
because a risk of cancer was likely to be detected on a single consultation with 
the practitioner and investigations and referrals were done sooner than later. 
Also, assessing a patient’s risk using their risk factors and symptoms was 
probably easier and quicker for some practitioners. A quicker than usual 
assessment also meant that practitioners could to decide with the patient on 
investigations and referral options without wasting time. In this direction, some 
practitioners said: 
 “It was easy to assess a patient’s risk of cancer by entering their symptoms 
and risk factors into the QCancer calculator. It was also easy to use the risk 
generated to explain why they I needed to refer them for investigations and for 
a more specialised attention in the hospital, where early diagnosis and 
treatment could be done sooner than later” (P1 [GP]: Focus Group3). 
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“I think when the tools are fully integrated in our IT systems and every 
practitioner get familiar with using them, it will be time saving in the long term, 
as the consultation, the assessments, investigations and referral processes 
will be faster” (P1 [GP]: Focus Group3). 
5.7.2.3 Identifying and modifying health risk behaviours 
Another perception before practitioners used the tools was about the potential 
benefit of the tools helping to identify and advise people to modify their health 
risk behaviours. In other words, using a patient’s risk information, they could 
be encouraged to modify health risk behaviours like smoking, excessive 
alcohol consumption and lack of regular exercises, which could lead to a 
reduction in the patient’s cancer risk level. This idea of identifying and 
encouraging patients to modify their health risk behaviours reflected in the 
views of practitioners who used the tools in patient consultations. Apart from 
maintaining that the tools helped to identify and advise individual patients 
about modifying their health risk behaviours, practitioners also suggested that 
the tools could be modified or redesigned for other conditions or asymptomatic 
individuals. Practitioners said: 
“I think there is a potential for using the tools for screening in other health 
categories. The tools could be modified or redesigned to suit other conditions 
in primary care. They could also be modified for asymptomatic patients, for 
example the QCancer 10 years’ risk tool, I understand can be used to predict 
of cancer in asymptomatic individuals” (P3 [GP]: Focus Group3). 
“I also found that using the tool helped in using the risks generated to advise 
patients who need behavioural changes. Their risk was small, and I told them 
to maintain healthier lifestyles by exercising, eating a healthy diet, less alcohol 
and to stop smoking if they were smoking. Yes, as I said, these tools can help 
to empower patient to take control of their risk factors and live healthier 




5.7.2.4 Ease of use 
Ease of use of the tools was not mentioned by practitioners who had not used 
the tools in patient consultation, but this was identified as an enabler to the 
use of the cancer risk assessment tools by practitioners who used the tools. 
Ease of use here describes how easy or difficult it was for practitioners to use 
any of the tools (e.g QCancer or RAT). Indeed, practitioners felt that the 
QCancer tool was easier to use than the RAT which seemed difficult to 
understand and use in patient consultations. A practitioner said: 
“QCancer is based on current presentation (QCancer). But I think, we don’t 
quite understand the RAT yet. The pictorial representation and multi cancer 
symptom approach is useful with QCancer” (P1 [GP]: Focus Group3).  
As perceived by practitioners after using a cancer risk assessment tool, the 
barriers to the use of the tools are presented in the next section. 
5.7.3 Perceived barriers to implementation after practitioners used the 
tools 
Following the use of cancer risk assessment tools in patient consultations, 
practitioners perceived several barriers to the use of the tools which are like 
those expressed before practitioners used the tools in patient consultations: 
additional consultation time in the short term; worry or anxiety relating to 
cancer referral & investigations; over-referral of patients; conflict with existing 
guidelines; symptoms suggestive of cancer need referral whatever the 
quantified risk; practitioner scepticism; need to integrate the tools into general 
practice system; need for training on use of the tools in patient consultations; 
need to involve in-hospital specialists in the use of the tools; and need to 
establish effectiveness of the tools. These are explained further below and 
informed by the relevant constructs from the CFIR (Damschroder et al., 2009) 





5.7.3.1 Additional consultation time in the short-term 
Before using the tools, there was perceived additional time required for the 
extra task of using cancer risk assessment tools in patient consultations. After 
using the tools with patients, practitioners perceived that additional 
consultation time will only be needed in the short-term, and that using the tools 
can save time in the long-term. From this point of view, it seems that time could 
be saved when the tools are integrated in the general practice IT system 
making it easier for practitioners to use the tools without having to switch 
between the patient’s records and the internet. When the tools are not 
integrated in the general practice system, switching from the patient’s records 
to the internet to access and use the tools, could be very time consuming. In 
line with this, a practitioner said: 
“I thought it was going to be time consuming using the tool. But I realised that 
will only be the case in the short term when you must google the tools before 
using for every patient. I think when the tools are fully integrated in our IT 
systems and every practitioner get familiar with using them, it will be time 
saving in the long term, as the consultation, the assessments, investigations 
and referral processes will be faster” (P1 [GP]: Focus Group3). 
5.7.3.2 Worry or anxiety relating to cancer referral & investigations 
Before using the tools, practitioners thought there would be anxiety or worry 
relating to cancer referrals and investigations. In contrast, the practitioners 
who used the tools said they did not observe any worries or anxiety in patients. 
Given the short time available for practitioners to use the tools before meeting 
with the researcher to express their views, it may be too early to conclude or 
rule out any future episodes of worries associated with the use of the tools. It 
is also possible that, even with the limited time that the tools were used, 
patients did not worry because practitioners took time to explain the use of the 
tools to patients, which might have helped to reassure and calm the nerves of 
patients. Also, as perceived by some practitioners, the neutral colour of the 
QCancer icon arrays might have helped to prevent anxiety or worry when they 
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were shown and explained to patients. In line with this, some practitioners 
expressed the following statements: 
“There was no problem. You are probably expecting them to be worried, but 
they were not. The patients I dealt with using the tool didn’t appear worried at 
all. I think that was partially because they understood that it was a small risk 
and it was not that they had cancer but just a risk” (P2 [GP]: Focus Group3). 
“…and using the tools, I think helped to reassure patients who probably were 
anxious about their symptoms before coming to see the GP. Knowing that their 
symptoms were not cancer related and that their symptoms would be 
investigated, and cancer ruled out, could have helped with to reduce anxiety” 
(P2 [GP]: Focus Group3). 
“Background colours of icons in QCancer for the risk levels could have been 
red rather than the blue sad faces which are more neutral. But then, I think we 
may have to leave them that way, because the neutral colour probably helped 
patients not to be anxious - red could have scared them” (P3 [GP]: Focus 
Group3). 
5.7.3.3 Over-referral of patients  
Before using the tools, it was perceived that using the tools could lead to over-
referrals of patients. In contrast, after using the tools practitioners felt this might 
not happen as they used their judgement alongside the tools to refer patients 
for investigations and specialists’ attention. This suggests that practitioners 
are not likely to depend entirely on the tools which could lead to over-referral. 
Applying their professional judgement when using the tools implies that only 
patients who are likely to have cancer will be referred for investigations or the 
attention of a specialist. Indeed, practitioners who used the tools felt that, so 
far just a few patients qualified for referral in a month of using the tools. A 
practitioner said: 
“Yes, we were thinking that using the tools in consultation could result in 
unnecessary …. over referrals. But as we have said before, we are not just 
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referring but we are using our clinical judgements as well, so we only referred 
those patients that needed to be referred and we haven’t seen many in a 
month – I don’t think there will be over-referrals” (P1 [GP]: Focus Group3). 
5.7.3.4 Conflict with existing guidelines 
Before using the tools, it was perceived that there could be conflict with 
existing guidelines like the NICE referral guidelines. After using the tools, 
practitioners maintained using the tools could conflict with NICE referral 
guidelines especially as the specialists in the hospitals only know and expect 
only referrals relating to NICE two-week or urgent referral guidelines. Like 
many practitioners in primary care, cancer specialists in secondary care may 
be more familiar with NICE guidelines associated with cancer referrals. In this 
respect, a practitioner said: 
“My concern is that the tools are not known to the secondary or hospital setup. 
So, I referred some patients, and I am concerned they may not recognise my 
QCancer referral as they are only used to NICE referral guidelines, that is the 
two-week waiting or urgent referrals. So, when I am thinking, if they see the 
patients, I referred using QCancer, they will ask - who is this? Is this a new 
doctor, a new GP?” (P1 [GP]: Focus Group3). 
5.7.3.5 Symptoms suggestive of cancer need referral whatever the 
quantified risk 
Before using the tools, it was perceived that patients with symptoms 
suggestive of cancer would need to be referred for cancer investigations and 
diagnosis even if the quantified risk was low. After using the tools, practitioners 
maintained this position, but they made clear that they only used the tools 
when they were not clear or wanted to differentiate cancer symptoms for other 
conditions. This implies that practitioners may not need to use a cancer risk 
assessment tool if a patient is already presenting with recognisable symptoms 
of cancer. In line with this, a practitioner said, “you know, I won’t use these 




5.7.3.5 Willingness to use the tools  
Practitioners, before using the tools had expressed that scepticism was a 
potential barrier to the implementation of cancer risk assessment tools. This 
could relate to the knowledge and beliefs of practitioners some of whom may 
not be innovators and may not like new tools. It may also be that they are being 
cautious about the new tools because of lack of evidence of their 
effectiveness.  
In contrast to the views held by those who used did not actively use the tools 
in patient consultations, those who used the tools were not sceptical about the 
tools. Indeed, practitioners said they were willing to roll out the tools after the 
necessary preparation or groundwork was completed. Practitioners said: 
"Yes, I will use the tools. I think the tools are useful in helping with clinical 
decision making as we already discussed” (P1 [GP]: Focus Group3). 
 
“Me too, I am happy to use the tools especially the QCancer, which is easier 
to use” (P3 [GP]: Focus Group3). 
“I have no problem using the tools, and I believe it will be good to use cancer 
risk assessment tools to facilitate early diagnosis of cancer, and as you know, 
early diagnosis will help with early treatment” (P2 [GP]: Focus Group3). 
5.7.3.6 Need to integrate the tools into general practice system 
Practitioners who used the tools in patient consultation experienced difficulties 
accessing the tools because the tools are currently not integrated into their 
general practice IT system. In fact, practitioners had to search for the QCancer 
tool from the internet for each patient they assessed for cancer risk. This was 
difficult and time consuming. This suggests the need to integrate the tools in 
the general practice IT system which will address the issues associated with 
too much time being spent on accessing and using the tools. In this 
connection, practitioners expressed the following views. 
169 
 
“There was a problem of accessing the tools as they are not integrated in our 
IT system. It was not easy downloading or googling the tools during patient 
consultation, but that was the only option as I wanted to use the QCancer tool 
to check whether the patient was at risk of cancer, as the symptoms were a 
bit unclear” (P2 [GP]: Focus Group3). 
“The tools are not linked with the current NHS system, so you can’t really use 
them in patient consultation, unless you google and then use, all that, while 
the patient is waiting” (P3 [GP]: Focus Group3). 
5.7.3.7 Need for training on how to use the tools in primary care 
consultations 
Another barrier identified by practitioners who used the tools was lack of 
understanding on the part of practitioners on how to use the tools. Practitioners 
said they had problems understanding and using the RAT. Hence, training on 
how to use the tools in patient consultations (including training needs like how 
the tools are integrate into the general practice IT systems and how to access 
them), is needed. In line with this, a practitioner said: 
“One problem is that the RAT is not very clear. The RAT is looking more 
complicated to use than the QCancer. We don’t quite understand how to use 
that tool. I think we need to have proper education or training on using these 
tools. The other day I met a lady from the Macmillan Cancer I support, and I 
asked them to see if they could come and give us a training session or talk on 
how to use the cancer risk assessment tools in patient consultations. I think 
we need to follow that up because the tools look good to use” (P2 [GP]: Focus 
Group3). 
5.7.3.8 Need to involve cancer specialists at secondary care settings  
Practitioners who used the tools also identified that Specialists in hospital 
settings need to be involved in the implementation of the cancer risk 
assessment tools, so they can expect referrals relating to the tools. Otherwise, 
any referrals to hospitals settings will not be recognised by consultants since 
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they are likely to be more familiar with cancer referrals based on NICE 
guidelines than any other tools like the cancer risk assessment tools. In 
relation to this, one practitioner said: 
“My concern is that the tools are not known to the secondary or hospital setup. 
So, I referred some patients, and I am concerned they may not recognise my 
QCancer referral as they are only used to NICE referral guidelines, that is the 
two-week waiting or urgent referrals. So, when I am thinking, if they see the 
patients, I referred using QCancer, they will ask - who is this? Is this a new 
doctor, a new GP?” (P1 [GP]: Focus Group3).  
5.7.3.9 Need to establish effectiveness of the tools 
As identified before using the tools in patient consultation, practitioners who 
used the tools maintained that, an evaluation of the impact of using the tools 
on outcomes such as investigations, referral, diagnosis and patient and 
practitioner satisfaction would be helpful. That any evidence of effectiveness 
associated with the use of the tools could encourage practitioners to 
implement the tools widely across general practices. The evidence could also 
inform policy issues relating to the recognition and appropriate integration of 
the tools into the general practice IT systems and alongside existing NICE 
guidelines. In this direction, a practitioner said: 
“The only thing is, as I have said before, we will need to use these tools for a 
while and then evaluate to see how effective they are against existing practice. 
I mean we have to assess the impact of using these tools on investigations, 
referral, diagnosis etc” (P1 [GP]: Focus Group3). 
The conclusion of this chapter is presented in Section 5.8 below. 
5.8 Conclusion of the chapter 
The results are presented in this chapter in respect of the research questions 
about how best to communicate cancer risk information to patients; and the 
enablers and barriers to implementation of cancer risk assessment tools from 
the perspectives of service users and primary care practitioners.  
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The analysis of the qualitative data was informed by two theoretical 
frameworks: the risk analysis framework (Fischhoff, 1995) for the question 
about how best to communicate cancer risk information; and the consolidated 
framework for implementation research (Damschroder et al., 2009) for the 
question about enablers and barriers to implementation. 
Service users and practitioners suggested several ways for effectively 
communicating cancer risk information to patients during a general practice 
consultation. These include tailoring a visual representation of risk; being open 
and honest; involving patients in the use of cancer risk assessment tools and 
providing time for listening and explaining to patient’s understanding. These 
perceptions were gathered when practitioners had not used the tools with 
patients in consultations. However, practitioners maintained these 
suggestions when they were interviewed after using the tools in general 
practice patient consultations.  
Before the use of cancer risk assessment tools, service users and practitioners 
perceived several enablers to the implementation of cancer risk assessment 
tools. These included: supporting clinical decision-making; identifying and 
modifying health risk behaviours; improving process and speed of assessment 
and treatment; and personalising care. After using the tools in general practice 
consultations, practitioners maintained these enablers, and stated an 
additional enabler - ease of use. 
Similarly, before the tools were used, participants perceived several barriers 
to implementation of cancer risk assessment tools including: additional time 
requirement; worry or anxiety related to referral for investigations; potential 
over-referral; conflict with existing guidelines; symptoms suggestive of cancer 
will need referral whatever the quantified risk; and need to pilot and evaluate 
for the effectiveness of the tools against current practice.  
After using the tools in patient consultation, practitioners maintained these 
barriers perceived earlier, and then added the following barriers to 
implementation of the tools: need for integration of the tools into all general 
172 
 
practice IT systems; need to involve secondary care or hospitals consultants 
and other relevant specialist in the use of the tools. These results are 





























CHAPTER 6 DISCUSSION 
6.1 Summary of the chapter 
In this chapter, the results are discussed in relation to the research questions 
which were to explore the perspectives of service users and practitioners 
about: (a) how best cancer risk information can be communicated to patients 
during consultations, and (b) the enablers and barriers to the implementation 
of cancer risk assessment tools in primary care. A summary of the main 
findings; statement of original findings; limitations and strengths of the study 
are stated. The findings are discussed in the context of the existing literature 
and the implications for practice and research. 
6.2 Summary of key findings  
Before using the cancer risk assessment tools in patient consultations, both 
service users and practitioners suggested several ways of effectively 
communicating cancer risk information to patients: tailoring visual 
representation of risk; being open and honest; informing and involving patients 
in the use of the tools; and providing time for listening, informing, explaining 
and reassuring in a professional way. After using the tools in patient 
consultations, practitioners maintained that these strategies helped 
communicate cancer risk with patients. 
Also, before using the tools, both service users and practitioners perceived the 
benefits of using cancer risk assessment tools as the enablers to the 
implementation of tools. These included: supporting decision-making; raising 
awareness for modifying health behaviours; improving process and speed of 
assessments and treatment; and personalising patient care. After using the 
tools, practitioners perceived ‘ease of use’ as an additional enabler to their use 
of the tools. 
In addition, perceived barriers to implementation identified before the tools 
were used included: additional time requirement; unnecessary worry related 
to referral for cancer investigations; over-referral; practitioner scepticism; 
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conflict with existing guidelines; need to refer patients with symptoms 
suggestive of cancer whatever the quantified risk; and the need for evidence 
of effectiveness before introducing the tools widely in primary care patient 
consultations. After using the tools, practitioners mentioned the following as 
additional barriers observed during the use of the tools: need to integrate the 
tools into IT systems of all general practices; need to involve secondary care 
consultants and need for training of practitioners about how to use the tools in 
patient consultations. 
6.3 Statement of original findings 
One important aspect of the originality of this study relates to the gathering of 
the views of service users in addition to those of practitioners, as most 
previous studies are based on the perspectives of practitioners on the barriers 
and facilitators to the use of cancer risk assessment tools in primary care. 
The findings also add to existing knowledge in terms of the strategies or ways 
suggested for enhancing communication of cancer risk information to patients. 
These include the importance of tailoring a visual representation to enhance 
patients’ understanding of the risk being communicated to them. Another way 
to effectively communicate cancer risk is by being open and honest on the part 
of both patients and practitioners. Others include involving patients in the use 
of the tools and providing time for listening while using a professional approach 
to explain, inform and reassure patients. This study sought to explore how 
cancer risk information may be best communicated to patients when using 
cancer risk assessment tools in primary care consultations. These findings are 
new and will bridge that gap about how best cancer risk information can be 
communicated to patients during consultations. 
6.4 Limitations and strengths  
The findings from this study were limited in various ways. One recurrent 
question I encountered during my PhD was, why the philosophical position of 
pragmatism and the use of Framework analysis were adopted instead of a 
pure interpretive position, for example, using grounded theory for data 
analysis. I acknowledge there may have been limitations to not using an 
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interpretive approach when collecting and analysing the data, but this was 
balanced by the specific aims of the study and the need to compare patient 
and practitioner views. While a pure interpretive or inductive approach may be 
common with most qualitative research, the nature of my research required 
me to adopt the pragmatic philosophical position, which allowed me to use 
methods that best addressed the research questions. 
It was also necessary to ground the research in relevant theoretical 
frameworks, which were useful in informing the interview guides and 
subsequent analysis of the data. The framework approach allowed both 
deductive as well as relevant inductive themes. A limitation arising from this 
approach was the potential for the researcher to consciously or unconsciously 
influence the way the questions were asked, and the type of data collected. 
However, I was careful enough to minimise this by piloting and revising the 
data collection tools with potential participants and my supervisors. 
Additionally, the interviews, data collection and analysis were carefully 
discussed with my supervisors to ensure objectivity, authenticity and accuracy. 
The initial data collection involved participants (service users and 
practitioners) who had not yet used the tools in clinical practice. It was thought 
important to collect additional data from practitioners who had used the tools 
with patients, to assess whether their views about the use of tools would differ 
from those who did not actively use the tools. Hence, an additional focus group 
was conducted with practitioners who had actively used the tools. 
While the additional focus provided additional useful information from 
practitioners after using the tools, there were limitations worth acknowledging. 
The additional focus group was conducted in one of the general practices that 
had participated in the earlier data collection. Hence, one limitation was the 
potential for some practitioners to be influenced by the perceptions they 
expressed before actively using the tools in consultations. It would have been 
ideal to gather the views of practitioners who had not participated in the earlier 
focus groups. It would have also been good to have more than one focus 
group, but this was the only practice willing to use the tools and then find time 
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to meet for a focus group, within the time frame available for the completion of 
the project and submission of the thesis. The honesty and professionality of 
practitioners in not allowing their pre-use perceptions to influence their post-
use perceptions of the tools was trusted. 
A further limitation is that many service users and practitioners might have 
received or seen the information inviting them to participate in this study but 
could not participate. It is possible that those who were unable to participate 
might have expressed different views from those who took part in the study. 
For example, practitioners who did not participate may have been less positive 
about them and less likely to take them up, the so-called late majority or 
laggards in taking up innovation (Rogers,1995). Their knowledge and beliefs 
about the new tools (Damschroder et al., 2009) might have differed from those 
who participated. This is because participants generally felt that cancer risk 
assessment tools would be beneficial, and the benefits would serve as 
enablers to the implementation of the tools. This raises a question of selection 
bias, a common problem with the selection of volunteers to qualitative 
interviews (Collier & Mahoney,1996).  
The finding of code (‘I have heard it all’) and meaning (‘I have understood it 
all’) data saturation (Hennink et al., 2016) in the data analysis process, an 
important guide for sample size selection in qualitative research, suggested 
that no new ideas would have been found if more participants were 
interviewed. 
Another limitation is in generalising the findings from this study to other 
populations because the sample size may be considered small. However, the 
primary aim of qualitative studies is usually not to generalise but to explore or 
generate ideas, which this study has effectively achieved. 
Although there are an increasing number of people from minority ethnic groups 
in the study area and in the UK, no service users from these groups responded 
to the invitation to participate in the study. Hence, all nineteen service users 
who participated in the study were White British. It is not clear why service 
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users from ethnic minorities did not respond. However, the study advertised 
for participants who had interest in the delivery of cancer services, for reasons 
such as having recovered from cancer or having a relative or a friend who had 
recovered from cancer or for some other reason. The advertisement for 
participants was spread widely, but it is possible that members of ethnic 
minority groups did not see the advertisement, were unable to understand it 
due to language difficulties, or had no interest in participating in the study.  
Previous research findings suggest that members of minority ethnic groups 
are less likely to participate in research if they lack confidence in knowing what 
to say, or if there was fear or worry of the unknown, or if there was a language 
barrier resulting in lack of understanding about the research (Lo & Garan, 
2008; Gill et al., 2013). It has also been suggested that people from minority 
ethnic groups are more likely to participate in research if they are approached 
with sensitivity and they understand or perceive the study to be beneficial to 
them (Ejiogu et al., 2011; Gill et al., 2013).  
As explained previously in the methods section and bearing in mind the 
importance of approaching potential participants with sensitivity, potential 
participants were provided with clear information about the research using a 
flyer, and they had enough time to decide on whether to participate in the 
study, before approaching the researcher. 
Among service user participants, there were fewer men than women. This may 
have been because women were more willing to participate in the study than 
men, although previous research has found that men and women, if they were 
eligible, were equally willing to participate in cancer research (Huang et al., 
2013). Among practitioners, there were more participants from ethnic minority 
groups than White British, but this may be due to the demography of general 
practitioners in the study. 
A key strength of the study was the comparison of service user and practitioner 
perspectives, and the use of both individual and focus groups interviews. The 
use of individual interviews helped to gather detailed or in-depth information 
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from individual participants, while the use of focus groups for some 
practitioners enabled the possibility for discussion with colleagues who were 
likely to work as a practice team when it came to the implementation of the 
cancer risk assessment tools in primary care consultations. Service users and 
practitioners were candid in expressing their views which helped to gather 
tangible findings to address the research question. 
The data collection, analysis and interpretation followed recognised processes 
to ensure the findings were valid. The rigour in data processes included the 
following. Recorded interviews were transcribed verbatim. The five stages of 
the framework approach (Ritchie & Spencer, 1994) were followed for data 
analysis. The data analysis was monitored and guided by the primary 
supervisor, with all three members of the supervisory team providing feedback 
during the process.  
In the conduct of the study, particularly in the analysis and interpretation of the 
data, the researcher applied his background knowledge and experience in 
nursing and psychology coupled with the expertise of his supervisory team, 
which included an experienced general practitioner (GP) and supervisors with 
a nursing background. The presence of a GP in the supervisory team helped 
to clarify and interpret certain terms and expressions used by participants, 
particularly those who were GPs. Additionally, the different backgrounds of the 
research team added diverse perspectives to the analysis and interpretation 
of the results. 
Reflection on the use of QCancer with service users (at Phase 1) and 
practitioners at Phase 2, and non-specific (any) risk assessment tools  
Although the thesis was initially structured around QCancer, the initial 
interview guide and questions for Phases 2 and 3 were directed more broadly 
across cancer risk assessment tools including QCancer and used to collect 
data from both service users and practitioners. Only data related to QCancer 
were presented in the initial thesis submitted. Subsequently data were 
reanalysed to derive themes more broadly relating to cancer risk assessment 
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tools since data had already been collected around cancer risk assessment 
tools. 
Reflection on any relative difference between the data gathered by the 
different means 
There were no major differences since both individual interviews and focus 
groups are usually used to generate ideas through the collection of in-depth 
qualitative data. The two methods can complement each other depending on 
what is suitable for participants. In this research, individual interviews were 
used for service users because it was suitable for them to attend, while both 
individual interviews and focus groups were used for practitioners depending 
on their availability to attend. Since they are different approaches or methods, 
there may be minor differences (as discussed below). It would have been ideal 
to use either only individual interviews or only focus groups for easy 
comparison of the data. Using the both individual interviews and focus groups 
according to the preference or suitability for practitioners’ schedule for 
example, may pose questions relating to selection bias. However, it was not 
within the control of the researcher as some practitioners could meet for focus 
groups while others could not but were willing to do individual interviews. In 
order not to miss potentially valuable information, these individual interviews 
were conducted with practitioners. 
The minor differences between individual interviews and focus groups lie in 
the process of collecting the in-depth data rather. In the individual interviews 
with service users and some practitioners, individuals had the freedom and 
privacy to express themselves with prompts from the research, thereby 
generating a wealth of in-depth data. For the focus groups, there was a 
possibility of group members interrupting each other or some out-speaking 
others. But there was also that advantage of group discussion whereby 
participants were prompted or encouraged to express their views after issues 
were raised by other participants. This resulted in the generation of in-depth 
data as the use of individual interviews did. Since the data collected through 
both individual interviews and focus groups were generally in-depth qualitative 
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ideas, it was possible to compare the ideas raised by service users with those 
of practitioners using the codes or themes and quotations from each group. 
6.5 Context of existing literature 
To the best of my knowledge this study is the first to investigate the 
perspectives of both service users and practitioners to help inform the 
implementation of cancer risk assessment tools in primary care consultations. 
The findings about communicating cancer risk information to patients, the 
enablers and barriers to implementation of the tools are discussed in the 
context of existing literature.  
6.5.1 Communicating cancer risk information to patients  
The scoping review in Chapter Two of this thesis found limited evidence on 
communicating cancer risk information when using cancer risk assessment 
tools with patients in primary care consultations. In fact, evidence suggests 
that discussion of risk information was less likely to occur if patients did not 
prompt practitioners (Guerra et al., 2009).  
In this study, both service users and practitioners, before the tools were used, 
suggested several ways to effectively communicate cancer risk information to 
patients. After using the tools in patient consultations, practitioners maintained 
these suggested ways of communicating risk. Firstly, tailoring a visual 
representation of the risk generated by a cancer risk assessment tool, is in line 
with the assertion that the use of simple visual aids can improve doctor-patient 
communication (Paling, 2003). It also relates to the risk communication 
framework stage of telling patients and explaining to their understanding what 
the cancer risk information means (Fischhoff, 1995). This strategy of tailoring 
risk information is also in line with the CFIR construct of adaptability which 
refers to the degree to which interventions like cancer risk assessment tools 
can be adapted, tailored, refined, or reinvented to meet local needs 
(Damschroder et al., 2009). In a related example, Dikomitis et al. (2015) found 
problems in the design of electronic decision support (eCDS) tools, resulting 
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in a recommendation for further development of these tools to make them 
more user friendly.  
With reference to the need to tailor and present cancer risk information 
visually, evidence from a systematic review also suggested that 
communication tools were more likely to increase patients’ understanding if 
they were tailored, structured and made interactive; and that illustrations such 
as vertical bar charts, might help to convey more understanding (Trevana, 
2006).  
In another systematic review investigating design features of graphs in health 
risk communication (Ancker et al., 2006), there was evidence of patients being 
more able to recognise proportions with part-to-whole sequential icon arrays 
[that is, icons arranged in an ordered pattern] (Fuller et al., 2001) than in 
randomly arranged icon arrays (Feldman-Stewart et al., 2000), and jittered 
icons [that is small unsteady or difficult to visualise icons] (Royak-Schaler et 
al., 2004). This may explain the dislike of random-arrangement arrays reported 
in a previous qualitative study (Schapira et al., 2001) and found in the current 
study. Both service users and practitioners in the current study agreed that, to 
improve patients’ understanding, the QCancer risk chart (for example), 
consisting of an icon array or Cates plot with a 10 by 10 arrangement of blue 
sad (each expressing 1% 2-year cancer risk) and yellow smiling (no risk) 
faces, should appear in rows or columns according to the colour of icons rather 
than being scattered about the graph. Participants thought that scattering blue 
sad faces gave the impression that they were more numerous, that the risk 
was higher, and that better structured graphics would ensure a visual 
representation which was clearer and easier for patients to understand.  
The importance of such design and other features also fit with the notion 
expressed in the CFIR that the design, quality and packaging characteristics 
of an intervention can contribute to the implementation of cancer risk 
assessment tools (Damschroder et al., 2009). 
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Being open and honest when communicating cancer risk with patients was 
another communication strategy mentioned by service users and practitioners. 
Being truthful with patients relates to the risk communication framework stage 
of treating patients nicely or with respect (Fischhoff, 1995). This is ethically 
important and contributes to building trust and credibility between patients and 
practitioners, as well as promoting autonomy and empowerment for patients. 
To demonstrate sincerity, practitioners need to communicate early and often 
with patients, and they must be willing to admit mistakes, deliver bad news 
and share required information in a professional and responsible manner 
(GMC, 2013).  
Although a few service users did not mind if they were not informed, and a few 
practitioners felt they might not inform patients, before using cancer risk 
assessment tools, most participants agreed that to effectively communicate 
cancer risk, patients should be informed and involved in the use of cancer risk 
assessment tools in the consultation. Informing and involving patients in the 
use of cancer risk assessment tools relates to the risk communication 
framework stage of making patients partners in the use of cancer risk 
assessment tools (Fischhoff, 1995).  
In relation to patient involvement, it is important to understand that 
practitioners can underestimate the degree to which patients wish to be 
informed about or involved in a decision-making process about their health 
(Elwyn et al., 1999). That is, decisions are sometimes made by assuming what 
patients prefer (Little et al., 2004), rather than involving them in that decision-
making process. If patients were not informed when a cancer risk assessment 
tool was being used this could detract from the importance of gathering their 
views or preferences in the decision-making process.  
Providing time for listening, informing, explaining and reassuring patients in 
the context of a professional approach was also cited by participants as 
important for improving effective communication. This relates to the risk 
communication framework stage of explaining to patients what the cancer risk 
information means (Fischhoff, 1995) - making clear that a risk of cancer is not 
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the same as a diagnosis of cancer. From the perspective of service users and 
practitioners in this study, not listening or not making efforts to explain issues 
to patients could destroy an otherwise trusted patient-practitioner relationship.  
Practitioners should explain using lay terms rather than technical medical 
expressions or jargon which could leave patients feeling worried and anxious, 
not understanding the options available, or with erroneous expectations of 
possible benefits and harms. As mentioned earlier, a previous systematic 
review showed that when patients use decision aids, they: improve their 
knowledge of the options; are helped to have more accurate expectations of 
possible benefits and harms or barriers, such as a positive effect on 
communication with their health practitioner in a consultation and some effect 
on the time required for this consultation (Stacey et al., 2011). 
The overall findings presented here about the communication needs of those 
aiming to use cancer risk assessment tools can be explained further by the 
CFIR, in terms of the networks and communication construct, which describes 
how the nature and quality of communications is important for the 
implementation process (Damschroder et al., 2009).  
6.5.2 Perceived enablers to implementation of cancer risk assessment 
tools 
Participants in this study perceived the benefits of cancer risk assessment 
tools as the enablers to the implementation of the tools. These perceptions 
were expressed before practitioners used the tools in patient consultations. 
After using the tools, practitioners added ease of use to the enablers to 
implementation of the tools.  
Participants felt that one enabler to the use of the tools was that cancer risk 
assessment tools could support decision-making especially with patients 
whose cancer symptoms were unclear, or when cancer was a differential 
diagnosis. In addition, the tools could help to speed up the assessment, 
diagnosis and treatment of cancer. These findings support findings from a 
previous study of GPs’ experiences of using diagnostic tools, which found that 
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the Risk Assessment Tool (RAT) helped GPs with lung and colorectal cancer 
symptom recognition and confirmed their decision about whether to refer 
(Green et al., 2015). In another study, embedding electronic decision-support 
tools was found to have educational benefits, with GPs reportedly learning 
about cancer symptoms using cancer risk assessment tools (Dikomitis et al., 
2015). Green et al. (2015) also found that embedding clinical decision support 
tools in clinical practice was more likely to be achieved when they were used 
to support, rather than supersede the clinical judgement of practitioners. This 
corresponds with the views expressed by practitioners in the current study that 
whatever the quantified cancer risk, they would refer patients with symptoms 
suggestive of cancer based on their clinical judgement. 
Another enabler to the use of the tools perceived by participants in the current 
study was that cancer risk assessment tools could have the benefit of helping 
to identify and raise awareness for promoting positive health behaviours in 
patients. This adds to findings from a recent systematic review of randomised 
controlled trials of cancer risk assessment tools in primary care, which 
suggests that health promotion messages within tools may have positive 
effects on behaviour change (Walker et al., 2015). 
Indeed, tools that have the potential to help with early detection of cancer risk 
as well as helping to raise awareness for people to modify their health 
behaviours, could be used both for purposes of early diagnosis and treatment 
and as a public health preventive measure for cancer and similar health 
conditions. This may be part of the reasoning behind suggestions by some 
participants that the QCancer risk predicting period should be more than the 
current period of two years, to allow for a longer period of monitoring and 
modifying health risk behaviours. Indeed, it appears that this view is shared by 
many people including the developers of the QCancer algorithm. There is now 
a QCancer algorithm designed to predict the risk of common cancers in men 
and women over a 10-year period (Hippisley-Cox & Coupland, 2015). 
However, the 10-year QCancer algorithm may worsen potential issues of false 
positives, false negatives, over-investigation, over-referral and patient anxiety 
that may relate to use of cancer risk assessment tools.  
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Another enabler was that cancer risk assessment tools could help to 
personalise patient care. One possible explanation for this relates to the fact 
that the QCancer quantified risk, for example, is based on an individual 
patients’ risk factors and symptoms rather than a risk calculated for a 
population or group of patients. Since the risk generated is for an individual 
patient, the referral and further investigations as well as the subsequent 
diagnosis and treatment or cancer care will be specific to that individual patient 
considering their individual demographic and psychosocial characteristics. 
Personalised or person-centred care is about taking into consideration the 
desires or values, social circumstances and lifestyles of people, while working 
with people as individuals to develop appropriate solutions (Sepucha et al., 
2008; Gill, 2013).  
The overall findings on the benefits of cancer risk assessment tools (perceived 
enablers to implementation) can be explained further by the CFIR 
(Damschroder et al., 2009). That is, participants who regarded positively the 
characteristics of a cancer risk assessment tool, such as its relative advantage 
and adaptability, were more likely to perceive it as beneficial for their practice 
(Damschroder et al., 2009). Similarly, in line with the construct of knowledge 
and beliefs described within the individual characteristics domain of the CFIR 
(Damschroder et al., 2009), individual participants, particularly practitioners, 
might have perceived the tools as beneficial because they had knowledge 
(understanding), positive beliefs and attitudes concerning cancer risk 
assessment tools. Barriers to the implementation of cancer risk prediction tools 
were also identified by participants in this study as discussed below. 
6.5.3 Perceived barriers to the implementation of cancer risk assessment 
tools  
Despite the perceived benefits of electronic decision-support tools, Dikomitis 
et al. (2015) found challenges to the implementation of these tools into routine 
practice, resulting in a need for training and guidance around their use. 
Similarly, the current study found barriers such as practitioners having trouble 
in understanding and accessing or using cancer risk assessment tools. Hence, 
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primary care practitioners needed training on accessing the tools when they 
are integrated in the general practice IT system and using them for patient 
consultations.  
Also, a previous study involving the use of a cancer risk assessment tool 
(QCancer) found several barriers that needed to be considered for the 
implementation of cancer risk assessment tools in primary care. These 
included: lack of trust on the part of some GPs in the risk calculation, especially 
when it conflicted with clinical judgement; variable interpretation of symptoms 
by participants leading to wide variations in risk assessment when the risk 
output was high, and the difficulties experienced by some GPs in 
communicating numerical risk outputs to patients (Chiang et al., 2015). 
Participants in the current study also expressed several other barriers to the 
implementation of cancer risk assessment tools.  
Firstly, it was felt that more time would be needed for consultations when using 
the tools to enable practitioners to inform, explain and listen to the patient, and 
then discuss further investigations with the patient if required. The average 
primary care consultation time of about ten minutes was not felt to be sufficient 
for a practitioner to effectively communicate cancer risk to a patient without 
patients feeling that they were being rushed or ignored.  
The need for extra time is an example of the construct of cost, an intervention 
characteristic expressed within the CFIR (Damschroder et al., 2009). 
Additional time, which is not always available in the face of increasing 
practitioner workload, could affect the implementation of cancer risk 
assessment tools. The requirement for extra time also relates to the construct 
of intervention complexity (Damschroder et al., 2009). Going online and 
manually entering the data needed for the risk calculation during the 
consultation (unless it is integrated into practice computer systems and linked 
with patient data), together with the need for explanation adds complexity. 
Indeed, practitioners who used the tools in patient consultations maintained 
that the current limited consultation time was a barrier to the implementation 
of the tools. However, this would only be a short-term barrier, because when 
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the tools are integrated into the general practice IT system and linked to patient 
data, and practitioners trained on how to use the tools, it will be less time 
consuming in the long-term. 
From the perspectives of service users and practitioners who were interviewed 
before the tools were used, the use of cancer risk assessment tools could 
potentially create unnecessary worry or anxiety for patients during the 
consultation or referral for further investigation. For some patients, the 
possibility of prompt investigation and early appropriate treatment of cancer 
may be helpful. For others, being told that they are at risk of cancer, being 
referred for cancer investigations, and waiting for the results could trigger 
worry and anxiety. This may be the case, whether the investigations prove 
positive or negative.  
However, practitioners who used the tools in patient consultations said they 
did not come across patients who were worried or anxious about being 
referred for cancer investigations. Instead, patients felt relieved that something 
was being done in the form of investigations, with a potential for early 
diagnosis and treatment, rather than leaving it too late. This supports a recent 
systematic review of randomised controlled trials of cancer risk assessment 
tools in primary care which found no increase in cancer worry (Walker et al., 
2015). Despite this, the point of worry and anxiety remains important. 
The QCancer (as an example of cancer risk assessment tools) predicts either 
a cancer which is present but not yet diagnosed, or a cancer that might 
develop within two years. This means that a patient can still develop cancer 
even if the initial investigations do not reveal cancer. The uncertainty of not 
knowing whether or when a cancer might develop could be the source of 
further distress to patients. Even if patients are cleared of cancer after being 
monitored for the two years, cancer may still develop in subsequent years not 
covered within the predicting period, even if the initial cancer risk factors that 
triggered the risk were modified. This perceived worry or anxiety adds to the 
construct of intervention complexity (Damschroder et al., 2009), as it poses 
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the problem of how best to communicate a patient’s cancer risk to them without 
causing undue anxiety or worry. 
Another barrier identified by participants before the use of the tools was over-
referral that could result from too many people being unnecessarily referred 
when cancer risk assessment tools were used in primary care consultations. 
However, after using the tools in patient consultations, primary care 
practitioners thought over-referral was not likely to be a problem because they 
used the tools alongside their professional judgement and only referred 
patients who they felt needed to be referred based on their symptoms and 
quantified cancer risk. This is in line with the notion that, Cancer Decision 
Support tools should prompt primary care practitioners to think about the 
possibility of cancer, and then decide on referral based on their clinical 
judgment (Macmillan Cancer Support, 2015). 
Although practitioners who used the tools in this study did not see over-referral 
as a problem, it may be too early to dismiss it. Over-referral may be observed 
later when the tools are more widely rolled out in primary care consultations, 
and in instances of workload or other quality opposing factors, there may be a 
temptation to rely on guidelines which can then lead to over-referral. This could 
put pressure on limited human and material resources in both primary and 
secondary care settings. Hence, the potential costs of over-referral will need 
to be weighed against not referring early enough. This is another example of 
the construct of cost within the domain of intervention characteristics 
(Damschroder et al., 2009), as a potential barrier to implementation of cancer 
risk assessment tools.  
This study also found practitioner scepticism as a barrier to implementation, 
which was expressed before practitioners used the tools in patient 
consultations. Practitioners in a stimulation study conducted in Australia 
appeared not to trust some risk outputs of the QCancer tool (Chiang et al., 
2015), which relates to practitioner scepticism expressed by some participants 
in this study.  
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Although practitioners who used the tools expressed in focus groups that 
scepticism was not a problem, and that they were willing to continue to use the 
tools in patient consultations, this perceived barrier remains important 
especially when the tools are more widely rolled out. 
Practitioners might be sceptical because they may perceive cancer risk 
assessment tools as new with limited evidence available on their impact on 
quality of practice and patient health outcomes. This is in line with the CFIR 
construct of evidence strength and quality described within the domain of 
intervention characteristics (Damschroder et al., 2009).  
Similarly, practitioners who are sceptical of the new tools may be the late 
majority or laggards who are usually the last to adopt an innovation as 
explained within the theory of Diffusion of Innovations (Rogers, 1995). Similar 
to the views of Rogers (1995), the CFIR explains that characteristics of an 
intervention (intervention source; evidence Strength & Quality; relative 
advantage; compatibility; adaptability; trialability; complexity; design quality 
and packaging and cost) may influence the rate of adoption of an innovation 
(Damschroder et al., 2009).  
The knowledge and beliefs as explained within the CFIR (Damschroder et al., 
2009) could also explain why some practitioners may be sceptical to adopt or 
use the cancer risk assessment tools. As the tools are new in the system, 
primary care clinicians may have limited knowledge and beliefs about their 
effectiveness, and how to access the tools during patient consultations.  
Indeed, practitioners who used the tools felt that they needed to be integrated 
into their general practice IT system, otherwise it would-be time-consuming 
switching from the practice IT system to download the tools from the internet. 
Some practitioners also appeared not to understand how to use the tools 
especially the RAT. Consequently, practitioners who used the tools identified 
lack of integration of the tools into the practice IT system and lack of training 
on how to use the tools as barriers to implementation of the tools. For a 
successful implementation of cancer risk assessment tools in primary care 
consultations, training on how to use the tools after they have been integrated 
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into the practice IT system, should be provided for all general practice 
clinicians.  
It may also be that many practitioners or clinicians are sceptical of using 
cancer risk assessment tools because they tend to trust the accuracy of their 
own clinical judgement over statistical predictions or algorithms (Kahneman, 
2011). It is important to remember that clinical judgement of clinicians is 
important and should be used as expected of them as trained professionals. 
Yet, it is equally important to remember that algorithms have been proven to 
be more accurate and reliable for predicting risk than the clinical judgement of 
clinicians (Kahneman, 2011). A meta-analysis of 136 studies that compared 
the efficacy of clinical judgement versus statistical prediction revealed that 
statistical predictions were equal or superior to clinical prediction methods for 
a wide range of circumstances (Grove et al., 2000).  
Furthermore, statistical tools or algorithms may have advantages over clinical 
judgement in different ways. Firstly, the volume of information such as the risk 
factors and symptoms required (in the case of QCancer) to predict a person’s 
risk of developing cancer within two years may be too much for the human 
brain to effectively hold and process. Clinicians may be able to process such 
information for a short-term prediction, but this could be more difficult for a 
prediction over a long-term period such as two or more years.  
Cancer risk assessment tools are also more reliable and therefore more 
objective than the human brain, by providing a repeatable and consistent risk 
prediction, given the same data inputs. Secondly, since the statistical 
calculation is faster it will save the clinician time, freeing up time for other 
things. It not surprising that practitioners who used the tools suggested that 
additional time requirement is only a barrier to implementation in the short-
term.  
Another barrier perceived by participants was that the tools might conflict with 
existing guidelines. This is in line with the construct of compatibility 
(Damschroder et al., 2009), i.e. whether interventions like cancer risk 
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assessment tools fit with existing workflows as expressed within the inner 
setting domain of the consolidated framework for implementation research 
(CFIR) (Damschroder et al., 2009). This conflict with existing guidelines issue 
will show itself when it comes to referral of a patient to secondary care 
specialists who may be familiar with NICE two-week or urgent referral 
guidelines, but not cancer risk assessment tools. It is not surprising that 
practitioners who used the tools in patient consultations also identified the 
need to involve cancer specialists in the referral pathway as their non-
involvement or lack of awareness of the implementation of the tools could 
constitute another barrier to implementation. 
Another barrier identified was the perception that patients with symptoms 
suggestive of cancer would need to be referred for further investigations 
irrespective of their quantified risk. It was understandable that practitioners 
with their medical knowledge and experience cannot fail to refer patients with 
high risk symptoms even if such patients have a low quantified risk; but with 
high risk symptoms suggestive of cancer, practitioners may find it easier to 
refer a patient for cancer investigations even without using a risk assessment 
tool. Indeed, it has been suggested that when using Cancer Decision Support 
tools, primary care practitioners who suspect a possible cancer diagnosis can 
refer a patient even if their quantified risk is low or does not meet the referral 
NICE guidelines (Macmillan Cancer Support, 2015).  
Furthermore, the Macmillan Cancer Support team who have integrated the 
QCancer and RAT and have called them the electronic Cancer Decision 
Support (eCDS) tools, have suggested that, these tools can complement 
existing NICE guidelines by flagging an alert on the computer screen about 
the possibility of cancer. Following this flagging on the computer, the clinician 
can then decide whether to refer a patient, based on NICE guidelines 
(Macmillan Cancer Support, 2015). 
Participants in this study felt strongly about the need for further research to 
establish the evidence of effectiveness of cancer risk assessment tools 
compared with current practice before rolling the tools out in primary care. The 
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domain of reflecting and monitoring (formal or informal evaluations of 
interventions) in the CFIR (Damschroder et al., 2009) supports this finding of 
the need to establish the effectiveness of the tools against current practice.  
With reference to the enablers and barriers to implementation of cancer risk 
assessment tools discussed above, the similarities and differences in the 
findings between the current study and the previous studies, particularly those 
relating to the cancer risk assessment tools such as the RAT and QCancer 
(Green et al., 2015; Dikomitis et al., 2015; Chiang et al., 2015), are reflected 
in the similarities and differences in their methods of enquiry. Like Green et al. 
(2015) and Dikomitis et al. (2015), this study used semi-structured interviews 
to collect data, which were analysed using framework analysis to explore the 
perceptions of primary care practitioners. However, Green et al. (2015) and 
Dikomitis et al. (2015) conducted their semi-structured interviews by telephone 
while the current study used face-to-face individual semi-structured interviews 
and focus groups to explore the perspectives of both service users and primary 
care practitioners. This study also enabled comparison of service user and 
practitioner perspectives to inform the use of the tools in primary care 
consultations.  
Chiang et al. (2015) also used face-to-face semi-structured individual 
interviews with general practitioners, but unlike the current study which was 
conducted in a UK primary care context, Chiang et al. (2015) conducted a 
study of simulated consultations with practitioners in a primary care setting in 
Australia.  
Despite different methodological approaches, and while findings from these 
previous studies remain relevant, the findings from this study are important in 
bridging the research gap not covered by these previous studies. For example, 
the gap identified through the scoping review in Chapter Two of this thesis 
relating to how best cancer risk can be communicated to patients when using 
cancer risk assessment tools in primary care consultations. This also 
corresponds with the research gap identified in a previous systematic review 
of 86 studies of the need to understand how to enhance patient and 
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practitioner communication when using a decision aid (Stacey et al., 2011). 
Overall, the findings from this study point to some important implications for 
practice and further research as discussed in Section 6.6 below. 
6.6 Implications for practice and further research 
The communication strategies suggested by participants should be used to 
enhance communication between patients and practitioners when using 
cancer risk assessment tools during primary care consultations. 
Several barriers to the implementation of cancer risk assessment tools were 
expressed by participants including: lack of integration of the tools into the 
general practice IT system; lack of involvement of cancer specialists at 
secondary care settings and poor knowledge and understanding of how to 
access or use the tools in patient consultations on the part of primary care 
practitioners. Therefore, it is recommended that tools should be properly 
integrated into the general practice IT systems, and practitioners should be 
trained on how to access and use the tools in patient consultations. 
Fortunately, the Macmillan Cancer Support and Cancer Research UK, are 
working with the major primary care IT providers (EMIS, SystmOne and 
Vision+) to integrate the eCDS tools into the general practice systems. Such 
an effort should be encouraged and supported to ensure all general practices 
in the UK have access to the tools in their IT systems. 
To avoid conflict with existing guidelines especially with referrals for 
investigations and diagnosis, cancer specialists should be involved in the 
implementation of the tools so, they are open to primary care referral for 
cancer investigations using cancer risk assessment tools. The implementation 
of the tools should also be flexible, so practitioners can refer patients with 
symptoms suggestive of cancer whatever their quantified risk if these fall within 
NICE cancer referral guidelines.  
In relation to the need for more evidence before rolling out the tools, further 
research on the impact of cancer risk assessment tools on patient outcomes 
such as rates of referral, investigation and diagnosis compared with current 
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primary care practice needs to be conducted. The experiences or perceptions 
of patients and practitioners following the implementation of the tools should 
also be explored alongside the measurement of quantitative outcomes. The 
concluding points for this chapter are outlined in Section 6.7 below.  
6.7 Conclusion of the chapter 
This chapter has highlighted the key findings that add to existing knowledge, 
and these findings have been discussed in relation to the existing literature 
and the relevant theoretical frameworks. The ways to best communicate 
cancer risk information to bridge the research gap in this area, and the 
enablers and barriers to implementation of cancer risk assessment tools add 
to the existing evidence from the few relevant studies already conducted in 











CHAPTER 7 CONCLUSION  
7.1 Summary of the chapter 
This conclusion chapter summarises the thesis, covering the previous 
chapters: the background to the study; scoping literature review; conceptual 
background literature, methodology, results and discussion. The current 
developments relating to cancer risk assessment tools since this study, my 
personal reflection and a statement of next steps are also outlined in this 
chapter. 
7.2 Summary of the thesis 
To conclude the work, key points from the chapters of the thesis are 
highlighted here. 
The background to the study 
The background to the research highlighted the problem of cancer globally 
and in the context of UK. Also, discussed were the efforts to improve early 
diagnosis of cancer in the UK such as the NAEDI policy and the increased 
interest in the development of cancer risk assessment tools for detection of 
cancer risk in symptomatic individuals. It also highlighted that, evidence about 
the use of cancer risk assessment tools in primary care was lacking, hence 
the need to explore the existing evidence using a scoping literature review. 
The scoping literature review 
Using a widely used framework (Arksey & O’Malley, 2005), the scoping 
literature review explored the evidence around use of cancer risk assessment 
tools available for symptomatic individuals in primary care. The results arising 
from the analysis of the evidence extracted from included studies were stated 
and discussed in relation to the existing literature. Research questions for 




Overall, the evidence from the scoping review suggested that there could be 
benefits if cancer risk assessment tools were used in patient consultations, but 
there are also barriers to implementation of the tools. A research gap relating 
to communication of cancer risk information was identified and the following 
research questions were stated for further exploration: (a) what are the 
perceptions of service users and practitioners about how best cancer risk 
information can be communicated to patients during consultations, (b) what do 
service users and practitioners perceive as enablers and barriers to the 
implementation of cancer risk assessment tools in primary care? Before 
moving on to address these research questions, a conceptual background 
literature was reviewed. 
The conceptual background literature review 
An understanding to the relevant concepts relating to the research were 
discussed within the conceptual background literature. For example, the 
policy, structure and functions of UK primary care in relation to cancer and 
cancer diagnosis. The ‘gatekeeping’ functions of primary care general 
practices which includes specialist referral of patients are outlined. 
Additionally, the cancer risk assessment tools for symptomatic individuals in 
primary care, the effects of risk assessment on individuals, communicating 
cancer risk and the relevant communication and implementation theoretical 
frameworks, are discussed within the conceptual background literature. To 
appropriately address the research questions identified, the methodology for 
the study is discussed. 
The methodology 
The methodology is discussed, highlighting pragmatism as the philosophical 
stance for this research. The qualitative research approach that informed the 
use of the relevant qualitative research methods is also discussed. 
Specifically, the methods included the use of individual and focus group 
interviews to collect qualitative data from service users and primary care 
practitioners, and the use of the framework approach for the data analysis.  
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The choice of a pragmatic philosophical stance was useful in terms of allowing 
for the use of framework analysis (Ritchie & Spencer, 1994) to appropriately 
address the research question, which presented with both deductive and 
inductive elements. Hence, the framework analysis approach facilitated the 
analysis of both the deductive and inductive themes. 
The results and discussion of the qualitative study 
The results from individual interviews with service users, and individual 
interviews and focus groups with practitioners are reported in a way that 
sought to address the research questions. Participants suggested ways to 
best communicate cancer risk information to patients. These include tailoring 
a visual representation of risk; being open and honest; involving patients in the 
use of cancer risk assessment tools and allowing enough time for informing, 
listening and explaining to patients in a professional manner. These add to our 
knowledge and bridges the research gap in this area. 
In addition, participants perceived several enablers (for example, supporting 
decision-making; improving speed of processes and ease of use) and barriers 
(for example, additional time requirement, worry or anxiety related to referral 
for investigations and need for integration of the tools into the GP IT system) 
to the implementation of cancer risk assessment tools. The findings about 
enablers and barriers support the existing evidence from the few recent 
published studies.  
To appropriately address the research questions, the perspectives of 
participants were presented in three parts. The first and second parts 
presented the collective perspectives of service users and primary care 
practitioners respectively, expressed before the use of the tools. The third part 
of the results described the perspectives of primary care practitioners after 
using the tools in patient consultations.  
The results are discussed in the discussion chapter, relative to the existing 
literature and the relevant theoretical frameworks, and key and original 
findings are highlighted.  
198 
 
Although the results are discussed in the discussion chapter relative to the 
existing literature and the relevant theoretical frameworks, it is important to 
discuss further in this concluding chapter, the original contribution of this study 
to knowledge and the implications of the other key findings. 
Original contribution to knowledge 
An important original contribution to knowledge that needs highlighting is the 
collection of data from service users to explore ways to best communicate 
cancer risk information, as well as to explore the barriers and enablers to the 
implementation of cancer risk assessment tools in the primary care 
consultation. 
The views of service users were compared with those of practitioners and 
there was general agreement among participants with most aspects. Most 
previous research (e.g. Hamilton et al., 2013; Green et al., 2015; Dikomitis et 
al., 2015; Chiang et al., 2015) in the subject area has been based on the views 
of practitioners, which although useful need to be complemented by the views 
of patients or service users.  
The implication of needing more consultation time to use the tool 
 
The need for extra time could imply the need for a policy decision on increasing 
the current consultation of time of 10 -12 minutes per patient. 
On a positive side, additional consultation time could mean practitioners will 
take time to involve patients by explaining, listening and reassuring them 
without appearing to be rushing through things. This could contribute to the 
promotion of patient centred care, which patients value and enhance 
experience with the care provided. 
However, with the increasing numbers of patients seeking primary care and a 
limited number of practitioners, more consultation time could mean more 
pressure on practitioners who could be spending longer hours to see all 
patients per day.  
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How the tools should be integrated within clinical systems 
The cancer risk assessment tools can be integrated within primary care clinical 
systems through the major primary care IT systems such as EMIS, SystmOne 
and Vision+. At the national level, the integration of the tools in primary care 
clinical systems can inform national policy pathways in the form of NICE 
guidelines. That is, the tools may be integrated into the NICE guidelines like 
other existing risk tools in primary care (e.g. QRisk). 
At the local level, the integration of the tools within clinical systems can inform 
local policy pathways agreed through Clinical Commissioning Groups (CCGs). 
Locally agreed pathways could include how and what to use the tools for. For 
example, there could be a local decision to use the tools for only assessment 
of risk, investigations and referral during patient consultations. There could 
also be local agreement through CCGs to use the tools outside consultations 
such as auditing or batch processing and then calling patients at risk to discuss 
investigations and referral for diagnosis. 
Possible training needs and how they should be undertaken 
The need for training as suggested by participants could cover several areas. 
One area of training would relate to helping practitioners to understand how 
the tools are integrated into the general practice IT system and how to access 
and use them appropriately during consultation. 
Practitioners could also benefit from training on what action to take after using 
the tools to generate certain risk levels. This relates to possible options such 
as triggering a referral to NICE guidelines, request investigations, or a decision 
to monitor the patient for change in the symptoms or risk level. 
A training programme that involves helping practitioners on how best to 
communicate a risk information to patients could also be undertaken as 
recommended by some participants. Helping practitioners to know what and 
how to communicate with patients will help patients to understand and receive 
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information about their cancer risk or referral for investigation, with less worry 
or anxiety. 
How the risk scores can interface with, and influence NICE guidelines 
 
Risk scores can interface and influence NICE guidelines in several ways. A 
generated risk score could trigger referral of a patient for investigation and 
diagnosis, if the risk score was high and the practitioner suspected cancer 
from the presenting symptoms. When the tools are integrated in the general 
practice IT system, during a consultation, a practitioner could be alerted 
about the possibility of cancer risk in a patient.  
The practitioner may then refer to NICE guidelines before deciding to refer the 
patient for cancer investigations and diagnosis. Conversely, where a 
practitioner is in doubt about a patient’s risk status after first using NICE 
guidelines, they can use the tools to generate a cancer risk level. This could 
then inform a decision for appropriate action. 
Since this study, there have been some developments relating to the research 
area. These are outlined below. 
7.3 Developments relating to cancer risk assessment tools since 
my study 
Current development since my research include plans to establish an early 
diagnosis school and plans for extensive research on the use of cancer 
diagnostics tools (including cancer risk assessment tools). Connected to this 
is the ‘CanTest’ Collaborative led by a team of experienced cancer diagnosis 
research experts including Professor Richard Neal (University of Leeds), 
Professor Willie Hamilton (University of Exeter), Professor Fiona Walter from 
University of Cambridge and other colleagues. The collaborative which 
involves four UK institutions, and four international partners, has been funded 
by CRUK for clinical cancer detection research in the UK and internationally 
(www.cantest.org). The overall research task is to examine which tests for 
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cancer or risk of future cancer (such as blood tests, imaging tests, decision 
support tools etc.) can be performed in primary care (www.cantest.org). 
Currently there are two common types of symptom-based cancer risk 
assessment tools for use in primary care settings in the UK: the QCancer and 
RAT. The updates for QCancer and RAT for the current year (2016) relate to 
a collaboration between the developers of QCancer (Hippisley-Cox & 
Coupland, 2011; Hippisley-Cox & Coupland, 2012; Hippisley-Cox & Coupland, 
2013) and RAT (Hamilton, 2009), Macmillan Cancer Support and three major 
IT providers to integrate the tools into the primary care (general practice) IT 
system. These IT systems are the EMIS Web, Vision+ and SystmOne 
(Macmillan Cancer Support, 2016), and the integrated tools are collectively 
known as the Macmillan electronic Cancer Decision Support (eCDS) tools. 
This CDS tool which alerts GPs of patients with a risk score of 2% or more is 
available to all Vision users in Scotland (Macmillan Cancer Support, 2016). 
The tool has three functions in patient consultations: providing risk indicator 
pop up alerts, data entry templates and practice reports.  
Macmillan Cancer Support (2015) updates indicate that, EMIS Web users in 
England and Wales are now able to access an updated version of the QCancer 
tool in EMIS Web 5.9. The update includes risk score prompts, a symptom 
checker template, an additional template to record QCancer outcomes and 
follow up, and new Safety Netting searches. The alert triggering threshold has 
changed from a 5% composite risk score, to a site-specific score of 2% or 
above. Further information on how primary care practitioners may activate the 
prompt function or access the active symptom checker and follow up templates 
is provided in the EMIS Health support centre. Figures 4 is an example of an 
EMIS Web QCancer alert as will appear on a user’s computer screen, while 






Figure 4 Example of an EMIS Web QCancer alert protocol 
  
Adopted from Macmillan Cancer Support (2016) 
 
 
Figure 5 Example of an EMIS Web QCancer symptom checklist template 
 
 Adopted from Macmillan Cancer Support (2016) 
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7.4 Personal reflection on completing this study  
This personal reflection takes into consideration six key stages of my 
experience in conducting this research project. These include: the preliminary 
stage of the research; going into the field to speak with research participants; 
the writing task; the final journey; the learning experience (knowledge gained) 
and personal development. 
7.4.1 The preliminary stage of the research 
At the beginning, I was very excited to start my PhD studies. But the 
excitement soon gave way to my first challenge of identifying the research 
question or questions by conducting a scoping literature review, developing an 
appropriate research methodology, and then submitting a protocol.  
With little chance of financial support, I decided to embark on the difficult option 
of self-funding my studies. Over the years this lack of funding has been for me 
the most depressing challenge. This financial challenge, and my commitment 
to complete the project within schedule as a full-time student compelled me to 
rethink the size of the project. These considerations brought about major 
changes in the plan of the study. 
7.4.2 Going into the field to speak with research participants 
The fieldwork involved travelling several miles a day to meet the research 
participants. It was very difficult to get practitioners who were willing to use the 
cancer risk assessment tools with patients and then meet with me to discuss 
their perceptions.  
Though the travelling and interactions with the research participants were very 
tiring, I found the field work to be an interesting part of the research process. 
It was interesting in terms of getting to know different parts of the study area 
and meeting new people, and I was excited to start collecting data from 
participants as a major step forward.  
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On reflection, I found that it was helpful that I already had a good 
understanding of the research area and the research question I was trying to 
address. It was also helpful that I did not know any of the participants at a 
personal level, so I interacted with them as a neutral person. Knowing that I 
was a researcher with an independent mind, the service users and 
practitioners also felt free to express their views about the questions asked 
during the interviews. As a qualified nurse, I have previous experience of 
nursing and interacting with many cancer patients and their families, and I felt 
within me that the use of cancer risk assessment tools to aid early detection 
of cancer risk leading to early diagnosis would be good. However, I was careful 
not to allow my personal views as a health professional to interfere with my 
role as a researcher, particularly in conducting the interviews with participants 
and the data analysis and interpretation. 
7.4.3 The writing task 
I feel good that the thesis has now taken shape. However, the shaping of my 
thesis was a slow and sometimes frustrating process. Fortunately, I was 
always encouraged by the people around me, particularly fellow research 
students and my PhD project supervisors. My family has also encouraged me 
a lot while waiting patiently for life to return to normal, as my moments of 
tension have sometimes spilled over to them. 
Indeed, I found it helpful to spend some quiet time alone to think deeply and 
work on my thesis, but I also found it helpful sharing my thoughts and ideas, 
and taking comments made by supervisors and other people through 
conference and seminar presentations.  
There were times I felt that the PhD thesis was a task that would never end. 
But from my experience, I can confidently say the key to completing such a 
project is perseverance, hard work, good time management and praying to the 
All Mighty God. In addition, I realised the importance of keeping the thesis and 
research question in focus when writing the different chapters. This has helped 
me to avoid getting side-tracked.  
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During the writing process, I often encountered the difficulty of depending too 
much on other authorities rather than my own primary ideas. My supervisors 
advised that, I should be careful to organise my materials in a way that will 
allow much of my original data to stand relatively free, while I use the existing 
evidence to support my arguments. Although putting this to practice was 
initially difficult, I persevered because I knew this approach was necessary for 
the originality of my work. Reflecting on my initial proposal, I am aware that 
my academic reasoning and writing with respect to the research process has 
improved. During the process of writing, I have had to revise my thesis outline, 
and on occasions adjusted my research question. This, no doubt came 
because of interaction with my supervisors and other researchers, and through 
the learning experience of preparing several drafts of my thesis chapters.  
7.4.4 The final journey 
Once I finished writing the thesis, I found it necessary to consider the final 
shape for submission. The University has policy and procedures on thesis 
presentation, which I considered carefully and applied to the presentation of 
my thesis. Many practical decisions such as the standard of word processing 
expected, the preferred font size, margins, and the binding specifications 
needed to be considered as soon as the thesis was completed. I was 
conscious of all these practical issues, to make it possible for the work to be 
done in the way required by the University.  
7.4.5 Learning experience (knowledge gain) and personal development 
My learning experience and personal development relating to this project 
include development in primary research skills, improvement in project and 
time management skills and improvement in my self-confidence. 
Development of primary research skills 
Upon reflection, I realised that I have acquired a lot of research skills while 
conducting this study. It was a great experience for me to have engaged in a 
research that involved primary data collection and analysis in a relatively 
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independent manner. The research methods relevant to my research and 
related areas informed by the appropriate philosophical stance and the 
relevant theoretical frameworks have been learned during the study. I have 
also gained practical experience of developing an interview guide and 
conducting individual and group interviews with service users and primary care 
practitioners. The importance of sampling and the choice of the most suitable 
sampling method have also been learnt. In addition, I have learnt about the 
importance of applying for ethics, governance and access approvals before 
commencing the research activities of recruitment of participants and data 
collection. 
I have gained substantial presentation skills through the practice of presenting 
my research findings at conferences, workshops and seminars within and 
outside the University of Lincoln. I have also gained some experience in writing 
for publication and I have learnt to take peer review comments as part of the 
research practice rather than taking them personally. The project supervisors 
were supportive in my development along these lines. 
Improved project and time-management skills 
On personal and professional levels, I have greatly benefited from the 
research experience through improving my project and time management 
skills. Specifically, the research process required extensive preparation and 
planning for each stage of the study, which had to be conducted in an 
organised manner with time schedules.  
However, I initially faced challenges in terms of ensuring the progress of the 
study per the timetable and in meeting deadlines and attending meetings on 
time. These challenges mainly started from the scoping literature review stage 
of the research, as I initially underestimated the duration of time required for 
literature review and I was constantly behind the schedule. This issue was 
addressed through adjusting the time-plan for the study and increasing my 
personal discipline and commitment to the time-plan. I avoided all 
unnecessary activities during the research process, and I set daily plans to do 
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a specific portion of the project every day, while making provisions for 
occasional days off within the plan. This was to help me avoid being over-
pressurised and over-stretched which could have impacted negatively on the 
project.  
In general, this research experience has contributed to the improvement of my 
time and project management skills, which is useful for my professional 
development. As I worked as a nurse on part-time basis to fund my studies, a 
positive approach to planning and self-discipline enhanced my ability to 
balance the demands of working as a nurse and my full-time studies. 
Improved self-confidence 
Looking back to the time I started my studies, my self-confidence has improved 
significantly because of the conduct of this research and benefitting from a 
good supervisory team. This was achieved through overcoming my fears and 
insecurity, communicating with my research participants and presentation of 
the findings and interaction with the research audience in a confident manner. 
The effort I put in, which included spending many hours to prepare for the data 
collection, and the encouragement from my supervisors, friends and family 
helped me to overcome the sense of insecurity and to conduct the data 
collection process in a confident manner. 
In fact, I believe my communication skills have also been enhanced after 
conducting this research. I have no doubt that I will benefit a lot from my 
improved self-confidence in the future as an individual and as an independent 
researcher with interest in primary care research, particularly in early detection 
of cancer risk and the use of cancer risk assessment tools. 
7.4.6 How will I do this research differently? 
If I were to do this research again, I will first ensure that there was adequate 
funding to cover the project over three years, given the financial difficulties I 
faced as a self-funding student. 
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I will also ensure that realistic objectives that are achievable within the time 
frame available for the research are set. I will try not to be distracted or misled 
and I will take control of the key stages of the research while consulting with 
more experience researchers. The next steps after this study are stated below. 
7.5 Statement of next steps 
The next steps will aim to address the research gap identified from this 
qualitative work. These steps will include:  
i. To conduct a trial of cancer risk assessment tools and compare with 
current practice using quantitative methods to measure outcomes of 
implementation including rates of referral, diagnosis and survival. This 
will also allow for the use of qualitative methods to explore the 
experiences of patients and practitioners involved in the trial 
implementation of the tools in primary care consultations. 
 
ii. To be able to conduct the trial, I intend to develop a research protocol, 
which I will use to apply for NHS ethics and governance approvals as 
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Appendix 1: Copies of conference abstracts 
Appendix 1.1: Abstract accepted for oral presentation at the Society for 
Academic Primary Care (SAPC) at the University of Leicester on 15th March 
2016 
Title of the abstract: Exploring Service User and practitioner 
perspectives of QCancer use in primary 
care consultations 




Community and Health Research Unit, 
University of Lincoln 
Contact Details (email) 11357484@students.lincoln.ac.uk 
Please indicate your preferred 
option: Parallel, Poster or 
Workshop.  
Parallel or Poster (No Preference) 
 
Introduction: QCancer is a novel cancer risk assessment tool that 
combines risk factors and symptoms to estimate an individual’s risk of 
developing cancer within two years. This study explored the perspectives of 
service users and primary care practitioners about using QCancer in the 
primary care consultation. 
Methods: We used qualitative methods to conduct individual and focus 
group interviews with service users recruited from the public and primary 
care practitioners (GPs and nurses) recruited from general practices in 
Lincolnshire (a large rural county in England) until data saturation was 
achieved. The qualitative data were transcribed verbatim and analysed 
using the Framework approach. 
Results: Thirty-six participants, 19 service users and 17 practitioners, were 
interviewed. They expressed a range of views about the implications of 
quantifying cancer risk using QCancer including potential conflict with 
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current cancer guidelines or that high risk symptoms would need referral for 
further investigation whatever the quantified risk. 
Participants, both service users and providers, agreed that QCancer was 
useful for consultations for cancer in: quantifying risk; supporting decision-
making; identifying, raising awareness of and modifying health behaviours; 
improving processes and speed of assessment and treatment; and 
personalising care. 
Participants also raised the need to address communication issues related 
to use of QCancer such as tailoring visual representation of risk; openness 
and honesty; informing and involving patients in use of QCancer and 
providing time for listening, informing, explaining and reassuring in the 
context of a professional approach. Participants also identified potential 
challenges to uptake of QCancer in general practice including: additional 
time required, unnecessary worry generated by false positives, potential for 
over-referral, practitioner scepticism about using the new tool, and the need 
for evidence of effectiveness before introducing QCancer in patient 
consultations. 
Conclusion: Service users and primary care practitioners perceived that 
QCancer would support and individualise decision making, help identify and 
modify health behaviours, increase knowledge, improve the processes and 
speed of cancer assessments and treatments and facilitate personalised 
care of cancer. Communication needs of users and potential barriers for 
both users and practitioners will need to be considered in planning for 
QCancer use in general practice consultations.  




Appendix 1.2: Abstract accepted for oral presentation at the College of Social 
Science Research Conference at the University of Lincoln on 4th July 2016  
Title: Exploring service user and practitioner perspectives of QCancer use in 
primary care consultations 
Authors: Akanuwe, J.; Siriwardena, A.; Black, S. & Owen, S. 
Introduction: This study explored perspectives of service users and primary 
care practitioners about using QCancer, a cancer risk assessment tool, in 
primary care consultations. 
Methods: Individual and focus group interviews with data analysed using the 
Framework approach. 
Results: 36 participants, 19 service users and 17 practitioners, were 
interviewed until data saturation was achieved. Participants expressed a range 
of views about the implications of quantifying cancer risk using QCancer 
including potential conflict with current cancer guidelines and, high risk 
symptoms would need referral for further investigation whatever the quantified 
risk. Participants agreed that QCancer would be useful in a number of ways 
including helping to identify and raise awareness for modifying health 
behaviours and personalising patient care. Participants discussed 
communication needs when using QCancer, which will add to knowledge in 
terms of how best to improve communication of cancer risk during the 
consultation. Potential challenges to uptake of QCancer were also identified. 
Conclusion: Participants perceived that QCancer would be potentially useful 
but communication needs of users and potential barriers for both users and 





Appendix 1.3 Abstract accepted for oral presentation at the Cancer Research 
UK Early Diagnosis Research Conference, London, 2017 
Which conference 
theme does your 
research fit under? 
□ Cancer screening  
□ Patient factors in timely presentation and 
diagnosis 
□ Optimising clinical practice and systems √ 
□ Risk assessment and risk stratification √ 
□ Inequalities 
□ Cancer data to achieve new insights in 
cancer control  
□ Health economics 
Abstract title Informing use of QCancer in the primary care 
consultation - perspectives of service users and 
practitioners 
Introduction: Earlier detection of cancer may help reduce the current high 
level of cancer mortality in the UK. Cancer risk assessment tools such as 
QCancer, which predict the absolute risk of cancer in symptomatic individuals, 
may help identify those at high risk needing investigation for possible cancer. 
Little is known about the views of service users and primary care practitioners 
on the use of QCancer in primary care consultations. The aim of this study 
was to explore the perspectives of service users and primary care 
practitioners on use of QCancer and how communication with patients might 
be enhanced when using QCancer in primary care consultations. 
Methods: The study was conducted in Lincolnshire, a large rural county in the 
East Midlands, using a qualitative research design. This involved individual 
interviews with service users recruited from the public, and both individual and 
focus group interviews with primary care practitioners including general 
practitioners and practice nurses. Data were recorded, transcribed verbatim 
and analysed using the Framework approach. Ethics approval was granted 




Results: We interviewed 36 participants (19 service users and 17 
practitioners) until data saturation was achieved. Four main themes emerged: 
the implications of quantifying cancer risk, usefulness of QCancer, 
communicating cancer risk, and barriers to implementation in primary care 
consultations.  
Participants expressed a range of views about the implications of quantifying 
cancer risk using QCancer. These included: potential conflict with current 
cancer risk guidelines and the need to refer patients with symptoms 
suggestive of cancer whatever their quantified risk.  
Participants agreed that QCancer would help to: quantify cancer risk; support 
clinical decision making; inform efforts to modify health behaviours, improve 
processes and speed of assessments, diagnosis and treatment; and, enable 
practitioners to personalise patient care.  
To enhance patient-practitioner communication of cancer risk, both service 
users and primary care practitioners suggested the following: tailoring a visual 
representation of risk; being honest and open with patients; involving patients 
in the use of QCancer; and allowing time for listening explaining, informing 
and reassuring patients.  
Potential challenges to the uptake of QCancer were also identified including: 
the additional time required for its use and communication; unnecessary worry 
caused by investigation of false positives; potential for over-referral; and 
practitioner scepticism with the need to establish the effectiveness of 
QCancer against current practice before introducing it more widely.  
Conclusion: Participants perceived the potential usefulness of QCancer but 
felt that communication needs of users and potential barriers should be 
considered when planning to implement QCancer. Before rolling out the tool, 
further research is needed to pilot and evaluate the impact of QCancer on 
outcomes such as rates of investigations, referrals, diagnoses as well as 
patient and practitioner experiences of using the tool. 
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Word count- 457 
Lead investigator Joseph Akanuwe (PhD Student) 
Other investigators Professor Niro Siriwardena 
Dr Sharon Black 
Professor Sara Owen 
Nominated presenter Joseph Akanuwe 
Host institution / 
organisation 
Community and Health Research Unit (CaHRU), 
School of Health and Social Care, University of 
Lincoln 
Research funded by Self-funded 
Expected completion 
date for results 
PhD due for completion in 2016 
We will be offering a limited number of bursaries to early career researchers 
(those studying for a Masters or PhD or who have finished their PhD within 
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If you are an early career researcher and your abstract is accepted, would you 















Appendix 1.4 Abstract accepted for poster presentation at the Society for 
Academic Primary Care (SAPC) Regional Conference in Lincoln, 2017 
Trent Regional SAPC Spring Meeting 
Title of the abstract: A systematic scoping review of the use of cancer risk 
assessment tools for early detection of cancer risk in 
primary care  
Author(s): Akanuwe JNA, Siriwardena AN, Black S, Owen S. 
Institution: 
 
Community and Health Research Unit, School of 




Please indicate your 
preferred option: 
Parallel, Poster or 
Workshop  
 
Parallel or Poster (No Preference) 
 
Abstract: maximum 350 words 
Introduction: Cancer risk assessment tools are designed to predict cancer risk 
using risk factors and symptoms of individuals. These tools could prompt 
investigations and referral for specialist attention, leading to early diagnosis and 
treatment and a potential reduction in the high mortality of cancer in the UK. 
While cancer risk assessment tools are thought to accurately predict the risk of 
specific cancers, this is based on statistical testing of data from databases 
rather than using the tools on actual patients. More needs to be known about 
the use and implementation in practice of cancer risk assessment tools to aid 
primary care detection of cancer. We aimed to scope the evidence relating to 




Methods: Using the framework proposed by Arksey and O’Malley, we 
conducted a systematic scoping review of the literature published in the English 
language from 2004 to 2015 to ensure relevance to current practice. Our search 
strategy included specific search terms which were used to search six 
electronic databases: Medline; CINAHL; Scopus; Cochrane; Science Direct 
and Psych INFO. A narrative synthesis was used to analyse the papers 
identified.  
Results: We retrieved 481 papers from the initial database search. After sifting 
titles and abstracts, 72 full text papers remained, of which 48 studies were 
excluded because these did not meet the inclusion criteria. The remaining 24 
studies were included in the review. These included randomised controlled 
trials (2); cohorts (11), survey (2); case control (3); qualitative (3), critical 
reviews (1) and other unspecific designs (2). This review found limited evidence 
on novel cancer risk assessment tools being used; perceptions of users and 
outcomes of using the tools. While there was also some evidence pointing to 
the usefulness of cancer risk assessment tools, there was limited evidence on 
how best to communicate cancer risk to patients when using a cancer risk 
assessment tool.  
Conclusion: The evidence available on the use of cancer risk assessment 
tools in primary care was limited. Further research is needed to explore how 
best cancer risk can be communicated to patients when using a cancer risk 








Appendix 1.5 Abstract accepted for oral presentation at the Society for 
Academic Primary Care (SAPC) ASM Conference (12-14 July 2017 at the 
University of Warwick 
Exploring service user and practitioner perspectives of using cancer risk 
prediction tools in primary care gp consultations 
Authors: Joseph Akanuwe, Dr Sharon Black, Prof Sara Owen & Prof Niro 
Siriwardena 
Introduction: The UK has one of the highest cancer mortality rates in Europe. 
The high mortality may be due to late presentation or detection of symptoms 
in primary care. Cancer Risk Assessment Tools e.g. RAT and QCancer 
combine risk factors and symptoms to estimate an individual’s risk of 
developing cancer within two or more years. 
The tools are integrated in the GP IT systems e.g SystmOne, EMIS and 
Vision+, and GPs are encouraged to use them. However, evidence about the 
use of cancer risk assessment tools is limited. For example, there is limited 
evidence on how best cancer risk information can be communicated to 
patients. Knowledge about the facilitators and barriers to implementation of 
the tools is also not clear. We aimed to explore the views of service users and 
primary care practitioners about how best to communicate cancer risk 
information to patients when using cancer risk assessment tools in patient 
consultations. The facilitators and barriers to implementation of the tools were 
also explored. 
Methods: We used individual and focus group interviews to collect qualitative 
data from 36 participants (19 service users recruited from the public and 17 
practitioners) recruited from Lincolnshire general practices. The data were 
transcribed verbatim and analysed using the Framework approach. 
Results: Participants identified ways to better communicate risk information 
including tailoring a visual representation of risk; providing time for informing, 
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listening, explaining, and reassuring in a professional manner; being open and 
honest and involving patients when using cancer risk assessment tools. 
The facilitators to implementation identified included: aiding decision making; 
improving processes, speed of assessment and treatment; identifying and 
modifying health risk behaviours and personalising care. The barriers to 
implementation included: additional consultation time, worry or anxiety, 
practitioner scepticism and the need to establish effectiveness of cancer risk 
assessment tools as compared to existing practice. 
Conclusion: We found ways to better communicate cancer risk information to 
patients. Facilitators and barriers to implementation of cancer risk assessment 
tools were also identified. Further research is needed to establish 
effectiveness of cancer risk assessment tools and the experiences of patients 














Appendix 2: Recruitment and data collection documents 
Appendix 2.1: Service user and practitioner invitation letters  
 Service user invitation letter - version 2 - 28/08/2014 
 
Room 3208, Bridge House Brayford Campus, University of Lincoln  
 Lincoln 
 LN6 7TS 
Dear Sir/Madam, 
INVITATION TO PARTICIPATE IN A QUALITY IMPROVEMENT STUDY, TO 
EXPLORE THE USE OF CANCER RISK ASSESSMENT TOOLS 
The protocol for the above research project was reviewed and approved by 
the School of Health and Social Care Ethics Committee at the University of 
Lincoln. We now wish to invite you to participate in this study which involves 
interviews with members of the public and practitioners in general practices to 
explore the feasibility of implementing cancer risk assessment tools for early 
diagnosis of cancer in primary care. 
Please find attached a participant information sheet which highlights details of 
the research project. If you decided to participate, you will be expected to 
complete and sign a consent form when you meet with the researcher for a 
face-to face interview. Participation is entirely voluntary, but we would be 
grateful if you would respond positively and participate in this quality 
improvement feasibility study which could be beneficial in terms of early 







Practitioner invitation letter - version 2 - 28/08/2014  
  
 
 Room 3208, Bridge House Brayford Campus, University of Lincoln  
 Lincoln, LN6 7TS  
  
Through:  
The Lincolnshire West Clinical Commissioning Group  
 
 Dear Madam/Sir,  
 INVITATION TO PARTICIPATE IN A QUALITY IMPROVEMENT STUDY, TO 
EXPLORE THE USE OF CANCER RISK ASSESSMENT TOOLS 
The protocol for the above project was reviewed by the University of Lincoln 
Ethics Committee and given a favourable outcome. We now wish to invite you 
to participate in this study which will involve interviews with individuals 
recruited from the public and separately with general practitioners in 
Lincolnshire general practices to explore the feasibility of implementing cancer 
risk assessment tools for early diagnosis of cancer in primary care.  
Please find attached a participant information sheet which highlights details of 
the research project. Also attached is a participant consent form which we 
would like you to complete and sign if you decide to participate in the study. 
Participation is entirely voluntary, but we would be grateful if you would 
respond positively and participate in this feasibility study which could be 
beneficial in terms of early diagnosis of cancer. 
Yours faithfully,  
Joseph Akanuwe  





Appendix 2.2: Service user and practitioner information sheets 
Service user information sheet - Version 2 - 28/08/2014  
EXPLORING THE USE OF NOVEL CANCER RISK ASSESSMENT TOOLS 
IN PRIMARY CARE CONSULTATIONS 
We would like to invite you to take part in a research study involving a face-to-
face interview with the researcher. Before you decide whether to participate it 
is important that you understand why the research is being conducted and 
what it would involve for you. Please take time to read the following information 
carefully. You might like to talk to others about it at this stage. 
What is the purpose of the study? 
Cancer related deaths are high in the UK compared to other European 
countries. This may partly be due to late identification of cancer symptoms and 
delayed referral to hospital consultants. Some cancer risk assessment tools 
have been designed for early detection of cancer risk in primary care. These 
would have the potential to save lives and improve patients’ quality of life. 
However, little is known about how these tools can be used in patient 
consultations. We need to answer questions like, how acceptable would 
patients find their health professional using a tool to detect the risk of cancer? 
In addition, if a risk of cancer is identified, what would be the best way to 
communicate the risk information to patients? We need your help to answer 
these questions. 
Why have I been selected? 
You have been invited as a member of the public who may have an interest in 
the delivery cancer services and we feel your participation in the study would 
be valuable in terms of providing relevant data for the research. 
Do I have to take part? 
It is up to you to decide whether to take part or not. Please contact the  
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researcher (contact details at the end of the information sheet), if you would 
like more information and have any questions. If you are interested in taking 
part, you will be asked to complete and sign a consent form on the day of the 
interview. Even if you decide to take part, you are still free to withdraw at any 
time without giving a reason. 
What will happen if I take part? 
The researcher will contact you with a research pack and you will be asked to 
contact the researcher if you decide to take part after reading the research 
pack:  
• 24 hours prior to the interview, the researcher will contact you to remind 
you and confirm your willingness to participate in the study.  
• The interview will last for about 30 minutes to 1 hour. 
• At the interview, you will be asked to sign a consent form to indicate that 
you understand what the research is about and how your information will 
be used and stored. 
• With your permission, the interview will be audio-recorded; this will be 
transcribed and written up without your name so you cannot be identified 
as having taken part. The original audio recordings will be discarded 
securely after the audio recorded data has been transcribed. 
What will I have to do? 
We want to know about your perceptions or views around the communication 
of cancer risk and diagnosis. As well as answering our questions about the 
use of assessment tools to detect cancer risk in consultation with your health 
professional and how any cancer risk might be discussed, you will also be 
given the opportunity to talk about any other issues which you feel may be 
important to the research. 
Are there any benefits in taking part? 
We cannot promise the study will help you personally but the information we 
collect will help to determine whether it is useful and practical to implement 
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cancer risk assessment tools in general practices in Lincolnshire; this will 
support early detection of cancer in primary care. 
What happens after the study? 
We will contact you with the results; the data collected from you will be 
destroyed securely when the study is fully completed, and the findings have 
been published or disseminated. 
What if there are any problems? 
We don’t expect there to be any problems, but if there are, we will deal with 
these promptly. If you have any complaints about the way you have been dealt 
with during the study, these can be forwarded to: 
Dr Zowie Davy 
Head of Research Ethics  
University of Lincoln 
Lincoln 
LN6 7TS 
Email: zdavy@lincoln.ac.uk Tel: 01522 837748 
Will my taking part in the study be kept confidential? 
As researchers, we will follow ethical and legal practice to handle information 
about you in confidence. All data will be anonymous. 
Where do I go for more information? 
You can keep this information sheet. Talk to others about the study if you wish 
including the clinical team (doctors and nurses) who look after you. If you wish 
to take part or have questions or want more information on the study, please 







Practitioner information sheet - version 2 - 28/08/2014 
EXPLORING THE USE OF NOVEL CANCER RISK ASSESSMENT TOOLS 
IN PRIMARY CARE CONSULTATIONS. 
We would like to invite you to take part in a research study involving a face-to-
face interview with the researcher. Before you decide whether to participate it 
is important that you understand why the research is being conducted and 
what it would involve for you. Please take time to read the following information 
carefully. You might like to talk to others about it at this stage. 
What is the purpose of the study? 
Cancer related deaths are high in the UK compared to other European 
countries. This may partly be due to late identification of cancer symptoms and 
delayed referral to hospital consultants. Some assessment tools have been 
designed to help practitioners detect the risk of cancer developing within two 
years. These would have the potential to save lives and improve patients’ 
quality of life. However, what is not known is how to help health professionals 
use these tools in their consultation with patients. We need to answer 
questions like, how acceptable would patients find their Practitioner using a 
tool to detect the risk of cancer? In addition, if a risk of cancer is identified, 
what would be the best way to communicate the level of risk to patients of 
having a diagnosis of cancer? We need your help to answer these questions. 
Why have I been selected? 
You have been invited because you may have an interest in the delivery of 
cancer services, your general practice is within the study setting, and we feel 
your participation in the study would be valuable in terms of providing relevant 
data for the research. 
Do I have to take part? 
It is up to you to decide whether to take part or not. Please contact the 
researcher (contact details at the end of the information sheet), if you would 
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like to take part, or if you have any questions about the research. Even if you 
decide to take part, you are still free to withdraw at any time without giving a 
reason. 
What will happen if I take part? 
The researcher will contact you with a research pack and you will be asked to 
contact the researcher if you decide to take part after reading the research  
• 24 hours prior to the interview, the researcher will contact you to remind 
you and confirm your willingness to participate in the study.  
• The interview will last for about 30 minutes to 1 hour. 
• At the interview, you will be asked to sign a consent form to indicate that 
you understand what the research is about and how your information will 
be used and stored. 
• With your permission, the interview will be audio-recorded; this will be 
transcribed and written up without your name so you cannot be identified 
as having taken part. The original audio recordings will be discarded 
securely after the audio recorded data has been transcribed. 
What will I have to do? 
We want to know about your perceptions, as a practitioner. As well as 
answering our questions about the use of assessment tools to detect cancer 
risk in consultation with your patients and how any cancer risk might be 
discussed with your patients, you will also be given the opportunity to talk 
about any other issues which you feel may be important to the research. 
Are there any benefits in taking part? 
We cannot promise the study will help you personally or your general practice 
in particular, but the information we collect will help to determine whether it is 
useful and practical to implement cancer risk assessment tools in general 





What happens after the study? 
We will contact your general practice with the results for forwarding to you; the 
data collected from you will be destroyed securely when the study is fully 
completed, and the findings have been published or disseminated. 
What if there are any problems? 
We don’t expect there to be any problems, but if there are, we will deal with 
these promptly. If you have any complaints about the way you have been dealt 
with during the study, these can be forwarded to: 
Dr Zowie Davy 
Head of Research Ethics  
University of Lincoln 
Lincoln 
LN6 7TS 
Email: zdavy@lincoln.ac.uk Tel: 01522 837748 
Will my taking part in the study be kept confidential? 
As researchers, we will follow ethical and legal practice to handle information 
about you in confidence. All data will be anonymous. 
Where do I go for more information? 
You can keep this information sheet. Talk to others about the study if you wish 
including the other members of the clinical team (doctors and nurses) in your 
general practice. If you wish to take part please contact the researcher whose 
contact details are stated below, to arrange a date for a face-to-face interview 
with the researcher.  
Joseph Akanuwe  
Email: 11357484@students.lincoln.ac.uk  
Mobile: 07508864099 




Appendix 2.3: Service user and practitioner consent forms 
 
Service user consent form - version 2 - 28/08/2014  
EXPLORING THE USE OF CANCER RISK ASSESSMENT TOOLS IN 
PRIMARY CARE CONSULTATIONS. 
Name of Researcher: Joseph Akanuwe  
1. I confirm that I have read and understand the information sheet dated 
28/08/2014 for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily.  
  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my legal rights 
being affected.  
 
3. I understand that the data collected during the study, will be 
anonymised and may be looked at by individuals from the research 
project team, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to this data.  
 
4. I understand that anonymised quotes from the data may be used for 
written publications and I consent to this.  
 
5. I consent to being audio recorded during the interview 
 
6. I agree to take part in the above study.  
 











If you have any concerns about the way the research is being carried out, 
please contact either of the Co-Chairs of the School of Health and Social Care 
Ethics Committee, Dr Paul Linsley (plinsley@lincoln.ac.uk) or Dr Zowie Davy 
(zdavy@lincoln.ac.uk). Their postal address is: Bridge House, Brayford Pool, 
University of Lincoln, Lincoln LN6 7TS. 
_______________   ________________ __________________  
Name of Participant    Date     Signature  
 
_______________ ________________ __________________ 


























Practitioner consent form - version 2 - 28/08/2014  
   
 
EXPLORING USE OF CANCER RISK ASSESSMENTS TOOLS IN PRIAMRY 
CARE CONSULTATIONS 
Name of Researcher: Joseph Akanuwe  
1. I confirm that I have read and understand the information sheet dated 
28/08/2014 for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my legal rights 
being affected.  
 
3. I understand that the data collected during the study, will be 
anonymised and may be looked at by individuals from the research 
project team, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to this data.  
 
4. I understand that anonymised quotes from the data may be used for 
written publications and I consent to this.  
 
5. I consent to being audio recorded during the interview 
 
6. I agree to take part in the above study.  
 











If you have any concerns about the way the research is being carried out, 
please contact either of the Co-Chairs of the School of Health and Social Care 
Ethics Committee, Dr Paul Linsley (plinsley@lincoln.ac.uk) or Dr Zowie Davy 
(zdavy@lincoln.ac.uk). Their postal address is: Bridge House, Brayford Pool, 
University of Lincoln, Lincoln LN6 7TS. 
 
_______________   ________________ __________________  
Name of Participant    Date     Signature  
 
_______________ ________________ __________________ 






















Appendix 2.4 Flyer for recruitment of service users  





Appendix 2.5 Interview guides for service users and practitioners 
Service user interview guide- version 2 - 28/08/2014  
1. Introduce myself. 
 2. Brief participant about QCancer. 
 3. Ask politely if participant has ever been affected by cancer directly or 
indirectly. This will help shape the interviewing process in a way as to prevent 
distress to participants, especially for individuals recruited from the public. 
I will like to begin by asking you a few questions about yourself. Your personal 
data will not be known to anyone outside the research team and will be stored 






I will now like to ask you to share with me what you know about cancer risk 
Knowledge of cancer risk 
1. Could you tell me what you might think are the possible risks around getting  
 cancer? 
 Prompt: What things do you know of that are linked to cancer? 
I will like us to talk about how the different risks of cancer are communicated 
between the GP and the patient. 
Communication of cancer risk 
2. Do you want to know what your risk of cancer might be?  
Prompt:  
a. Are you aware of any public health messages around cancer?  
b. What public health measures are you aware of? 
c. Has your GP ever discussed this? 
d. What did your GP ever discuss about your risk of cancer? 
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3. Do you think GPs should discuss different risks around cancer with you if 
you were attending with concern around e.g lung or bowel cancer? 
a. How long should a consultation be? 
b. What information would you need? 
c. Would you want anyone with you? 
d. What else would you like conveyed? 
I am now going to show you a cancer risk assessment tool called QCancer. 
This tool could be used by GPs to assess patients’ risk of cancer as in the 
examples I am about to show you. 
Questions around QCancer 
Vignette (example) 1: Imagine a 47-year-old man who lives in the Postcode - 
LN6 7TS. He is an Ex-smoker and a Non-drinker who has symptom of blood 
on coughing. By entering these details in the QCancer calculator for men, this 
individual has a 1% risk of having a cancer as yet undiagnosed, and therefore 
a 99% chance that he is clear. In other words, in a group of 100 people with 
the same risk factors, 1 is likely to have a cancer as yet undiagnosed and 99 
will not. This is shown by the chart below.  
 
1 man (blue sad face) is at risk of a cancer which has not been diagnosed 
whilst 99 men (yellow smiley faces) do not have a risk. That is, 1% risk of 




Now I will like to ask you a few questions about the QCancer examples I have 
just shown you. 
4. If you were told that you had a 1% estimated risk of cancer: 
a. How would you feel about this level of risk? 
b. What would you want to be told further about this level of risk? 
c. What would your actions be after being told about this level of risk? 
Vignette (Example 2): Imagine a 56-year-old male; who lives in the Postcode 
–LN6 7TS. He is an Ex-smoker and also a Non-drinker but has the symptom 
of blood on coughing. Again, using the QCancer calculator for men, in this 
example the older man has a 4% risk of having a cancer as yet undiagnosed, 
and correspondingly, a 96% chance that he is clear. In other words, in a group 
of 100 people with the same risk factors, 4 are likely to have a cancer as yet 
undiagnosed and 96 will not, as shown by the chart below. 
 
4 men (blue sad faces) at risk of a cancer not yet diagnosed, 96 men (yellow 
smiley faces) not at risk. That is, 4 % Risk of a cancer as yet undiagnosed.  
.......................................................................................................................... 
Now I will like to ask you a few questions about the QCancer examples I have 
just shown you. 
5. If you were told that you had a 4% estimated risk of cancer: 
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a. How would you feel about this level of risk?  
b.  What would you want to be told further about this level of risk? 
c.  What would your actions be after being told about this level of risk? 
Vignette (Example 3: Imagine a 66-year-old man, living in the Postcode- LN6 
7TS. He is an Ex-smoker and Non-drinker but with the symptom of blood on 
coughing. Using QCancer calculator for men, in this example there is a 10% 
risk of this older man having a cancer as yet undiagnosed, and 
correspondingly, a 90% chance that he is clear. In other words, in a group of 
100 people with the same risk factors, 10 are likely to have a cancer as yet 
undiagnosed and 90 will not, as shown by the chart below. 
 
10% Risk of a cancer as yet undiagnosed 
.......................................................................................................................... 
Now I will like to ask you a few questions about the QCancer examples I have 
just shown you. 
6. If you were told that you had a 10% estimated risk of cancer: 
a. How would you feel about this level of risk? 
b.  What would you want to be told further about this level of risk? 
c. What would your actions be after being told about this level of risk? 
Could we look at some more questions about QCancer please? 
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7. How useful do you think it might be for you if a GP were to use QCancer as 
a tool for assessing your risk of cancer? 
Prompt: Could you mention more examples of how QCancer might be useful?  
8. How do you think the GP should use this tool in the consultation?  
Prompts: For example, should the GP inform you they are going to use it?  
9. How would you feel about your GP using the tool with you?  
Prompts: 
a. For example, seeing the results on the computer screen. 
b. Or explaining the results to you. 
10. What information would you like to be given about risk of cancer? 
 Prompts: How should that information be given to you (would you prefer 
written or verbal information or both)? 
11. What ethical issues do you feel will arise if the GP uses QCancer without 
telling the patient? 
Prompts: What do you think about patient choice in relation to the use of 
QCancer? 
12. How can the use of QCancer by GPs in consultation help individual 
patients? 
Prompt:  
a. Could you tell me some examples of how it might help? 
b. How can the use of QCancer help with the modification of risk factors? 
Is there anything else you would like to say that I have not asked you already? 
This is the end of our discussion. Thank you for your time. I will like to assure 
you that appropriate measures will be taken to ensure that the data collected 








Primary care practitioner interview guide 1- version 2 - 28/08/2014  
I will like to begin by asking you a few questions about yourself and your 
practice. Your personal data will not be disclosed to anyone outside the 






Practice name: ........................................................ 
Practice location: ..................................................... 
Practice size: ........................................................... 
I will now like to ask you to share with me what you know about cancer risk. 
Assessment of risk 
1. Could you tell me what you think are the possible risks around getting  
 cancer? 
 Prompt: What things do you know of that are linked to cancer? 
2. How do you currently assess your patients for risk of cancer? 
Prompt:  
a. Have you used any cancer risk assessment tools? 
b. If yes what type of CRATs do you use? 
c. If no, please explain why? 
I am now going to ask you some questions about communicating cancer risk 
with your patients. 
Communication of cancer risk 
3. Do you currently discuss cancer risk with patients and families? 
 Prompt:  
 a. When cancer risk is discussed. 
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 b. How cancer risk is discussed. 
 c. What things are discussed? 
4. As a GP, how do you feel about discussing the risk of cancer with your 
patients? 
 Prompt:  
 a. How long do you feel a consultation should last? 
 b. What information would you give your patients? 
 c. How would you convey this?  
 e. What support might patients want? 
 f. Would you want anyone with your patients? 
I will like to ask you about how best QCancer may be implemented. 
Implementation of QCancer 
5. How do you feel QCancer might be implemented as a cancer risk 
assessment tool in your practice? 
 Prompt on:  
 a. When should the tool be used? 
 b. How should it be used? 
 c. With whom should it be used? 
 d. What internal and external resources are needed for implementation? 
 e. What barriers and facilitators may influence implementation? 
 f. What benefits/disbenefits do you feel such a tool may bring?  
I am now going to show you a cancer risk assessment tool called QCancer. 
This tool will be used by general practitioners to assess patients’ risk of cancer 
as in the examples I am about to show you. 
Questions around QCancer  
Vignette (example) 1: Imagine a 47-year-old man who lives in the Postcode - 
LN6 7TS. He is an Ex-smoker and a Non-drinker who has symptom of blood 




By entering these details in the QCancer calculator for men, this individual has 
a 1% risk of having a cancer as yet undiagnosed, and therefore a 99% chance 
that he is clear. In other words, in a group of 100 people with the same risk 
factors, 1 is likely to have a cancer as yet undiagnosed and 99 will not. This is 
shown by the chart below.  
  
1 man (blue sad face) is at risk of a cancer which has not been diagnosed 
whilst 99 men (yellow smiley faces) do not have a risk. That is, 1% risk of 
cancer not yet diagnosed within 2 years 
.......................................................................................................................... 
Now I will like to ask you a few questions about the QCancer examples I have 
just shown you. 
6. What do you think about a 1%, 2-year cancer risk as estimated by the 
QCancer tool? 
Prompt: What would your actions be? 
Vignette (Example 2): Imagine a 56-year-old male; who lives in the Postcode 
- LN6 7TS. He is an Ex-smoker and also a Non-drinker but has the symptom 
of blood on coughing. Again, using the QCancer calculator for men, in this 
example the older man has a 4% risk of having a cancer as yet undiagnosed, 
291 
 
and correspondingly, a 96% chance that he is clear. In other words, in a group 
of 100 people with the same risk factors, 4 are likely to have a cancer as yet 
undiagnosed and 96 will not, as shown by the chart below. 
 
4 men (blue sad faces) at risk of a cancer not yet diagnosed, 96 men (yellow 
smiley faces) not at risk. That is, 4 % Risk of a cancer as yet undiagnosed. 
.......................................................................................................................... 
Now I will like to ask you a few questions about the QCancer examples I have 
just shown you. 
7. What do you think about a 4% 2-year cancer risk as estimated by the 
QCancer tool? 
Prompt: What would your actions be? 
Vignette (Example 3: Imagine a 66-year-old man, living in the Postcode - LN6 
7TS. He is an Ex-smoker and Non-drinker but with the symptom of blood on 
coughing. Using QCancer calculator for men, in this example there is a 10% 
risk of this older man having a cancer as yet undiagnosed, and 
correspondingly, a 90% chance that he is clear. In other words, in a group of 
100 people with the same risk factors, 10 are likely to have a cancer as yet 




10% Risk of a cancer yet undiagnosed 
.......................................................................................................................... 
Now I will like to ask you a few questions about the QCancer examples I have 
just shown you. 
8. What do you think about a 10% 2-year cancer risk as estimated by the 
QCancer tool? 
Prompt: What would your actions be? 
Could we look at some more questions about QCancer please? 
9. How useful would it be or not be for you as a GP to use QCancer as a tool 
for assessing your patients’ risk of cancer? 
10. As a GP, how do you think this tool should be used in your consultation?  
Prompts: Should you inform the patient that you are going to use the tool? 
11. How best do you feel QCancer as a cancer risk assessment tool should 
be implemented to help with early diagnosis of cancer? 
Prompt on:  
a. When should the tool be used? 
b. What should it be used for? 
c. How should it be used? 
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d. With whom should it be used? 
e. What internal and external resources are needed for implementation? 
f. What barriers and facilitators may influence implementation? 
g. What benefits will the tool bring?  
12. As a GP, how would you feel about using this tool alongside your patient?  
Prompts: 
 a. The patient seeing the results on the computer screen. 
 b. Helping to convey the results to the patient. 
13. What information would you give to your patient about cancer risk, how 
would you convey this and what other actions may be required? 
Prompts: 
 a. How that information should be given to the patient (written or verbal or 
both)? 
 b. How do you think that your use of QCancer in a patient consultation as 
you’ve explained it might change depending on the level of risk found? 
14. What ethical issues do you think will arise with the use of QCancer? 
Prompt: Prompts: What do you think about patient choice in relation to the use 
of QCancer? 
15. How do you think the use QCancer in consultation could help individual 
patients? 
Prompt:  
 a. Could you tell me some examples? 
b. How can the use of QCancer help with the modification of risk factors? 
Is there anything else you would like to say that I have not asked you already? 
This is the end of our discussion. Thank you so much for your time.  
As stated in the information sheet, this audio recorded interview will be 
transcribed and analysed. I will like to assure you that appropriate measures 
will be taken to ensure that the data collected from you is stored securely and 
your privacy and confidentiality will not be compromised. 
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Primary care practitioner interview guide 2 - version:2 - 21/07/2017  
Start by Introducing myself to participants/practitioners then tell introduce topic 
as follows: 
You may recall that we met some time ago to discuss your perceptions about 
implementing cancer risk prediction tools in primary consultations. The themes 
identified from the information you provided included: ways to best 
communicate cancer risk information to patients, enablers (facilitators) and 
barriers to implementation of the tools. I now wish to discuss further your 
perceptions after using the tools.  
 
Q1. Informed by Fischhoff’s framework for risk communication (Fischhoff, 
1995) 
 
i. What cancer risk assessment tool/s did you use in patient 
consultation? 
ii. How difficult or easy was it using the tool in patient consultation? 
iii. What made it easy or difficult to use the tool in patient consultation?  
iv. How did you communicate cancer risk information to patients? 
a. What made it easy or difficult to communicate cancer risk 
information? 
b. What strategies did you use to help you communicate the risk 
information effectively? 
c. How did patients respond or react to the way you communicated 
cancer risk to them? 
Prompts on issues relating to the ways identified for communicating risk: 
• How did you tailor a visual representation in explaining risk to 
patients? 
• How did you involve patients when you used a cancer risk 
assessment tools? 
• How did you reassure patients when explaining cancer risk to them? 
 
Q2. Informed by constructs from the Consolidated Framework for 




i. What motivated or encouraged you to use the cancer risk 
assessment tool/s? 
Prompt: ask if the tools were useful in: 
• Aiding decision making 
• Improving processes, speed of assessment and treatment 
• Identifying and modifying health risk behaviours  
• Personalising care. 
Barriers 
i. What challenges did you encounter or experience when using the 
tool/s? 
ii. What strategies do you suggest for addressing the challenges to the 
implementation of the tool/s?  
Prompts on issues relating to challenges/barriers 
• How did the tool you used compare or conflict with existing guidelines? 
•  Was the allocated consultation time adequate to use the tool/s? 
• How did patients react to referrals for cancer investigations e.g 
worry/anxiety? 
• Please explain how willing or ready you or other practitioners were in 
using the tool/s (practitioner scepticism)? 
Is there anything you would like to add? 
Your views will be kept confidential and the data will be anonymised and used 
for only the purpose of this research. 














Appendix 3 Ethics and governance approval documents 




Appendix 3.2 Governance and access document 
 
Our Ref: LCHS Assurance    
Your Ref:  Research & Innovation Department  
Please ask for: Janice Wiseman  Lincolnshire Community Health Services 
Fen House, Fen Lane, North Hykeham, LN6 8UZ  
Telephone: 01522 502023 ext. 233 Calls via Text Relay are welcome 
E-mail address: Janice.wiseman@lincs-chs.nhs.uk  
Website: www.lincolnshirecommunityhealthservices.nhs.uk   
Date: Tuesday 16th December 2014   
 
Mr Joseph Akanuwe Chief Investigator   
School of Health and Social Care, Bridge House, Brayford Campus   
University of Lincoln  
LN6 7TS    
 Dear Mr Akanuwe  
 NHS Assurance for Phase 3 – West Lincolnshire Clinical Commissioning 
Group (CCG)  
Study Title:  Exploring the Feasibility of Implementing QCancer Use for Early 
Detection of Cancer in Primary Care  
Thank you for submitting your application for the above study. Your application 
has been reviewed by the Lincolnshire Community Health Services NHS Trust. 
We provide a research governance function for GP practices in Lincolnshire. 
We provide assurance that research studies meet nationally agreed research 
governance criteria to assist GP practices in deciding whether to take part in 
a research study.  
I am pleased to confirm that this application has satisfied the governance 
criteria for Research sites. This assurance is issued on the basis that the study 
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is conducted in accordance with the following version of the protocol and 
supporting documents submitted with your application (see below).  
Approved documents  
 
You are required to notify us of any of the following as these may affect the 
level of assurance provided:  
Any amendments to your study. These must be submitted through IRAS. 
Unless notified otherwise, and subject to REC approval you may implement 
amendments 35 days following submission.  
• All Serious Adverse Events relevant to the conduct of the research project 
at GP practices in Lincolnshire.  
• Any deviations from the protocol or protocol breaches including any urgent 
safety measures that are required to be taken to protect research 
participants against any immediate hazard to their health and safety  
• All incidents or complaints in relation to the conduct of the research project 
at GP practices in Lincolnshire.  
Please note this letter does not place any obligations on GP practices, as 
Independent Contractors, to participate in this study. The agreement by an 
Independent Contractor to participate in the research study constitutes NHS 
Document   Version  Date  
Ethics Approval form       
University of Lincoln 
ethics approval letter  
   3rd December 2014  
Research proposal  2.0     
Interview schedule       
Practitioner invitation 
letter  
2.0   28/08/2014  
Practitioner Information 
Sheet  
2.0   28/08/2014  
Practitioner Consent 
Form  
2.0   28/08/2014  
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Permission for that Independent Contractor; please liaise with Independent 
Contractors directly to gain agreement.  
As part of the Research Governance Framework it is important that the 4 
Lincolnshire CCGs are notified of the outcome of the research, therefore we 
will request a report of your findings. We will also enter your research onto the 
Lincolnshire CCG research database. We may also request brief updates of 
your progress from time to time, depending on the duration of the study. 
Similarly, if at any time details relating to the research project or research team 
change, please can you let us know. If you have any queries regarding this 
please contact Janice Wiseman, Research & Innovation Manager, at the 
above address.  
Yours sincerely  
   
 Janice Wiseman  
Research & Innovation Manager  
CC: Lincolnshire Community Health Services NHS Trust Research Team 
Inbox  
  Professor Siriwardena, Research Collaborator, University of Lincoln  
  Dr Karen Windle, Research Collaborator, University of Lincoln  
  Dr Sarah Amsler, Reader of Educational Research, University of  












Our Ref: Letter of HR Assurance    
Your Ref: Research & Innovation Department  
Please ask for: Janice Wiseman, Lincolnshire Community Health Services 
Fen House, Fen Lane, North Hykeham, LN6 8UZ 
Telephone: 01522 502023  Calls via Text Relay are welcome  
Website: www.lincolnshirecommunityhealthservices.nhs.uk   
E-mail address: Janice.wiseman@lincs-chs.nhs.uk  
Date: Tuesday 16th December 2014    
Mr Joseph Akanuwe, Chief Investigator   
School of Health and Social Care, Bridge House, Brayford Campus   
University of Lincoln, LN6 7TS    
Dear Mr Akanuwe  
Letter of HR Assurance  
Study Title: Exploring the Feasibility of Implementing Cancer Risk Assessment 
Tools for Early Detection of Cancer in Primary Care  
Researcher activity: Carrying out interviews with GPs within the Lincolnshire 
West CCG in their GP  practices.  
The information supplied about your role in research in the Lincolnshire West 
CCG has been reviewed and you do not require an honorary research 
contract. We are satisfied that such pre-engagement checks as we consider 
necessary have been carried out.  
You may present this assurance to an independent contractor within West 
Lincolnshire CCG when negotiating access to conduct research. This 
assurance is effective from the 16th December 2014 and ends on the 01st 




Guidance for Independent Contractors receiving this Letter of HR Assurance  
The subject of this assurance is considered to be a legal visitor to your 
premises. The subject is not entitled to any form of payment or access to other 
benefits provided by you to employees and this letter does not give rise to any 
other relationship between the subject and you, in particular that of an 
employee.  
While undertaking research through your premises, the subject will remain 
accountable to their employer, the Sheffield Teaching Hospitals NHS Trust, 
but they are required to follow your reasonable instructions or those given on 
your behalf in relation to the terms of access.  
Where any third party claim is made, whether or not legal proceedings are 
issued, arising out of or in connection with your right of access, the subject is 
required to co-operate fully with your investigations in connection with any 
such claim and to give all such assistance as may reasonably be required 
regarding the conduct of any legal proceedings. The subject must act in 
accordance with your policies and procedures, which you should make 
available upon request, and with the Research Governance Framework.  
The subject is required to co-operate with you in discharging your duties under 
the Health and Safety at Work etc Act 1974 and other health and safety 
legislation and to take reasonable care for the health and safety of themselves 
and others while on your premises. Although not a contract holder, the subject 
must observe the same standards of care and propriety in dealing with 
patients, staff, visitors, equipment and premises as is expected of a contract 
holder and must act appropriately, responsibly and professionally at all times.  
If the subject has a physical or mental health condition or disability which may 
affect their research role and which might require special adjustments to their 
role, if they have not already done so, they must notify you and their employer 
prior to commencing their research role with you.  
The subject of this assurance is required to ensure that all information 
regarding patients or staff remains secure and strictly confidential at all times. 
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They must ensure that they understand and comply with the requirements of 
the NHS Confidentiality Code of Practice  
(http://www.dh.gov.uk/assetRoot/04/06/92/54/04069254.pdf) and the Data 
Protection Act 1998. Furthermore, they should be aware that under the Act, 
unauthorised disclosure of information is an offence and such disclosures may 
lead to prosecution.  
As an Independent Contractor, you will not indemnify the subject against any 
liability incurred as a result of any breach of confidentiality or breach of the 
Data Protection Act 1998. Any breach of the Data Protection Act 1998 may 
result in legal action against them and/or their substantive employer.  
The subject should ensure that, where they are issued with an identity or 
security card, a bleep number, email or library account, keys or protective 
clothing, these are returned upon termination of this arrangement. They should 
also ensure that while on the premises they wear their ID badge at all times, 
or are able to prove their identity if challenged. As an Independent Contractor, 
you accept no responsibility for damage to or loss of personal property.  
You may terminate the subject’s access at any time. We would suggest that 
this should be either by giving seven days’ written notice to the subject or 
immediately without any notice if they are in breach of any of the terms or 
conditions described in this letter or if they commit any act that you reasonably 
consider to amount to serious misconduct or to be disruptive and/or prejudicial 
to your interests and/or business or if they are convicted of any criminal 
offence. The subject must not undertake regulated activity if they are barred 
from such work. If the subject is barred from working with adults or children, 
you may immediately terminate their access. Their employer should 
immediately withdraw them from undertaking this or any other regulated 
activity and they MUST stop undertaking any regulated activity immediately.  
The subject’s substantive employer is responsible for their conduct during this 
research project and may in the circumstances described above instigate 
disciplinary action against them. If the subjects circumstances change in 
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relation to their health, criminal record, professional registration or suitability 
to work with adults or children, or any other aspect that may impact on their 
suitability to conduct research, or their role in research changes, they must 
inform their substantive employer through its normal procedures. They must 
also inform you.  
Yours sincerely  
   
Janice Wiseman  
Research & Innovation Manager  
CC:  Research.Team@lincs-chs.nhs.uk  























Appendix 4 Details of codes from the Framework analysis 
Appendix 4.1 Data summaries from stage 2-4 of Framework analysis for service users – communicating risk 
Participant  Theory/deductive 
themes 
Subthemes/codes Key themes Quotes 
Service 
user 1 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
- Reassurance that it could be 
something else, not just cancer 
- Explain other reasons for the risk 
2. Reassurance and 
explanation 
 
“I will like some reassurance and I would like to be told about what other 
reasons could be causing this level of risk. I’m aware that there are lots of 
things, so I will want reassurance that it could be something else but not 




-Tell them the 
numbers 
-Explain what the 
numbers mean 
-take time to inform the patient and 
explain -allowing them to listen 
2. Informing, listening, 
explaining 
“I think it is important to take time to inform the patient by explaining and 




Treat them nicely/with 
respect 
-Being open and honest  
-Manners and attitude of clinicians 
 
-I don't hide anything 
-I will expect him to give me the 
information he thought it was, that I 
needed to know. 
3. Being open and 
honest with patients 
“I will like to be told the truth about what this 10% means and whether I've 
got a chance” (SU3: individual interview). 
 
“I would tell you the truth, I don't hide anything, so I will expect him to give 






Make them partners -The word prompt is important 
because a lot of patients might be 
embarrassed to tell you something 
4. Involving patients 
when using cancer risk 
assessment tools  
“I think the word prompt is important because a lot of patients might be 
embarrassed to tell you something but if they are prompted, they can then 




-Tell them the 
numbers 
 
-Explain what the 
numbers mean 
-Need reassurance about treatment 
-Explanation about treatment and 
surviving it 
-Providing time and listening 
 
2. Providing time for 
informing, listening, 
explaining and 
reassuring in a 
professional away  
 
“I think with that, if you're looking more likely that you're going to have 
something then I suppose you would probably want some reassurance, 
more also about treatment. But whereas before it's coming up which you 
were worried, I think it's probably now that you need reassurance that is 
finding it early and treatment, if it can be treated and if they know the risk of 




Make them partners -Prompting people to communicate 
their concerns 
4. Involving patients  “What I feel is patients should be involved when using the tools, and they 
should prompt them to discuss their concerns.” (SU 6: individual interview)  
Service 
user 7 
-Make them partners -Show and explain how the tool works  
-Showing the results can be scary but 
showing can be scarier 
4. Involving patients by 
showing how the tools 
work 
“I'd like them to show me how it works, and I'd like them to explain it to me. 
Showing the results can be scary but not to be shown the results can be 
scarier.” (SU 7: individual interview).  
Service 
user 8 
-Make them partners -Practitioner engaging with the patient  
-I think with that I'd be more involved 
in that consultation 
-I am more likely to act upon the 
findings  
- Seeing from the screen 
4. Involving patients by 
engaging them 
“I think because if the practitioner engages with the patient and uses that 
together with what I'm seeing from the screen together, I think with that I'd 
be more involved in that consultation, I'm more involved in my own 
treatment, and therefore I am more likely to act upon the findings of that.” 





-Make them partners -like to be informed before they use 
the tool 
4.Involving patients by 
informing them 
“Absolutely, yes, I would like to be informed before they use the tool.” (SU 
9: individual interview) 
Service 
user 10 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-They could just say, this is a tool to 
help with the assessment for your risk 
of cancer 
2. Informing and 
explaining in a clear 
and professional way 
“Should use it as part of my consultation with the doctor. But it will be 
helpful if they could just say, this is a tool to help with the assessment for 
your risk of cancer.” (SU 10: individual interview 
Service 
user 11 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-It is good with visual thing (smiley 
and sad faces chart)  
1.Visual 
representation 
“Yeah very good. It is good with visual thing (smiley and sad faces chart) 
as compare to others.” (SU 11: individual interview). 
Service 
user 12 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-Simplified visual representation of 
risk e.g. smiley and sad faces 
-Liking the pictorial representation 
because it is simple but it's effective  
-I think it is simple and clear so most 
people will be able to understand 
1.Tailoring a visual 
representation of risk 
 
“I really like this. I like the pictorial representation; I like the fact that it is 
simple but it's effective because it draws you really right to the point. You 
know the happy faces and a mixed of smiley and sad faces can get you an 
idea. I think it is simple and clear so most people will be able to 
understand this and take that information on board as opposed to if the 
doctor just mentions cancer risk it will put you off. But if you look at this 
and they talk you through this I think that will be really useful” (SU12: 
individual interview) 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-Listen to patients during consultation 
-Explain to patient’s understanding 
 
 
2.Providing time for 
informing, listening, 
explaining  
“You wouldn't want to feel that you've been rushed, you would want them 
to take time to talk with you, and if they try to cut this conversation short 
you would think that they didn't care, and again that could reduce your 
confidence” (SU12: individual interview 
Service 
user 13 
 -Want to know why 





“Once he says I am at risk of cancer I would want to know why, and I 




Tell them the 
numbers 
Explain what the 
numbers mean 
-Avoid speaking in difficult medical 
terms 
-Bring it down to the level of the 
person 
2.Informing and  
explaining in simple 
terms 
“Yes, you wouldn't want them to speak in difficult medical terms; you 
would want them to bring it down to the level of the person you're speaking 
to” (SU14: individual interview) 
Service 
user 15 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-Discuss the patients' risks with them 
in a professional way  
-Help patient understand and feel less 
worried  
2.Taking time to 
explaining in a 
professional away  
“In my opinion clinicians should discuss the patients' risks with them, but 
they should take time to do so in a professional and responsible manner in 
order to help the patient understand and feel less worried about their 
situation” (SU15: individual interview). 
-Make them partners -Involve patients 
-Patients seeing the results on 
computer screen 
4. Involving patients 
when using cancer  
risk assessment tools 
- “Again, I will like to be involved and I will like to see them using the tool 
and I like to see the smiley faces on the screen, and I will expect them to 




-Tell them the 
numbers 
-Explain what the 
numbers mean 
-Nothing too clinical or too medical.  
-It should all be basic terminology 
-Bring it in real terms like this is how 
treatable it is 
2. Explain to patients 
in a non-technical term 
“Nothing too clinical. I won't want anything too medical. You know it should 
all be basic terminology, they should bring it in real terms like this is how 







-If it turns out that you actually at risk 
-they didn't tell you the right thing 
3. Not being honest “If they decide that you are not at risk and it turns out that you actually at 
risk, then that is an ethical issue because they didn't tell you the right 
thing.” (SU 17: individual interview) 
Service 
user 18 
-Tell them the 
numbers 
-Explain what the 
numbers mean 
-Show the patient the graphics 
-All those yellow smiley faces that will 
probably make somebody feel at 
ease. 
-The blue sad faces could be 
arranged in rows than scattered 
1.Tailoring a visual 
representation of risk 
 
“Somebody could show the patient the graphics, the yellow smiley faces 
and blue sad faces. With all those yellow smiley faces that will probably 
make somebody feel at ease. But if all the blue sad faces could be 
arranged in rolls so they are concentrated in the same area it will probably 
make someone more reassured than if they are scattered.” (SU 18: 





-Be honest and clear and expect the 
same from the practitioner 
-Open conversation, open details 
from both sides  
3.Being open and 
honest with patients 
“When I go to the doctor I expect to be honest with him and be clear as best 
as I can and you would expect the same from the practitioner, open 
conversation, open details from both sides to avoid misunderstanding” 















Appendix 4.2 Data summaries from stage 2-4 of Framework analysis for practitioners – communicating risk 
No  Theory/deductive 
themes 
Subthemes/codes Key themes Quotes 
 1 -Tell them the numbers 
-Explain what the numbers 
mean 
-Give sufficient time  
-Provide clear plan  
-Provide information on how to explain a 
person’s risk (to both patient and practitioners) 
-Give both oral and written information about 
cancer risk to patients 
2.Providing time for 
informing, listening, 
explaining and reassuring in 
a professional away  
 
 
“What I feel is, I would try and give as much time as possible 




-Make them partners 
 
-All of the above 
- the only time you might do it without 
informing the patient is when you are 
uncertain 
3. Being open and honest 
with patients 
“I think the only time you might do 
it without informing the patient is when you are uncertain, you 
might go back and use it and then call the patient and inform 
them when you are sure of the risk” (P1 [GP]: Focus Group2). 
 2 -Tell them the numbers 
-Explain what the numbers 
mean 
-Convey information based on patient’s 
understanding 
-Provide information on how to explain a 
person’s risk (to both patient and practitioners) 
 
2.Providing time for 
informing, listening, 
explaining and reassuring in 
a professional away  
 
- “I normally give them a chance to ask questions, what they 
think, what they know about cancer and the kind of support 
they will need” (P3 [GP]: individual interview). 
“talking about risk is quite difficult” (P3 [GP]: Focus Group1). 
- “do the patients actually understand me, what I am trying to 






-Make them partners 
-All of the above 
-Involve patients (patients to see results on 
computer screen) 
4. Involving patients when 
using cancer risk 
assessment tools  
“If you don't tell them before using the tool it means you are not 
being honest. I mean you can't do anything without telling the 
patient, you need their consent” (P4 [GP]: individual interview). 
4 -Tell them the numbers 
-Explain what the numbers 
mean 
-Simplify presentation of risk 
-Should be user friendly 
-Providing a simplified visual representation 
of risk e.g. smiley and sad faces 
1.Tailoring a visual 
representation of risk 
“It’s more a question of more time really, because at the 
moment we're in crisis, GPs are in crisis, and the future is 
very bleak for GPs. Because you come in at 5 in the morning 
and you get back home in the night and it’s a nightmare 
really. So, we don't want more work” (P6 [GP]: Focus 
Group1) 
Treat them nicely/with 
respect 
- will be open and honest with patient  3. Being open and honest 
with patients 
“I will be quite open and honest with them that, you've come 
with these symptoms, some of them are already in, and we can 
use the tool to work out what it is. If you bear with me I will 
check your risk and I could put those figures and what is 
coming out is your risk, and we can try that” (P6 [GP]: Focus 
Group1). 
5 -Tell them the numbers 
-Explain what the numbers 
mean 
- The graphs and charts to explain their risk 1.Visual representation-
graphs/charts 
“If they do not understand the graphs and the charts then I 
will be more than happy to explain it to them and their risk.” 
(Practitioner 9: individual interview)  
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Appendix 4.3 Data summaries from stage 2-4 of Framework analysis for practitioners (used the tools)– communicating risk 




-Tell them the numbers 
 
-Explain what the numbers 
mean 
 
-Pictorial representation convinced patients  
- The yellow smiley faces and blue sad 
faces were easy to understand 
- The presentation and icon arrays were 
very user friendly 
-Showed them the QCancer chart, the 
yellow smiley and blue sad faces 
1.Tailoring a visual 
representation of risk 
“The pictorial representation and multi cancer symptom 
approach is useful with QCancer” P1 [GP]: Focus 
Group 3). 
 
“I showed them the QCancer chart, the yellow smiley 
and blue sad faces, and it was easy for them to 
understand” P1 [GP]: Focus Group3) 
-Treat them nicely/with 
respect 
-Didn’t hide anything from patient 
-Was honest throughout consultation 
3.Being open and honest with 
patients 
“I didn’t hide anything from the patient, I was honest 
with them throughout. I think that help to ease their 
worry” (P1 [GP]: Focus Group3). 
-Tell them the numbers 
-Explain what the numbers 
mean 
 
- explained the need to do investigations 
-They understood and were alright with 
that 
2.Providing time for informing, 
listening, explaining and 
reassuring in a professional 
away 
I explained that I needed to do some investigations and 
possibly to refer them. They understood and were 
alright with that (P1[GP]: Focus Group3). 
 
-Make them partners 
 
-All the above 
 
-I informed them 
-Asked for their consent to use the tool.  
-They agreed  
-I involved them from the beginning 
4.Involving patients when 
using cancer risk assessment 
tools 
“As I said, I informed them and asked for their consent 
to use the tool. They agreed and I involved them in the 
use of the tool from the beginning, when I was about to 




-Tell them the numbers 
-Explain what the numbers 
mean 
 
-Pictorial presentation will convince the 
patient 
- The presentation and icon arrays are also 
very user friendly 
1.Tailoring a visual 
representation of risk 
“The Pictorial presentation will convince the patient 
about their risk as it is yellow smiley faces and blue 
sad faces are easy to understand. The presentation 
and icon arrays are also very user friendly” (P2 [GP]: 
Focus Group 3). 
-Make them partners 
 
-All the above 
 
-I also involved them from the beginning 
-Patient was happy for me to carry on 
4.Involving patients when 
using cancer risk assessment 
tools 
“Yes, I also involved them from the beginning by 
taking time in explaining what I wanted to do to 
assess their risk of cancer and the patient I was 




-Tell them the numbers 
-Explain what the numbers 
mean 
 
-took time in explaining  
-reassured by explaining 
- it’s only a risk and not a cancer diagnosis 
- They understood and were alright with 
that 
2.Providing time for informing, 
listening, explaining and 
reassuring in a professional 
away 
“I reassured the patient by explaining that the risk is 
only a risk and not a cancer diagnosis. I explained what 
a 2% risk, meant, which is not a diagnosis of cancer, 
but a risk. I also explained that, early detection of risk 
will help with early investigations, diagnosis and early 




Appendix 4.4 Data summaries from stage 2-4 of Framework analysis for service users – enablers to implementation 
Participant  Theory/dedu
ctive themes 





-Promotes consistent decisions 1.Supporting decision 
making 






-Some examples of what can be used to 
reduce the risk 
What to do to identify the risk” 
3. Identify and reduce 
risk 
“I guess I would like to be told some examples of what can potentially be 
used to reduce the risk, what to what to do, how to react and any potential 





-What the risks are and meaning 
-What to do to reduce the risk 
3. Identify the risk and 
how to reduce them 
“What my risks are, what the risks mean, what they will do, what I can do to 






-Earlier detection of cancer symptoms 
 - things can be picked up 
2.Improving process and 
speed of assessment 
and treatment 
- “I think my first worry is that I may have cancer and most of us will like to 
know early so they can get it sorted. But a lot of things can be picked up, 






-Information about modifying health 
behaviours 
-Identification and modification of cancer 
risk factors 
 
3. Identifying and 




“I think it might be just raising awareness, so people realise what's happening, 
and what can go wrong with them and where the risks are and may be, they 
can reinforce them where someone else like the young person who has given 
up smoking it might be used to reinforce by saying well you've got a very low 
risk so if you've given up smoking carry on with that. Rather than saying 





-What can be done now 
-Any medical interventions such as tests 
and referral for further tests 
3.identifying the risk and 
acting on it 
“Well I'd like to be told what can be done now, not in the next 2 years but 
now. Any medical interventions such as tests and referral for further tests or 





-structured decision making 1.Supporting decision 
making 





-Using their own clinical knowledge and 
judgment for a decision 
-Risk assessment tool is to confirm or 
help them confirm decision 
1.Use for confirming 
decisions 
“Well, they are trained professionals, the practitioners, so they will be using 
their own clinical knowledge and judgment obtained from their training to 
make a decision, and risk assessment tool is to confirm or help them 







-Highlighting individual  
-It makes you think about the choices 
that you can make e.g. exercise, correct 
food, drink, smoke etc 
3. Highlighting risk and 
what to do 
“Erh, well, it's highlighting individual risks based on the answers you give, 
and it can only be seen as benefit, erh as it makes you think about the 
choices that you can make e.g. exercise, correct food, drink, I don't smoke 
so that doesn't matter. But I think it's just giving me a snapshot of what 





-Earlier detection of cancer symptoms 
-Provides structured risk assessment 
2.Improving process and 
speed of assessment 
and treatment 
- “it will help with early diagnosis through early detection of cancer risks” 
(SU10: individual interview). 
-So, they can change their lifestyles 
-stop smoking or drinking alcohol 
3. Identifying and 
modifying health risk 
behaviours 
- “to be forewarned is to be forearmed, so they change their lifestyles such as 







-Show or tell you how the risk could be 
lowered 
-what you should do to lower the risk 
3. Advice on how 
patients can lower their 
risk 
“It could be useful if they could show or tell you how the risk could be 






-Will help clinicians to know the patient  
-Promote individualised patient centred 
care 
- Care will be more patient-centred 
4.Personalising care “I think it will make the care more patient-centred because you're presenting 
them with their own risk not a general risk, it's personal to them and it will just 
make the consultation more patient focused, and I think it will make patients 
feel more involved in the consultation and just feel more cared for I think” 





-explain that to the person that they do 
have a greater risk of cancer 
- tell them preventive measures 
3.Telling patients the 
risk and prevention 
measures 
“Therefore, you do explain that to the person that they do have a greater 
risk of cancer. But you tell them the prevention, the prevention; you must 
give them the prevention, if you can in certain, in cases of cancer, at an 





-Helps to make decision 
-Support early detection of cancer risk  
1. Support decisions on 
early detection 
“I think it is a good idea. That's useful because it is a preventive medicine; 
approach isn't it, to help make decisions and support early detection of 





-Advice on how to maintain a healthy 
lifestyle  
-How to reduce cancer risk factors 
3.Advice on healthy 
lifestyle 
“Again, as with the 1% risk, I would expect to be advised on how to maintain 
a healthy lifestyle and reduce the factors that contribute to the risk of 





- A tool they can depend on but use it as 
a support 
1. Use it as a support “I think it will be a really good idea. I think clinicians are under a lot of 
pressure and very quick appointments. So, if they've got a tool, they can 





-It is an assessment and not a diagnostic 
tool 
- helpful for assessing and modifying risk 
over a long period of time 
3. modify their risk 
factors 
“I think as it is an assessment and not a diagnostic tool, it will be helpful 
may be to assess risk over a long period of time, so that people can then 
modify their risk factors and so instead of QCancer capturing those who will 
have cancer within 2 years, the tool could be used to assess for the risk for 












-the tool will help the practitioners to ask 
the right questions 
-Adds to clinician's knowledge and skills 
-Useful if combined with clinical 
knowledge and skills 
1.Supporting decision 
making 
 “Yes, it is useful because the tool will help the practitioners to ask the right 
questions, and I know you have just 5 or 10 minutes with the doctor, and if 
the use of the risk assessment tools helps with the process then I think they 
should be used” (SU18: individual interview). 
- can help to identify the individual's risk 
--Support lifestyle advice and patient 
motivation to reduce cancer risk 
-Encourage patients to check risk and 
seek advice from GP 
3. Identifying and 




“It can help to identify the individual's risk, isn't it? Because the input you've 
given is about your own risk rather than the general population, and if it's 
done over some years and your risk is increasing they could turn around 
and say well we need to increase or make more changes in your life style. 
So, if they were to do it every 5 years and if they see that the risk is 
increasing then maybe they could start giving me some lifestyle advice” 





-Promote individualised patient centred 
care 
 
4.Personalising care “So, it needs to be about me. I think it’s an excellent idea, the tool. I mean 
it's dealing with the individual very specifically and there's an opportunity to 




Appendix 4.5 Data summaries from stage 2-4 of Framework analysis for practitioners – enablers to implementation 
No Theory/deductive 
themes 
Subthemes/codes Key themes Quotes 
1 Relative advantage -More accurate and specific information for individual 
patients 
-Individualised assessment and care 
-Reassurance for both low and high cancer risk 
-Reduced complaints from different patients 
4.Personalising patient care  
 
“Patients will go away with a lot more targeted 
information about their personalised risk of cancer 




Relative advantage Promoting understanding 
and behaviour 
-Patient education about cancer risk 
-Support lifestyle advice and patient motivation to 
reduce cancer risk 
-Encourage patients to check risk and seek advice 
from GP 




“They don't understand the risks, you know what I 
mean? I mean like someone who is a smoker, he is 
smoking, smoking. You can use this tool to help them 
modify their lifestyle. People who are refusing referral, 
you can use the tool to estimate their risk to show and 
explain to them” (P2 [GP]: individual interview 
3 Relative advantage -Will help to improved speed of assessment  
-Earlier detection and treatment 
-More rapid investigation and referral 
-Improved outcomes 
-Capture of cases missed by two-week wait  
2.Improving process and speed of 
assessment and treatment 
 
“Well as a tool, it's useful, for helping practitioners' 
ability to spot cancer or the possibility of cancer at an 
earlier stage than we could do. You know all emphasis 
is on cancer care, and GPs are sometimes a bit, a bit 
stuck to know what to pick as symptoms of cancer” (P3 
[GP]: Focus Group1). 
Relative advantage -They could also check and then come to us 
-You could recheck the cancer risk with the patient 
to see whether you have the same result 
3.Identifying and modifying health 
risk behaviours 
 
“I am saying they could also check and then come to 
us, and they could be helping us as well. If what they 
regard as risk, you know almost the fact that they've 
come that might suggest they regard whatever number 
they've got as something we will be able to discuss with 
them. We go over it and you could recheck. You could 
recheck the cancer risk with the patient to see whether 
you have the same result” (P3 [GP]: Focus Group1). 
4 
 
Relative advantage -the tools could aid decision making 
-Aid at initial consultation  
-For cancer screening programmes in general 
practice 
-Those with suspicion of cancer 
-For patients with vague or doubtful or borderline 
symptoms 
-Empowering patients in decision making 
-Breaking bad news to patients 
- Will generate data e.g. for research  
1.Supporting decision making 
 
“I think somebody where you thought they have a 
cancer, probably you wouldn't go on a QCancer, and 
you would do what you do now. I think with people who 
are at the borderline, I think for these people you might 
want to use it” (P4 [GP]: Focus Group2). 
5 
 
Relative advantage -For a differential decision or diagnosis 
 
1.Supporting decision making 
 
- “I think one of the ways I can use this tool is when you 
have got a differential in your mind, how can you put 
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the cancer which may be at the lower end of the 
spectrum to come on top?” (P5 [GP]: Focus Group1). 
 
“GP experience is more important than tools and 
guidelines” (P5 [GP]: individual interview), 
 
“I will recommend that CRATs like QCancer be 
available to patients to use before coming to their 
GP.” (P5 [GP]: individual interview) 
6 Relative advantage -Will generate data e.g. for research 
need more investigations, we need more test 
2.Improving process and speed of 
assessment and treatment 
 
- “With everyone on board because we need more 




























-Faster consultation, the assessments, investigations 







“I think when the tools are fully integrated in our IT systems and every 
practitioner get familiar with using them, it will be time saving in the 
long term, as the consultation, the assessments, investigations and 
referral processes will be faster” (P1 [GP]: Focus Group3). 
 
“It was easy to assess a patient’s risk of cancer by entering their 
symptoms and risk factors into the QCancer calculator. It was also 
easy to use the risk generated to explain why they I needed to refer 
them for investigations and for a more specialised attention in the 
hospital, where early diagnosis and treatment could be done sooner 
than later” (P1 [GP]: Focus Group3). 
-QCancer is based on current presentation (Q cancer) 
and easier to understand 
-We don’t quite understand the RAT yet  
-The pictorial representation and multi cancer symptom 
approach is useful with QCancer 
4.Ease of use “QCancer is based on current presentation (Q cancer). But I think, we 
don’t quite understand the RAT yet. The pictorial representation and 








-The tools will help to guide the clinician to see the 
broad level of differential diagnosis. 
- It also facilitates referral of patients  
-Quantitative risk value to help make decision 
1.Supporting 
decision making 
“I think the tools will help to guide the clinician to see the broad level 
of differential diagnosis. It also facilitates referral of patients by 
presenting quantitative risk value to help explain risk and make a 
decision” (P2 [GP]: Focus Group3). 
-The tool helped in using the risks generated to advise 
patients who need behavioural changes. 
-Told them to maintain healthier lifestyles by exercising, 
eating a healthy diet, less alcohol and to stop smoking 
if they were smoking.  
-The tools can help to empower patient to take control 





“I also found that using the tool helped in using the risks generated to 
advise patients who need behavioural changes. Their risk was small, 
and I told them to maintain healthier lifestyles by exercising, eating a 
healthy diet, less alcohol and to stop smoking if they were smoking. 
Yes, as I said, these tools can help to empower patient to take 






-Potential for using the tools for screening in other 
health categories e.g asymptomatic individuals 
-Modify or redesigned the tools to suit other conditions 
in primary care 





“I think there is a potential for using the tools for screening in other 
health categories. The tools could be modified or redesigned to suit 
other conditions in primary care. They could also be modified for 
asymptomatic patients, for example the QCancer 10 years’ risk tool, I 
understand can be used to predict of cancer in asymptomatic 
individuals” (P3 [GP]: Focus Group3). 
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Appendix 4.7 Data summaries from stage 2 - 4 of Framework analysis for service users – Barriers to implementation 
Participant  Theory/deductive themes Subthemes/codes Key themes Quotes 
Service user 1 Compatibility/complexity -Everybody should use the same sort 
of guidelines 
4.Conflict with existing 
guidelines 
 
“I think it is good for everybody to have the same sort of 
guidelines, so to use risk assessment tools everybody 
should use the same sort of guidelines” (SU1: individual 
Interview). 




 -It doesn't matter whether it's 1% or 
2%  
-Something is actually not right 
something should be done  
5.Need for referral whatever 
the risk level 
“It doesn't matter whether it's 1% or 2% but so you have 
peace of mind and something is actually not right 
something should be done it and it should be assessed.” 
(SU 2: individual interview). 
Service user 3 Patient needs & resources -If not explained well, worried be 
about having cancer 
2.Worry about cancer “If the level is high and they don’t explain well I would be 
worried that I already have cancer.” (SU 3: individual 
interview) 
 
Service user 4 
 
 -People worry when they go for 
consultations 
-People have questions to ask 
2. People worry at GP 
consultation 
“I think an awful lot of patients go into a consultation, 
whatever it is, whether it's hospital or GP surgery and 
there are several questions they want to ask and then 
they forget or because they are just anxious.” (SU 4: 
individual interview). 
Service user 5 
 
 -Worry when cancer is mentioned 
-Cancer as bad news 
2.Worry about cancer “Yeah, when they start talking about cancer then I would 
worry straight away.” (SU 5: individual interview). 
Service user 6 Patient needs & resources -Worry due to investigations  
-Emotionally I would be quite 
distraught and worried 
2.Worry due to 
investigations 
“I think they may be, have to assess their patients first to 
see if they were going to promote great anxiety on the 
patients by using some of these tools. I think emotionally I 
would be quite distraught and worried, and this is where 
having another person in there is important, I think. But I 
think until you've got some sort of appointment and then 
further tests and so forth, you will be in a state of limbo, I 
think, you know, not being able to concentrate properly” 
(SU6: individual interview) 
Service user 7 Patient needs & resources -More time to discuss risk of cancer) 




“more time to use the tool in consultations” (SU7: individual 
interview)  
 
Service user 8 Patient needs & resources -Worry the risk could be cancer 
-Some kind of clarification will be 
good 
2. Worry the risk could be 
cancer 
“Again, would worry about that the risk could be cancer, 
so I think just some kind of clarification about the 
likelihood of it developing further will be good” (SU 8: 
individual interviews). 
Service user 9 
 
 
Complexity to see whether it is cancer 5.Symptoms suggestive of 
cancer need referral 
whatever the quantified risk 
“to see whether it is cancer or something else” (SU9: 
individual interview) 
 
Service user 10 
 
Patient needs & resources -I would be quite frightened  2. Worry about a high-risk 
level 
“I would be quite frightened, I think. At 66 years old and if 
I was coughing out blood, I don't quite know because I've 
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no medical background, but it doesn’t sound very good to 
me. It's quite high, 10%, isn't it? I think it's quite high and I 
will be worried.” (SU 10: individual interview). 
Service user 11 Patient needs & resources –Anxiety due to referral 
-Misinformation of a person’s risk 
-They can be too worried especially if 
they don't explain that it is just a risk 
2.Worry/anxiety relating to 
cancer referral & 
investigations 
 
“Some people may not understand and they can be too 
worried especially if they don't explain that it is just a risk 
but it is not guaranteed that they will get cancer, then it is 
not good enough ethically” (SU11: individual interview). 
Service user 12 Reflecting & monitoring -Need for further investigation of 
symptoms and risk of cancer  
 
 
7.Need to establish effective 
of CRATs 
 
“But I think if you are going to roll something out rather than 
going to everybody I would start with the doctors, see how 
the doctors do with it after evaluation and then move on to 
the practice nurses” (SU12: individual interview). 
 
Service user 13 Complexity -It doesn't really matter about 
percentages 
- the fact is the symptom is there 
which is quite worrying 
5.Symptoms suggestive of 
cancer need referral 
whatever the quantified risk 
“It doesn't really matter about percentages; I know 1% is 
less risk. But the fact is the symptom is there, the 
coughing out of blood, which is quite worrying” (SU13: 
individual interview). 
Service user 14 Patient needs & resources -It's getting serious at 10% risk 
-I would not happy at this level of risk 
2.Worry about a high-risk 
level 
“Well it's getting serious isn't it, so I would not be very 
happy at this level of risk, 10%.” (SU 14: individual 
interview) 
Service user 15 Patient needs & resources -Problem is the GPs tend to spend 
just about 10 minutes  
-10 minutes may not be enough for 
detailed discussion with the patient 
1.Current consultation time 
too small 
“But the problem is the GPs tend to spend just about 10 
minutes which may not be enough for a more detail 
discussion with the patient, which is unfortunate.” (SU 15: 
individual interview) 
Service user 16 Patient needs & resources -When you hear of cancer, you think 
of death 
-All sort of thoughts come to your 
mind and you worry.” 
2.Worried about cancer “I think when you hear of cancer, you hear a lot of noises 
in your heard. You think you are going to die, and all sort 
of thoughts come to your mind and you worry.” (SU 16: 
individual interview). 
Service user 17 Patient needs & resources -Potential for over referral 
-Potential burdening of resources 
3.Over-referral & over 
burdening of services 
 
“It could be useful if the right patients are referred but it 
could also lead to over referral as some people may have 
a certain risk but will not have cancer after they have 
been referred and tested” (SU17: individual interview) 
Service user 18 Patient needs & resources -10 minutes per consultation is short 
 
1.Current consultation time 
too short 
“I think one of the problems with these consultations is 
the 10 minutes which seems quite short.” (SU 18: 
individual interview). 
Service user 19  -There's still going to be anxiety 
-The more information will help in 
dealing with that anxiety. 
2. Anxiety related to cancer “It's always gona be there, even if it's understood there's 
still going to be anxiety there, and the more there is 
information at the earlier stage the better the chance 






Appendix 4.8 Data summaries from stage 2-4 of Framework analysis for practitioners – Barriers to implementation 
No Theory/deductive 
themes 
Subthemes/codes Key themes Quotes 
1 Patient needs & 
resources 
-Time and workload pressure 
-I think we should have 15 minutes’ 
appointments.  
 
-That will give us a little bit extra 
time, which is assuming the patient 
has only one problem 
 





- “the uncertainty and putting all the data manually” (P1 (GP): Focus 
Group2) 
 
- “It should be integrated in our system, SystmOne, rather than every 
time we have to go on Google to get it. Like you put all that information 
in, it will be difficult, it should be completely automatic, and think of the 
investigations, people are more likely to use it” (P1 [GP]: Focus 
Group2) 
 
- “Well I believe if, in the ideal world, you may be aware of that, if 
there is a push to implement that; I think we should have 15 minutes’ 
appointments. That will give us a little bit extra time, which is 
assuming the patient has only one problem, but they have multiple 
problems in one appointment, I think it will be done well if something 
like cancer risk assessment, communication, organising of the test 
that follow, 15 minutes will be ideal” (P1 [GP]: individual interview). 
Reflecting & monitoring -Getting it in real life and then 
reporting back 
7.Need to establish 
effective of CRATs 
 
“One of the things I think will be really useful is, it's been devised but 
getting it in real life and then reporting back on that, it will be really 
useful to know how good a tool it is (P1 [GP]: individual interview) 
Knowledge & beliefs of 
individuals involved 
-They need to tell us. So, for 
cancers, unless we have those 
things it will probably be difficult to 
use the tool 
6.Practitioner scepticism 
about using CRATs 
“I think for it to be useful there needs to be some benchmarks for us 
to really relate with. If you say 7% or 6%, should I worry? I think they 
need to tell us. So, for cancers, unless we have those things it will 
probably be difficult to use the tool” (P1 [GP]: Focus Group2). 
 2 Patient needs & 
resources 
-Which is creating unnecessary 
anxiety 
2.Worry/anxiety relating 
to cancer referral & 
investigations 
“The thing is if you tell the patient they've got 1% cancer, which is 
creating unnecessary anxiety” (P2 [GP]: individual interview). 
Reflecting & monitoring -Need to compare with current 
practice before and after 
implementing CRATs 
 
7.Need to establish 
effective of CRATs 
 
“review, we have to make sure that it is better than what we are already 
doing” (P2 [GP]: Focus Group2) 
3  
Patient needs & 
resources 
-Need for sufficient secondary care 
capacity for rapid assessment 
 
3.Over-referral & over 
burdening of services 
 
“I think we should not be worried about resources. Now many more 
people are dying from cancer, so they want more referral and 
diagnosis earlier. I am not sure using the tool is cheaper but I will say 
it is good for patient safety because people will be diagnosed earlier 




Knowledge & beliefs of 
individuals involved 
-Initially I was very sceptical about 
this tool 
6.Practitioner scepticism 
about using CRATs 
“Until you said this thing, you know initially I was very sceptical about 
this tool” (P3 [GP]: individual interview) 
4 
 
Patient needs & 
resources 
-Potential for over referral and 
burden or strain on NHS resources 
3.Over-referral & over 
burdening of services 
“But on the other side it will put a strain on the NHS; you know what I 
mean, on the services there. You know, you don't want to over burden 
the services as well” (P4 [GP]: individual interview). 
5 Patient needs & 
resources 
-Generating unnecessary patient 
anxiety 
2.Worry/anxiety relating 
to cancer referral & 
investigations 




Complexity -Some symptoms need referral 
whatever the risk percentage 
-High risk prompts further 
investigation 
5.Symptoms suggestive 
of cancer need referral 
whatever the quantified 
risk 
“as I said, if I suspect cancer and I put in the tool 1%, 2% doesn't matter 




Knowledge & beliefs of 
individuals involved 
-Some practitioners may be 
sceptical 
6.Practitioner scepticism 
about using CRATs 
“GP experience is more important than tools and guidelines” (P5 [GP]: 
Focus Group1). 
 
6 Compatibility/complexity -Current risk assessment is based 
on practitioners’ knowledge of 
patients' symptoms, cancer risk 
factors and NICE guideline 
 
Referral also depends on 
important single risk factors e.g. 
age 
 
4.Conflict with existing 
guidelines 
 
“I will be quite confused about using the tool. I mean you know with 
the NICE guidelines; you couldn't focus on another criterion for any 
other risk here” (P6 [GP]: Focus Group1). 
 
Complexity -Varying perception of risk from 1-
10%, e.g. 4%-10% risk of cancer 
is high and needs referral with 
investigations for low risk e.g 1% 
5.Symptoms suggestive 
of cancer need referral 




“Since they've got symptoms, it is urgent x-ray straight away. I 
always send my patients for x-ray and say not to worry about the 
symptom, because I am going to investigate. Because even if he 
came with 1%, that's the thing. Regardless of what QCancer said I 
will refer them for investigation with the symptoms. So, it doesn't 
matter 1% or 0%, I will always do one thing, investigation if the 
symptoms are suggestive of cancer” (P6 [GP]: Focus Group1). 
 
 
 7 Patient needs & 
resources 
-Increase the length of 
consultation 
-Depending on how the 
consultation starts and runs 
1.More consultation time “Well I think it might increase the length of consultation. Yeah, it 
depends on the consultation, how it runs and how it starts.” 





Appendix 4.9 Data summaries from stage 2-4 of Framework analysis for practitioners (used the tools) – Barriers to 
implementation 
Participants  Theory/deductive 
themes 







-The tools are useful  
-For clinical decision making  
1.Willingness to 
use the tools 
"Yes, I will use the tools. I think the tools are useful in helping with clinical 
decision making as we already discussed” (P1 [GP]: Focus Group3). 
Patient/practitioner 
needs & resources 
 
-The tools are not known to the secondary 
or hospital setup.  
-They may not recognise my QCancer 
referral as they are only used to NICE 
referral guidelines, that is the two-week 
waiting or urgent referrals 
4.Need to involve 
in-hospital 
specialists in use of 
the tools  
“My concern is that the tools are not known to the secondary or 
hospital setup. So, I referred some patients, and I am concerned they 
may not recognise my QCancer referral as they are only used to NICE 
referral guidelines, that is the two-week waiting or urgent referrals. So, 
when I am thinking, if they see the patients I referred using QCancer, 




-We will to use these tools for a while and 
then evaluate. 
-Need to see effectiveness of the tools 
they are against existing practice.  
-Need to assess the impact of using these 
tools on investigations, referral, diagnosis 
etc 




“The only thing is, as I have said before, we will need to use these tools 
for a while and then evaluate to see how effective they are against 
existing practice. I mean we have to assess the impact of using these 






needs & resources 
 
-Have no problem using the tools 
-believed it will be good to use the tools 
1.Willingness to 
use the tools 
“I have no problem using the tools, and I believe it will be good to use 
cancer risk assessment tools to facilitate early diagnosis of cancer, and 
as you know, early diagnosis will help with early treatment” (P2 [GP]: 
Focus Group3). 
-Problem of accessing the tools as they 
are not integrated in our IT system. 
- It was not easy downloading or googling 
the tools during patient consultation. 
2.Need to integrate 





“There was a problem of accessing the tools as they are not integrated 
in our IT system. It was not easy downloading or googling the tools 
during patient consultation, but that was the only option as I wanted to 
use the QCancer tool to check whether the patient was at risk of cancer, 
as the symptoms were a bit unclear” (P2 [GP]: Focus Group3). 
-Problem is the RAT is not clear. 
-The RAT is more complicated to use than 
the QCancer.  
-We don’t quite understand how to use that 
tool.  
We need to have proper education or 
training on using these tools. 
3.Need for training 
on using the tool in 
consultation 
 
“One problem is that the RAT is not very clear. The RAT is looking 
more complicated to use than the QCancer. We don’t quite understand 
how to use that tool. I think we need to have proper education or 
training on using these tools. The other day I met a lady from the 
Macmillan Cancer I support, and I asked them to see if they could 
come and give us a training session or talk on how to use the cancer 
risk assessment tools in patient consultations. I think we need to follow 







needs & resources 
 
-Happy to use the tools 
-Will use the QCancer which is easier to 
use 
1.Willingness to 
use the tools 
“Me too, I am happy to use the tools especially the QCancer, which is 
easier to use” (P3 [GP]: Focus Group3). 
-The tools are not linked with the current 
NHS system 
2.Need to integrate 
the tools into 
general practice 
system 
“The tools are not linked with the current NHS system, so you can’t really 
use them in patient consultation, unless you google and then use, all 
that, while the patient is waiting” (P3 [GP]: Focus Group3). 
 
 
